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Abstract
In multiple sclerosis (MS), lymphocytes and monocytes penetrate the blood brain barrier 
(BBB), causing inflammation and leading to myelin damage and subsequent loss in the 
white matter of the central nervous system (CNS). Chemotactic cytokines (chemokines), 
contribute to the recruitment of immune cells into the CNS, and are expressed by 
astrocytes, the most abundant cell type in the CNS, and endothelial cells. CCL2 and 
CXCL10 are chemokines expressed in MS lesions, which are thought to be pivotal in 
chemoattraction of T  cells and monocytes into the CNS. Astrocytes, microglia, and 
endothelial cells produce proteases, such as matrix metalloproteinases (MMPs), which 
contribute to the destruction of the BBB, facilitating cellular entry. Increased expression of 
MMP2 and MMP9, amongst others, has been shown previously in autopsied MS brain, 
and increased levels of the cell surface peptidase CD26, expressed by T cells and 
endothelial cells, have been linked to disease activity. Interactions between proteases and 
chemokines expressed in the same milieu can result in chemokine processing that 
dramatically increases or decreases their activity. To assess the potential effects of 
chemokine cleavage in MS, recombinant proteins were used in an in vitro study which 
examined processing of CCL2 and CXCL10 by MMP2, MMP9 and CD26, using mass 
spectrometry to identify enzymatic cleavage products. MM P9 removed four residues, and 
CD26 cleaved a dipeptide, from the N-termini of both CCL2 and CXCL10. MMP2 N- 
terminally cleaved four residues from CCL2, and five from CXCL10. C-terminal truncation 
of CXCL10 was observed with MMPs 2 and 9, which each removed four residues.
Cleavage by CD26 was rapid, and complete with CXCL10 within 30min. MMP truncation of 
CCL2 was complete within 3h, but with CXCL10, remained incomplete by 48h. Astrocyte 
supernatant was examined by mass spectrometry for the presence of these truncated 
chemokines, but low levels prevented detection. Protease expression was investigated, to 
identify the likelihood that cleaved CCL2 and CXCL10 arise in vivo in MS. The MMP 
mRNA expression profile of cytokine-treated and untreated astrocytes examined by real 
time PCR showed that MMP2 mRNA was highly expressed with and without cytokine 
treatment, and MMP9 mRNA was increased following treatment with the pro-inflammatory 
cytokines tumour necrosis factor and interleukin-1 p. MS brain tissue was examined using 
dual-labelling immunofluorescence for CD26 expression, which was found in lesions to be 
associated with T cells and monocytes in perivascular cuffs, and macrophages within the 
parenchyma, but not with astrocytes. The chemotactic activity of the cleaved forms of 
CCL2 and CXCL10 identified in this study was investigated using real time in vitro 
migration assays. THP-1 cells, a monocytic cell line, exhibited a two-fold reduction in 
migration to cleaved CCL2 isoforms, compared to the intact form. Preliminary experiments 
with Jurkat cells, a T cell line, indicated that migration remained unaffected, or was slightly 
increased, by cleaved CXCL10 compared to the intact form. Collectively, this study 
demonstrated that cleavage of CCL2 and CXCL10 by proteases, found at elevated levels 
in MS, may be an important regulator of chemokine activity. In particular, CD26 may play a • 
key role in regulating chemokine activity, and thus cell migration into the CNS, as it 
demonstrated rapid and highly specific proteolytic activity and is highly likely to encounter 
chemokines as it was associated with T cells and macrophages that express the 
appropriate chemokine receptors.
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Chapter 1
General introduction
1.1 Immune regulation in the central nervous system (CNS)
The brain is a delicate organ with a limited regenerative capacity, which could suffer 
catastrophic damage if subjected to significant inflammation. Axons and dendrites, in 
particular, are very sensitive to inflammation due to their long, thin processes, high 
energy requirement, and low capacity for regeneration (Neumann and Takahashi,
2007). In the past, the brain was thought of as an ‘immunologically privileged’ site, not 
subject to infiltration of immune cells as part of routine surveillance. It was known that 
leukocytes existed in large numbers in the CNS during diseased states, but they were 
thought to be absent in healthy brain tissue (Antel and Owens, 1999). More recent 
discoveries have clarified that immune cells enter the CNS without it being subject to 
disease, but that this is highly regulated, and varies with age and brain region (Galea et 
a/., 2007).
The CNS can be thought of as a collection of compartments: the parenchyma; the 
ventricles, housing the choroid plexus and cerebrospinal fluid (CSF); and the meninges 
(Fig. 1.1). It was shown in 1923 that antigens injected into the brain parenchyma did 
not elicit an immune response, but did so if implanted Into the ventricles. Almost 60 
years ago, Medawar showed that the efferent immune response, i.e. the ‘effector’ 
phase designed to eliminate pathogens, is mostly intact in the CNS, but the afferent, or 
‘sensing’ phase involving antigen recognition, is significantly lacking. The protective 
barrier formed by blood vessels and glial cells of the CNS, namely the blood brain 
barrier (BBB), was investigated in a quest to explain these differences observed in the 
CNS. The BBB was previously held wholly responsible for the CNS immune privilege, 
but it is now known that other features, such as details of the microenvironment, and 
specialised afferent communication to nearby lymphatic organs, are more important 
(reviewed in Galea et a/., 2007). As such, the CNS is best considered an 
immunologically specialised site, where immune reactions are present. There are 
several cell types involved in the immune response of the CNS, including T  cells, B 
cells, phagocytes, and glial cells.
1.1.1 T cells
Maintaining an appropriate balance between reacting to pathogens and self-tolerance 
is essential for normal function of a healthy immune system. T  cells develop in the 
thymus and play crucial roles in cell-mediated immunity. T  cells recognise peptide 
antigens, displayed by major histocompatibility complex (M HC) molecules expressed 
on other cells. All nucleated cells express MHC class I proteins, which bind to T  cell 
receptors (TCRs) on T  cells expressing the coreceptor CD8 (Burrows et al., 2008).
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Figure 1.1 Compartments of the central nervous system
Within the ventricles, the choroid plexus produces cerebrospinal fluid (CSF), which 
bathes the brain parenchyma. Ventricular CSF is continuous with CSF found in the 
subarachnoid space, between the inner meninges covering the brain surface, and the 
outer meninges. Antigens injected into the ventricles elicit an immune response, 
demonstrating that these are not immunologically privileged sites. In the case of 
adaptive immunity, the immune privilege of the CNS is restricted to parenchymal 
compartments. The subfornical organ is circumventricular, in that it lacks a blood-brain 
barrier (BBB), and does not experience immune privilege (Galea et al., 2007)
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T  cell possession of the CD4 coreceptor, however, restricts TC R  binding to cells 
expressing M HC class II, namely antigen presenting cells (APCs). Immune responses 
are geared towards detection of pathogens by breaking down the proteins involved into 
peptides, which are captured by MHC molecules on APC, and then presented to TCRs. 
The capacity of an antigen-MHC complex to activate T  cells correlates with the duration 
and strength of TC R  binding, with lengthy, high affinity binding being characteristic of 
TC R  agonists (Mantzourani et a/., 2007). T  cells that recognise self-peptides are largely 
eliminated during negative selection processes in the thymus (Yan and Mamula, 2002).
T  cells can be broadly divided into effector or memory populations, with an additional 
subset that includes natural killer (NK) T  cells and y5 T  cells, which recognise antigen 
using molecules other than MHC class I or II (La Rosa and Orange, 2008). Memory T  
cells can be either C D 4+ or CD8+, and facilitate a rapid proliferation of T  cells in 
response to previously encountered antigens (Sprent and Suhr, 2001). Effector T  cells 
cover diverse functions, as discussed below.
Effector T  cell populations include helper, regulatory, and cytotoxic T  cells. Helper T  
cells (Th) are of the C D 4+ subset, secrete cytokines involved in T  cell and B cell 
proliferation, and attract and activate other immune cells, such as macrophages. C D 4+ 
T  cells can also differentiate into regulatory, or suppressor, T  cells, which are vital in 
maintaining immunological tolerance as they suppress auto-reactive T  cells, and shut 
down T  cell responses (La Rosa and Orange, 2008). Cytotoxic T  cells (CTLs), mainly 
of the C D 8+ subset, are implicated in direct killing of resident target cells via secretion 
of perforin and granzymes (Trapani et a/., 2000).
CTLs are rarely found in the normal CNS, but during inflammation and microbial 
infection, their numbers can increase dramatically, and stimulation of brain cells may 
result in antigen presentation to T  cells via expression of M HC molecules (Pedemonte 
et at., 2006). CTLs surround, and accumulate in, CNS lesions during many neurological 
diseases, such as multiple sclerosis (MS) and virus-induced inflammatory brain 
diseases, and are known to be important in autoimmune CNS diseases.
In addition to categorising T  cells according to the presence of either CD4 or CD8  
surface molecules, C D 4+ T  cells can be further subdivided according to the profiles of 
the cytokines they secrete. Cytokines are secreted proteins, critical in most immune 
responses, acting in either pro-inflammatory or anti-inflammatory ways. C D 4+ T  cells, 
termed ThO cells when in an undifferentiated state, are considered to produce the 
majority of cytokines, once activated (Berger, 2000). Activated ThO cells can become
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either Th1 o rT h 2  cells, depending on the local environment, with interleukin (IL)-12 
stimulating Th1 activity, and IL-4 promoting Th2 differentiation (Berger, 2000). Recently, 
a third subset of CD4 T  cells, namely Th17 cells, has also been identified (Korn et al.,
2007).
Pro-inflammatory cytokines, such as interferon (IFN)-y, IL-2, and tumour necrosis factor 
(TNF), arise from Th1 cells, and are responsible for destruction of intracellular 
parasites and perpetuation of autoimmune responses, such as in MS (Frossi et al.,
2008). Th1 cells increase the production of immunoglobulin (Ig) G antibodies and 
encourage cell-mediated immunity (Berger, 2000). Th2 cells produce anti-inflammatory 
IL-10, and IL-6, and cytokines associated with allergic responses and promotion of IgE, 
such as IL-4, IL-5, and IL-13 (Frossi et al., 2008). Th2 cells are involved in defense 
against extracellular pathogens. Th1 and Th2 cytokines are antagonistic in action, and 
the correct Th1:Th2 balance is critical in maintaining appropriate immune responses, 
thereby limiting tissue damage caused by pro-inflammatory Th1 responses, or allergic 
responses created by an excessive Th2 response (Berger, 2000). Th17 effector T  cells 
produce the cytokine IL-17 and are implicated in defense against some pathogens, 
tissue inflammation, and organ-specific autoimmunity (Korn et al., 2007).
T  cells can engage in immune surveillance of the CNS, albeit to a lesser extent than in 
other organs under basal conditions, and contribute to inflammatory and immune 
responses (Xiao and Link, 1998). In addition to evidence that activated T  cells can 
migrate from the blood into the CNS, using a sheep model, it has been shown that T  
cells do not need to be activated to enter the CSF (Seabrook et al., 1998). Suggestions 
about the pathways taken by T  cells when entering the CNS include infusion into the 
CSF, and exiting along major cranial nerves or arteries, meaning they would enter 
deep cervical lymph nodes and be able to engage in an immune response if the 
appropriate antigen was present, or rejoin the circulating lymphocyte pool (Seabrook et 
al., 1998). In healthy individuals, the number of T  cells entering the CNS is low (Hickey, 
1999), but the efficiency with which they gain access varies according to area. T  cells 
enter the spinal cord with greater efficiency than when accessing the brain (Phillips and 
Lampson, 1999), probably because recruitment mechanisms differ (Engelhardt and 
Ransohoff, 2005). Studies have indicated that the migratory phenotype of T  cells 
necessary to cross the BBB is induced by several signals, including interleukin-2 (IL-2) 
(Pryce et al., 1997).. It is thought that T  cells enter the CNS in a random fashion, as no 
receptors have yet been identified that serve to target specific leukocytes to the CNS  
(Hickey, 1999).
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In patients with inflammatory disorders of the CNS, T  cells are one of the most 
common cell types found in affected areas and in the C SF (Pedemonte et al., 2006). It 
has been suggested that the CSF experiences an enrichment of Th1 T  cells capable of 
differentiation into effector cells upon discovery of antigen, and that these cells are 
recruited by chemotactic cytokines called chemokines (Giunti et al., 2003).
1.1.2 B cells
B cells are important in the humoral immune response, particularly in responding to 
microbial infections. They are produced in the bone marrow, circulate in the blood and 
lymph, and undergo differentiation after encountering an antigen, and signals from T  
helper cells. Activated B cells can become long-lived memory cells, specific to 
previously encountered antigens, or plasma cells, which produce antibodies 
(immunoglobulins: IgA, D, E, G, and M). Antibodies can bind antigens, preparing the 
product for phagocytosis by macrophages, for example, and they can also activate the 
complement system (Briere et al., 2001).
W hen inflammation is not present in the CNS, B cells are mainly absent, but 
inflammatory CNS diseases are associated with significant numbers of them in the 
CNS and CSF (Cepok e t a i ,  2006). During CNS inflammation, immunoglobulins 
produced within the subarachnoid space, namely oligoclonal bands (OCB), are often 
detected and demonstrate that B cells have a role in the immune response (Thompson 
and Keir, 1990). B cells may also have antibody-independent roles in CNS immune 
responses, as they can function as antigen-presenting cells (APC) (Antel and Bar-Or, 
2006).
The role of B cells in routine CNS surveillance is poorly understood. One study 
indicated that B cells can target their antigen in the CNS and produce oligoclonal IgG 
against it, suggesting memory B cells can be receptive to antigens as they drain from 
the CNS to deep cervical lymph nodes (Knopf et al., 1998). Given the short life span of 
antibody-secreting cells, and the limited ability of antibodies to cross the BBB, it is most 
likely that the B cells involved in CNS immune surveillance are of the memory subset. 
Memory B cells have been found to accumulate in the CSF during CNS inflammation, 
particularly the subset with an IgD'/IgM'phenotype (Cepok et al., 2006). Several 
findings indicate that, unexpectedly, B cells might undergo rapid division in the CNS  
akin to a germinal centre reaction, as short-lived plasma blasts (immature precursors of 
plasma cells) are found in the inflamed CSF (Cepok et al., 2006), together with all B 
cell subsets (Corcione et al., 2005).
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1.1.3 Mononuclear phagocytes
Monocytes are produced in the bone marrow, circulate in the bloodstream, and can 
move into tissues, where they mature into macrophages. In the CNS, these 
macrophages occur as microglia. Monocytes/macrophages and microglia are likely to 
play a substantial role in the immune surveillance of the CNS, as aside from their 
phagocytic activity, they are involved in antigen presentation and control of T  cell 
responses (Aloisi et al., 2000), as discussed in Section 1.1.4.1 below. The phagocytic 
ability of these cells is mediated by opsonins, such as IgG, or complement, on the 
target antigen. Mononuclear phagocytes may also alter the ability of T  cells to 
penetrate the CNS parenchyma via their upregulation of inducible nitric oxide synthase 
(iNOS), leading to increased nitric oxide (NO) expression, as well as increased 
production of T N F  (Tran et al., 1998). These mediators act on endothelial cells (ECs), 
causing an upregulation of adhesion molecules and contribute to the compromised 
state of the BBB seen in MS. Activated macrophages secrete IFN-y and IL-3, in 
addition to TNF, all of which interfere with myelination by damaging oligodendrocytes 
(OLGs) (Merrill et al., 1993).
1.1.4 Glial cells
Glial cells represent the non-neuronal, supportive cells of the CNS, including macroglia 
(astrocytes and OLGs), and microglia. Collectively, glial cells support neurons in a 
number of ways, including OLGs providing insulation of neurons with myelin, and 
astrocytes providing nutrition, maintenance of homeostasis, and participation in signal 
transmission. They produce many molecules involved in inflammatory and immune 
functions, such as cytokines and proteases (Von Bernhardi and Ramirez, 2001).
1.1.4.1 Microglia
During both development and adulthood, bone marrow derived myeloid cells enter the 
CNS and become perivascular macrophages, or more rarely in adults, microglia 
(Simard and Rivest, 2004) (Fig. 1.2). Microglia represent approximately 5 - 20%  of 
resident glial cells, and are the major immunocompetent cells in the brain, capable of 
presenting antigen (Farber and Kettenmann, 2005). The exact precursor subtype 
responsible for microglia is unknown, but microglial cells are reportedly similar to 
uncommitted myeloid precursors, with the capacity to differentiate into dendritic-like 
cells (Servet-Delprat et al., 2002). Following antigenic stimulation, for example, 
microglia become activated, adopt an amoeboid morphology, migrate to sites of injury, 
proliferate, and engage in phagocytosis (Imai et al., 1997). Microglia possess highly 
motile and long, interdigitating processes which form a network that covers the entire
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CNS, strongly suggesting a role for resting microglia in immune surveillance (Neumann 
and Takahashi, 2007).
An innate immune receptor expressed on cell membranes, namely Triggering Receptor 
Expressed on Myeloid cells - 2 (TREM 2), is expressed on microglia (Kiialainen et al., 
2005). The TR EM 2 receptor associates with the adaptor protein and signalling 
molecule DnaX-Activating Protein of 12 kDa (DAP12), thereby enabling TREM 2  
stimulation to initiate signalling via DAP12. DAP12 triggers a protein tyrosine kinase 
called extracellular signal-regulated kinase (ERK), which is involved in an intracellular 
signal transduction pathway (Takahashi et al., 2005). TR EM 2 signalling has been 
found to be essential for phagocytosis of apoptotic cellular membranes (Neumann and 
Takahashi, 2007). Without this TREM 2-D A P12 receptor-signalling complex, CNS  
tissue homeostasis would be disturbed by delayed debris clearance and increased 
production of inflammatory cytokines by microglial cells.
In addition to phagocytosis, microglia can respond to threats to the CNS by releasing 
cytotoxic and inflammatory modulators (e.g. cytokines such as IL-1(3, and complement 
proteins) and cell killing via release of NO and superoxide ions (Von Bernhardi and 
Ramirez, 2001). Aside from this pro-inflammatory role, evidence is accumulating that 
microglia might have neuroprotective properties, through stimulation of myelin repair, 
eradication of toxins in the CNS, and prevention of neurodegeneration in chronic brain 
diseases (G lezer et al., 2007). There is evidence that microglia may function co­
operatively with astrocytes in generating responses to brain injury, exhibiting reciprocal 
regulation (Martin et al., 1994).
1.1.4.2 Astrocytes
Astrocytes are the most abundant glial cell, and are highly diverse, exhibiting varied 
reactive responses to pathogenic brain insults. In the healthy CNS, they remove 
excess ions (particularly potassium) from the external environment of neurons, recycle 
neurotransmitters, are involved in uptake of glucose and glutamate, and glycogen 
storage (Fatemi et al., 2004), and are considered to be a major component of the BBB 
(Fig. 1.2) (Kramer-Hammerle et al., 2005).
Astrocytes signal to each other using calcium: the messenger molecule inositol 
triphosphate (IP3) diffuses from one astrocyte to another via gap junctions, activating 
calcium channels on organelles, and resulting in calcium release into the cytoplasm, 
which may prompt production of more IP3 and culminate in a calcium wave  
propagating from cell to cell (Bellinger, 2005).
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Figure 1.2 Complex cellular interactions at the blood-brain barrier
A brain capillary wall is shown, with the major cell types capable of signalling to each 
other. Pericytes form a close association with the endothelial cells due to their 
enclosure within the basal lamina. Astrocytic end feet contact the outer surface of the 
basal lamina. Microglia share the perivascular space with synaptic terminals, neurons, 
and, in arterioles, smooth muscle cells. Endothelial cells are influenced by ligand- 
receptor interactions arising on both their blood or brain surfaces. Some of these 
interactions lead to increases in intracellular calcium. Following receptor activation of 
endothelial cells, the arrows indicate their ability to release substances to either the 
blood or brain side (Abbott et al., 2006).
They respond to the firing of adjacent neurons by exhibiting rapid electrical activity, and 
are receptive to neurotransmitters such as norepinephrine and glutamate (Murphy et al., 
1993). Astrocytes can release glutamate, thereby signalling back to neurons 
(Carmignoto, 2000). Calcium signalling from astrocytes can contribute to neuronal 
plasticity and learning by influencing synaptogenesis and synaptic transmission 
(Ostrow and Sachs, 2005).
Activated astrocytes contribute to CNS diseases by the production of proinflammatory 
cytokines, proteases, adhesion molecules, such as intercellular adhesion molecule 
(ICAM)1 and ICAM2, chemokines, and NO (Von Bernhardi and Ramirez, 2001). Unlike 
microglia, astrocytes cannot generate large amounts of free radicals, but they do have 
some phagocytic ability. Astrocytes produce cytokines that are able to act on microglia, 
such as colony-stimulating factors, which can stimulate microglial migration after injury. 
The interaction between astrocytes and microglia is complex, but it is thought that 
microglial-derived products are neurotoxic, while astrocytes tend to play a 
neuroprotective role by producing neurotrophic factors and eliminating neurotoxins 
(Von Bernhardi and Ramirez, 2001). Astrocytes respond to CNS trauma by becoming 
hypertrophic and proliferating. This astrocytosis, however, can restrict repair in MS by 
hindering migration of remyelinating cells (Malik et al., 1998).
1.1.4.3 Oligodendrocytes
OLGs are glial cells that produce and maintain the ‘myelin sheath’ that surrounds 
axons, providing insulation to facilitate salutatory conduction. The sheath can be of a 
simple cytoplasmic type, or composed of multiple myelin lamellae. In addition to this 
vital role of myelin production, OLGs can also contribute to the growth and 
maintenance of axons within white matter (Edgar et al., 2004).
OLGs that produce myelin have been categorised as types I -  IV according to their 
morphology and axonal interactions. Type I OLGs are found around blood vessels, 
neurons, and fibre tracts, in the forebrain, cerebellum, and spinal cord. Type II OLGs 
are seen in white matter, near to nerve fibres. Type III OLGs are found in the medulla 
oblongata, spinal cord, and cerebral and cerebellar peduncles. Type IV OLGs adhere 
to nerve fibres at the entrance of nerve roots (Baumann and Pham-Dinh, 2001). W hen  
OLGs approach axons to begin myelination, the OLG exhibits an undifferentiated 
structure, and it is not known if the microenvironment or genetic programming 
determines the subtype the OLG will become. The maturation of OLGs is characterised 
by stages of expression of myelin-related genes and cell surface markers, such as
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myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligidendrocyte 
glycoprotein (M O G ) (W ebber et al., 2007).
Microglia can directly interact with OLGs, damaging them, and contributing directly to 
the demyelination of axons and other tissue injury (Irani, 2005). Different mechanisms 
of myelin destruction have been suggested in MS, with either the OLG, or the myelin 
sheath being the target (Kornek and Lassmann, 2003). Antibodies against various 
myelin proteins have been found in MS patients, such as anti-MOG antibodies, 
although their exact role is unclear (Reindl et al., 1999). Remyelination is potentially a 
powerful neuroprotective therapy to ameliorate disability in MS. Cytokines of the IL-6 
superfamily can promote OLG survival - a significant finding given that astrocytes and 
microglia are the predominant source of IL-6 cytokines in the inflamed CNS (Ransohoff 
et al., 2002).
1.1.5 Endothelial cells (ECs)
Brain ECs comprise the main component of the BBB (Fig. 1.2) and contribute to the 
immune response of the CNS by responding to, transporting, and secreting cytokines 
(Verma et al., 2006). ECs are unique in possessing differing compositions of their cell 
membranes according to the environment they face, with lipid, receptor, and 
transporter components differing between the face in contact with the blood, and the 
membrane facing the brain. This polarisation is thought to help with the functions of the 
BBB, namely preventing harmful substances from entering the brain, and controlling 
the passage of substances to and from the brain. ECs comprising the BBB differ from 
those elsewhere in the body due to their absence of fenestrations, reduced pinocytic 
vesicular transport, and more extensive tight junctions between them, which limit the 
flux of hydrophilic molecules between cells (Ballabh et al., 2004).
Tight junctions consist of three membrane proteins (claudin, occludin, and junction 
adhesion molecules), and also cytoplasmic accessory proteins, including zonula 
occludens (ZO) -1, -2, and -3 (Ballabh et al., 2004). Occludins and claudins collectively 
form intramembranous strands which contain channels that allow diffusion of ions and 
hydrophilic substances (Matter and Baida, 2003). Junctional adhesion molecules are 
little explored, but are thought to play roles in adhesion between cells, and monocyte 
transmigration through the BBB (Aurrand-Lions e t a i ,  2001). In MS, leukocyte 
migration into the brain can trigger signalling cascades that result in the loss of occludin 
and ZO  proteins from tight junctions, thereby contributing to BBB breakdown (Bolton et 
al., 1998).
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Brain ECs can receive immune challenges from one side (e.g. the blood), and respond 
by secretion of cytokine into the other (i.e. brain) (Fig. 1.2). Brain EC secretion of 
cytokines IL-1 a, IL-10, granulocyte macrophage colony-stimulating factor (GM -CSF), 
IL-6, and TN F  has been demonstrated, with a preference for secretion into the blood, 
rather than the brain (Verma et al., 2006). Lipopolysaccharide (LPS) induces release of 
specific cytokines from brain ECs, and is known to disrupt the barrier function of the 
BBB (Singh and Jiang, 2004). W hen brain ECs are exposed to TNF, IL-1 (3, IFN-y, or 
LPS, the transendothelial electrical resistance is decreased due to increased 
permeability of the tight junctions, thus reducing the ability of the BBB to impair the 
passage of peripheral blood mononuclear cells (PBMCs) into the CNS (Wong et al., 
2004). Brain ECs are important in the immune response of the CNS, as they constitute 
a major component of the BBB that can secrete cytokines in an inducible, varied, and 
polarised fashion.
1.1.6 The blood brain barrier
Ehrlich’s seminal observation that injecting dyes into peripheral blood vessels resulted 
in poor staining of the brain, compared to other organs, sparked further experiments 
that led to an increasing elucidation of the specialised structure of the BBB. The BBB 
was linked to the state of immune privilege by Barker and Billingham, who described 
how the scarcity of transport vesicles in brain ECs, and the occluding junctions 
between their plasma membranes, together with neuroglial end processes (Fig. 1.3), 
could significantly restrict immune cell infiltration. The barrier function of the BBB is well 
established, but routine transport across the BBB is possible, however (reviewed in 
Bechmann et al., 2007). Lipophilic substances (e.g. oxygen and carbon dioxide) diffuse 
freely along concentration gradients; smaller molecules, such as glucose and amino 
acids, utilise transporters to cross the BBB; and receptor-mediated endocytosis is 
employed for larger molecules (e.g. insulin and leptin) (Ballabh et al., 2004).
All brain regions possess a BBB, except for circumventricular organs (Fig. 1.1), such as 
the pineal gland. These areas are important sites for communicating with the CSF, and 
have blood vessels with fenestrations that allow diffusion of blood-borne molecules, 
thus helping to regulate the autonomic nervous system and endocrine glands (Ballabh 
et al., 2004). The BBB is not simply composed of ECs, as it includes the capillary 
basement membrane (BM), astrocytic end-feet enrobing the vessel walls, and pericytes 
within the BM (Fig. 1.2), that wrap around ECs. The astrocytic end-feet enhance the 
barrier properties of ECs by inducing and maintaining a tight junction diffusion barrier 
(Ballabh et al., 2004). Pericytes are thought to be involved in angiogenesis, vessel 
structural integrity, and the formation of tight junctions (Allt and Lawrenson, 2001).
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Figure 1.3 Location of the three main barrier sites in the CNS
The CNS presents 3 main barriers to penetration by cells or substances. The first is 
mainly created by brain ECs, which form the BBB (1). The basement membrane (BM) 
of the blood vessel, pericytes within the BM, and astrocytic end feet also contribute to 
the composition o f the BBB. Circumventricular organs contain specialised 
neurosecretory or chemosensitive neurons and are the only brain region to lack a BBB. 
Their leaky endothelium is separated from other brain regions by a glial barrier and  
from the C SF by an ependymal barrier (Ballabh et al., 2004). The second barrier is the 
arachnoid epithelium (2), which comprises the middle layer o f the meninges. The outer 
layer o f the meninges is composed of the dura mater, and the pia m ater constitutes the 
inner layer. The epithelium of the choroid plexus (3), which is responsible for CSF  
secretion, forms the third physical barrier. All 3 barriers utilise tight junctions to reduce 
the permeability o f the intercellular pathway (Abbott et al., 2006).
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The barrier created by tight junctions between ECs is tightest in the capillary 
endothelium (Ge et al., 2005), so leukocytes tend to traverse the endothelium at 
postcapillary venules (Bechmann et al., 2007). The vessel wall in pre- and post­
capillary zones of the BBB is separated from the neuropil by an additional compartment, 
or perivascular space, created by protrusions from the pia mater of the brain surface. 
This compartment, termed the Virchow-Robin space, is partially filled with CSF via its 
connections with the subarachnoid space. Cells crossing the vessel in this region do 
not directly enter the neuropil, but are instead often retained in this perivascular space. 
Accumulation of inflammatory cells in the Virchow-Robin space is one of the hallmarks 
of MS, and some other neuroimmune diseases, creating characteristic ‘perivascular 
cuffs’. The Virchow-Robin space may be responsible for initiating and sustaining an 
immune response to foreign antigens in the brain, as macrophages found there 
express M HC class II, and are well positioned to interact with lymphocytes from the 
blood (Vos et al., 2005). As neuroinflammation proceeds, cells may then pass the glia 
limitans, which underlies the pia mater, in a considerably more restricted step than the 
process of passing from the blood into the perivascular space. For cells to pass the glia 
limitans, APCs must present antigen in the perivascular space (Greter et al., 2005).
The glia limitans serves as both a mechanical and functional barrier. Astrocytic end feet 
of the glia limitans constitutively express the death ligand CD95L, which may account 
for perivascular apoptosis, designed to prevent activated T  cells from stimulating 
immune responses (Bechmann et al., 1999).
1.2 Multiple sclerosis
MS was first identified by Jean-Martin Charcot in 1868, and was considered a rarity by 
American physicians for the next 50 years. Many cases were misdiagnosed, but 
increased training of neurologists, and ensuing improvements in diagnosis, saw MS 
rated as one of the most prevalent neurological diseases (Talley, 2005). MS is 
commonly described as a disease of the CNS white matter, involving immune-driven 
inflammation and demyelination, culminating in sclerotic plaques and axonal damage  
(Bar-Or et al., 1999). It is a complex disease, often resulting in severe disability for the 
individual, whilst presenting a significant economic burden to society. The estimated 
lifetime costs incurred by health care and social systems in the UK are £1 million per 
MS patient (Altmann and Boyton, 2004; Orton et al., 2006). Whilst treatments for the 
symptoms of MS have improved substantially, as has diagnosis, utilising magnetic 
resonance imaging (MRI), a cure remains elusive.
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1.2.1 Symptoms of MS
Symptoms of MS are many and varied within and between patients, depending on 
which areas of the CNS are damaged, to what extent, and on how the disease 
progresses. Physiological symptoms are related to the CNS, and the musculoskeletal 
and autonomic nervous sytems. Commonly, fatigue, spasticity, muscle weakness, pain, 
depression, cognitive dysfunction, deterioration of speech, visual disturbance, bladder 
and bowel disturbances, and sexual dysfunction, are experienced (Crayton and 
Rossman, 2001; Huijbregts et al., 2006), The fatigue experienced by MS patients can 
result from either the disease, or as a side effect of treatment, is often worsened by 
heat, and can exacerbate the morbidity of MS by limiting the patient’s reserves to deal 
with accompanying symptoms (Bakshi, 2003).
1.2.2 Diagnosis of MS
MS is often misdiagnosed as other conditions can mimic it, such as the demyelinating 
inflammatory disease, neuromyelitis optica (Charil eta l., 2006). MRI has emerged as 
playing a prominent role in the diagnosis of MS, but this is combined with information 
from the clinical history and physical examination of the patient by a neurologist, 
together with laboratory tests for the presence of OCB in the CSF and increased IgG, 
to establish as firm a diagnosis as is possible. MRI criteria for diagnosing MS has 
changed frequently over the last two decades. Currently, disease dissemination must 
be shown in ‘space and time’, whereby evidence of multiple lesions detected at least 
six months apart, and occurrence of at least two distinct attacks, is required (Charil et 
al., 2006).
1.2.3 Clinical subtypes of MS
MS can be divided into different clinical subtypes based on the clinical course of the 
disease. Approximately 90%  of patients exhibit relapsing-remitting MS (RRM S) initially, 
with acute attacks involving worsening of neurological function (relapses), alternating 
with periods of full or partial recovery (remissions) (Fig. 1.4) (Schwarz et al., 2006). A  
minority (30% ) remain with this disease course, but 60%  of RRMS patients find as the 
disease progresses, recovery from attacks is incomplete, leaving permanent axonal 
damage, and eventually the disease course is often described as secondary 
progressive MS (SPM S). SPM S is characterised by the frequency of relapses levelling 
off, and steady deterioration occurring, without remission (Fig. 1.4) (Compston, 2004; 
Guttmann et al., 2006). Approximately 10% of patients present with what is described 
as primary progressive MS (PPM S) in onset, which typically involves a progressive 
decline without distinct relapses or remissions (Fig. 1.4) (Schlaeger et al., 2006; Al-
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Araji and Mohammed, 2005; Lublin and Reingold, 1996). The rarest disease course is 
progressive relapsing MS (PRM S), where progressive disability occurs from the onset, 
with clear relapses, with or without recovery (Fig. 1.4) (Podojil and Miller, 2006).
1.2.4 Epidemiology
MS accounts for the majority of neurological disability of young adults in the Western 
World, affecting approximately 1.1 -  2.5 million people worldwide, with a prevalence of 
1/1000 in the UK (Compston, 1998). MS is generally considered to be increasing, as 
seen in Canada (Orton et al., 2006), Australia (Barnett et al., 2003), and the USA  
(Noonan et al., 2002), for example. W omen are approximately twice as likely to suffer 
from MS as men (Reipert, 2004). This sex ratio can vary regionally, however, 
exceeding 3.2 females to every male in Canada, for example (Orton et al., 2006). The 
onset of this complex disease often occurs between the ages of 20-40 years, with over 
90%  of patients experiencing onset before 50 years of age (Noseworthy et al., 1983). 
Childhood-onset MS is rare, with only 3-10%  of patients developing MS before the age 
of 18 years (Banwell et al., 2007).
In general, there is an increasing prevalence of MS in climates more distant from the 
equator, where it is almost zero (Fig. 1.5) (Sharpe, 1986). Migrant studies suggest 
moving from high-risk to low-risk areas generally decreases the chance of MS 
developing, particularly if the migrant is under 15 years of age, strengthening the theory 
that environmental factors are most important before or around adolescence (Marrie,
2004). Substantial evidence supports a geographical link, including the study of over 
5000 World W ar II veterans, which also suggested racial and environmental factors are 
involved (Kurtzke et al., 1979). This higher prevalence of MS with increasing latitude 
has been linked to levels of exposure to ultraviolet-B (UVB) radiation in early life and 
associated vitamin D production (Fig. 1.5) (Grant, 2006). A latitudinal gradient has also 
been proposed in the British Isles, as the Orkney and Shetland Islands have a very 
high prevalence of MS of 309 and 184 per 100,000, respectively, whereas the 
southerly Channel Islands have a much lower prevalence, of 113 and 87 per 100,000, 
in the Bailiwicks of Jersey and Guernsey, respectively (Sharpe et al., 1995). A gradient 
has also been observed within Ireland, with a prevalence of 185 per 100,000 in County 
Donegal in the north, and 121 per 100,000 in County Wexford in the south (McGuigan 
et al., 2004). Regional differences can also be attributed to factors other than latitude, 
however, as variations in genetic predisposition and diagnostic accuracy may play 
significant roles. Interestingly, seasonal variations of the onset of MS have been 
identified, with fewer outbreaks being observed in winter months, suggesting wintertime 
radiation is associated with greater protection (Abella-Corral et al., 2005).
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Figure 1.4 Clinical disease courses of multiple sclerosis
Four disease courses of MS have been identified, according to their characteristics and 
progression over time. Relapsing remitting MS (RRMS) involves periodic attacks 
followed by full recoveries, and is the most common disease course at onset. Many 
patients progress from RRMS to secondary progressive MS (SPMS), where fewer 
attacks are experienced, with incomplete recovery. Primary progressive MS (PPMS) 
involves a progressive accumulation of disability with no clear relapses or remissions. 
The rarest disease course is progressive relapsing MS (PRMS), characterised by 
progression from onset, with distinct relapses, with or without full recovery (Podojil and 
Miller, 2006).
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Figure 1.5 Geographical variation in prevalence of multiple sclerosis per 100,000 
population
The prevalence of MS increases with increasing distance from the equator. Tropical 
areas, such as Asia and South America, tend to have lower levels (shown in green) of 
<30 per 100,000, but temperate areas, including northern Europe, northern USA, and 
Canada, experience a high prevalence of >80 per 100,000 (shown in red). Intermediate 
levels of MS of 30-80 per 100,000 (shown in orange) are found in southern Europe and 
the southern USA, for example (Marrie, 2004)
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Evidence exists that the symptoms of MS, as well as the risk, are reduced by 
experiencing higher levels of UVB, and hence, vitamin D (Embry et al., 2000). This 
protective effect of vitamin D was confirmed in a large longitudinal study of over 90,000  
women in the USA which showed that taking vitamin D supplements reduced the life­
time risk of MS by 40%  (Chaudhuri, 2005). The exact role vitamin D plays is unknown, 
but it has been suggested that differentiation of oligodendrocytes (OLGs), and their 
adhesion to axons, is dependent on sufficient vitamin D during development 
(Chaudhuri, 2005). Vitamin D can reduce inflammatory cytokine production by 
controlling gene expression, so a deficiency could contribute to the inflammation 
observed in MS (Mark and Carson, 2006). Higher levels of vitamin D from dietary 
intake, as found in fish and dairy products, are also associated with a reduced risk of 
MS (Munger et al., 2004). In addition, lower levels of vitamin D were found in MS 
patients during relapses, compared to in remission (Soilu-Hanninen et al., 2005).
Clusters of the disease within countries exist, particularly on islands, such as in 
Sardinia (Sotgiu et al., 2004). Worldwide epidemiological clusters of MS have also 
been found, for example those which mirror the distribution of the tick-borne bacterial 
pathogen Borrelia burgdorferi, responsible for Lyme disease. Lyme disease can also 
lead to CNS demyelination (Batinac et al., 2007), and it has been postulated that MS 
might be prevented or cured by the use of antibiotics against this microorganism, but 
this is yet to be investigated (Fritzsche, 2005).
1.2.5 Aetiology
The aetiology of MS remains obscure, but is believed to involve exposure to unknown 
environmental factors in those with a genetic susceptibility (Ristic et al., 2005). The  
genetic element is thought to result from variants of alleles in several genes, which 
increase susceptibility in some people, but not others, depending on post- 
transcriptional regulation and external influences (Baranzini and Oksenberg, 2005). 
Genes coding for human leukocyte antigen (HLA) class I antigens were first associated 
with MS in 1972, with HLA class II, T-cell receptor |3, CTLA4, ICAM1, and SH2D2A  
genes being amongst those that are also thought to contribute (Dyment et al., 2004). 
The major histocompatibility complex (MHC) region of chromosome 6, and 
chromosomes 17p11, 3q21-24, 18p11, and 17q22-24 have been identified as potential 
areas linked to MS. An association between MS and type-l diabetes has also been 
postulated, based on HLA genetic susceptibility factors (Sotgiu et al., 2004). It is clear, 
however, that factors other than genetics are involved in the risk of developing MS, as 
studies of monozygotic twins have shown a concordance of approximately only 30% , 
and dizygotic twins display approximately 5%  concordance (Sadovnick et al., 1993).
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Environmental factors implicated in MS aetiology are many and varied. One study has 
found immigrants from low risk areas coming to the UK do not adopt the high risk seen 
here (Dean et al., 1976). Other studies have shown people migrating from high risk 
areas to low risk ones achieve an intermediate risk (Visscher et al., 1977). In the UK, 
children of immigrants are born with a similar risk to those from non-immigrant parents, 
demonstrating that environmental factors can act rapidly (Elian et al., 1990).
Other bacterial infections in addition to Borrelia burgodorferi have been implicated in 
MS aetiology. The common respiratory pathogen Chlamydia pneumoniae is known to 
infect ECs, which is thought to assist in the migration of monocytes into the CNS  
(Stratton and Wheldon, 2006). C.pneumoniae is associated with CNS infections, and 
is also commonly detected in white blood cells. Once cells carrying this bacteria have 
entered the CNS, they are capable of infecting microglia, astrocytes, and neuronal cells 
(Ikejima et al., 2006). The incidence of C.pneumoniae infection in 155 MS patients, 70 
patients with other neurological diseases, and 499 healthy controls, was examined in 
an attempt to clarify the prevalence of this pathogen in MS patients. Chlamydia 
infection was found to be more frequent in MS patients than healthy controls, adding 
further weight to the suggestion that the pathology of some MS cases may be an 
infectious syndrome triggered or fuelled by such a pathogen (Parratt et al., 2007).
Viral infections have been linked with either the aetiology or progression of MS, 
including Epstein-Barr virus (EBV), human herpes virus 6 (HHV-6), and multiple 
sclerosis-associated retrovirus (M SRV) (Sotgiu et al., 2004). Epitopes of viral 
pathogens exhibiting similar conformations to myelin antigens may invoke an anti-viral 
immune response that can also result in T  and B cells mounting an anti-myelin 
response in MS; a process known as molecular mimicry (Batinac et al., 2007). No one 
specific pathogen has been pinpointed as being the molecular mimic in MS, and it is 
possible that infection with several pathogens is responsible. Furthermore, the diversity 
of the disease phenotype may be explained by variability in the mechanism of 
molecular mimicry, i.e. whether HLA class 1 or 2 restricted T-cells, and antibodies, are 
involved. Induction of MS by molecular mimicry alone is questionable, and it has been 
suggested that it serves only to prime the immune system via exposure to a molecular 
mimic of a CNS self-antigen, which is later followed by a non-specific immunological 
challenge (Libbey et al., 2007).
1.2.6 Pathology
In MS, multiple sharply demarcated lesions, or plaques, of variable size are found 
randomly distributed within the CNS, predominantly in the white matter, but grey matter
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can also be involved. Although the distribution of lesions is random, they are 
particularly common in areas such as the optic nerve, spinal cord, brainstem and 
periventricular regions, and they are associated with post-capillary venules and larger 
veins (Akenami et al. 2000). Blood vessels from the edge of large lesions can have 
lesional projections extending along them, termed ‘Dawson’s fingers’. New plaques 
exhibit ongoing inflammation and lipid breakdown as myelin is destroyed, with early 
acute plaques containing mainly lymphocytes. Chronic, older plaques reveal 
established gliosis, and fewer inflammatory cells such as lymphocytes and 
macrophages, but greater numbers of plasma cells than acute lesions (Hickey, 1999).
At the microscopic level, plaques reveal activation of ECs, infiltration of macrophages 
and lymphocytes, myelin swelling, and a reduction in OLGs. T  cells and macrophages * 
are common, whilst plasma cells are not. Chronic active plaques reveal foamy 
macrophages digesting myelin, and lymphocytes both in perivascular areas and at the 
advancing edge of myelin loss. Axonal damage can be seen, but typically, axons are 
preserved in chronic active plaques. Astrocytes in the demyelinated area are reactive. 
Active demyelination of the frontal white matter is thought to be associated with the 
fatigue experienced in MS (Lassmann, 1998). Chronic-inactive plaques are thought of 
as glial scars, where reactive astrocytes demonstrate extensive gliosis, OLGs are 
severely reduced or absent, myelin loss is clearly marked, and a few macrophages and 
lymphocytes are seen. Axon loss may be dramatic in older plaques, and is often the 
cause of persistent neurological disability in MS (Claudio et al., 1995). Bo and 
colleagues (1994) examined actively demyelinating lesions and reported high levels of 
MHC class II on microglia and macrophages, but none on astrocytes and ECs. Zeinstra 
et al. (2003), however, reported that astrocytes in active lesions of MS post-mortem  
brain tissue expressed both MHC class II (induced by IFN-y) and the B7 co-stimulatory 
molecules necessary for astrocytes to function as APCs. Cells associated with lesions 
show changes in size and shape, suggestive of transformation from microglia into 
phagocytic macrophages that may be involved in demyelination.
Lesions contain not only evidence of injury (involving axonal damage, myelin loss, and 
apoptotic OLGs), and the presence of immune cells, but molecular components can 
also be seen, such as Igs, proinflammatory cytokines, chemokines, and adhesion 
molecules (Hickey, 1999). It is important to consider that the pathology of MS is 
heterogeneous, with significant variations between patients. This is demonstrated by 
the occurrence of contrasting events, such as either destruction or proliferation of 
OLGs (Baranzini and Oksenberg 2005).
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1.2.7 Pathogenesis of MS
The pathogenesis of MS is best summarised as damage to axons and destruction of 
myelin, caused by inflammatory events. Myelin forms a sheath that coats axons, 
protecting them, and facilitating efficient saltatory conduction of nerve impulses. Axonal 
loss originates from failure of the myelin-producing OLGs to remyelinate (Compston,
2004). It is well debated as to what initiates the inflammatory reaction that leads to 
lesion formation, and a full understanding of the pathogenesis still presents a challenge.
There is substantial evidence for an autoimmune pathogenesis. The structure of myelin 
is in part maintained by MBP, and it is residues 84-102 and 143-168 of MBP that are 
targets of the T  cell response in MS (Ota et al., 1990). High levels of flexibility of T  cell 
receptors (TCRs) on autoreactive cells may assist T  cell sensitisation to myelin 
antigens in the peripheral blood due to molecular mimicry (Fig. 1.6, inset). Myelin- 
reactive C D 4+ T  cells are considered critical in triggering autoimmune responses in MS 
and it has been demonstrated that they have lower activation thresholds, independent 
of co-stimulation, which may lead to breakdown of self-tolerance and the resultant 
autoimmune response (Bielekova et al., 2000). Myelin-reactive T  cells are present in 
healthy individuals as well as in MS patients, indicating it is the high frequency of 
activated autoreactive T  cells that is significant (Markovic-Plese et al. 2004). CD4+ T  
cells are considered pivotal in initiating inflammation, but neuropathological findings 
suggest changes in OLGs may also be important in initiation of MS - a 
'neurodegenerative' hypothesis (Prat and Antel, 2005). Recent evidence derived from 
MRI suggests that normal-appearing white matter is also altered in the MS brain, in that 
MBP suffers a loss of positive charge, rendering it more susceptible to proteolytic 
attack (Mastronardi and Moscarello, 2005).
It is generally accepted that activated peripheral blood lymphocytes are chemoattracted 
to the BBB, where upregulation of adhesion molecules on ECs leads to increased 
binding to their ligands on PBMCs (Prat and Antel, 2005). Interactions of adhesion 
molecules with PBMCs slow their passage along the blood vessel and facilitate the 
rolling and adhesion process required for transmigration across ECs. In MS, the BBB 
is disrupted by proteases, which allows excessive infiltration into the brain parenchyma 
of T  cells, B cells, and macrophages (Fig. 1.6). These immune cells thereby form the 
perivascular cuffs detected histologically in MS lesions (Markovic-Plese et al. 2004). 
Myelin-reactive T  cells are reactivated by neural antigens presented by M HC class II 
molecules on ECs and microglia, and autoantibody production, demyelination and 
axonal damage result from the myriad of changes that ensue (Fig. 1.6). Astrocytes are 
also capable of processing autoantigens and may be involved in antigen presentation
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and activation of C D 4+ T  cells (Soos et al., 1998). Many cellular functions contribute to 
this pathology, with cytokines, adhesion molecules, chemokines, proteases, 
complement, NO, and glutamate, all playing a part (Fig. 1.6) (Prat and Antel, 2005).
The persistent and recurrent nature of MS may indicate that an expanded immune 
response has been raised following distribution of neural antigens to lymph nodes, or 
due to contributions from endogenous cells, such as microglia and astrocytes.
1.2.7.1 Breakdown of the BBB
A key process in the pathogenesis of MS lesions is recruitment of peripheral blood 
mononuclear cells (PBMCs) across the BBB. Breakdown of the BBB is an initial step in 
the development of inflammatory demyelinating lesions. This can be demonstrated by 
the use of gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA), which acts as 
an MRI contrast agent, revealing BBB dysfunction (Kraus and Oschmann, 2006). The  
mechanism of BBB breakdown in MS is not fully known, but is thought to involve both 
direct inflammatory events and indirect non-inflammatory effects. Soluble mediators, 
such as the cytokines IFN-y, TNF, and IL-1(3 (Minagar et al., 2004), metalloproteinases 
(Cossins e ta l., 1997), NO (Hill et al., 2004), and mast-cell-derived histamine (Kruger, 
2001), all act as inflammatory mediators in the breakdown of the BBB. In addition, 
alterations in the microenvironment of the brain ECs, such as loss, or functional 
alterations, of glial cells, may contribute indirectly to BBB breakdown (Lassmann, 1991).
1.2.7.2 Cell migration into the CNS
Leukocyte infiltration occurs in several disorders of the CNS, including intracerebral 
haemorrhage (Gong et al., 2000), hyperglycemia following transient ischaemia (Lin et 
al., 2000) and autoimmune diseases such as MS (Wong et al., 2007). The exact 
mechanisms involved in cell migration across the BBB have not been fully described, 
but it is known that endothelial adhesion molecules play a key role (Wong et al., 2007). 
Movement of cells through the vascular endothelium is preceded by leukocyte tethering, 
rolling, activation, and firm adhesion. Extravasation follows adhesion, although 
adherence can occur without migration (Greenwood et al., 2002).
An increase in the permeability of the BBB is an early and pivotal event in the 
development of CNS inflammatory diseases. Inflammatory cytokines, such as TNF, are 
thought to contribute to the decreased integrity of the BBB by changing the distribution 
of junctional proteins (Wong et al., 2004). Without cytokine stimulation of ECs, very few  
PBMCs are thought to adhere, and the basal expression of cerebral EC adhesion 
molecules is low (Wong and Dorovini-Zis, 1996). The physical process of migration of 
inflammatory cells may also increase the permeability of tight junctions.
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Figure 1.6 Schematic of cellular events occurring in the pathogenesis of multiple 
sclerosis
Initiation is thought to involve CD4+ T cells becoming activated in the peripheral blood 
by peptides which possibly mimic the epitopes of CNS antigens (see inset). 
Chemoattraction, mediated by chemokines and chemokine receptor interactions, draws 
the activated cells to the CNS. The increased expression of adhesion molecules and 
proteases on the T cells leads to their adhesion to, and passage through, the basal 
lamina of capillaries of the BBB. Once in the brain parenchyma, microglial cells present 
CNS antigens which activate these T cells further, triggering an inflammatory response 
involving production of cytokines, chemokines, NO, glutamate, and free radicals. 
Positive feedback loops maintain the response, which eventually causes damage to 
myelin, OLGs, and neurons.
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For a cell to migrate across the BBB, it must first adhere to the endothelium. PBMCs 
adhere by extending pseudopodia to the EC surface. Once attached, they arrange 
themselves so that they are at a contact point between two ECs, where they become 
flattened and extravasate between them (Wong et al., 2007). Adhesion is possible due 
to the expression by ECs of the adhesion molecules E-selectin, intercellular adhesion 
molecule-1 (ICAM -1), and vascular cell adhesion molecule-1 (VCAM -1), which interact 
with ligands on PBMCs, namely carbohydrate epitopes, leukocyte function antigen-1 
(LFA-1), and very late antigen-4 (VLA-4), respectively (Wong et al., 2007). Lymphocyte 
adhesion to brain ECs utilises VCAM-1 and ICAM-1, and is regulated by chemokines 
(Quandt and Dorovini-Zis, 2004). Following adhesion, the migration of T  cells also 
involves interactions between ICAM-1 and lymphocyte function-associated antigen-1 
(LFA-1) (Laschinger et al., 2002).
1.2.7.3 Inflammation
Once immune cells are in the CNS, antigen presentation is required for the initiation 
and perpetuation the inflammatory response. Under inflammatory conditions, MHC  
class II and co-stimulatory molecules (CD80 and CD86), are upregulated on microglia 
and macrophages, rendering them capable of presenting antigen (Markovic-Plese and 
McFarland, 2001). Astrocytes are also capable of stimulating memory T  cells by 
presenting antigen in a manner independent of co-stimulation (Cornet et al., 2000).
The exact pathogenic mechanisms are not completely clear, and whether inflammation 
is the foremost event in MS pathology, or not, remains a source of debate. Some 
researchers have suggested that levels of tissue degeneration and neuronal injury are 
independent of the number of actively demyelinating lesions, resulting instead from 
diffuse inflammation throughout the brain, which is accentuated in lesions (Lassmann, 
2003).
There is evidence from MRI studies that extensive axonal dam age is present in the 
early stages of MS, and that relapse severity and the subsequent disability do not 
always correlate with the inflammatory activity of lesions (Filippi et al., 2003). Lesions 
without C D 4+ T  cells or leaked plasma proteins have been found in normal-appearing 
tissue obtained from early MS cases, suggesting that they occurred prior to disruption 
of the BBB. These ‘pre-demyelinating’ lesions have depleted numbers of OLGs and 
may indicate a pathology involving the presence of an antigen derived from CSF, which 
is toxic for OLGs and axons, such as a bacterial toxin (Gay, 2006).
The type of inflammation seen in MS may vary depending on the stage of disease. It is
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thought that adaptive immune responses are more important in the relapsing-remitting 
stage, and innate immunity is more prominent in the progressive stage (Vaknin- 
Dembinsky and W einer, 2007).
1.2.7.4 Humoral immune response in MS
The humoral immune response was identified as a major contributor to the 
pathogenesis of MS when research by Kabat et al., approximately 60 years ago, 
revealed raised levels of Igs in the CSF of over 90%  of patients (reviewed in Reindl et 
al., 2006). OCB can be detected when intrathecal synthesis of IgM is present, and the 
correlation of this, with disease relapse activity, in MS has proved useful for monitoring 
purposes. Production of OCB may result from either B cell stimuli leading to increased 
IgG in the CSF, or from autoantigen immune complexes being triggered by an 
infectious agent (Sharief and Thompson, 1991).
B cells are important in MS on two counts, and probably play an active role throughout 
the disease process. Firstly, autoreactive B cells produce autoantibodies (with plasma 
cells doing this constantly), replicate memory B cells, and secrete cytokines. Secondly, 
they activate autoreactive T  cells by acting as APCs (Nikbin et al., 2007). Ectopic 
lymphoid structures containing proliferating B cells and plasma cells have been found 
in the meninges of some patients with SPMS, indicating B cell differentiation can occur 
in the CNS (Serafini et al., 2004). Cytokines and chemokines most probably drive this 
homing and proliferation of B cells in secondary lymphoid organs (Corcione et al.,
2005). The CSF of MS patients has been found to contain large numbers of B cells with 
a memory phenotype, compared to peripheral blood, which may contribute to MS 
pathogenesis, once they have matured into antibody-secreting cells (Cepok et al., 
2001).
The complement system comprises nearly 40 soluble proteins and receptors that 
function as regulators and effectors, with a role in the innate immune system in 
protecting the host against pathogens (Fujita et al., 2004). In adaptive immune 
responses, complement is associated with regulation of B and T  cells, such as cell 
activation, signalling and differentiation (Carroll, 2004). The complement system is 
thought to play both pro-inflammatory and neuroprotective roles in MS pathogenesis 
(Rus et al., 2006). Complement acts via a cascade that is initiated by either the 
classical, alternative, or lectin pathways, depending on what factors activate it. The  
classical and alternative pathways are important in MS, as they are mainly activated by 
antigen-antibody complexes, and LPS, respectively (Barnum and Szalai, 2006). 
Activation of all pathways leads to the generation of C3 and C5 convertases. C3 and
27
C5 cleavage generate the anaphylatoxins C3a and C5a, with C5a having chemotactic 
properties. C3a and C5a contribute to CNS inflammation by attracting and activating 
leukocytes. C5b initiates assembly of the C5b-9 membrane attack complex (MAC), 
which forms pores and lyses cells, and is implicated in demyelination (Ramm et al., 
1985). Lysis of OLGs and neurons by the MAC is thought to be responsible for 
complement-mediated demyelination (Barnum and Szalai, 2006). Myelin prepared from 
CNS tissue has been shown to activate C1 and is vulnerable to attack from C5b-9  
(Vanguri and Shin, 1986).
Complement can be neuroprotective, as C5a can protect against glutamate-induced 
neurotoxicity (Osaka e t a i ,  1999), and C3a can protect against neuronal cell death 
normally induced by the excitotoxin N-methyl-D-aspartic acid (NMDA) (van Beek et al.,
2001). C3a and C5a have also been shown to induce nerve growth factor (NGF) 
mRNA expression in astrocytes, suggesting a role for them in neuronal survival 
(Jauneau et al., 2006).
1.3 Chemokines
Chemokines derive their name from cftemoattractant cytokines, and are low molecular 
weight proteins (8-14 kDa), with chemotactic properties that attract immune cells to 
sites of inflammation, such as is seen in MS pathogenesis. They were highly conserved 
during evolution, and are present in many vertebrates, assisting in directing immune 
responses when the host is threatened by pathogens. An increasing number of 
chemokine functions are emerging, such as having roles in immune surveillance, 
angiogenesis, apoptosis, cell adhesion, haematopoiesis, and growth regulation (Cartier 
et al., 2005). Chemokines act by binding to cell surface G protein-coupled receptors 
(GPCRs) expressed on many immune cell types. The N-terminus of chemokines is 
paramount in this receptor binding and in their activation (Forssmann et al., 2004).
Their activity is tightly controlled by many factors, including receptor expression and 
chemokine processing. Situations can arise, however, where chemokines aid the 
destruction of healthy cells, such as neurons in MS, for example. Chemokines are 
implicated in the pathogenesis of various diseases, such as asthma and AIDS, and 
along with their receptors, have sparked the interest of pharmaceutical companies as 
therapeutic targets (Ribeiro and Horuk, 2005).
1.3.1 Classification and structure of chemokines
In excess of forty chemokines have been identified, which have been characterised into 
four groups according to the position of the conserved cysteine residues, i.e. CXC (a),
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CC ((3), C (y), and CX3C (5 ), with X  representing an adjacent amino acid (Fig. 1 .7 (i)). 
Chemokines from each subfamily contain four conserved cysteines, except for the C 
family, which only have two (equivalent to the second and fourth cysteines of the other 
groups). The CXC and CC families are the most common, whilst there are only two C 
chemokines, and one CX3C chemokine (fractalkine) (Thorpe, 2003).
Chemokine nomenclature was confusing, as several systems were used and many 
were named according to function, with frequent overlap. They are now named 
according to the structural subfamily they belong to, followed by “L” for ligand, and then 
a number that designates the encoding gene - CCL2, for example, previously known as 
monocyte chemoattractant protein-1 (M CP-1) (Fig. 1.8) (Proudfoot 2002).
A subdivision of CXC chemokines also exists, namely the ELR-CXC chemokines, 
which possess an amino acid motif of glutamic acid-leucine-arginine (ELR) at the N- 
terminus. CXCL1 and CXCL8 are examples of ELR chemokines, which are generally 
strong neutrophil attractants. Non-ELR chemokines, such as CXCL10 and CXCL12, 
predominantly attract lymphocytes. CC chemokines (e.g. CCL5) predominantly attract 
monocytes, basophils, eosinophils, and T-cells. The C chemokine, XCL1, is a 
chemoattractant for T-cells and NK cells (Hedrick et al., 1997). CX3CL1, also known as 
fractalkine, attracts monocytes and T-cells, and is unique amongst chemokines by 
being present in both membrane-bound and soluble forms (Bazan et al., 1997).
Observed three-dimensionally, chemokines exhibit the first two cysteines near the N- 
terminus, followed by an area known as the N-loop, three anti-parallel (3-strands which 
are interspersed with turns called 30s, 40s, and 50s loops, and then the C-terminal a- 
helix. The third and fourth cysteines (if present) are found in the 30s and 50s loops 
(Fernandez and Lolis, 2002). The a-helix lies across the (3 sheet and is involved in the 
biological activity of chemokines (Fig. 1.7(H)) (Clore et al., 1990).
Classification according to function characterises chemokines as either inflammatory or 
homeostatic. Inflammatory chemokines are expressed in response to pathogenic 
stimulation or proinflammatory cytokines, and serve to recruit monocytes, granulocytes, 
and T  cells to inflammatory sites. Homeostatic chemokines are generally expressed 
constitutively within secondary lymphoid organs and are involved in immune 
surveillance by cells of the adaptive immune system (Cartier et al., 2005).
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Figure 1.7 Structure of chemokines
(i) Chemokines are grouped according to their structure, dependent on the 
arrangement of the first two cysteine (shown as ‘C ’) residues, intervening amino acids 
are represented with an X ’. The four groups (C, CC, CXC, and CX3C) all contain 
disulphide bonds important to their tertiary structure, which typically join the first to third, 
and the second to fourth cysteine residues. CCL2 is an example o f a CC chemokine, 
with two adjacent cysteines near the N-terminus.
(ii) 3-D  schematic of the CXC chemokine CXCL10, demonstrating characteristic 
features of the chemokine family. The N-terminus connects to three strands o f the (5- 
sheet (in blue), stabilised by two pairs o f conserved cysteines (9:36 and 11:53), the 30s  
and 40s loops, and the C-terminal or-helix (in yellow). The corresponding amino acid 
sequence is colour-coded to indicate secondary structure elements related to the 
schematic (Fernandez and Lolis, 2002).
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(i) The four chemokine classes
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Image source: http://en.wikipedia.org/w/index.php?title=Chemotaxis&oldid=196092071
(ii) Three-dimensional structure of CXCL10
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Adapted from (Swaminathan et al., 2003), © (2003), with permission from Elsevier.
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1.3.2 Chemokine receptors
Chemokines bind to GPCRs, which belong to the extensive family of seven- 
transmembrane domain receptors that transmit intracellular signals via heterotrimeric 
guanosine triphosphate (GTP)-binding proteins. Once a chemokine has bound to its 
receptor, the G protein heterotrimer dissociates into the a and {3y subunits, and several 
cascades of intracellular events occur. Effects of these signalling pathways include 
mobilisation of intracellular calcium, activation of chemotaxis and other functions in 
leukocytes, such as degranulation, phagocytosis and an increase in the respiratory 
burst (Cartier et al., 2005).
Chemokine receptors have been named according to the chemokine class that 
activates them, followed by “R” for receptor, and then a number assigned according to 
their chronological identification -  C X C R 1, for example. The majority of the 19 
receptors characterised so far belong to the CC family (Fig. 1.8) (Proudfoot 2002).
Each chemokine receptor family shows approximately 50%  sequence homology 
amongst their members. Structural similarities exist for all chemokine receptors, such 
as the polypeptide chain being approximately 350 amino acids long, with a relatively 
short and acidic N-terminal domain containing cysteine residues, and an intracellular C- 
terminal domain containing serine and threonine residues that are phosphorylated on 
receptor activation. Redundancy exists in the chemokine receptor system, in that 
chemokines can activate more than one receptor, and receptors can respond to 
several different chemokines (Fig. 1.8). Homeostatic chemokines tend to be more 
specific in their interactions, e.g. CXCL12 binds exclusively to CXC R 4 (Cartier et al.,
2005).
Chemokine receptor expression is controlled by basal levels of transcription, and can 
be increased by calcium levels, cyclic AMP, cytokines such as IL-2, IL-4, IL-7, IL-10, 
transforming growth factor-1 (3 (TGF-(31) (Jourdan et al., 2000), and growth factors such 
as basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) 
(Salcedo et al., 1999), and epidermal growth factor (Phillips et al., 2005). Conversely, 
inflammatory cytokines, such as TNF, IFN-y, and IL-1 p, can reduce chemokine 
receptor transcription (Gupta et al., 1998). CCR2 expression by monocytes is rapidly 
inhibited by IFN-y, rendering the cells less responsive to chemokines, and perhaps 
serving to retain monocytes at inflammatory sites and engage in feedback in regulating 
cell recruitment from blood (Penton-Rol et al., 1998). Inflammatory cytokines can first 
induce chemokine expression, and later on, suppress chemokine receptor expression, 
which would help to end an acute inflammatory response, such as during wound 
healing (Devalaraja and Richmond, 1999).
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Figure 1.8 Chemokine receptors and their ligands
Chemokines are categorised according to the spacing o f the N-terminal cysteine 
residues. Receptors for the CXC subclass are shown in blue; the CC subclass in red; 
and minor subclasses C and CX3C in green, all paired to their chemokine ligands. The 
common names for chemokines derive from their function, or from the cell type that 
produced them, but have been replaced with a simpler, systematic system. Note 
receptors can have multiple ligands, and chemokines can bind to several receptors.
Abbreviations: BCA-1, B-cell-attracting chemokine 1; CTACK, cutaneous T-cell- 
attracting chemokine; ELC, Epstein-Barr-virus-induced gene 1 ligand chemokine; 
ENA78, epithelial-cell-derived neutrophil-activating peptide 78; GCP-2, granulocyte 
chemotactic protein 2; Gro, growth-regulated oncogene; IL-8, interleukin 8; IP-10, 
interferon-inducible protein 10; l-TAC, interferon-inducible T-cell a-chemoattractant; 
MCP, monocyte chemoattractant protein; MDC, macrophage-derived chemokine; MEC, 
mucosae-associated epithelial chemokine; MIG, monokine induced by interferon-y; MIP, 
macrophage inflammatory protein; NAP-2, neutrophil-activating peptide 2; RANTES, 
regulated on activation, normal T-cell expressed and secreted; SDF-1, stromal-cell- 
derived factor 1; SLC, secondary lymphoid-tissue chemokine; TARC, thymus and  
activation-regulated chemokine; TECK, thymus-expressed chemokine.
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Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology
(Proudfoot, 2002), © (2002)
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1.3.3 Chemokine -  chemokine receptor interaction
Amino acid residues of chemokines interact with the N-terminal residues of receptors. It 
is thought that this results in a conformational change of the receptor that exposes a 
binding pocket and allows interactions of this with specific chemokine amino acids. 
Proteases released during inflammatory responses can alter chemokine activity by 
cleaving residues important in this interaction (Huang et al., 2003).
Many chemokines form dimers. The organisation of dimers varies according to the 
structural class of chemokine. Dimers of CC chemokines tend to be elongated and 
involve the N-termini but no contact of the C-termini, whereas CXC dimers are compact 
and have critical interactions of the C-termini of the monomeric subunits. The ability to 
form dimers has been shown to be vital for the activity of some chemokines in vivo, but 
not in vitro (Proudfoot et al., 2003).
Chemokines can also interact with glycosaminoglycans (GAGs), such as heparin 
sulphate. This may facilitate gradient formation in vivo, by immobilising chemokines, 
and it may also induce oligomerisation of chemokines (Hoogewerf et al., 1997). High 
concentrations of chemokine also promote oligomerisation, which may then encourage 
receptor oligomerisation and enhanced function (Fernandez and Lolis, 2002). Dimers 
are likely to be involved in binding cell surface sugars, thereby facilitating chemokine 
localisation prior to receptor binding (Proudfoot et al., 2003).
1.3.4 Chemokine signalling
Once a chemokine has bound to its cell surface receptor, cytoskeletal rearrangements 
can occur, along with regulation of adhesion (dependent on integrin), and binding or 
detachment of cells via extensions and retractions of pseudopodia. This enables co­
ordinated, directional migration (Curnock et al., 2002). The precise mechanics of a 
cell’s response to a chemotactic gradient is yet to be clarified, but most chemokines 
activate G-protein sensitive phospholipase C (PLC) isoforms, which generates IP3 and 
results in elevated intracellular calcium. Chemotaxis has been observed without 
detection of calcium mobilisation, suggesting other mechanisms can be employed 
(Turner et al., 1995). In addition to calcium influx, kinase activation is also associated 
with chemokine receptor engagement (Davis et al., 2003). Chemokines can activate 
multiple signalling pathways that regulate cell growth and transcriptional activation, in 
addition to migration. This is achieved by chemokine inhibition or activation of various 
signalling molecules, such as inhibition of adenylate cyclase, activation of 
mitogen/extracellular signal-regulated kinase (MEK)-1 and/or extracellular signal-
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regulated kinase (ERK)-1/2, upregulation of nuclear factor-kappa B (NF-kB), and signal 
transducer and activator of transcription (STAT)1 and STAT3 transcriptional activity 
(Curnock et al., 2002).
GPCRs are known to form homo- and heterodimers (e.g. C XCR4 with CCR2 and CD4) 
although the functional consequences of this have not been fully elucidated (Angers et 
al., 2002). It has been suggested that homodimerisation might be necessary in G- 
protein independent activation of JAK/STAT, for example, and heterodimerisation could 
facilitate additional receptor regulation. Receptors may homodimerise when prompted 
by their ligands, or in their absence, and enhance the receptor response to the ligand 
(Busillo and Benovic, 2007). Specialised microdomains of the plasma membrane called 
lipid rafts, enriched in sphingolipids and cholesterol, have also been implicated in 
enhancing the response of some receptors to chemokines (Wysoczynski et al., 2005).
Chemokine receptor desensitisation via continued chemokine stimulation is well 
documented, and leukocytes exposed to chemokines rapidly become unresponsive to 
repeated stimulation (Baggiolini et al., 1994). Desensitisation is linked to 
phosphorylation of serine residues in the C-terminal region of the receptor, and is a 
process which could regulate migration along a chemotactic gradient (Giannini et al., 
1995). G PC R  signalling can also be regulated via internalisation of the receptor 
(following phosphorylation induced by ligand activation), recycling of the G PC R  back to 
the plasma membrane, and degradation via lysosomes (Marchese et al., 2003).
1.3.5 Chemokines and receptor expression in normal CNS and diseased states
Constitutive chemokine expression in the CNS principally involves CX3CL1 by neurons 
and CXCL12 by astrocytes, but evidence is mounting that many others are upregulated 
in various diseased states. Several chemokine receptors have also been detected in 
the CNS by immunohistochemistry, including CCR1 through to CCR6, all members of 
the CXCR family,, and CX3CR1. Most of these receptors were detected in diseased 
CNS tissue, but CCR2, CCR3, CCR5, CXCR2, CXCR3, and C XCR4 have been 
reported as constitutively expressed in healthy human adult brain (Cartier et al. 2005).
It is thought that chemokines and their receptors are expressed in healthy CNS tissue 
to influence the migration of neurons and their progenitors, to contribute to glial cell 
proliferation during development, and to modulate synaptic activity. During neurological 
diseases, such as MS and Alzheimer’s disease, the presence of these chemokines and 
their receptors becomes closely linked with the pathogenesis.
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Chemokine receptors are not only expressed by leukocytes, but also by microglia, 
astrocytes, oligodendrocytes, and neurons in the CNS, and there is increasing 
evidence that they are involved in neuronal death (Cartier et al., 2005).
1.3.6 Chemokines in MS
In MS, chemokines are key targets for further investigation, as they contribute to 
inflammation and destruction by attracting T  cells and macrophages to the CNS, and 
may be involved in communication between inflammatory cells and neurons (Cartier et 
al., 2005). Chemokines also act to increase expression of adhesion molecules and 
activate recruited and resident cells of the CNS (Haringman et al., 2004). Studies using 
detection by immunohistochemistry have revealed elevated levels of CCL2, CCL8, and 
CCL7 in acute and chronic MS lesions compared to no immunoreactivity in normal 
controls (Me Manus et al., 1998; Van Der Voorn et al., 1999). These chemokines were 
detected on astrocytes and inflammatory cells, linked to areas where inflammation was 
evident, indicating a role in the pathogenesis of MS. In post-mortem brain tissue,
CCL2, CCL3, CCL4, and CCL5 have been detected in actively demyelinating 
inflammatory plaques (Simpson et al., 1998). Elevated chemokine levels tended to be 
linked with specific cells, with CCL2 associated with astrocytes and macrophages.
Chemokines need to engage with their receptors for chemotaxis to occur. Chemokine 
receptors C C R 1, CCR2, CCR3, and CCR5 have been detected on macrophages and 
microglia within chronic active lesions containing the corresponding chemokine ligands 
(Fig. 1.8) (Simpson et al., 2000a). Detection of CCR2 is of particular interest to this 
study, given it is the receptor for CCL2. Similarly, T  cells and astrocytes within lesions 
express CXCR3, the receptor for CXCL10 (Cartier et al., 2005).
In addition to these four receptors, CCR8 has been found on activated microglia and 
phagocytic macrophages in actively demyelinating lesions (Trebst et al., 2003). A  
further discovery involved detection of the receptor CXC R 3 on T  cells and astrocytes 
within active lesions, together with its ligands CXCL10 and CXCL9, located on 
macrophages in the plaque, and astrocytes in the parenchyma (Simpson et al., 2000b). 
Expression of chemokines and their receptors on cells in the CSF of MS patients has 
also been scrutinised, as there is growing evidence that increased CSF chemokine and 
receptor levels are associated with neurological dysfunction and relapses (Bartosik- 
Psujek and Stelmasiak, 2005). CXCL9, CXCL10, and CCL5 have been found to be 
consistently elevated in the CSF of MS patients, together with an increase in T  cells in 
the CSF, bearing the corresponding receptors C XCR3 and CCR5 (Teleshova et al.,
2002). The CSF from MS patients suffering an acute relapse was analysed, and 
increased levels of CCL3 were found, along with decreased CCL2 levels (Miyagishi et
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al., 1995). Decreased levels of CCL2 in the CSF of relapsing MS patients was also 
found in a different study, along with a rise in CXCL8 and CCL5 (Bartosik-Psujek and 
Stelmasiak, 2005). It has been suggested that this decrease in CCL2 observed in CSF  
occurs because large numbers of migrating cells are consuming CCL2 during lesion 
formation (Mahad et al., 2006). It is also possible that CCL2 is being sequestered by 
astrocytes and microglia due to receptor internalisation, resulting in high levels in 
lesions, but with limited secretion destined for the CSF. Increased CXCL10 (correlating 
with C XCR3 expression on CSF C D 4+ cells) and decreased CCL2 concentrations in 
the CSF have been associated with relapses (Mahad et al., 2002). Studies on post­
mortem brain tissue, however, show a population of astrocytes and microglia in MS 
lesions with significantly increased expression of CCL2 (Van Der Voorn et al. 1999; 
Simpson et al., 2000a). A  study using blood and CSF from MS patients found little 
evidence that CCL2 and CCR2 were of much significance in the early active form of the 
disease (Sorensen et al., 2004).
1.3.6.1 Chemokines in EAE
Studies on chemokine expression pertinent to MS have also used the animal model, 
experimental autoimmune encephalomyelitis (EAE). EAE is a CD 4+ T  cell-mediated, 
inflammatory demyelinating condition, induced by immunisation with PLP, MBP, or 
MOG, or by transfer of CNS antigen-specific autoreactive T  cells (Kuerten and Angelov, 
2008). In EAE: CCL3 production has been found to correlate with increasing disease 
severity; CCL2 was observed late, in acute disease, correlated with relapses and anti- 
CCL2 treatment during relapsing EAE reduced CNS macrophage accumulation; and 
CCL5 was observed throughout, with seemingly little importance to the disease course 
(Kennedy et al., 1998). CCL2 and CCR2 (-/-) knockout mice are resistant to EAE and 
show significantly reduced CNS mononuclear infiltration (Mahad and Ransohoff, 2003). 
Levels of CXCL10 have been linked to relapses in mice with EAE (Fife et al., 2001).
1.4 Matrix metalloproteinases (MMPs)
Matrix metalloproteinases (MMPs), or matrixins, comprise a growing family of 
endopeptidases that contain zinc and are capable of degrading extracellular matrix 
(ECM ) components such as collagens, proteoglycans, elastin, laminin, and fibronectin 
(Table 1.1). Many other M M P substrates have been identified, such as proteinases and 
their inhibitors, growth factors, cell surface receptors, adhesion molecules, clotting 
factors, and chemokines (Szabo et al., 2004). MM Ps are synthesised as 
preproenzymes and predominantly secreted from cells as proenzymes, which are
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activated in the extracellular compartment, by MMPs, or proteases of the serine family, 
such as plasmin. Proteolytic activity involving hydrolysis of the internal bonds of their 
protein substrates can then begin, if a neutral pH and calcium ions are available. These  
enzymes play important roles in both normal physiological processes and in 
pathological events (Gingras et al., 2000).
1.4.1 Classification of MMPs
In excess of 25 MMPs have been described to date (Table 1.1), which originate from 
different genes but show significant homology due to their domain structure (Fig. 1.9). 
Certain domains characterise the substrate affinities that categorises MMPs into 
subgroups. The four main groups of MMPs based on substrate specificity are 
gelatinases, collagenases, stromelysins, and membrane-type (MT) (Table 1.1). Most 
MMPs are secreted, apart from MT-MMPs, which are anchored to the membrane via 
their unique C-terminal sequence (Liu and Rosenberg, 2005).
1.4.2 Structure of MMPs
Differences or similarities in the structure of MMPs facilitate additional classification, as 
members of each group have distinguishing conserved domains. The propeptide and 
N-terminal catalytic domains are shared by many MMPs, and it is the C-terminus 
haemopexin-like domains, fibronectin-like repeats, and transmembrane domains that 
correspond to the four main substrate-specific groups (Yong et al., 1998). A pre­
domain effectively labels the MMP for secretion and is absent in the latent enzyme 
form. Inactive M M Ps possess a pro-domain, or N-terminal domain (Borkakoti, 1998). 
The “metallo” in their name derives from the two zinc ions in their core domain, one of 
which contributes to the catalytic activity of the enzyme. The zinc-binding site is a 
conserved sequence of the catalytic domain (Baramova and Foidart, 1995). At the C- 
terminus of all MMPs except matrilysin, a haemopexin domain is found, which is a 
haem-binding peptide involved in substrate specificity. Gelatinases have an additional 
domain, namely the fibronectin domain, responsible for collagen-binding (Fig. 1.9) 
(Matrisian, 1992).
1.4.3 Activation of MMPs
MMPs can be activated in a number of ways, such as by organomercurial compounds, 
but endogenous activation must be tightly controlled given their potential for protein 
destruction (Leppert et al., 2001).
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Table 1.1 Matrix metalloproteinase (MMP) nomenclature & substrates
Group Number Trivial name Main physiological substrates
Collanenases
Gelatinases
Stromelysins
Membrane- 
type MMPs
Matxilvsins
Other MMPs
M M P-l Interstitial /fibroblast collagenase Interstitial (=fibrillat) collagens.
MMP-S Neutrophil collagenase/ collagenase-2 (Types I, H, II I, V I  X )
M M P-13 Coltagenase-3
M M P-lS e Collagenase-4 ?
MMP-2 72 kDa-gelatinase/gelatinase A Basement membrane (=non-fibrillar)
MMP-9 92 kDa-gelatinase/gelatinase B Collagens (types IV. V ) FN1‘
MMP-3 Strcmelysin-1/transin FN, LN, various collagens
MMP-10 Strcmelysin-2 /  transia-2 Other MMPs (?)
M M P -l 1 Stromelysin-3 a-l-Protease inhibitor
M M P-14 MT1-M MP Pro-MMP-2
M M P-15 MT2-MMP Pro-MMP-2
M M P-16 MT3-MMP Pro-MMP-2
M M P-17 MT4-M MP Pro-MMP-2
MMP-24 MT5-M MP Pro-MMP-2
MMP-25 MT6-MMP, leukolysin ?
MMP-7 Matrilysiu /pump FN, LN, vitronectin
MMP-26 Matrilysin-2 Collagen IV. FN, FG, pro-MMP-9
M M P-12 Metalloelastase/macrophage elastase Elastin
M M P-19 (Initially called MM P-IS [S]) Collagen IV  LN, NG, TC, FN
MMP-20 Enamelysin Amelogenin
MMP-2 3 J Femalysin 9
MMP-27 - Collagen I, gelatin, casein
MMP-2S Epilysin Casein
Reprinted from (Leppert et al. 2001) © (2001), with permission from Elsevier.
M M Ps have descriptive names that often refer to their substrates, as well as an M M P  
number. Those nam ed MMP-4, -5, and -6  were eliminated once it was discovered they 
were already described. Substrate preference and domain content have been used to 
categorise M M Ps into groups such as gelatinases, stromelysins, collagenases, and  
membrane-type (M T)-M M Ps.
NB: M M P18 is found in Xenopus and not humans; M M P 23 is identical to the obsolete 
MM P21 and M M P22
Abbreviations: FN, fibronectin; LN, laminin; FG, fibrinogen; NG, nidogen; TC, tenascin C
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The catalytic domain of MMPs contains an active site with a zinc ion bound to three 
conserved histidines. The N-terminal propeptide sequence has a cysteine residue that 
chelates the zinc ion in the catalytic site, thereby keeping the enzyme in its latent 
proform (Fig. 1.9). Intermediate activation of MMPs is achieved by conformational 
changes that disrupt the cysteine-zinc binding, exposing the catalytic site. Full 
activation requires ensuing autocatalytic cleavage of the propeptide from the core 
protein, a process known as the cysteine switch, which results in a decrease in mass of 
the enzyme. Once activated, MMPs can act synergistically by activating other MMPs 
(Fu et al., 2001).
Stimulating a coculture of astrocytes and microglia with LPS has been shown to 
produce active M M P-2 and -9 (Liu and Rosenberg, 2005), which are dependent on 
interactions with the plasmin/plasminogen system, with plasmin being involved in the 
activation of proMMP-9 (Lijnen et al., 1998). The activation mechanism of M M P-2 is 
more complicated than for MMP-9, as M T-M M P and the endogenous M MP inhibitor, 
tissue inhibitor of metalloproteinase-2 (TIMP2), form a trimolecular complex with 
proMMP-2, producing the active form close to the cell surface (Sato et al., 1996). This 
M T-M M P/M M P-2/T IM P2 complex is often used by cancer cells during metastasis and 
is also important in ischaemic injury (Liu and Rosenberg, 2005).
1.4.4 Function and expression of MMPs
MMPs facilitate cell migration and tissue remodelling by degradation of the ECM during 
both normal and pathological processes. Tissue alterations during menstruation, 
morphogenesis, growth, and wound repair are some examples of the many processes 
that involve MMPs (Page-M cCaw  et al., 2007). In the CNS, MMPs facilitate beneficial 
activities such as angiogenesis, myelinogenesis, axonal growth, and migration of 
neuronal precursors (Yong et al., 2001). The function of MMPs is controlled by 
regulation of their gene expression and translation, inhibition by TIM Ps, and secretion 
of them as inactive forms that require activation (Opdenakker et al., 2001).
MMPs can be expressed constitutively at a certain level in most cell types, but the 
majority are induced and tissue-specific (Agapova et al., 2001). ECs, leukocytes, 
tumour cells, astrocytes, and trophoblasts are all examples of cells that express M M P2  
constitutively, and M M P9 is found in large amounts in neutrophils (Rooprai and 
McCormick, 1997). All types of brain cells produce MMPs, with each cell type having 
an MMP profile associated with it. MMPs can either be secreted into the ECM or 
expressed as a plasma membrane bound form. MM Ps are not stored for future use, 
with their secretion being stimulated when needed by multiple factors (Nagase, 1997).
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Figure 1.9 Structure of MMPs
(i) All MM Ps share three domain structures in common: a pre-domain which assists in 
extracellular secretion; a pro-domain which preserves the M M P in an inactive state and 
must be removed for activation; and a catalytic domain containing the proteolytically 
active zinc ion chelated by three histidine residues. Most M M Ps have a haemopexin 
domain, involved in substrate and inhibitor binding. Other possible domains include the: 
furin domain which provides an alternative cleavage site for activation; fibronectin and 
type V collagen (col V) domains involved in substrate recognition; transmembrane 
domain, which provides a region for transmembrane localisation.
(ii) The crystal structure o f recombinant M M P2 (a) is shown alongside a hypothetical 3- 
D model of intact M M P9 (b). The 3 fibronectin repeats are shown in blue and the Zn2+ 
ions as white spheres. M M P9 has several glycosylation sites, and a collagen V-like 
spacer, lacked by M MP2. M M P9 is the most complex M M P identified to date.
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(i) Schematic of domain structure
Hinge
Pre Pro Catalytic Haemopexin
Furin Col V T  ransmembrane
Fibronectin
Reprinted from (Leppert et al. 2001) © (2001), with permission from Elsevier.
(ii) 3-D structures o f (a) M M P2 and (b) M M P9
a: MMP2 b: MMP9
Active domain 
~ Z r?* -binding dom ain
v Cottagen ViiKe domain
Hemcpaxiri domain
Fibronectin repeats
Prodomain
Reprinted from (Opdenakker ef al., 2001) © (2001), with permission from Elsevier.
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Proinflammatory cytokines, such as IL-1(3 and TNF, can modulate the expression and 
regulation of MMPs. Conversely, MMPs can function as sheddases or convertases by 
transforming membrane-bound cytokines, cytokine receptors, and adhesion molecules 
to soluble forms (Leppert et al., 2001). M M P production can be stimulated by 
oncogenes, LPS, and growth factors, such as epidermal growth factor. Prostaglandin 
E2 has been shown to both inhibit and enhance transcription of MMPs, depending on 
the cell type and inflammatory state (Ruwanpura et al., 2004). Free radicals are known 
to activate and interact with MMPs. Direct effects of free radicals include oxidation or 
nitrosylation of MMPs, thereby activating them. Indirectly, transcription factors integral 
to the M M P transcription process, such as NF-kB, can be affected by free radicals (Gu 
et al., 2002).
1.4.5 Inhibition of MMPs by TIMPs
Tight regulation of MMPs to prevent excessive proteolytic activity is greatly assisted by 
endogenous proteins known as TIMPs. TIM Ps comprise four members (TIMPs 1-4) 
which form complexes with pro- and activated MMPs, blocking their activity. The four 
TIM Ps have similar structures, but their tissue distribution and regulation are varied and 
they have other complex functions aside from inhibiting MMPs. TIMP1 complexes with 
M M P9 and inhibits apoptosis (Guedez et al., 1998). T IM P2 assists in the activation of 
M M P2 by M T-M M P, but inhibits MMP2 at higher concentrations (Strongin et al., 1995). 
TIM P3 has several cell surface activities, including: inhibition of M MP3, M M P7 and MT- 
MMPs; blocking of the V EG F receptor-2, thereby inhibiting angiogenesis (Qi et al., 
2003); and promotion of cell death by blocking the shedding of cell surface death 
receptors via inhibition of a disintegrin and metalloprotease 17 (ADAM 17) (Ahonen et 
al., 2003).
1.4.6 MMPs in MS
MMPs can contribute to disease pathogenesis when they are over-expressed. Much 
has been documented about the role of MMPs in inflammatory diseases, including 
neurological disorders, such as MS. Astrocytes, microglia, and ECs of the CNS, 
together with macrophages and T  cells, secrete various MMPs that contribute to MS 
pathogenesis. It is likely that MMPs are involved in BBB damage, brain oedema, 
lymphocyte infiltration, degradation of myelin, and axonal damage (Fig. 1.10) (Yong et 
al., 2001). The increased M M P production seen in patients with CNS disorders is often 
viewed as a target for inhibitory drugs. MMP inhibitors have been proposed as a 
treatment for MS, but careful use of a highly specific drug would be necessary, to avoid 
eliminating the useful role of MMPs in tissue repair, particularly as MS is likely to 
require protracted therapy.
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Figure 1.10 M M P invo lvem ent in the neuropathology o f MS
Leukocytes express MMPs, which help them to enter the CNS. The basement 
membrane surrounding blood vessels is disrupted and consequently the BBB is 
disrupted. The CNS contains significant levels of MMPs that are widely distributed, 
leading to perpetuation of an inflammatory response. This results in demyelination, 
destruction of OLGs, and axonal damage.
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Development of inhibitors for specific MMPs has proved difficult, but it is hoped that the 
use of a relatively selective M M P inhibitor that does not penetrate the BBB will be 
possible in MS, with minimal side effects. As leukocyte M M P activity is a target of MMP  
inhibition, an agent that is not CNS diffusible could still inhibit cell migration into the 
C N S (Y o n g e fa /., 2007a).
In the brain, gelatinases, stromelysins, and M T-M M Ps make up the majority of MMPs 
present, with MMPs 2, 3, and 9, being the most significant (Muir et al., 2002). M M P3 is 
known to activate M M P9, as is NO, by causing removal of the peptides that maintain 
the inactivity of the zinc binding site (Gu et al., 2002). M M P2 and 9 act on less ECM  
substrates than M MP3, but process important constituents of the basal lamina (Yong et 
al., 1998). It has been suggested that over-expression of MMPs and a relative 
decrease in their T IM P  inhibitors, may produce persistent proteolysis, resulting in the 
neuronal loss that represents the steady advancement of symptoms of secondary 
chronic progression in MS (Lindberg et al., 2001). The serum, CSF, and brain tissue of 
MS patients all demonstrate an increase in MMPs 1, 2, 3 ,7 , 9, and 12 (Kurzepa et al. 
2005). M M P9 in particular, is thought to assist with T  cell migration into the CNS. High 
levels of M M P9 are detected in astrocytes and macrophages in demyelinating lesions, 
and in the CSF of MS patients (Szabo et al., 2004).
Latent M M P9 is found in vesicles within neutrophils, and this can be released during 
inflammation (Ramos-DeSim one eta l., 1999). A 10 month study of 21 RRM S patients 
revealed high serum levels of MM P9 during relapses, which correlated with increasing 
numbers of lesions detected by MRI (Lee et al., 1999). The ratio of M M P9 and its 
inhibitor, T IM P1, has been suggested as a useful indicator in assessing potential BBB 
destruction in MS. Patients with RRMS often have a high CSF M M P9/TIM P1 ratio, 
which was found to decrease after 6 months of IFN-p therapy (Boz et al., 2006). 
Microglia and astrocytes produce MMP9 when stimulated with LPS in vitro (Gottschall 
and Deb, 1996), and M M P2 has been detected in the foot processes surrounding blood 
vessels as it is produced constitutively by astrocytes (Liu and Rosenberg, 2005).
1.5 Dipeptidylpeptidase IV (CD26)
The cell surface ectopeptidase dipeptidyl peptidase IV (DPPIV) has the Enzyme 
Commission (EC) number 3.4.14.5 and is identical to the C D26 antigen (Kahne et al., 
1999). CD26 was first described in 1966, and has long been known to cleave 
dipeptides from peptides or proteins with either a proline or alanine in the penultimate 
position. As substrate size increases, CD26 has been found to lose proline specificity 
and increase the speed of hydrolysis (Demuth et al., 2005). Proteins with the cyclic
46
amino acid proline in the N- or C-terminal penultimate position are normally protected 
from proteolytic attack, so the discovery of this peptidase provoked much interest 
(Mentlein, 1999).
1.5.1 Structure of CD26
CD26 is a type II integral membrane protein of 110 kDa, possessing a large 
extracellular domain, a transmembrane domain, and a cytoplasmic tail of six amino 
acids (Fig. 1.11) (Tanaka et al., 1992). The short, intracellular, hydrophillic N-terminus 
is followed by a hydrophobic membrane anchor comprised of 22 amino acids, and then 
738 residues, containing potential glycosylation sites, located extracellularly. The C- 
terminus contains the catalytic region, which is fully conserved between human and rat 
sequences (Mentlein, 1999).
1.5.2 Function of CD26
The function of CD26 eluded discovery for many years, as its unique specificity 
implicated it in collagen metabolism, but the glycine-proline sequence, frequently seen 
in collagen, is often followed by a proline-proline bond, which CD26 cannot cleave. In 
the 1990’s, studies focused on the role of CD26 in immune responses, such as T  cell 
activation and proliferation (Mentlein, 1999). It is now known that this peptidase can 
inactivate many extracellular proteins of biological significance, including neuropeptides, 
hormones, cytokines, and chemokines, but information about in vivo substrates is still 
limited (Mentlein, 1999). CD26 is not thought to have a unique physiological role, as 
little difference in phenotype is seen in Fischer rats that lack it (Tiruppathi et al., 
1993).The cell type and conditions in which it is expressed affect the functionality of 
CD26, which includes acting as an enzyme, receptor, and potent co-stimulatory protein. 
CD26 can bind to a variety of proteins, including an association with adenosine 
deaminase (ADA) and it has been shown to be identical to the ADA binding protein 
(Kameoka et al., 1993). On the surface of T  cells, CD26 also interacts with CD45, a 
transmembrane protein with tyrosine phosphatase activity, which has been suggested 
to result in increased tyrosine kinase activity and T  cell activation (Torimoto et al.,
1991). Controversy remains as to whether the enzymatic activity of CD26 is required 
for its signalling role (Kahne et al., 1999).
CD26 is important in immune responses, is involved in apoptosis, acts as an adhesion 
molecule for collagen and fibronectin, and has been implicated in the pathogenesis of 
autoimmune diseases, cancer, and human immunodeficiency virus (HlV)-related  
diseases (Boonacker and Van Noorden, 2003).
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Figure 1.11 Structure of human CD26 (DPP IV)
CD26 is a type II transmembrane protein with a cytoplasmic hydrophilic N-terminus 
composed o f 6 amino acids, a 22 amino acid hydrophobic membrane anchor, and a 
large extracellular domain containing a flexible segment, regions rich in sugars and  
cysteines, and a C-terminal catalytic domain with a serine-protease type centre. The 
serine at residue position 630 forms a catalytic triad with the aspartate at position 708, 
and histidine at 740. CD26 is inhibited by m etal ions (e.g. Pb2+ and Zn2+) and 
compounds that covalently modify the active site, such as di-isopropyl 
fluorophosphates (Puschel et al., 1982), or non-covalent reversible inhibitors.
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CD26 has diverse functions in T  cells and in regulating peptides, and is found both 
intracellularly and extracellularly (Tanaka et al., 1993). (See also 4.1 and Fig. 4.1).
1.5.3 CD26 expression
Many cell types express this cell surface glycoprotein. In humans, epithelial cells of 
liver, intestine, and kidney express membrane-bound CD26 constitutively, and a 
soluble form is present in the blood and CSF. In particular, tissues and fluids of the 
body involved in nutrition and excretion, such as the intestinal lumen, urine, bile, and 
pancreatic fluid, are rich in CD26, where it most likely serves a digestive function by 
degrading peptides (Brandsch et al., 1995). ECs express CD26, it is found at the 
capillary epithelia of endocrine organs, and in specialised fibroblasts, as in the 
mammary gland (Atherton et al., 1992), or skin (Raynaud et al., 1992). The  
concentration found in the blood is very high compared to other enzymes, with an 
estimated lower limit of 3pM (Demuth et al., 2005). On T  cells, CD26 expression occurs 
late in thymic differentiation and is thought to be limited to the helper/memory CD4+  
population (Morimoto et al., 1989). Other immune cells expressing CD26 include some 
subsets of macrophages (Jackman eta!., 1995).
In the CNS, CD26 is found in the CSF, particularly in the circumventricular organs 
(Mitro and Lojda, 1988). Capillaries of the brain and some ependymal cells express 
high levels, and in the peripheral nervous system, CD26 is expressed by the 
perineurium and Schwann cells (Haninec and Grim, 1990). Neuronal cells of the 
embryonic brain express abundant CD26 (Bernstein et al., 1987). The location of this 
peptidase facilitates proteolytic attack on bioactive peptides in body fluids, and it is 
often found at sites considered to be physiological barriers, such as the BBB.
1.5.4 CD26 in MS
In inflammatory disorders, migrating T  cells have been shown to be those which 
express high levels of CD26 (Mackay, 1996). Studies have demonstrated large 
numbers of CD 26+ T  cells in the circulation of patients with MS (Hafler et al., 1985), 
and rheumatoid arthritis (Nakao et al., 1989), suggesting CD26 might play a role in 
chemokine-induced migration of T  cells. CD4+ T  memory cells with high CD26  
expression have been found to correlate with disease severity and activity in MS 
(Krakauer et al., 2006). Peripheral blood C D 8+ cells positive for CD26 decreased  
following treatment of MS patients with IFN-(3 (Jensen et al., 2006). Expression of 
CD26 on six MBP-specific CD4+ T  cell clones from MS patients was examined, and 
found to be high, with a 3-4 fold increase in enzymatic activity compared to resting T  
cells from peripheral blood. In addition, CD26 inhibitors suppressed IFN-y, IL-4, and
49
TN F production of antigen-stimulated T  cell clones. It is possible that CD26 is involved 
in regulating activity of autoreactive T  cells (Reinhold et al., 1998). (See also 4.1).
1.6 Chemokine Processing
Due to the extensive connections and frequent colocalisation of cytokines and 
proteases, cleaved forms of chemokines have come under scrutiny. Chemokines are 
capable of acting as powerful stimuli of M M P and D PP IV  expression in various cell 
types. In return, proteases can cleave chemokines, producing receptor agonists with 
greater, lesser, or no activity as a result. Numerous examples of chemokine-protease 
interactions have been reported, yet it remains virtually impossible to predict the 
outcome in terms of biological activity. Redundancy in the chemokine and receptor 
system, local or systemic processing (i.e. inducible proteases and chemokines acting 
at cellular or tissue-specific locations, or proteolysis in the circulation), speed of 
proteolysis (Lambeir et al., 2001), and involvement of numerous other molecules, all 
add to the uncertainty of the results of chemokine truncation. Loss of the disulphide 
bridges of chemokines is generally accepted as loss of biological activity through 
GPCRs, whereas angiostatic properties mediated by GAG binding of the C-terminus 
appear to occur independently of chemokine tertiary structure. Limited N-terminal 
cleavage of inflammatory chemokines can produce dramatic results. N-terminal 
deletion of ELR+ CXC chemokines can lead to enhanced chemotactic potency and 
might produce an increase in angiogenic activity, but the angiostatic ability of ELR'
CXC chemokines does not appear to be affected (Van Damme et al., 2004).
Much has been documented about the relationship between structure and activity of 
CCL2 (Clark-Lewis et al., 1995). The ten N-terminal amino acids of CC chemokines are 
thought to be critical in receptor activation, binding and specificity (Iwata et al., 1999). It 
has been demonstrated that a CCL2 analogue lacking three N-terminal residues had 
lowered binding affinity and activity than intact CCL2 (Gong et al., 1996). CCL5 lacking 
eight N-terminal residues is inactive in chemotaxis and is a potent inhibitor of H IV  
infection (Arenzana-Seisdedos et al., 1996). This blocking of H IV  infection serves to 
illustrate how structural modification of chemokines can produce variants lacking in 
chemotactic activity, but retaining the ability to bind to their receptor(s). These modified 
chemokines thereby act as antagonists, with the potential to be utilised therapeutically 
as anti-inflammatory agents (Struyf et al., 2003).
1.6.1 Cleavage of chemokines by MMPs
Reports of chemokine cleavage have documented N-terminal processing at position 4- 
5 of CXCL12 by M M P2, and also cleavage of CCL7 at the same position, resulting in a
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loss of binding to the receptor (McQuibban et al., 2001). M M P2 and M M P9 are known 
to truncate CXCL8 and CXCL7 at the N-terminus. M M P2 appears particularly potent, 
cleaving CCL2, CCL8, CCL13, and CCL7 to complete inactivation (McQuibban eta l., 
2002). M M P9, however, was found to cleave CXC and not CC chemokines members 
(Van den Steen et al., 2000). It is not always the case that truncation of chemokines 
results in inactivity, as unpredictably it can sometimes result in a more potent ligand for 
the receptor. Reports on chemokine activity following C-terminal truncation are scarce, 
but one study found enhanced receptor activation following C-terminal processing of 
CXCL7 (Ehlert et al. 1998). Amino-terminal cleavage of CXCL8 by M M P9 has been 
shown to produce a ten-fold increase in activity (Van den Steen et al., 2000). MMPs 8 
and 9 have also been shown to process CXCL9 and C XC L10 at the carboxy-terminus 
(Van den Steen et al., 2003).
1.6.2 Cleavage of chemokines by CD26
CD26 has a diverse range of substrates, including substance P, growth hormone 
releasing factor, neuropeptides, the fibrin a-chain, and several chemokines (Boonacker 
and Van Noorden, 2003). CD26 has been shown to process CCL4 at the N-terminus, in 
addition to other CC chemokines such as CCL5 (Guan et al. 2004). CCL5 is not only a 
substrate for CD26, but when combined with it, can augment the normal chemotactic 
response of T  cells (Iwata et al., 1999). As CD26 alone was not shown to provoke 
chemotaxis, it has been suggested that CD26 activity is needed for enhancement of T  
cell migration across endothelia. This is in keeping with findings that T  cells highly 
positive for CD26 have the greatest migratory capacity and prevalence at chronic 
inflammatory sites in vivo (Brezinschek et al., 1995). In contrast, monocyte migration 
did not occur to the cleaved form of CCL5, and simultaneous incubation of intact CCL5  
with CD26 reduced migration (Iwata et al., 1999).
1.6.3 Implications of chemokine processing for multiple sclerosis pathogenesis
The processing of chemokines by MMPs, or other enzymes such as membrane- 
anchored CD26, is an interesting consideration when examining the pathogenesis of 
MS. Since in MS pathology there is a considerable body of evidence for simultaneous 
and colocalised production of MMPs and chemokines, the role of chemokine 
processing in the initiation and termination of the immune response is of great interest.
In addition to truncation of chemokines (which results in their inactivation, 
enhancement, or antagonism), MMPs also regulate chemokines by cleaving 
chemokine ligands. Chemokines can be bound, retained, and concentrated by ligands 
designed to create chemotactic gradients that contribute to immune cell influx (Parks et
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al., 2004). Inflammatory processes involve the recruitment of cells by chemokines, but 
this must be halted if cessation of inflammation and subsequent tissue recovery is to 
occur. Identifying proteinases that cleave chemokines is currently inadequately 
characterised, and yet may serve as an important mechanism for quelling 
chemoattractant signals.
1.7 Treatment of Multiple Sclerosis
Most treatment offered to patients with MS involves long-term immunological therapy 
targeting the peripheral immune response, on the assumption that MS is an 
autoimmune disorder. Acute attacks are treated with high doses of glucocorticoid 
(Frohman et al., 2007). Although disease-modifying treatments (DMTs) have 
progressed significantly, their efficacy in preventing disease progression is 
questionable, and common symptoms such as fatigue, cognitive impairment, pain, and 
depression are often not alleviated by immune-based therapies (Chaudhuri and Behan,
2005). It is likely that combination therapies will develop, particularly given the complex 
nature of MS. Current DMTs approved for long-term treatment of MS include three 
interferon-beta (IFN-p) drugs, and glatiramer acetate (GA)(Neuhaus et al., 2006).
IFN-p is a polypeptide predominantly produced by fibroblasts, with both the 
intramuscular and subcutaneously administered pharmaceutical versions of IFN-p1a  
being glycosylated in line with the natural form, but IFN-p1b differing from it slightly, 
and lacking glycosylation of the asparagine at position 80 in the amino acid chain 
(Neuhaus et al., 2006). IFN-p exerts many immune effects, but is thought to act mainly 
by reducing the secretion of MMPs (with M M P9 being of central importance), thereby 
minimising the destruction of the BBB and migration of T  cells into the CNS (Stuve et 
al., 1996). In addition, it is thought that IFN-p also downregulates M HC class II 
expression on APCs (Hall et al., 1997), suppresses T  cell proliferation (Rep et al.,
1996), induces Th2 cytokine expression (e.g. IL-10) and decreases that of Th1 
cytokines (e.g. IFN-y) (Rep et al., 1999), and inhibits monocyte activation (Van 
Weyenbergh et al., 1998). IF N -p ia  and IFN-p1b are thought to differ in their effects on 
cytokine profiles, with the former enhancing production of anti-inflammatory IL-4 and IL- 
10, and the latter decreasing secretion of pro-inflammatory IFN-y (Sega et al., 2004).
Recombinant IFN-p and intravenous Igs can reduce the frequency and severity of 
attacks in some patients, but others fail to respond. Treatment with IFN-p often leads 
to production of anti-IFN-p antibodies, which cause a decline in treatment efficacy 
through neutralising the drug over time (Gibbs and Oger, 2007).
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GA, known as Copaxone, induces upregulation of C D 8+T  cells with regulatory or 
suppressing roles, with untreated patients showing a deficit in C D 8+suppression. CD8+ 
T cells from patients receiving GA also show potent cytotoxicity, restricted to HLA 
Class I, which can destroy CD4+ cells in a GA-specific manner (Tennakoon et al.,
2006). The immunomodulatory effects of GA apply to cells specific for MBP and 
possibly other myelin antigens, and it has been postulated to exert neuroprotective 
effects (Farina et al., 2005).
1.7.1 Other treatments
Mitoxantrone causes cross-linking and strand breaks in DNA by interacting with an 
enzyme called topoisomerase-2, involved in the breaking and rejoining of DNA (Smith, 
1983). It is known to have cytotoxic, immunosuppressive, immunomodulatory, antiviral, 
and antibiotic effects (Neuhaus et al., 2004). Mitoxantrone is used as a second line 
drug for progressive and worsening MS that is not controlled by IFN-p or GA (Edan et 
al., 2004).
T  cell vaccination (TCV) involves isolation of T  cells that react to either MBP or MOG, 
inactivation by irradiation, and injection as a vaccine to sensitise the immune system to 
recognise these autoreactive cells, with the goal of eliminating them from the blood. 
Clinical trials using a small number of patients have confirmed the safety and efficacy 
of TCV, as relapse rates and neurological disability progression were reduced, 
suggesting it may be of use in patients who do not respond to treatment with IFN-p  
(Achiron et al., 2004).
In the quest for improved therapies, the use of stem cell therapies to repair brain 
lesions appeared an attractive proposition, but recent information gleaned on the 
pathogenesis of MS, and the risk of producing tumours from transplanted cells, 
rendered this approach less feasible than first thought (Lassmann 2005). Therapy 
involving intense immunodepletion, followed by an autologous haematopoietic stem  
cell transplant (HSCT), is currently being assessed worldwide as a potential therapy for 
patients unresponsive to other treatments. Although evidence suggests that allogenic 
HSCT is more effective at eliminating the host’s aberrant immune system, the mortality 
risk is 15-35% , compared to 3-5%  for autologous. HSC T currently remains an 
experimental approach with many uncertainties, and results from the 300 patients 
treated so far cannot confirm if it is effective in modifying disease progression as 
randomised controlled trials were not used (Silani and Cova, 2008).
Cannabis is considered beneficial in controlling muscle stiffness, pain, and spasms,
53
and may even offer neuroprotection as cannabinoids affect oxidative responses, 
glutamate and ion influxes (Jackson et al. 2005). A cannabis-based oral spray called 
Sativex is available on prescription to MS patients in Canada. UK regulators, however, 
have decided that further data is required before Sativex is available for MS patients in 
this country (Pryce and Baker, 2005). Sativex contains delta-9-tetrahydrocannabinol 
and cannabidiol, and was found to improve pain and sleep disturbance and 
demonstrated maintenance of the analgesic effect, in a randomised trial of 66 patients, 
lasting a mean duration of 463 days (Rog et al., 2007).
Drugs targeting specific sections of the inflammatory response are being developed, 
such as the humanised monoclonal antibody anti-VLA-4, and immunomodulators, such 
as statins. Natalizumab (Tysabri) is an antagonist, which binds to a4-integrins on 
leukocytes, preventing them from interacting with adhesion molecules on ECs. Several 
studies have reported decreases in relapse rates and lesion development following 
treatment with natalizumab, but when used in combination with IFN-(S1 a, two MS 
patients developed progressive multifocal leukoencephalopathy (PML), and dosing was 
suspended in 2005. It has recently been reintroduced as a monotherapy for patients 
with RRM S (Kappos et al., 2007).
Chemokine antagonists may prove helpful in curbing the infiltration of inflammatory 
cells across the BBB (Galimberti et al. 2004). Several pharmaceutical companies are 
involved in the development of antagonists to chemokine receptors, including CCR1 
and CCR5, as high numbers of monocytes expressing both of these have been found 
in perivascular cuffs (PVCs) and at demyelinating edges of MS lesions (Ribeiro and 
Horuk, 2005).
The antibiotic, minocycline, is a potent inhibitor of gelatinases (M M Ps 2 and 9) and was 
found to reduce MRI Gd-enhancing lesions and relapse frequency in a 2 year study of 
10 patients with RRMS, further supporting a substantial role for these MM Ps in the 
disease process (Zabad et al., 2007)
There is pressure to produce DMTs that address the demyelination and axonal loss 
problems central to MS. Neuroprotective agents and ion channel blockers are currently 
under investigation to prevent some of this damage (Kappos et al. 2004). Disruption of 
ion channels expressed by T  cells, for example, can lead to immune suppression by 
preventing their response to antigenic challenge (Panyi et al., 2004).
Neuroregenerative approaches to treating MS remain speculative, and the principal 
therapeutic aim persists to reduce neural and glial tissue damage by targeting key 
aspects of the immunological cascade using DMTs.
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1.8 Aims of thesis
It is apparent that the interactions between MMPs and chemokines are complex and 
not fully understood. A  greater comprehension of the chemokine substrates of MMPs 
and CD26, and the effect cleavage has on their chemotactic activity, is needed to 
identify potential therapeutic targets amongst chemokines or their receptors, such as 
an antagonistic cleavage product. This thesis aims to contribute to this knowledge.
Four major aims were addressed in the research undertaken in this thesis:
•  To investigate the proteolytic processing of recombinant human chemokines 
(CCL2 and CXCL10) by enzymes (M M P2, M M P9, and CD26), using gel 
electrophoresis and mass spectrometry to characterise the cleavage 
products (Chapter 2)
•  To assess primary human astrocyte supernatants for the presence of 
cleaved chemokines using western blotting and mass spectrometry, and 
astrocyte lysate samples for the whole spectrum of MMPs and TIM Ps using 
R T-PC R  (Chapter 3)
•  To investigate MS brain tissue by dual-labelling immunofluorescence to 
identify cell types expressing CD26, and compare expression to that in 
normal control brain (Chapter 4)
•  To assess the migration of T  cells and monocytes using cell lines and 
PBMCs to the cleaved isoforms of CCL2 and CXCL10 (obtained after 
proteolytic processing by MMP2, M MP9, and CD26) compared to migration 
to the intact forms (Chapter 5)
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Chapter 2
Chemokine cleavage: truncation of CCL2 
and CXCL10 by MMP2, MMP9 and CD26
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2.1 Introduction
Chemokines play a pivotal role in regulating migration of leukocytes, both during 
immune surveillance and in inflammatory states. Precise control of leukocyte trafficking 
is vital to health, and chemokines are regulated at four levels. Firstly, gene expression 
and protein secretion regulate chemokine expression, including storage in granules of 
leukocytes or ECs, or being exported as inactive membrane-bound forms (Von 
Hundelshausen et al., 2007). Chemokine activity can also be altered by interactions 
with GAGs, leading to retention on cell surfaces at high concentrations and possible 
protection from processing. Thirdly, chemokines can be bound by non-signalling 
receptors, known as decoy receptors, such as D6, or the Duffy antigen receptor for 
chemokines (DARC), and lastly, they can be processed by proteases to forms with 
different activities, which allows rapid changes in their activity without transcription 
(Comerford and Nibbs, 2005).
Most chemokines are secreted proteins composed of 67-127 amino acids, which can 
be isolated in both intact and truncated forms from supernatants obtained from cells 
stimulated with cytokines in vitro (Struyf et al., 2001). Cytokines can induce both 
chemokine and protease production, so simultaneous upregulation of these is likely to 
be a natural phenomenon occurring in organ, or cellular compartments in vivo, during 
episodes of inflammation. Positive feedback loops can contribute to conditions where  
protease-cytokine interactions abound. Interleukin-1 (3, for example, is a potent inducer 
of other cytokines (e.g. IL-6) (Musso et al., 1990), chemokines (e.g. CCL2) (Harkness 
et al., 2003), and MMPs (e.g. MMP9) (see 1.4) (Yoo et al., 2002) from several cell 
types. Secreted proteases induced by IL-1 (3 can then convert inactive forms of 
cytokines to active ones (e.g. M MP9 processing of pro-IL-1 (3 to active IL-1 (3) (Chauvet 
et al., 2001), or cleave active cytokines to produce more potent versions (e.g. N- 
terminal cleavage of CXCL8 by M M P9) (Van den Steen et al., 2003).
The results of processing by proteases can also result in negative feedback, as is the 
case with truncation of some chemokines. In addition to inactivating chemokines, as is 
seen with proteolysis of CXCL1 by M M P9 (Proost et al., 2006), processing can also 
generate chemokine antagonists that bind to their receptor but are unable to evoke 
chemotaxis (e.g. CCL7 cleaved by M MP2) (Van Lint and Libert, 2007). These  
examples demonstrate that a single protease, such as M MP9, can act upon cytokines 
and/or chemokines to render them either more or less active. Chemokines reported to 
be prone to attack from MMPs include CCL2, CCL7, CCL8, CCL13, CXCL8 and 
CXCL12 (reviewed in W olf et al., 2008).
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Cytokine-protease-chemokine interactions are not limited to MMPs as the protease. 
Interleukin-12, for example, induces CD26 expression on T  cell membranes (see 1.5) 
(Salgado et al., 2000). CD26 has many substrates, including several chemokines, with 
potentially wide-reaching effects, due to the soluble form of this protease being present 
in the circulation (Mentlein, 1999). CD26 highly selectively cleaves a dipeptide from 
substrates with a proline or alanine residue at the penultimate position of the N- 
terminus. Some chemokines that possess this sequence are modified by a 
pyroglutamate, which protects them from truncation by CD26 (Proost et al., 1999). 
CD26 can induce M M P9 expression (Gonzalez-G ronow et al., 2001), which is of 
interest in MS given both enzymes are implicated in the pathogenesis.
Cathepsin G, elastase and proteinase-3 are enzymes that can be released from 
neutrophil and monocyte granules when the cell is activated. As these cells can also 
secrete CC and CXC chemokines, there is great potential for cleavage. Other enzymes 
known to engage in proteolysis of chemokines include CD13, uPA, plasmin and 
thrombin (Tables 2.1, 2.2, 2.3) (reviewed in W olf et al., 2008).
Truncation of proteins may be pertinent to many diseases, impacting on activities such 
as inflammation, tumour development and metastasis, and infection with HIV. Indeed, it 
was the observations of tumour-derived proteases assisting in cellular invasion that led 
to further investigations of interactions between proteases, cytokines, and chemokines 
(Chang and W erb, 2001). Chemokine cleavage is a complex area of study, due to the 
unpredictable nature of how the pathology of diseases is affected, the excessive 
number of factors involved, and the technical skills required to detect cleavage 
products in tissue (Van Damme et al., 2004). The last decade has seen numerous 
reports of proteolytic chemokine processing, but in vitro studies may not tally with 
results in a physiological environment, where greater control of protease and 
chemokine expression exists.
2.1.1 N-terminal truncation of chemokines
Studies on chemokine cleavage have been focused on the N-terminus, due to N- 
terminally truncated forms being isolated from natural sources, and the importance of 
this region for receptor binding and activity (Proost et al., 2006). Chemokine receptors, 
and all chemokines except XCL1, possess 2 disulphide bridges likely to be involved in 
stabilising the structural conformation to enable binding, which if lost, frequently results 
in failure to act via GPCRs (Oppermann, 2004). The N-terminal region, before the first 
cysteine residue, is exposed with a disordered conformation, making it prone to 
processing. Minor losses at the N-terminus can lead to drastic alterations in the
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chemotactic activity of many chemokines (Table 2.1 and 2.2) (reviewed in W olf et al., 
2008). CXCL7 is a special case, in that to become active in attracting neutrophils, 7 
residues from the N-terminus must first be removed by chymotrypsin or cathepsin G 
(Von Hundelshausen et al., 2007).
N-terminal cleavage of CC chemokines commonly reduces their chemotactic potential, 
but can also increase activity (Table 2.1). Truncation of CXC chemokines can effect not 
only their chemotactic potential, but also angiogenesis, due to the angiogenic activities 
of chemokines with an ELR motif, and angiostatic properties of CXC chemokines 
without this motif (Lentsch, 2002). In contrast to CC chemokines, removal of N-terminal 
amino acids from CXC chemokines with an ELR motif often leads to enhanced 
inflammatory activity due to a greater chemotactic potential, and possibly also an 
increase in angiogenesis (Table 2.2). Chemokines with an ELR motif exhibit many 
naturally occurring truncated forms, and it appears that possession of the ELR motif in 
the aminoterminus is linked to high susceptibility of cleavage in this region by some 
MMPs (Van Damme et al., 2004). Truncation of the N-terminus of CXC chemokines 
lacking an ELR motif, such as CXCL10, produces little effect on the angiostatic 
potential of these chemokines, in contrast to ELR-bearing chemokines. CXCR3 ligands 
(CXCL9, -10, and -11) are more likely to be cleaved C-terminally but are prone to N- 
terminal attack by CD26 (Proost et al., 2001). CD26 truncation of CXC R 3 ligands at the 
N-terminus has been shown to result in loss of binding and chemotaxis of these 
chemokines, yet maintenance of their angiostatic properties, emphasising the need to 
evaluate the effects of cleavage on chemotaxis and angiogenesis independently In vivo 
(Proost et al., 2001).
CD26 is of particular importance in N-terminal truncation of chemokines (Table 2.1 and 
2.2). Research into H IV  has revealed that N-terminal truncation by CD26 of the ligands 
of C XCR4 and CC R 5 in vitro impacted on susceptibility to infection (Proost et al., 
1998a).
2.1.2 C-terminal truncation of chemokines
Reports of chemokine cleavage at the carboxy-terminus are rare compared to the 
greater susceptibility observed at the N-terminus, and much remains to be discovered 
(Table 2.3) (Edwards et al., 2005). The leucine residue is highly conserved in CXC  
chemokines, and when it occurs as the C-terminal amino acid, studies on CXCL8  
suggest that it may render the residues next to it, as more prone to proteolysis (Ehlert 
e t a i ,  1998).
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Table 2.1 N-terminal processing of CC chemokines by proteases and effects on 
activity
Reports o f N-terminal truncations of CC chemokines following interactions with 
enzymes are shown. N-terminal cleavage of CC chemokines often reduces their 
chemotactic potential, but can also increase it. Several different proteases are able to 
cleave CC chemokines at the N-terminus, but it can be seen that M M Ps and CD26 play 
highly significant roles. C D 26 is highly selective for substrates with a proline or alanine 
at position two of the N-terminus, a sequence possessed by approximately one-third of 
human chemokines. The characteristic N-terminal dipeptide removal by CD26 is 
frequently observed. The most common truncation observed by M M Ps is removal of 
four residues, but this is variable (Van Damme et al., 2004). Chemokines investigated 
in this study are highlighted in bold.
* Amino acids remaining after processing detailed in brackets 
t  = increased, [  = decreased, uPA = urokinase-plasminogen activator
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C H EM O K IN E PRO TEASE(S) EFFECT ON A C T IV IT Y  A N D  REC EPTO R
ISO FO R M  * INVO LVED A FFIN ITY
CCL2 (5-76) M M Ps 1 ,3 ,  8 I  chem otaxis in in vivo in flam m atory  
m odel
CCL3L1 (3 -7 0 ) CD26 t  monocyte chemotaxis and affinity for 
CCR1,5;
i  affinity for CCR3; 
anti-HIV activity
CCL5 (3 -6 8 ) CD26 I  chemotaxis and affinity for CCR1,3; 
t  affinity for CCR5; 
t  anti-HIV activity
CCL5 (4-68) Cathepsin G lactivity
CCL7 (5 -7 6 ) MM Ps 1,2,3,13,14 Ichemotaxis and affinity for C C R 1,2,3
CCL8 (5-76) M M P3 CCR2 antagonist
C C L11 (3-74) CD26 fchemotaxis for C C R 3+ cells; 
Unchanged anti-HIV activity
CCL13 (4-75) M M P1, 3 f  migration in an in vivo inflammatory 
model;
CCR2 and CC R3 antagonist
CCL13 (5-75) M M P1, 3 ^migration in an in vivo inflammatory 
model;
CCR2 and CCR3 antagonist
CCL13 (8-75) MMP1 f  migration in an in vivo inflammatory 
model;
CCR2 and CCR3 antagonist
CCL14 (9 -7 4 ) uPA, plasmin t  chemotaxis and affinity for CCR1,3,5, 
but plasmin further degrades active 
product;
Anti-HIV activity
CCL15 (22-92) Elastase t  activity for C C R 1+ cells
CCL15 (24-92) 
(27-92)
Cathepsin G t  activity for monocytes and C C R 1+ cells
CCL15 (29-92) Cathepsin G, 
Chymase
t  activity for C C R 1+ cells
CCL22 (3-69) 
(5 -6 9 )
CD26 f  activity for lymphocytes but not 
monocytes;
1 affinity for CCR4
CCL23 (27-99) Cathepsin G 
Chymase
f  activity for C C R 1+ cells
CCL23 (30-99) Elastase t  activity for CCR1 +cells
Adapted from (Van Damme et al., 2004), © (2004), and (Wolf et al., 2008) © (2008), with
permission from Elsevier.
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Table 2.2 N-terminal processing of CXC chemokines by proteases and effects on 
activity
Reports of N-terminal truncations of CXC chemokines following interactions with 
enzymes are shown. Several different proteases are able to cleave CXC chemokines 
at the N-terminus, but it can be seen that MM Ps and CD26 play highly significant roles. 
N-terminal cleavage o f CXC chemokines more commonly increases their activity, 
especially when the substrate has an ELR motif, as shown with those that bind to 
CXCR1 or 2. For C XC chemokines lacking an ELR motif, the most common outcome is 
a reduction in activity, or no change. M M P processing most commonly removes 4 or 5 
residues from the N-terminus of CXC chemokines, but this can be seen to vary, yet 
there are no deviations from the dipeptide removal when C D 26 is the protease. 
Chemokines investigated in this study are highlighted in bold.
* Amino acids remaining after processing detailed in brackets 
t  = increased, I  = decreased, uPA = urokinase-plasminogen activator
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C H EM O K IN E PRO TEA SE(S) EFFEC T ON A C TIV ITY  AND
IS O F O R M * INVO LVED R EC EPTO R  A FFIN ITY
CXCL5 (8-78) M M P8, 9 |  activity
CXCL5 (9-78) Cathepsin G |  activity for neutrophils
CXCL5 (10-78) MMP1 No information
CXCL6 (3 -7 7 ) CD26 Unchanged chemotaxis and affinity for 
C XCR1.2
CXCL6 (5-77) 
(6-77)
M M P8, 9 No changes
CXCL6 (7-77) M M P9 No changes
CXCL8 (6 -7 7 ) M M P8,13,14 t  chemotaxis and affinity for C X C R 1,2
CXCL8 (6 -7 7 ) Plasmin, thrombin, 
Cathepsin L
|  activity for neutrophils
CXCL8 (7 -7 7 ) M M P1, 9 No information
CXCL8 (8-77) Proteinase-3 t  activity
CXCL8 (9-77) Plasmin f  activity for neutrophils
CXCL9 (3-103) CD26 ^activity
CXCL10 (3 -7 7 ) CD26 ^activity; CXCR 3 an tagonist
C XC L11 (3-73) CD26 ^activity; CXC R 3 antagonist
CXCL11 (3-73) 
(5-73) 
(7-73)
CD13 ^activity for lymphocytes and C X C R 3+ 
cells;
antagonistic effects
CXCL12 (3 -6 8 ) CD26 ^activity; CXC R 4 antagonist
CXCL12 (4-67) Elastase No activity
CXCL12 (5 -6 7 ) M M P1.3, 9,13,14 No activity
CXCL12 (5 -6 7 ) M M P2 CXCR3-m ediated neurotoxicity
CXCL12 (6-67) Cathepsin G No activity
Adapted from (Van Damme et al., 2004), © (2004), and (Wolf et al., 2008) © (2008), with
permission from Elsevier.
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Table 2.3 C-terminal and core processing of chemokines by proteases and
effects on activ ity
C H EM O K IN E  
ISO FO R M  *
PR O TEASE(S)
IN VO LVED
EFFEC T ON A C T IV IT Y  AND  
R EC EPTO R  A FFIN ITY
CCL20 (1-19) Cathepsin D No information
CCL20 (1-52) 
(1-55)
Cathepsin D No activity
CCL20 (59-70) Cathepsin D Antimicrobial activity
CCL20 (1-66) Cathepsin B No change
CCL21 (1-58) 
(59-111)
Cathepsin D No activity
CXCL9 (1-90) 
(1-93) 
(1-94)
M M P9 No information
C XC L10 (1 -6 8 ) M M P9 No inform ation
C XC L10 (1 -7 1 )  
(1-73)
M M P8 No inform ation
M et-CXCL10 (1 -7 6 ) Furin No change
CXCL12 (1 -6 7 )
(NB Intact was 1-68)
Carboxypeptidase N ^activity
Adapted from (Wolf etal., 2008) © (2008), with permission from Elsevier.
Reports o f C-terminal and core truncations o f chemokines following interactions with 
enzymes are shown. Several different proteases, including MMPs, but not CD26, are 
able to cleave chemokines at the C-terminus, although the numbers o f known 
interactions are markedly few er than at the N-terminus. Little is known about the effects 
of C-terminal processing on chemokine activity. Processing in the core region can also 
occur, as illustrated by processing of CCL20 by cathepsin D, resulting in inactivation 
(W olf et al., 2008). Chemokines investigated in this current study are highlighted in 
bold.
* Amino acids remaining after processing detailed in brackets
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Using chemically synthesised analogues, truncation beyond the leucine of CXCL8 was 
found to cause a tenfold reduction in binding to, and activation of, PBMCs (Clark-Lewis 
et al., 1991). This could be explained by a role of leucine in maintenance of the a- 
helical structure, without which, CXC chemokine structure might be disturbed. The C- 
terminal a-helix is thought to be involved in the dimeric structure of CXCL8, a 
chemokine which attracts monocytes and neutrophils. Serum levels and secretion from 
PBMCs of CXCL8 are elevated in MS, and are reduced following IFN-J31 a treatment 
(Lund et al., 2004). The bacteria Streptococcus pyogenes secretes an enzyme that has 
been shown to cleave CXCL8 within the a-helix of the C-terminus, resulting in reduced 
neutrophil migration (Edwards et al., 2005). This reduced activity is explained by 
impairment in interactions of the C-terminus with GAGs, which usually help to anchor 
CXCL8 to the EC surface, where it assists with neutrophil slowing, prior to 
transmigration (Middleton et al., 1997). GAG binding of the C-terminus of a chemokine 
mediates angiostatic activities that appear to operate independently of chemokine 
tertiary structure (Van Damme et al., 2004).
The three-dimensional arrangement of the C-terminal residues affects their 
susceptibility to proteolytic attack. Dimeric CXCL7, for example, has terminal residues 
that form mobile ‘fraying ends’ as opposed to helical structures, thereby representing 
easy targets for proteolysis (Ehlert et al., 1998). Analyses of C-terminal truncation of 
CXCL7 have indicated that changes in activity accompanying cleavage, are linked 
more to the nature of the missing residues than the number of them. By performing an 
increasing number of deletions from the C-terminus, Ehlert and colleagues (1998) 
showed that a CXCL7 isoform lacking 4 residues showed a three-fold increase in 
activity above the full-size form, and removal of 5, 6 or 7 amino acids yielded versions 
all with approximate five-fold potency above the intact form. These results supported 
the conclusion that negatively charged C-terminal residues are vital for the neutrophil- 
stimulating activity of CXCL7, but loss of uncharged residues has little effect (Ehlert et 
al., 1998).
Interestingly, studies on CXCL8 have also shown an increase in activity when acidic 
residues were removed from the C-terminus, and a decrease in activity if basic 
residues are lost (Clark-Lewis et al., 1991). The charge distribution of residues at the 
C-terminus of CXC chemokines may well be involved in receptor binding, with clusters 
of acidic residues (as seen on the N-terminus of CXCR1 and CXCR2), interacting with 
groups of basic residues (as found on C-terminal helices of CXC chemokines with an 
ELR motif) (Baggiolini et al., 1994). If the cluster of basic residues found on the C- 
terminus of CXCL7 is broken up by acidic residues, the full force of receptor binding
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may not be seen, accounting for the increased potency observed with the loss of some 
C-terminal residues. C-terminal truncation can lead to changes in activity of 
chemokines by preventing binding to their receptors, as is thought to be the case if C- 
terminal basic residues are removed from CXCL10 (Campanella et al., 2003).
M M P8 has been shown to process the C-terminus of CXCL10, by cleaving it at 
positions 71 and 73, but the effects on activity are unknown. Similarly, M M P9 has been 
reported to degrade CXCL10, and process CXCL9 at 3 sites in the carboxyterminal 
region,-and was considered more effective than M M P8 at degrading these chemokines 
(Van den Steen et al., 2003). C-terminally truncated CXCL9 exhibited a 30-fold 
decrease in its biological activity, possibly due to loss of the immobilised chemokine 
gradient formation due to a failure of the highly basic C-terminus to interact with ECM  
GAGs (Clark-Lewis et al., 2003).
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2.2 Aims and objectives
The chemokines CCL2 and CXCL10 were selected for analysis because several 
studies have pointed to their involvement in the pathogenesis of MS (Mahad et al.,
2002; Simpson et al., 1998 and 2000b; Moreira et al., 2006). M M P2 was investigated 
as it is implicated in MS, with elevated levels marking the chronic stages of the disease. 
Activated T  cells express M M P9 (Rosenberg, 2005), and increased serum and CSF  
levels of M M P9 are associated with RRMS (see 1.4.6) (Avolio et al., 2003). Changes in 
the expression of CD26 on T  cells are thought to correlate with disease activity in MS 
(Selleberg et al., 2005), and this molecule is known to cleave several chemokines (see 
1.5.4) (Ludwig et al., 2002). Gathering data from in vitro investigations may help to 
identify possible isoforms of CCL2 and CXCL10 that could be generated in vivo in MS, 
as it is highly likely that these chemokines are exposed to M MP2, M M P9, and CD26  
during the pathogenesis of the disease. Thus, the aims of the work in this chapter were 
to:
•  Assess the in vitro cleavage of CCL2 and CXCL10 by M MP2, M M P9, and CD26, 
using gel electrophoresis and mass spectrometry
•  Provide a chemokine/protease digestion sample that can subsequently be 
processed for use in migration experiments (see Chapter 5)
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2.3 Materials and Methods
All chemicals used throughout were obtained from Sigma (Dorset, UK). Pipettes used 
were manufactured by Gilson and obtained from Anachem (Luton, UK). Experiments 
were repeated at least 3 times, unless otherwise stated.
2.3.1 In vitro digestion of recombinant chemokines
To assess the proteolytic effects of MMP2, M M P9, and CD26 on CCL2 and CXCL10, 
chemokines were incubated in vitro with enzymes in appropriate buffers. Samples were 
taken at various time points (Table 2.4) for analysis by gel electrophoresis (see 2.3.2) 
and mass spectrometry (MSpec) (see 2.3.4), to identify any cleavage products present, 
and for use in migration experiments in Chapter 5.
CCL2 and CXCL10 recombinant proteins (from E.coli) were obtained from Peprotech 
EC (London, UK). Human CCL2 was an 8.6 kDa protein containing 76 amino acids, 
and human CXCL10 was an 8.5 kDa protein consisting of 77 amino acids.
MMP2, M M P9 and C D26 recombinant proteins were obtained from R&D Systems 
(Abingdon, UK). M M P2 originated from a DNA sequence encoding the human pro- 
M M P2 enzyme (EC 3.4.24.24) (-71  kDa) expressed in Chinese Hamster ovary (CHO) 
cells, M M P9 from a DNA sequence encoding the human M M P9 enzyme (EC 3.4.24.35) 
( -7 7  kDa) expressed in CHO  cells, and CD26 from a construct of human CD33 Signal 
Peptide (Met 1 - Ala 16) + mature human D PPIV /C D 26 (Asn 29 - Pro 766, expressed 
with a C-terminal His tag in a mouse myeloma cell line, NSO) (EC 3.4.14.5) ( -1 1 5  kDa).
2.3.1.1 Reconstitution of chemokines and enzymes
Recombinant chemokines CCL2 (20pg) and CXCL10 (25pg) were reconstituted from 
lyophilised stock in 200pl and 250pl ultrapure water, respectively, giving final 
concentrations of 100pg/ml (~11.6pM  of CCL2 and ~11.7pM  CXCL10). The 
recombinant enzyme M M P2 was provided in a liquid form and was diluted with TCN  
buffer (50m M Tris-HCI, 10mM CaCI2, 150mM NaCI, pH 7.5) to give a final 
concentration of 100pg/ml (-1 .4p M ). Recombinant M M P9 was supplied lyophilised, 
and was reconstituted in 100pl TCN buffer to yield 100pg/ml (-1 .3p M ). Recombinant 
CD26 was supplied at a concentration of 0.5mg/ml in a filtered solution of 25m M  2-(N - 
morpholino) ethanesulfonic acid (MES), 0.7 M NaCI, pH 4.9, and was further diluted 
with 25mM Tris base, pH 8 to give a final concentration of 100pg/ml (0.87pM ).
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2.3.1.2 Activation of MMPs using aminophenyl mercuric acetate (APMA)
APM A is an organomercurial compound that activates MM Ps by catalysing removal of 
the pro-domain, thereby allowing the substrate to access the catalytic site, necessary 
for enzymatic activity (Von Bredow et al., 1998). Recombinant MMPs were activated by 
incubation with 1mM APM A  in assay buffer (100m M Tris-HCI, 100mM NaCI, 10mM  
CaCI2, 0 .01%  Tw een®  20), for 1h with MMP2, and 2h with M MP9, at 37°C. A 10mM  
solution of APM A was made by dissolving 0 .0176g APM A in 3ml dH20  with 1 drop of 
6M NaOH. This was vortexed, and 1M HCI added until the solution just turned cloudy, 
then 0.1M  NaO H was added until the solution was clear again. The volume was made 
up to 5ml with dH20 , the pH was adjusted to 10-11, and the solution used immediately 
or stored for up to 48h at 4°C.
2.3.1.3 Co-incubation of chemokines with enzymes
Each chemokine was incubated seperately with each enzyme in Eppendorf tubes for 
up to 72h at 37°C. Samples (2 x 5pl) were taken from each of these 6 different 
mixtures, at various time points, from the total volume of 10-130pl for each tube (see 
Table 2.4), for analysis by gel electrophoresis and MSpec. Final concentrations of 
0.4pM M M P2 and 9 were each incubated with 4pM each of CCL2 and CXCL10 in 
assay buffer, giving an enzyme to substrate ratio of 1:10. This ratio was adopted from a 
published method (Van den Steen et al., 2003).
To establish a suitable concentration of CD26, final concentrations of 0.04, 0.2, and 
0.4pM CD26 were tested in preliminary experiments, combined with 4pM  of CCL2 and 
CXCL10 separately in 25mM Tris base. Data from exploratory experiments indicated 
that 0.04pM  gave identical results to 0.2pM (data not shown), so the lowest 
concentration of 0.04pM  was used, giving an enzyme to substrate ratio of 1:100.
The time course for each incubation mixture was determined using information from a 
published method (Van den Steen et al., 2003), together with preliminary experiments 
using MSpec analysis of samples after 3, 6 and 24h for all chemokine:protease 
incubation mixtures (data not shown).
2.3.1.4 Control samples for chemokine digestion experiment
It is possible that the chemokines or enzymes could degrade, irrespective of enzymatic 
activity, when kept in solution at 37°C. To control for this, all chemokines and enzymes 
were incubated separately in the appropriate assay buffer. MM Ps were activated using 
APMA, which was not subsequently removed, so this was included in the control
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chemokine and M M P solutions to account for any degradative effects it may have on 
the recombinant proteins. To show that cleavage products resulted from proteolytic 
actions of the enzyme on the chemokine, the enzymes were first inactivated before 
being incubated with chemokines. MMPs were found to resist heat-inactivation (data 
not shown) and thus were inhibited by addition of a final concentration of 20mM  
ethylenediaminetetraacetic acid (EDTA). CD26 was heat-inactivated (HI) by heating to 
95°C for 5min. Samples were taken from these controls at the timepoints detailed in 
Table 2.4, for analysis by gel electrophoresis and Mspec.
2.3.1.5 Stopping the proteolytic reaction following sample collection
Samples taken at various time points for analysis by gel electrophoresis had the 
proteolytic reaction stopped by conducting the sample preparation procedure used for 
gel electrophoresis. This entailed adding 2.5pl NuPAG E®  lithium dodecyl sulfate (LDS) 
sample buffer (Invitrogen, Paisley, UK), 1pl NuPAG E® reducing agent (Invitrogen), and 
1.5pl dH20  to 5pl of sample, and heating at 70°C for 10min. Samples destined for 
MSpec analysis were mixed with an equal volume of sample preparation solution (0.5%  
trifluoroacetic acid (TFA) in dH20) to stop the reaction. All samples were then stored at - 
80°C before gel electrophoresis or MSpec analysis were performed.
2.3.1.6 Preparation of digested chemokine samples for use in migration assays
Endpoint samples (6-72h, depending on the chemokine and protease involved) of each 
chemokine with each enzyme, and of CCL2 and CXCL10 incubated with APM A and 
assay buffer alone, were collected for use in migration assays (Chapter 5). These 
samples were passed through Microcon® YM 50 centrifugal filter units (Millipore, UK) 
as soon as the digestion was completed. This procedure removed the enzyme, thereby 
leaving the separated chemokine, for use in migration assays, and is described in full in
5.3.8.1. To ensure that the Microcon® ultrafiltration had not removed chemokine 
cleavage products in addition to the enzyme, samples passed through were also 
examined by gel electrophoresis.
2.3.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
2.3.2.1 Principles of SDS-PAGE
SD S-PAG E separates proteins by electrophoresis, using sodium dodecyl sulphate 
(SDS) to denature the proteins, and polyacrylamide gel as a support and separation 
medium.
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Table 2.4 Chemokine/protease and control samples taken during digestion
investigations
TO TA L
VO LU M E
TIM E (H)
0.5
SAM PLE
M M P2 + CCL2 120
EDTA + M M P2 + CCL2
M M P9 + CCL2 120
EDTA + M M P9 + CCL2
CD26 + CCL2 130
HI CD26 + CCL2
CCL2 + APM A + buffer 120
M M P2 + CXCL10 130
EDTA + M M P2 + CXCL10
M M P9 + CXCL10 130
EDTA + M M P9 + CXCL10
CD26 + CXCL10 130
HI CD26 + CXCL10
CXCL10 + APM A  + buffer 120
M M P2 + A PM A + buffer
M M P9 + A PM A + buffer
CD26 + buffer
Samples were taken at the time points indicated and processed for mass spectrometry, 
gel electrophoresis, or migration assays accordingly. Final concentrations were as 
follows: CCL2/CXCL10 = 4pM; MMPs = 0.4pM; CD26 = 0.04pM
HI = heat-inactivated; EDTA = ethylenediaminetetraacetic acid
*lndicates endpoint samples were collected for use in migration assays in Chapter 5
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As SDS is an anionic detergent, it possesses a net negative charge within a wide pH 
range, which virtually destroys the complex tertiary structure of proteins that would 
otherwise have affected their migration through a gel matrix. Polypeptides bind to SDS in 
a manner proportional to their molecular mass, with approximately 1g of protein binding 
to 1.4g of SDS, resulting in proteins that possess an almost identical charge to mass 
ratio. SDS imparts a large negative charge to the linearised proteins, making them  
strongly attracted to an anode in an electric field, where their separation in the gel 
depends solely on differences in their mass (Schagger and Von Jagow, 1987).
Most protein samples are denatured further by the use of a reducing agent, such as 
beta-mercaptoethanol or dithiothreitol (DTT), and heat. This reduces disulphide bridges 
involved in tertiary structure, and breaks up oligomeric subunits related to quaternary 
structure. To determine the accurate molecular weight of a protein in a gel, the sample 
should be denatured. Non-reducing SDS-PAG E omits the use of these agents and 
facilitates further investigations where structure is important (Laemmli, 1970).
The polymer of acrylamide monomers that the gel is composed of forms a meshwork of 
pores of different diameters, dependent upon the percentage of acrylamide present, 
which allows the movement of different sized proteins at different rates. Large proteins 
encounter more resistance than smaller ones, and remain closer to the loading well. The  
smaller, uppermost ‘stacking’ portion of the gel, with a lower percentage of acrylamide, 
allows compression of proteins into thin layers before they enter the lower resolving gel, 
which separates the proteins by size. A tracking dye is normally added to the samples so 
that progression of proteins through the gel can be visualised. Separated proteins are 
seen as distinct bands once the gel has been stained with either Coomassie Brilliant 
Blue, or silver stain (Sorensen eta!., 2002a; Rabilloud et al., 1994).
The buffer used during electrophoresis allows an ion gradient to form during the initial 
‘stacking’ of the proteins in the gel region with larger pores, thereby focussing the 
proteins into sharp bands. As electrophoresis continues, the ion gradient is removed so 
that proteins are then separated by their size, and thus weight, in the resolving gel. To 
enable determination of the weight of unknown proteins, the distance they travel is 
compared relative to a marker consisting of proteins of known molecular weights, by 
using a graph of the relative migration distance against the logarithm of the relative 
molecular mass (M r) of the standards (Laemmli, 1970).
Precast N uPAG E®  bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane (Bis-Tris) gels 
(invitrogen, UK) were used in this project, and do not contain SDS, but were designed
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for denaturing electrophoresis. They utilised Bis-Tris chloride as the gel buffer at neutral 
pH, and 50m M  MES with 50mM Tris at pH 7.2, as the running buffer. This meant that 
during electrophoresis, MES, instead of the more conventional glycine, was the ion 
running behind chloride towards the anode, and Tris in the tank buffer, migrated to 
displace the Bis-Tris that moved towards the cathode (Hachmann and Amshey, 2005). 
Maintenance of approximately neutral conditions using this system reduced the reactivity 
of amino acid side chains during electrophoresis, thereby minimising protein 
modifications and making Bis-Tris gels a good choice for subsequent MSpec 
applications that require protein integrity (Haebel et al., 1998).
2.3.2.2 Pre-cast gels
All equipment and reagents used with pre-cast gels were from Invitrogen (Paisley, UK). 
Pre-cast, 1 mm thick, 12-well, 12% Bis-Tris gels were found to give the best results for 
resolution of chemokines. These were used in an XCell SureLock™ Mini-Cell II tank 
apparatus, with MES running buffer. NuPAGE® running buffer (20X) was diluted to 1X  
with dH20 , and 500pl of NuPAG E® antioxidant was added to the 200ml running buffer 
destined for the central chamber, comprising the electrode encased by the gel(s). 
Running buffer without antioxidant was added to the outer region of the tank until it was 
two-thirds full. Samples (10pl), prepared as described in 2.3.1.5, were pipetted into the 
wells of the gel, which was run at a constant 200 volts for ~ 1h. Once the dye front had 
almost reached the bottom, gels were removed from their plastic cassettes.
2.3.3 Silver staining of gels
2.3.3.1 Principles of silver staining
Silver staining is a highly sensitive technique, due to the autocatalytic nature of the 
reduction of silver ions, capable of detecting nanogram quantities of protein, in either 
histological sections or gels. Silver ions from the staining solution bind to protein, where 
they are later reduced to metallic silver by the developing solution, and appear as black 
deposits. Typically, either silver nitrate is used in silver stains together with 
formaldehyde, in an alkaline carbonate solution as the developer, or a silver-ammonia 
complex is developed by formaldehyde in dilute citric acid (Rabilloud et al., 1994).
In order to have the option of subsequent analysis by mass spectrometry of silver- 
stained bands of interest in a gel, a modified silver-staining kit was used. Sensitising 
solution is normally aldehyde-based, but the one used in this method did not contain 
glutaraldehyde or formaldehyde, which would otherwise modify lysine residues and 
prevent complete digestion of the band by trypsin (Matsumura et al., 1999). Trypsin is 
used in MSpec analysis to generate peptide fragments of a protein band within the gel.
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The fragments can then have their masses determined by matrix assisted laser 
desorption ionisation (MALDI) MSpec and the protein identified using database 
searches (Hurkman and Tanaka, 2007).
The silver staining process used in this method involved fixation to remove interfering 
ions and detergent, and to immobilise the proteins in the gel matrix. A sensitising step 
followed, designed to increase the contrast of the stain. The ensuing staining step 
bound silver ions to the protein, before they were reduced to metallic silver by the 
developer. The reduction reaction was stopped when the desired staining intensity was 
reached, by addition of a further solution, which formed complexes with any free silver 
ions. Appropriate alcohol or water washes were used after each step to remove the 
previous solution.
Silver staining was used instead of Coomassie blue, as it is up to 100-fold more 
sensitive (Budowle, 1984), which would assist with detection of low levels of protein, 
such as minor cleavage products.
2.3.3.2 Silver staining technique
Following a brief rinse in ultrapure H20  after SDS-PA G E (see 2.3.2.2), gels were 
stained using reagents from a SilverQuest™ kit (Invitrogen), following the 
manufacturer’s recommended protocol. Ultrapure water (>18 megohm/cm resistance) 
was used throughout the staining procedure, each step was performed on an orbital 
shaker at 50rpm, and the volume of solutions used per gel at each stage was 100ml. 
Gels were immersed in 100ml fixative (10%  v/v glacial acetic acid, 40%  v/v ethanol, in 
water) for at least 20min. Following fixation, gels were washed in 30%  ethanol for 
10min, before being placed in sensitising solution (30%  ethanol, and10%  sensitiser 
[10-30%  w/v M ES and 7-13%  w/v N,N-dimethylformamide] in water) for 10min. A  
10min wash in water preceded 15min incubation in staining solution (1% stainer [10- 
30%  w/v silver nitrate] in water). Gels were then rinsed for 20-60 seconds in water, and 
left in developing solution (10%  developer [15% w/v carbonic acid, dipotassium salt], 1 
drop developer enhancer [30-60%  w/v formaldehyde], in water) for 4-8min until the 
required band intensity was reached, when 10ml of stopper (10-30%  w/v Tris base, 10- 
30%  EDTA) was added directly to the gel and left to shake for a further 10min. Finally, 
gels were rinsed with water, scanned using an Epson flatbed scanner, and images 
obtained using Corel Photo Paint 8 software.
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2.3.3.3 Calculating the relative molecular mass of samples in silver-stained gels
A graph was plotted of the log of the M r of the bands from the molecular weight 
standard, against the the relative distance (%) travelled by each band, compared to the 
total distance run by the gel, using the dye front distance. The equation of the trendline 
was rearranged to allow the approximate M r of the unknown bands to be calculated, 
based on their relative distance travelled.
2.3.4 Mass Spectrometry
Mass spectrometry is used to measure the molecular mass of a sample to within 
approximately 0 .01-0 .2%  of the total mass, which enables detection of minor mass 
changes such as post-translational modifications or amino acid substitutions. 
Potentially, sub-picomole levels of a sample with a M r of up to 300 kDa can be used. 
Apart from M r measurement, mass spectrometers can be used for amino acid and/or 
oligonucleotide sequencing, to monitor reactions, such as protein digestion, and to 
provide information about protein structure (Karas et al., 1990).
2.3.4.1 Principles of MALDI mass spectrometry
Matrix assisted laser desorption ionisation (MALDI) is a useful tool for analysis of non­
volatile organic compounds of high Mr. It is reasonably tolerant, compared to other 
ionisation techniques, to the additives that are found in some samples, and offers a 
reliable and straightforward method of analysing proteins, peptides, glycoproteins, 
oligosaccharides, and oligonucleotides (Yan et al., 2000).
A mass spectrometer has 3 main parts: the ionisation source, the analyser and the 
detector. Samples are mixed with an organic compound with strong absorption at the 
laser wavelength, i.e. a matrix solution, and spotted onto a stainless steel target plate 
numbered with 100 circles. The solvent evaporates and the matrix crystallises, and 
once in the mass spectrometer, the pulses of light from the laser irradiate the sample 
on the target. UV  lasers are commonly used in MALDI, particularly nitrogen lasers with 
excitation at 337nm. The laser pulses excite the matrix molecules and energy is 
transferred to the sample within the matrix, and both sample and matrix desorb from 
the condensed state and enter the vapour phase. Proton transfer from the matrix to the 
sample can now occur, thereby resulting in ion formation (Fig. 2.1(i)). The  
transformation of laser energy to sample excitation energy is efficient and avoids the 
sample decomposition that could occur if it received excessive direct energy. A high 
potential is applied to accelerate the ions down a drift tube, which contains a vacuum to 
prevent any impediment to their journey. The ions are passed through a series of
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extraction and focusing electrodes and lenses in the analyser region, where separation 
according to mass (m) -to-charge (z) ratios (m/z) occurs, before the ions are detected 
(Fig. 2.1 (ii)) (Schiller et al., 2004).
MALDI is a soft ionisation technique that limits fragmentation and produces singly- 
charged ions, even with large proteins. This means mass analysers with high m/z 
capabilities are used in conjunction with MALDI, such as the time-of-flight (TOF) 
analyser. Other analysers are available, such as q u ad ru p les , with different m/z range 
coverage, accuracy, or resolution, but they all serve to separate the ions formed, 
according to m/z ratios (Schiller et al., 2004). The TO F mass analyser measures the 
time for ions to travel between the accelerator electrode and the detector, i.e. along the 
drift tube, and uses this data to determine the m/z value, with heavier particles taking 
longer to reach the detector.
The laser pulses produce discrete groups of ions intermittently, which facilitates 
measurement of the flight time. If a series of electrodes at different potentials, called a 
reflectron, is present, the energy spread of ions is more focused and the resolution of 
the TO F analyser increased (Fig. 2.1 (ii)). Reflectrons are repelling devices that cause 
ions to change direction and accelerate back towards the detector. This effectively 
reduces the differences in kinetic energy distribution between ions, as higher energy 
ions will travel further into the reflectron and have a longer flight path, with an end 
result of all ions of a specific m/z arriving at the detector in a narrower time span. If a 
pulsed orthogonal beam pusher is incorporated into the instrument, ions are introduced 
into the analyser in focused groups perpendicular to their flight path (Ens and Standing, 
2005).
Tandem (M S-M S) mass spectrometers have more than one analyser and are useful in 
acquiring structural and sequence data. If the analysers are of different types, the 
instrument is classed as a hybrid mass spectrometer, such as the quadrupole-time-of- 
flight version (Ens and Standing, 2005).
MALDI can be used in either positive or negative ion mode, depending on whether the 
sample either gains or loses a proton respectively, i.e. (M +H )+ or (M -H)', where M 
represents the molecular ion. Positive mode is generally used for protein and peptide 
analysis, and negative mode for oligonucleotides and oligosaccharides. In positive 
mode, other species commonly identified are (M +NH4)+ and salt adducts such as 
(M +N a)+. Traces of doubly charged molecular ions at half the m/z value, or dimers at 
twice the m/z value, can sometimes be identified (Schiller et al., 2004).
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Figure 2.1 Schematic diagrams illustrating the main processes involved in 
MALDI-TOF mass spectrometry and a TOF mass spectrometer
(i) Prior to M ALDI M Spec analysis, samples are mixed with matrix and spotted onto a 
target plate. When dry, the matrix crystallises and forms co-crystals with the sample. In 
the mass spectrometer, an electrical field is applied, and a pulsed laser fired onto the 
sample. Desorption occurs as the matrix absorbs the laser energy, causing rapid 
heating and subsequent sublimation o f matrix molecules. Matrix and analyte clusters 
expand into the vapour phase, and are ejected from the target surface. Excited matrix 
molecules are stabilised by proton transfer to the analyte, and cation attachment to the 
analyte occurs, such as addition of H +, N a+, or fC. The matrix evaporates away to leave 
free analyte ions.
(ii) Singly charged ions generated from the desorption-ionisation process pass through 
a charged grid, and are accelerated into the TO F drift tube, which is under a high 
vacuum. The length o f this tube is typically 0.5-3 m long and determines the possible 
mass resolution. To improve resolution, a reflector can be incorporated to reflect ions at 
the end o f the flight tube to reach a "reflector-detector", thereby lengthening the field- 
free path travelled. Low mass ions reach the end o f the flight tube in a shorter time than 
high mass ions, and as they are equally charged, separation based on mass is 
achieved. A detector at the end o f the tube produces a signal upon impact o f each ion, 
and m/z spectra are produced from this signal as a function of time.
[M + H f  = Ion formed by interaction o f a molecule with a proton; TOF  = time-of-flight
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In positive ion operation, ionisation of the sample is often assisted by the inclusion of 
0.1%  trifluoroacetic acid (TFA) in the matrix, but this is not used in negative ion MALDI, 
where it suppresses the formation of sample ions (Schiller et al., 2004).
The detector must suit the type of analyser used in the instrument, and is commonly of 
a photomultiplier, electron multiplier, or micro-channel type. The ion current is 
monitored by the detector, which also amplifies it and transmits signals to the data 
system, which records it as mass spectra. The m/z values are plotted against their 
intensities, and the resulting spectra show the molecular mass of the sample 
components and their relative abundance (Barnes and Hieftje, 2004).
2.3.4.2 Matrix requirements for MALDI mass spectrometry
The matrix used in MALDI MSpec has a significant impact on the results obtained and 
must be selected according to the sample being analysed. Matrices consist of small 
organic compounds, which absorb the laser energy strongly at the applied wavelength, 
and separate the analyte molecules, to avoid cluster formation. MALDI preparations 
should ideally have a low concentration of analyte molecules and an excess of matrix 
on the target plate, which helps to prevent fragmentation of the analyte. Typically, a 
sample concentration of 10pmol/pl is mixed with an equal volume of matrix of around 
10 mg/ml, but these concentrations can vary depending on the samples being analysed. 
Small volumes (0.5 -  2pl) of the analyte/matrix mix are used for spotting onto the target 
plate (Groos and Strupat, 1998). Table 2.5 summarises different matrices and the 
sample types they are commonly used for. Most importantly, a matrix should be 
selected that has good absorption properties with the laser used, and that mixes well 
with the analyte to give homogeneous co-crystalisation (Schiller et al., 2004).
2.3.5 Analysis by mass spectrometry of chemokine/enzyme incubation samples
2.3.5.1 Choice and application of matrix
Both a-C H C A  and sinapinic acid (20mg/ml, 50%  v/v acetonitrile, 0.1%  v/v TFA) were 
assessed with recombinant chemokine samples to determine which gave the greatest 
sensitivity. A stock solution of a-CHCA  was prepared (25mg/ml, 0.1%  v/v TFA, in 
methanol) and due to low solubility, it was sonicated for 5min in a Branson 1210 
sonicator bath (Branson Power Company, USA) to increase dissolution. W hen Zip 
Tips® were used (see 2.3.5.2), the final concentration of a-C H C A  was 12.5mg/ml, as 
the matrix solution was mixed with an equal volume of acetonitrile (ACN) + 0.1%  TFA, 
for elution of the sample.
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Table 2.5 Matrices used in MALDI-TOF mass spectrometry
M A TR IX SA M PLE
a-cyano-4-hydroxycinnamic acid 
(a-C HCA)
Peptides, proteins
3,5-dimethoxy-4-hydroxycinnamic acid 
(sinapinic acid)
Proteins
2,5-dihydroxybenzoic acid (DHB) Sugars, nucleotides, peptides
Hydroxypicolinic acid (HPA) Oligonucleotides, glycopeptides
Dithranol Synthetic polymers, large organics, 
lipids
Several matrix compounds used in M ALDI-TO F mass spectrometry are shown, 
together with the sample type they are most commonly used for. Proteins with a mass 
of less than 10 kDa are often used with a-CHCA, whilst sinapinic acid is better suited to 
proteins larger than 10 kDa. DHB is a useful matrix when the samples are polar. H P  A 
is frequently used with oligonucleotides, with masses greater than 3 .5  kDa (Schiller et 
al., 2004).
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Preliminary experiments were performed to investigate the most effective method of 
sample addition to the target plate, matrix alone was spotted and allowed to dry, before 
the sample was spotted on to the top of this, or the sample was pre-mixed with matrix 
and applied in a one-step method).
2.3.5.2 Use of Zip Tips® in sample preparation for analysis by MSpec
Mass spectrometry is often complicated by the presence of salts and contaminants in 
the sample, which can obscure the protein of interest, particularly when it is present at 
low concentrations (Monroe et al., 2007). To concentrate and purify samples for 
optimal results with MALDI-quadrupole/TOF (M ALDI-Q TO F) analysis, Zip Tips®  
(Millipore) were used prior to spotting samples onto the target plate. Zip Tips® are 10pl 
pipette tips that contain chromatography media. Various resins are available for 
different applications, and for concentrating small proteins such as chemokines, Zip 
Tips® with 0.6pl of a C 18 resin were used, composed of 15pm silica with 20nm pores.
Chemokine/protease digestion samples were analysed by M ALDI-Q TO F both with, and 
without, the use of Zip Tips® in the sample preparation stage. It was expected that Zip 
Tips® should desalt and concentrate the samples, but it was necessary to eliminate the 
possibility that artefacts could result from their use. Preliminary experiments were thus 
conducted where samples were compared after being mixed with matrix and spotted 
onto the target plate, or first passed through a Zip Tip®  according to the following 
protocol, which is hereafter called “zip tipping”.
The chemokine/protein digest sample was first mixed with an equal volume (5pl) of 
sample preparation solution (see 2.3.1.5). The Zip Tip®  was wetted twice with 10pl 
acetonitrile (ACN), which was then expelled before two equilibration steps involving 
slow uptake and expulsion of 10pl equilibration/wash solution (0.1%  TFA  in dH20). The  
digest sample was cycled slowly through the Zip Tip® 7 -  10 times in an Eppendorf 
tube, and finally expelled. Three x 10pl of wash solution (0.1%  TFA in dH20) were then 
drawn up and ejected, before 2pl of elution solution (0.1%  v/v TFA, 50%  v/v ACN, 50%  
v/v methanol, 12.5mg/ml a-CHCA) was aspirated and cycled 3 - 4  times into a clean 
Eppendorf tube before being spotted directly onto the target plate.
2.3.5.3 MALDI-QTOF of cleavage products
Preliminary data supported the use of Zip Tips® in preparation for MSpec, and this was 
performed as detailed above in 2.3.5.2. Samples were analysed using an Applied 
Biosystems/MDS Sciex API “Q-Star” Pulsar i hybrid quadrupole time-of-flight mass
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spectrometer. This was fitted with an orthogonal MALDI ion source, and an 
neodymium-doped yttrium aluminium garnet (Nd:YAG) laser, which was used at an 
energy of 20-30% , and a repetition rate of 500H z -  1kHz. The instrument was 
governed by “o-MALDI Server 4 .0” software, and was used in positive ionisation mode. 
Analysis was performed for 5min for each sample. Mass spectra showing m/z values, 
with their intensity, were acquired using Analyst QS software (Applied Biosystems, 
Warrington, UK).
2.3.5.4 Interpretation of mass spectra
The m/z value for intact CCL2 and CXCL10 was obtained by MSpec analysis of the 
recombinant proteins. Peaks obtained after digestion were then compared to this value, 
and differences in the m/z values matched to losses of amino acids, based on the 
known average masses of the residues, and the sequence supplied by the 
manufacturer of the chemokines (Peprotech EC).
82
2.4 Results
2.4.1 Gel electrophoresis of CCL2 incubated with MMP2 or MMP9
A downward shift of bands from all samples involving incubation of CCL2 with either 
MM P2 or M M P9 for 3-6h (Fig. 2.2) was detected, compared to intact CCL2 (where the 
MMPs were inhibited with EDTA). Bands seen after 3h incubations of CCL2 with MMPs 
2 and 9, appeared at a slightly higher position and were blurred, compared to bands 
involving 6h exposure to enzyme, suggesting digestion was still ongoing. The 
approximate M r of intact CCL2 was calculated to be 7.7 kDa, 3h incubation with M M P2  
reduced this by ~0.2 kDa to ~7.5 kDa, and at 6h, a total loss of -0 .5  kDa reduced it to 
-7 .2  kDa. M M P9 reduced the mass of CCL2 even further overall, yielding -7 .3  kDa at 
3h (a loss of -0 .4  kDa), and -7 .1  kDa at 6h (a total loss of -0 .6  kDa). Controls of CCL2  
and M M P2 incubated separately in buffer indicated that no spontaneous breakdown of 
either CCL2 or M M P2 occurred. Inhibition of MMPs 2 and 9 with EDTA prevented the 
shift in bands of CCL2 to a lower M r, leaving it unprocessed (Fig. 2.2).
2.4.2 Gel electrophoresis of CXCL10 incubated with MMP2 or MMP9
All samples involving incubation of CXCL10 with either M M P2 or M M P9 for 24-48h  
resulted in multiple bands being observed, compared to intact C XCL10 (where the 
MMPs were inhibited with EDTA) (Fig. 2.3). W here multiple bands occurred, the 
uppermost band corresponded to the band for intact CXCL10. The upper two bands at 
24h incubations of CXCL10 with MMPs 2 and 9, situated close to each other, were of a 
greater density than comparable upper bands from the 48h samples. The lower 2 
bands, of lanes with multiple bands, were of a lower density than the upper 2 bands in 
all cases. W hen CXCL10 is incubated with M M P9 for 48h, it is still being processed 
after 24h, confirmed by the reduction in density of the uppermost band at 48h 
compared to 24h. The approximate M r of intact CXCL10 was calculated to be 6.7 kDa, 
and 24-48h incubation with either MM P2 or M M P9 produced bands with M x s of -6 .7 ,
6.1, 4.1 and 3.5 kDa, representing intact CXCL10, and losses o f -0 .6 , 2.6 and 3.2 kDa. 
Control samples of CXCL10 in buffer and M M P9 in buffer, did not produce any 
unexplained bands, and confirmed that the recombinant proteins did not auto-degrade 
during the incubation (Fig. 2.3).
2.4.3 Gel electrophoresis of CCL2 and CXCL10 incubated with CD26
A slight downward shift of bands from all samples involving incubation of CCL2 or 
CXCL10 with CD26 for 0.5-6h was detected, compared to the intact chemokines 
(where CD26 was heat-inactivated) (Fig. 2.4).
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Figure 2.2 Chem okine cleavage: electrophoresis  using B is-Tris 12% silve r- 
stained gel o f CCL2 at 3 and 6h incubation w ith M M Ps 2 or 9
CCL2 (4pM) n/as incubated with either MMP2 or MMP9 (0.4pM) in assay buffer 
(100mM Tris-HCI, 100mM Nad, 10mM C ad2, 0.01% Tween® 20) for 6h at 37°C. 
Samples were taken at 3 and 6h, and some were passed through YM50 Microcons® to 
remove the enzyme. LDS sample buffer and reducing agent were added to the 
samples, which were denatured by heating at 70°C for 10min. SDS-PAGE was 
performed using MES running buffer, and the gel was silver-stained. Downward shifts 
of the bands in lanes 2, 3, 4, 6, 7, and 8, can be detected following cleavage of CCL2 
by either MMP2 or MMP9.
Lanes shown above had 10pl of the following samples loaded:
(I)  SeeBlue Plus 2 marker; (2) MMP2/CCL2 3h; (3) MMP2/CCL2 6h;
(4) MMP2/CCL2 6h after passing through a YM50; (5) MMP2/EDTA/CCL2 6h;
(6) MMP9/CCL2 3h; (7) MMP9/CCL2 6h; (8) MMP9/CCL2 6h after passing through a 
YM50; (9) MMP9/ED TA/CCL2 6h; (10) MMP2/APMA/buffer Oh;
( I I )  MMP2/APMA/buffer 48h; (12) CCL2/buffer control 6h
m
%
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Figure 2.3 C hem okine cleavage: electrophoresis  using B is-Tris 12%  s ilve r- 
stained gel o f C XCL10 at 24 and 48h incubation w ith M M Ps 2 or 9
CXCL10 (4pM) was incubated with either MMP2 or MMP9 (0.4ijM) in assay buffer 
(100mM Tris-HCI, 100mM NaCI, 10mM CaCI2, 0.01% Tween® 20) for 72h at 37°C. 
Samples were taken at 24 and 48h, and some passed through YM50 Microcons® to 
remove the enzyme. LDS sample buffer and reducing agent were added, and the 
samples denatured by heating at 70°C for 10min. SDS-PAGE was performed using 
MES running buffer, and the gel was silver-stained. Multiple bands can be detected 
following cleavage of CXCL10 by both MMP2 and MMP9, but not in controls involving 
EDTA inhibition of MMPs.
Lanes shown above had 10pl of the following samples loaded:
(I) SeeBlue Plus 2 marker; (2) MMP2/CXCL10 24h; (3) MMP2/CXCL10 48h; (4) 
MMP2/CXCL10 48h after passing through a YM50; (5)MMP2/EDTA/CXCL10 24h; (6) 
MMP9/CXCL10 24h; (7) MMP9/CXCL10 48h; (8) MMP9/CXCL10 48h after passing 
through a YM50; (9) MMP9/ED TA/CXCL10 24h; (10) MMP9/APMA/buffer Oh;
( I I )  MMP9/APMA/buffer 48h; (12) CXCL10/buffer control 48h
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After 30min incubations of CCL2 and CXCL10 with CD26, no further shift is seen with 
the corresponding bands where the time was extended to 6h. The approximate M r for 
CCL2 was calculated to be 8.5 kDa, which was decreased by -0 .6  kDa to -7 .9  kDa, 
following 0.5-6h incubation with CD26. The approximate M r for intact CXCL10 was 
calculated to be 7 kDa, which was reduced by -0 .2  kDa to -6 .8  kDa, following 0.5-6h  
incubation with CD26 (Fig. 2.4). Control samples of CD26 alone in buffer revealed that 
the enzyme did not degrade products during 6h incubation (data not shown).
2.4.4 Optimisation of MALDI-QTOF mass spectrometry for use in identification of 
chemokine cleavage products
The visual representation of chemokine cleavage products obtained with the use of 
silver-stained gels was supported by an accurate determination of their masses using 
M ALDI-Q TO F MSpec. MSpec was optimised for analysis of chemokine-protease 
samples by investigating aspects of sample preparation and application to the target 
plate. The use of Zip Tips® to concentrate and desalt samples prior to analysis was 
found to dramatically improve results by increasing peak intensity, reducing 
background, and removing salt adducts (Fig. 2.5). Premixing samples with matrix prior 
to spotting onto the target was found to give substantially better results than applying 
samples onto dried matrix already on the target (data not shown). The matrix selected 
for use in analysis of chemokines and their cleavage products was a-CHCA, as this 
resulted in mass spectra with greater intensity, lower background, and no salt adducts 
(Fig. 2.6).
2.4.5 MALDI-QTOF mass spectrometry of CCL2 incubated with MMP2
Mass spectra of Zip tipped samples of CCL2 incubated with activated M M P2 for 3h 
showed that the intact CCL2 molecule was no longer present. The dominant peak had 
an m/z of 8263 (Fig. 2.7a), representing a reduction in mass of 411. This difference in 
mass is equal to the sum of the average masses of the 4 N-terminal residues of CCL2. 
The mass spectrum obtained after CCL2 was incubated with M M P2 for 6h confirmed 
that 8263 m/z remained as the dominant peak and had not been processed further (Fig. 
2.7b). W hen M M P2 was inhibited by 20mM EDTA, the only peak seen at 6h was that of 
8674 m/z, corresponding to intact CCL2 (Fig. 2.7c). Matrix salt adducts (401, 524, and 
568 m/z), and contaminants (8452 and 8641 m/z), were observed in 3h samples.
2.4.6 MALDI-QTOF mass spectrometry of CCL2 incubated with MMP9
Mass spectra of zip tipped samples of CCL2 incubated with activated M M P9 gave 
identical results as with M M P2 (see 2.4.5).
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Figure 2.4 C hem okine cleavage: electrophoresis  using Bis-Tris 12% s ilve r- 
stained gel o f CCL2 and CXCL10 at 0.5 and 6h incubation w ith  CD26
CCL2 or CXCL10 (4pM) were incubated with CD26 (0.04ijM) in assay buffer (25mM 
Tris) for 6h at 37°C. Samples were taken at 30min and 6h, LDS sample buffer and 
reducing agent were added, and samples denatured by heating at 70°C for 10min. 
SDS-PAGE was performed using MES running buffer, and the gel w as silver-stained. 
Slight downward shifts in the bands in lanes 3, 4, 6, and 7 can be seen, compared to 
lanes 2 and 5.
Lanes shown above had 10pl of the following samples loaded:
(1) SeeBlue Plus2 MW marker; (2) Heat-inactivated CD26/CCL2 6h;
(3) CD26/CCL2 30min; (4) CD26/CCL2 6h;
(5) H eat-in activated CD26/CXCL10 6h; (6) CD26/CXCL10 30min;
(7) CD26/CXCL10 6h; (8) Mark12 MW marker
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Figure 2.5 O ptim isation o f m ass spectrom etry: m ass spectra show ing the effects  
of zip tipping a chem okine-p ro tease sam ple p rior to M ALD I-Q TO F analysis
CCL2 was incubated at 37°C with MMP2, without activation with APMA, and samples 
were taken at 15min. Samples were analysed by MALDI-QTOF MSpec, using a-CHCA 
as the matrix, and were either mixed with matrix and spotted onto the target plate 
directly, or were first zip tipped, before analysis.
(a) Mass spectrum of CCL2, with a peak at 8682.9 m/z. The peak intensity was 
relatively low, at a maximum of 200 counts, and the background noise was quite high. 
The peaks seen to the left of the spectrum at ~ 1000-1600 m/z, with a dominant peak at 
1600 m/z, derive from clusters of matrix molecules with potassium and sodium ions 
(Neubert et al., 2004).
(b) Mass spectrum of the same sample analysed in (a), but incorporating zip tipping 
before analysis by MSpec. The CCL2 peak at 8682 m/z is clearly dominant, with a 
much stronger intensity of 1392 counts. Background is minimal, and matrix cluster 
peaks are barely seen.
(a) Without zip tipping, CCL2 and MMP2, 15min incubation
+TOF MS: 300 MCA scans from Sample 60 (CHCA_CCL2MMP2lnactive0hr22Mar05) of IHelenChemokines.wiff 
a=3.56486746421487600e-004, t0=5.84361010882930710e+001
Low intensity
Salt
adducts
High background
m/z. amu
(b) W ith zip  tipping, CCL2 and M M P2, 15m in incubation
a=3.56486746421487600e-004. t0=5.84361010882930710e+001
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Figure 2.6 Optimisation of mass spectrometry: mass spectra comparing 
sinapinic acid and a-CHCA as the matrix prior to MALDI-QTOF analysis of a zip 
tipped chemokine-protease sample
Two matrices were tested with samples from the chemokine-protease incubation 
experiment to establish which one gave the greatest sensitivity. CCL2  was incubated at 
37°C with MMP2, that had not received prior treatment with APMA, and samples were 
taken at 6h. Samples were prepared for M ALDI-Q TO F M Spec analysis by zip tipping, 
follwed by mixing with either sinapinic acid, or a-CHCA, as the matrix.
(a) Mass spectrum of CCL2 from the incubation mixture, using sinapinic acid as the 
matrix. The dominant peak is that o f CCL2, seen at 8682 m/z. The peak intensity was 
relatively low, at a maximum of 119 counts, and the background noise was high. The 
peaks seen to the left o f the spectrum at ~ 1000-1600 m /z are likely to derive from the 
matrix.
(b) Mass spectrum of the same sample analysed in (a), but using a-CHCA  as the 
matrix. The dominant peak is that of CCL2, seen at 8682 m/z, with a very high intensity 
of 1723 counts. Background was low, and clustered matrix-associated peaks to the left 
of the spectrum are not seen.
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(a) CCL2 & MMP2 at 6h, zip tipped, and premixed with sinapinic acid matrix
+TOF MS: 300 MCA scans from Sample 65 (CCL2MMP2lnactive_6hr_ZiptipPremixSPNA) of IHelenChemokines.wiff 
a=3.56486746421487600e-004, t0=5.84361010882930710e+001
Low intensity
Salt
adducts
High background
125.4044
m/z. amu
b) CCL2 & M M P2 at 6h, zip tipped, and prem ixed w ith  a-C H C A  M atrix
+TOF MS: 300 MCA scans from Sample 67 (CCL2MMP2lnactive_6hr_ZiptipPremixCHCA) of IHelenChemokines.wiff 
a=3.56486746421487600e-004, t0=5.84361010882930710e+001
Same mass 
peak as (a)
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Figure 2.7 Chemokine cleavage: mass spectra from MALDI-QTOF analysis of 
CCL2 incubated with MMP2 for 3 and 6h, and with inhibited MMP2
Recombinant human CCL2 (4pM) and M M P2 (0.4pM ) were incubated in assay buffer 
(100m M  Tris-HCI, 100m M  NaCI, 10mM CaCi2, 0.01%  Tween® 20) for 6h at 37°C. 
Samples were taken at 3 and 6h and the reaction stopped by addition o f an equal 
volume of 0.5%  TFA and freezing at -80°C. Samples were zip tipped, mixed with a- 
CHCA matrix, spotted onto a target plate and analysed by M A LD I-Q TO F MSpec.
(a) 3h incubation resulted in no peak being present that corresponded to the m/z of 
intact CCL2. The dominant peak was 8263, which represented a reduction o f 411 from 
intact CCL2. This difference in mass was equal to the sum of the average masses of 
the 4 N-terminal amino acids of CCL2. N.B. M ajor peaks representing matrix salt 
adducts were also seen (401, 524, and 568 m/z), and contaminants (8452.7  and
8641.8 m/z) in the spectra shown, but not in repeat analyses.
(b) 6h incubation resulted in an absence of peaks in the 400-600 m /z range, but a 
single dominant peak o f 8263 m/z was seen.
(c) 6h incubation in the presence o f20m M  EDTA resulted in a single peak o f 8674 m/z, 
corresponding to intact CCL2
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a) 3h
+TOF MS: 220 MCA scans from Sample 220 (MMP2_CCL2_3hr_1Mar07) of IHelenChemokines.wiff 
a=3.56343690874399970e-004, t0=3.68134000911360600e+001
(b) 6h (c) 6h with inhibited MMP2
i=3.56343690874399970e-004.
8674.
m/z amu
-►  8263.
m/z amu
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Briefly, at 3h intact CCL2 was not seen and the dominant peak had an m/z of 8263 (Fig. 
2.8a), representing a reduction in mass of 411 (equal to the sum of the masses of the 4 
N-terminal residues). Longer incubation (6h) did not reveal any changes (Fig. 2.8b). 
W hen M M P9 was inhibited by 20mM EDTA, the only peak seen at 6h was that of 8674  
m/z, corresponding to intact CCL2 (Fig. 2.8c).
2.4.7 MALDI-QTOF mass spectrometry of CCL2 incubated with CD26
Mass spectra of zip tipped samples of CCL2 incubated with CD26 for 30min showed 
that the intact CCL2 molecule was present at half the intensity of a product of 8449.8  
m/z (Fig. 2.9a). The dominant peak represented a rapid reduction in mass of 225. This 
difference in mass is equal to the sum of the average masses of the 2 N-terminal 
residues of CCL2. The mass spectrum obtained for 6h showed a single peak of 8449.8  
m/z, representing the cleaved form, with no further processing (Fig. 2.9b). Heat- 
inactivating CD 26 prior to use resulted in a single peak of intact CCL2 at 8674.7 (Fig. 
2.9c).
2.4.8 MALDI-QTOF mass spectrometry of CXCL10 incubated with MMP2
Mass spectra of zip tipped samples of CXCL10 incubated with activated M M P2 for 24h  
showed that the intact CXCL10 molecule was the dominant peak. Minor peaks at less 
than 25%  the intensity of this were noted at 437.1 and 926.2 (matrix salt adducts), and
8058.9 and 8144.5 m/z (Fig. 2.10a). The total mass of the first 5 N-terminal residues of 
CXCL10 equals 552, which corresponded to the reduction of intact CXCL10 to the 
minor peak seen at 8058.9 m/z. In addition, the peak at 8144.5 represents a loss of 
467 from intact CXCL10, which is very similar to 468, the total mass of the first 4 C- 
terminal amino acids. At 48h, intact CXCL10 still dominates, but the relative intensities 
of the peaks at 8059.1 and 8143.3 m/z have increased. Peaks representing matrix salt 
adducts (437.1 and 962.2 m/z) have also increased from 24h to 48h (Fig. 2.10b). At 
72h, the only non-matrix peak visible was that of 8062.7 m/z, at a very low intensity of 7 
counts (Fig. 2.10c). As the intensity was much reduced compared to earlier spectra, 
the accuracy was reduced, and this was most likely the same peak as 8059 m/z seen 
at 24 and 48h, deemed to represent a loss of 5 N-terminal residues. It is possible that 
by 72h, CXCL10 has been almost completely degraded by activity at other cleavage 
sites within the molecule. Inhibiting MMP2 with EDTA abrogated the production of 
cleavage products, producing only a single peak at 24h pertaining to intact CXCL10  
(Fig. 2.10d).
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Figure 2.8 Chemokine cleavage: mass spectra from MALDI-QTOF analysis of 
CCL2 incubated with MMP9 for 3 and 6h, and with inhibited MMP9
Recombinant human CCL2 (4pM) and M M P9 (0.4(jM) were incubated in assay buffer 
(100m M  Tris-HCI, 100m M  NaCI, 10m M  CaCI2, 0.01%  Tw een® 20) for 6h at 37°C. 
Samples were taken at 3 and 6h and the reaction stopped by addition of an equal 
volume of 0.5%  TFA and freezing at -80°C. Samples were zip tipped, mixed with a- 
CHCA matrix, spotted onto a target plate and analysed by M A LD I-Q TO F MSpec.
(a) 3h incubation resulted in no peak being present that corresponded to the m/z of 
intact CCL2 (8674 m/z, determined by analysis o f CCL2 alone). The dominant peak  
was 8263, which represented a reduction of 411 from intact CCL2. This difference in 
mass was identical to the reduction found with M M P9 and is equal to the sum of the 
average masses o f the first 4 N-terminal amino acids. N.B. M ajor peaks representing 
matrix salt adducts were also seen (401, 505, and 568 m/z), and contaminants (8452.8  
and 8641.5 m/z) in the spectra shown, but not in repeat analyses.
(b) 6h incubation resulted in an absence o f peaks in the 400-600 m /z range, but a 
single dominant peak o f 8263 m /z was seen.
(c) 6h incubation in the presence of 20m M  EDTA resulted in a single peak o f 8674 m/z, 
corresponding to intact CCL2
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(a) 3h
+TOF MS: 207 MCA scans from Sample 221 (MMP9_CCL2_3hr_1Mar07) of HelenChemokines.wiff 
a=3.56343690874399970e-004, t0=3.68134000911360600e+001
-401.0174
(b) 6h (c) 6h with inhibited MMP9
Max. 227.0 counts.
a=3.56343690874399970e-004,1
227 
220
210
200
190
8674.6849
m/z amu
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Figure 2.9 C hem okine cleavage: m ass spectra from  M A LD I-Q TO F analysis of 
CCL2 incubated w ith  CD26 fo r 30m in, 6h and w ith inactivated CD26
Recombinant human CCL2 (4pM) and CD26 (0.04pM) were incubated in assay buffer 
(25mM Tris) for 6h at 37°C. Samples were taken at 30min, 3h (not shown) and 6h, and 
the reaction stopped by addition of an equal volume of 0.5% TFA and freezing at -80°C. 
Samples were zip tipped, mixed with a-CHCA matrix, spotted onto a target plate and 
analysed by MALDI-QTOF MSpec.
(a) 30min incubation resulted in a peak at 8675 m/z that corresponded to the m/z of 
intact CCL2, but this was less than half the intensity of the dominant peak of 8449.8 
m/z. The peak at 8449.9 m/z represented a reduction of 225 from intact CCL2, which 
equals the sum of the average masses of the first 2 N-terminal amino acids.
(b) 6h incubation resulted in a single dominant peak of 8449.8 m/z being seen, which 
equals the mass of intact CCL2 minus an N-terminal dipeptide.
(c) 6h incubation with CD26 being first heat-inactivated, resulted in a single peak of
8674.7 m/z, corresponding to intact CCL2.
97
(a) 30min
+TOF MS: 300 MCA scans from Sample 249 (CD26_CCL2_30min_2ndgo_1Mar07) of HelenChemokines.wiff
(b) 6h (c) 6h with heat-inactivated CD26
i=3.56343690874399970e-004.
m/z amu m/z amu
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Figure 2.10 Chemokine cleavage: mass spectra from MALDI-QTOF analysis of 
CXCL10 incubated with MMP2 for 24, 48 and 72h, and with inhibited MMP2
Recombinant human CXCL10 (4}jM) and M M P2 (0.4pM ) were incubated in assay 
buffer (100m M  Tris-HCI, 100m M  NaCI, 10mM CaCI2, 0.01%  Tween® 20) for 72h at 
37°C. Samples were taken at 24, 48 and 72h, and the reaction stopped by addition of 
an equal volume of 0.5%  TFA, and freezing at -80°C. Samples were zip tipped, mixed 
with a-CHCA matrix, spotted onto a target plate and analysed by M A LD I-Q TO F MSpec.
(a) 24h incubation resulted in observation o f the dominant peak at 8611 m/z, which 
corresponded to the m /z o f intact CXCL10. Several minor peaks of less than 25%) 
intensity of the m ajor peak were seen, notably matrix salt adducts (437.1 and 926.2  
m/z), and cleavage products at 8058.9 and 8144.5 m/z. The peak at 8058.9 m/z 
represented a reduction o f 552 from intact CXCL10, which equals the sum of the 
average masses of the first 5 N-terminal amino acids. The peak at 8144.5  involved a 
loss of 467  from intact CXCL10, closely resembling 468, which is the sum of the 
average masses o f the first 4 C-terminal amino acids.
(b) 48h incubation revealed the dominant peak remained that o f intact CXCL10 at 8611 
m/z, but relative to this, the intensity of the peak at 8059.1 m/z, representing a loss o f 5 
N-terminal amino acids, had increased to - 3 7  %>. The peak at 8143.3 m /z had also 
increased relative to the dominant peak, and this loss o f 468 was indicative o f removal 
of the first 4 C-terminal amino acids.
(c) 72h incubation resulted in a very low intensity peak o f 8062.7  m/z, o f only 7 counts, 
suggesting that C XCL10 has been completely degraded.
(d) 24h incubation in the presence o f 20m M  EDTA produced no evidence o f cleavage, 
with a single high intensity peak o f intact CXCL10 at 8611 m/z.
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(a) 24h (b) 48hI +TOF MS: 300 MCA scans f a=3.56343690874399970e-C Max. 300.0 counts.
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2.4.9 MALDI-QTOF mass spectrometry of CXCL10 incubated with MMP9
Mass spectra of zip tipped samples of CXCL10 incubated with activated M M P9 for 24h 
showed that intact CXCL10 is present in large amounts, but does not represent the 
dominant peak, which is seen at 8143.3 m/z. This peak was also seen to a lesser 
extent with CXCL10 and M MP2, and represents a loss of 468 Da, the same mass as 
the first 4 C-terminal residues. Minor peaks at ~15%  intensity of the major peak were 
visible, including 7748.8 and 8215 m/z peaks (Fig. 2.11a). The sum of the average 
masses of the first 4 N-terminal residues is 396 Da, the loss of which, from CXCL10, 
yields the peak seen at 8215 m/z. Combining the mass of this N-terminal loss with the 
mass of the first 4 C-terminal residues equals 864, which reflects the same reduction of 
CXCL10 to produce a peak at 7747 m/z. Intact CXCL10 was still present at 48h, but its 
intensity had reduced somewhat, compared to the major product of 8143.4 m/z. The  
minor peak of 7748.8  m/z had almost doubled in relative intensity by 48h (Fig. 2.11 b). 
Peaks at 72h were only of very low intensity (18 counts or less), apart from matrix 
peaks. The masses of 8145.87 and 7749.8 m/z were present, representing peaks seen 
at 48h plus a mass of 2 Da. A third peak at 8216 m/z was seen, consistent with the 
peak at 8215 m/z seen at 24h (Fig. 2.11c). Inhibition of M M P9 with EDTA prevented 
formation of cleavage products (Fig. 2 .1 1d).
2.4.10 MALDI-QTOF mass spectrometry of CXCL10 incubated with CD26
Mass spectra of zip tipped samples of CXCL10 incubated with CD26 for 30min were 
striking in that intact CXCL10 had already been completely processed, resulting in a 
single peak of 8415.4 m/z (Fig. 2.12a). This represented a reduction in mass of 196, 
which is the same as the total average masses of the 2 N-terminal residues of CXCL10, 
and indicates that CD26 processed both CCL2 and CXCL10 by removing a dipeptide 
from this region. The mass spectrum obtained for 6h was identical, indicating no further 
processing occurred (Fig. 2.12b). Heat-inactivating CD26 prior to use resulted in a 
single peak of intact CXCL10 at 8611.4 (Fig. 2.12c).
2.4.11 MALDI-QTOF mass spectrometry of control samples from chemokine- 
protease digestion
All recombinant chemokines and enzymes were tested for spontaneous degradation by 
incubation at 37°C in assay buffer for 24-48h. No degradation products were found (Fig. 
2.13), which supported the gel electrophoresis results.
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Figure 2.11 C hem okine cleavage: m ass spectra from  M ALD I-Q TO F analysis of 
CXCL10 incubated w ith  M M P9 for 24, 48 and 72h, and w ith  inhibited MMP9
Recombinant human CXCL10 (4pM) and MMP9 (0.4ijM) were incubated in assay 
buffer (100mM Tris-HCI, 100mM NaCI, 10mM CaCI2, 0.01% Tween® 20) for 72h at 
37°C. Samples were taken at 24, 48 and 72h, and the reaction stopped by addition of 
an equal volume of 0.5% TFA, and freezing at -80°C. Samples were zip tipped, mixed 
with a-CHCA matrix, spotted onto a target plate and analysed by MALDI-QTOF MSpec.
(a) 24h incubation resulted in observation of a dominant peak at 8143.3 m/z, 
representing a loss of 468 from intact CXCL10, which corresponded to the sum of the 
average masses of the first 4 C-terminal amino acids. Intact CXCL10 is shown in the 
high intensity peak at 8611.5 m/z. Minor peaks of ~15% intensity, or less, of the 
dominant peak were seen, notably at 7748.8 m/z (equal to CXCL10 with 4 residues 
cleaved from both N- and C-termini) and 8215 m/z (equal to CXCL10 minus 4 residues 
at N-terminus).
(b) 48h incubation revealed the dominant peak to remain that of 8143.4 m/z, 
representing CXCL10 lacking 4 C-terminal amino acids. Intact CXCL10 was still visible 
as a peak at 8612 m/z, but the peak intensity relative to the dominant peak was 
reduced from that seen at 24h. The minor peak of 7747.4 m/z had almost doubled in 
relative intensity compared to levels at 24h, potentially indicating an increase in 
cleavage of 4 residues from both the N- and C-termini.
(c) 72h incubation resulted in very low intensity peaks (maximum of 18 counts) at 
8145.87 and 7749.8 m/z, representing the peaks seen at 24 and 48h, plus a mass of 2 
Da. A peak of 8216 m/z is visible, most likely consistent with the peak at 8215 m/z seen 
at 24h, as accuracy will have reduced in line with the intensity, suggesting that the 
majority of CXCL10 has been degraded.
(d) 24h incubation in the presence of 20mM EDTA produced no evidence of cleavage, 
with a single high intensity peak at 8611 m/z.
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Figure 2.12 Chemokine cleavage: mass spectra from MALDI-QTOF analysis of 
CXCL10 incubated with CD26 for 0.5 and 6h, and with inactivated CD26
Recombinant human CXCL10 (4pM) and CD26 (0.04pM ) were incubated in assay 
buffer (25m M  Tris) for 6h at 37°C. Samples were taken at 30min, 3h (not shown) and 
6h, and the reaction stopped by addition of an equal volume of 0.5%  TFA and freezing 
at -80°C. Samples were zip tipped, mixed with a-CHCA matrix, spotted onto a target 
plate and analysed by M A LD I-Q TO F MSpec.
(a) 30min incubation resulted in a single peak at 8415.4 m /z that was a loss of 196 
from intact CXCL10, and corresponded to the sum of the average masses o f the first 2 
N-terminal amino acids. No intact CXCL10  was seen.
(b) 6h incubation resulted in no change from 0.5h, with a single peak at 8415.2 m/z.
(c) 6h incubation with the CD 26 being first heat-inactivated, resulted in a single peak of
8611.4 m/z, corresponding to intact CXCL10.
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(a) 0.5 h
+TOF MS: 300 MCA scans from Sample 250 (CD26_CXCL10_30min_2ndgo_1Mar07) of HelenChemokines.wiff 
a=3.56343690874399970e-004, t0=3.68134000911360600e+001
b) 6h
m/z amu
(c) 6h w ith  heat-inactivated CD26
m/z amu
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Figure 2.13 Chemokine cleavage controls: mass spectra from MALDI-QTOF 
analysis of CCL2 and CXCL10 incubated with APMA and assay buffer for 6h and 
48h respectively
Recombinant human CCL2 (4pM) and CXCL10 (4\jM) were incubated in assay buffer 
(100m M  Tris-HCi, 100m M  NaCI, 10mM CaCI2, 0.01%  Tween® 20) + APMA for 6 and 
48h respectively at 37°C. This was to control for degradation ofchem okines in the 
absence o f enzymes. At the end of the incubation period, samples were added to an 
equal volume of 0.5%  TFA and stored at -80°C. Samples were zip tipped, mixed with a- 
CHCA matrix, spotted onto a target plate and analysed by M A LD I-Q TO F MSpec.
(a) 6h incubation o f CCL2 in assay buffer resulted in observation o f a single peak at 
8674 m/z, representing the intact molecule. No degradation products were found.
(b) 48h of incubation o f CXCL10 in assay buffer resulted in observation of a dominant 
peak at 8611 m/z, representing the intact molecule. No significant degradation products 
were found.
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(a) CCL2 after 6h
+TOF MS: 105 MCA scans from Sample 226 (CCL2_APMA_6hr_1Mar07) of HelenChemokines.wrff 
a=3.56343690874399970e-004, t0=3.68134000911360600e+001
(b) CXCL10 after 48h
+TOF MS: 72 MCA scans from Sample 238 (CXCL10_APMA_48hr_1Mar07) of HelenChemokines.wiff 
a=3.56343690874399970e-004, t0=3.68134000911360600e+001
60)
m/z, amu
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2.5 Discussion
Incubation of recombinant CCL2 and CXCL10 independently with MMPs 2 and 9 and 
CD26 produced a variety of truncated chemokine forms that were detected both by gel 
electrophoresis and M ALDI-Q TO F MSpec. Both chemokines were processed by each  
of the enzymes, with cleavage sites pertaining to the N- and C- termini being involved. 
Results are summarised in Table 2.6 and Figure 2.14. Data obtained using gel 
electrophoresis was consistent with M ALDI-QTOF MSpec findings, giving enough 
sensitivity to detect even minor losses, such as removal of 2 residues by CD26. 
Accurate determination of the masses of chemokines and their cleavage products was 
only possible using MSpec, however, but the gels proved useful as visual evidence.
The multiple bands seen in the gel showing CXCL10 incubated with M M P2 or M M P9  
support the M Spec findings that this chemokine is cleaved in more than one place by 
these MMPs, and that cleavage is incomplete at 48h. The gel showing CCL2 incubated 
with enzymes demonstrated a simple downward shift of the bands, indicating the less 
complicated nature of the processing that occurred, which was confirmed by the 
‘cleaner’ spectra with few peaks obtained by MSpec. Thus, gel electrophoresis and 
MSpec were found to complement each other well, for a study of this kind.
The cleavage by M M P2 of CCL2 found in the work in this thesis is in disagreement with 
previous studies, where M M P2 was found unable to process CCL2. The same study 
found, however, that CCL2 was processed between residues 4 and 5 by M MPs 1, 3 
and 8, which is in agreement with the cleavage site found here (McQuibban et al.,
2002). The identical processing of CCL2 by several members of the MMP family is not 
an unexpected finding, as MMPs exhibit considerable overlap in their substrate 
specificity. M M P2 and 9 in particular have a preference for similar primary sequences, 
in that they commonly cleave proteins at sites with a hydrophobic residue in the first 
position upstream (P 1’) of the scissile bond. M M P2 demonstrates a preference for 
hydroxyproline at P5’ and P5, and a proline (P/Pro) separated from a glycine (G/Gly) by 
one residue on the N-terminal side of the scissile bond (Seltzer et al., 1990). M M P9  
preferentially processes bonds with a small amino acid immediately downstream (P1), 
and a Pro as the third residue downstream (P3) (Netzel-Arnett et al., 1993).
With this evidence in mind, it was not surprising that the bond between the alanine 
(A/Ala) and isoleucine (l/lle) of CCL2 was cleaved by both M MPs 2 and 9, as Ala is a 
small amino acid, and lie is very hydrophobic (Urry, 2004). Also consistent with the 
preference of M M P9 for a small amino acid in the P1 position, were the bonds found to 
be processed in CXCL10, i.e. between serine (S/Ser) and arginine (R/Arg) at the N- 
terminus, and Ser and lysine (K/Lys) at the C-terminus.
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Table 2.6 Summary of principal findings following the incubation of recombinant 
human CCL2 and CXCL10 with MMP2, MMP9 or CD26
CCL2 CXCL10
MMP2 Removal of residues 1-4 from N-terminus (411 Da) 
within 3h
Slow and partial removal of residues 1-5 
from N-terminus (552 Da) and 1-4 from C- 
terminus (468 Da), incomplete at 48h. 
Possible degradation by 72h
MMP9 Removal of residues 1-4 from N-terminus (411 Da) 
within 3h
Slow and partial removal of residues 1-4 
from C-terminus (468 Da), and to a lesser 
extent, 1-4 from N-terminus (396 Da), 
incomplete at 72h
CD26
Rapid removal of dipeptide 
from N-terminus (225 Da) 
almost complete within 
30min
Very rapid removal of dipeptide from N- 
terminus (196 Da), complete within 30min
Recombinant human CCL2 and CXCL10 (4\jM) were incubated separately with MMP2, 
M M P9 (OApM) and CD 26 (0.04pM), for up to 72h (see Table 2.4), and the resultant 
cleavage products were analysed by M A LDI-Q TO F mass spectrometry. M M P2 and  
M M P9 both cleaved CCL2 at the same N-terminal position, and in addition, processed  
C XCL10 between residues 4 and 5  o f the C-terminus. M M Ps 2 and 9 also processed  
CXCL10 at the N-terminus, but in different locations. C D 26 rapidly removed a dipeptide 
from both CCL2 and CXCL10.
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(a) CCL2: 76 residues
MMPs 
CD26 2 and
QPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPK
EAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT
(b) CXCL10: 77 residues
Figure 2.14 Am ino acid sequences of CCL2 and CXCL10 indicating the sites  
w here M MP2, M M P9 and CD26 w ere found to cleave
Cleavage sites within the amino acid sequences of CCL2 and CXCL10 and the 
enzyme(s) involved are shown, based on incubation at 37°C of recombinant human 
proteins for up to 72h (see Table 2.4), followed by MALDI-QTOF mass spectrometric 
analysis. Sequences start with the N-terminus. CCL2 is cleaved in 2 positions at the N- 
terminus: MMPs 2 and 9 both cut between residues 4 and 5, and CD26 removed a 
dipeptide. CXCL10 was cleaved in 4 positions: by MMPs 2 and 9 at different positions 
at the N-terminus and the same position at the C-terminus, and CD26 removed 2 
residues from the N-terminus.
CD26 MMP2
VP RTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRV 
EIIATMKKKGEKRCLNPESKAIKNLLKAVSKEMSKRSP
MMPs 
2 and
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Interestingly, these cleavage sites contradict the strong preference for a hydrophobic 
residue at P 1’, as both Arg and Lys are strongly hydrophilic. The preference of MMP9  
for cleaving bonds where P3 is a Pro is upheld in cleavage of both CCL2 and CXCL10  
at the N-termini, but not with C-terminal cleavage of CXCL10. It can be seen, therefore, 
that sequence preferences are not rigid, and it is difficult to predict exactly where an 
enzyme will cleave.
M M P2 and M M P9 have preferences for cleavage at similar sequences, yet differ in 
their processing of chemokines. The reason for this is not fully understood, but may be 
due to the location of the haemopexin domain, which is located further from the 
catalytic site in M M P9 due to its extended collagen type V  domain (Mattu et al., 2000). 
Positioning of the haemopexin domain is considered important, as it is known to serve 
as a secondary binding site for chemokine substrates of M M P2 (Van den Steen, 2003).
Comparing previous studies of chemokine cleavage to the findings reported here 
reveals many discrepancies. Results from this study are not in agreement with the 
frequent opinion that M M P9 processes CXC, but not CC chemokines. C-terminal 
truncation of CXCL10 by M M P9 was documented elsewhere as producing a product 
lacking 9 residues (1-68), before it was fully degraded within 24h (Van den Steen et al.,
2003), whereas cleavage detailed in this thesis involved loss of 4 C-terminal amino 
acids, coupled with additional N-terminal processing by M M P9, with the reaction being 
slow and incomplete at 72h. It is important to consider differences in technique, 
however, as in Van den Steen’s study, the M M P9 used was natural, being derived from 
human neutrophils. The authors also conceded that the 1-68 isoform of CXCL10 was 
only detected as a very low intensity fragment and several more heterogeneous 
cleavages were thought to contribute to its degradation. Comparing gel electrophoresis 
results with this study also flagged differences, as whilst multiple bands were found 
here, Van den Steen reported a single band representing CXCL10 cleavage by M MP9. 
An isoform of CXCL10 lacking 4 C-terminal amino acids has been reported, along with 
a further variant lacking 6 C-terminal residues, following incubation with M M P8 (Van 
den Steen et al., 2003).
It is well established that CD26 cleaves several chemokines with a Pro or Ala as the 
penultimate residue at the N-terminus. Ligands for CXCR3, including CXCL10, have 
been shown elsewhere to lose an N-terminal dipeptide when exposed to this enzyme 
(Proost et al., 2001), which is in agreement with findings documented here. Iwata and 
colleagues (1999) have shown that CD26 cleaved a dipeptide from CCL5 in 
accordance with enzyme specificity, but under identical experimental conditions, failed 
to observe any cleavage of CCL2, using a form identical to that used in this current
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study, with glutamine as the N-terminal residue. This conflicts with data reported here, 
where CD26 was found to rapidly process CCL2. It is known that despite possessing a 
sequence prone to N-terminal attack by CD26, CCL2 is normally protected by a 
pyroglutamatic acid residue, which was replaced by a glutamine in the recombinant 
form used in this current study (Van Coillie et al., 1998). Discrepancies may have 
arisen due to different sources of CCL2 being used in different studies, and it should be 
noted that CCL2 used here originated from production in E.coli.
The speed with which cleavage can occur is pivotal in affecting the outcome in vivo, 
and the relevance of some chemokine:protease interactions may be questionable if 
they take several days to occur. CD26 exhibited strikingly rapid activity, cleaving all of 
CXCL10, and most of CCL2, within 30min. Noteworthy also is that CD26 was used at a 
ten-fold lower molarity than the MMPs, and did not process the chemokines any further 
when incubated for 6h, suggesting it is highly specific.
The physiological significance of chemokine processing is potentially a very important 
regulator of their function. Results obtained in this study and previously indicate that 
the interactions of chemokines with proteases are numerous and often complicated. N- 
terminal residues of chemokines have been shown to be important in receptor binding 
and chemotaxis. In addition, the basic residues at the C-terminus of CXCL10 have 
been shown to be critical for binding to CXCR3, but less important in binding 
polysaccharides (Campanella et al., 2003). If the in vitro results documented here 
prove to be applicable to the in vivo situation and two or more of the enzymes tested 
here are co-expressed, it is possible that an isoform of C XC L10, cleaved at both 
termini, would result.
Previous studies indicate that an intact N-terminus is necessary for the receptor binding 
and signalling properties of CCL2 (Proost et al., 1998b; McQuibban et al., 2002), and 
thus it was expected that all cleaved CCL2 isoforms identified in this current study 
would exhibit severely impaired chemotactic potential. Similarly, on the basis of 
previous reports, it was anticipated that CXCL10 cleaved by M MP2, M M P9, and CD26, 
would exhibit reduced chemotactic potential due to removal of N-terminal residues 
(Proost et al., 2001). M M P9 cleaved CXCL10 more extensively at the C-terminus than 
the N-terminus, making it possible that the CXCL10 isoform isolated from this 
incubation was more likely to remain unaltered in its in vitro chemotactic activity, in line 
with previous findings. Furin cleaved 4 C-terminal residues from CXCL10, which did not 
alter the activity on CXCR3 (Hensbergen et al., 2004), and these 4 residues are not 
thought critical for binding to CXCR3 or GAGs (Campanella et al., 2003).
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2.6 Summary
Proteolytic processing of chemokines is a complex area of study that can have 
dramatic effects on their activity. Results from gel electrophoresis and M ALDI-QTOF  
MSpec using recombinant CCL2 and CXCL10, incubated individually with MMPs 2 and 
9 and CD26, are summarised in Table 2.6 and indicate that each chemokine is cleaved 
by each enzyme. Processing often involved removal of 2-5 amino acids from the N- 
terminus, but C-terminal cleavage of CXCL10 was also observed with MMPs 2 and 9. 
CXCL10 was cleaved at both termini by MMPs 2 and 9. The speed of the reaction was 
enzyme-dependent, with CD26 completing cleavage of an N-terminal dipeptide from 
CXCL10 within 30min, whereas activity of the MMPs on CXCL10 remained incomplete 
at 48h. The effects on biological function, particularly on chemotactic potential, of 
cleavage of CCL2 and CXCL10 warranted further investigation, which was undertaken 
using in vitro migration assays in Chapter 5.
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Chapter 3
Astrocyte expression of chemokines CCL2 
and CXCL10, and MMPs, and TIMPs
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3.1 Introduction
3.1.1 Astrocytes
Astrocytes constitute approximately half of all cells in the human brain and spinal cord, 
making them the most abundant glial cell in the CNS (Carroll-Anzinger and Al-Harthi, 
2006). The human brain has the highest ratio of glia to neurons of >10:1 (Araque et al., 
2001). During brain development, astrocytes originate from neuroepithelial cells 
following the generation of neurons (Namihira et al., 2004). Astrocytes form a mesh 
throughout the brain, with their distinctive star-shape comprising processes that 
connect with neurons and blood vessels, providing perfect morphology for sensing 
parenchymal disturbances (Banaclocha, 2007).
It is thought that there are two main types of astrocytes, differentiated by their 
morphology and distribution, but not function. Protoplasmic astrocytes have short, thick, 
highly branched processes, and are common in grey matter, whereas fibrous 
astrocytes have long, thin, less branched processes, and typically exist in white matter. 
Interlaminar astrocytes, and polarised astrocytes are unique to humans and primates, 
and represent additional populations (Oberheim et al:, 2006).
Astrocytes contribute indirectly to CNS leukocyte trafficking by their involvement in 
maintenance of the BBB, but they also affect it directly, by expressing cytokines, 
chemokines, and their receptors, thereby influencing adhesion molecule expression in 
brain ECs, and creating chemotactic gradients (Ostrow and Sachs, 2005). In response 
to cytokines and other stimuli, astrocytes secrete a variety of chemokines, including 
CCL2 and CXCL10, (Huang et al., 2000), MMPs, such as MMPs 2 and 9 (Yin et al.,
2006) and TIM Ps 1 and 2 (Leveque et al., 2004).
Inflammatory conditions can activate astrocytes, causing proliferation, cytoskeletal 
remodelling, migration, and an increased production of cytokines. These functional, 
structural, and biochemical changes constitute reactive gliosis, and are significant early 
responses to CNS injury (Ostrow and Sachs, 2005). Reactive astrocytes show rapid 
enhanced expression of the intermediate filament, glial fibrillary acidic protein (GFAP), 
and engage in astrogliosis, where they exhibit hypertrophy of their cell bodies and 
cytoplasmic processes, proliferate, and accumulate between intact and damaged  
tissue, leading to glial scar formation. This scar tissue has been implicated in failure to 
remyelinate and regenerate axons in MS (Zhang et al., 2006). Interestingly, 
proliferation of astrocytes in vitro occurs in response to CCL2 (Rezaie et al., 2002) and 
also CXCL10 (Flynn et al., 2003), which might contribute to the astrogliosis seen in MS.
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3.1.2 Astrocyte specific cell markers
Astrocytes exhibit considerable phenotypical plasticity both in vivo and in vitro, with 
primary cultures being very heterogeneous in terms of receptor expression and calcium 
signalling, even within the same cell culture. This is exemplified by the ability of two 
astrocytes derived from a single mitosis of the parent cell to differ in their response to 
neuroligands (Shao and Me Carthy, 1994). To help identify astrocytes, two markers are 
commonly used: glial fibrillary acidic protein (GFAP) and S100-(3.
3.1.2.1 Glial fibrillary acidic protein (GFAP)
Glial fibrils of astrocytes are mainly composed of the protein GFAP, a class III 
intermediate filament protein of approximately 50 kDa (Rutka et al., 1997), involved in 
maintenance of the shape of astrocytes, and is a specific marker that differentiates 
mature astrocytes from other glial cells (Patanow et al., 1997). In utero, GFAP  
production in human astrocytes can commence at 25 weeks after conception (Cohen  
and Rossmann, 1994), with activation of the transcription factor STAT3 being 
necessary for GFAP expression in neural precursor cells (Takizawa et al., 2001).
GFAP is important in neuronal migration due to its involvement in the formation of 
fibres from astrocytic processes, along which neurons move (Liesi et al., 1992). Whilst 
GFAP is primarily associated with maintenance of astrocyte cell shape, it may also 
operate with other cytoskeletal components, the ECM, and kinases, to form a dynamic 
cell-signalling apparatus (Rutka et al., 1997). This suggestion is supported by findings 
that intermediate filaments might be used as ‘docking sites’ for kinases, and that GFAP  
assists in linking microfilaments, integrin receptors, and the ECM (Tsujimura et al.,
1994).
3.1.2.2 S100-P
S100-(3 is considered to be a marker of immature astrocytes, and is expressed earlier 
in development than GFAP (Namihira et al., 2004). S100 proteins are small (10-12 kDa) 
and acidic, exhibiting high specificity in their cell and tissue expression patterns 
(Marenholz et al., 2004). S100 protein was first isolated from the CNS in 1965, and is 
found in the cytoplasm and nuclei of astrocytes, OLGs, and Schwann cells. The S100  
family consists of 20 proteins in humans, possessing 22 -  57%  sequence homology 
(Marenholz et al., 2004). Members of the S100 protein family are calcium-binding 
proteins, which also have zinc and copper-binding sites, and participate in regulation of 
protein phosphorylation in the CNS via inhibition of protein kinase C (Steiner et al.,
2007). S100 proteins are multifunctional signalling molecules, thought to be involved in 
cell differentiation, cell cycle progression, and the structure and function of the 
cytoskeleton (via regulation of assembly of components such as GFAP, microtubules,
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or vimentin) (Bianchi et al., 1993). Altered levels of S100 have been associated with 
neurodegenerative disorders, cancer, and lowered expression has been observed in 
cardiomyopathies (Marenholz et al., 2004).
S100 proteins are composed of two differentially expressed subunits (a and (3) 
produced by separate genes. The beta subunit (S100-(3) is highly conserved in the 
brains of vertebrates, and its expression has been localised to astrocytes (Friend et al., 
1992), where it is found diffusely in the cytoplasm, and associated with membranes 
and cytoskeletal components (Adami et al., 2001). In addition to its role in regulating 
intracellular processes, S100-(3 is also secreted. The secreted form mediates the 
interactions of glial cells with other glial cells and neurons, partly via involvement of 
S100-p with the cell surface receptor for advanced glycation end products (RAGE), 
found on inflammatory cells and neurons (Donato, 2001). Brain trauma leads to an 
increase of S100-(3 levels in blood, as is also seen in chronic disorders, such as MS 
and Alzheimer’s disease (Sheng et al., 1994). Nanomolar concentrations of S100-(3 
encourage neuron growth, whereas micromolar levels promote apoptosis (Huttenen et 
al., 2000).
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3.2 Aims and objectives
Astrocytes are a source of both chemokines and MMPs in the brain, and are thus of 
key importance in view of the effects of these enzymes on chemokines, as described in 
the previous chapter. The aim of the work in this chapter was to determine whether 
astrocytes express the truncated forms of CCL2 and CXCL10 in vitro, thus supporting 
the likelihood that they are of significance in MS. Accordingly, the following objectives 
were addressed:
•  To characterise primary human astrocytes used in this project by 
immunofluorescence and western blotting
•  To identify the presence of CCL2, CXCL10, and chemokine cleavage products 
detailed in Chapter 2, in astrocyte supernatants by western blotting and MALDI- 
Q TO F MSpec
• To determine the expression profile of MMPs and TIM Ps by TaqM an®  real-time 
polymerase chain reaction (PCR) in astrocytes, thereby identifying MMPs which 
may play important roles in chemokine cleavage in the CNS
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3.3 Materials and Methods
3.3.1 Primary human astrocytes
3.3.1.1 Source of primary human astrocytes and ethical approval
Astrocytes were a gift from Dr I. Romero of the Open University (OU), Milton Keynes, 
UK. Non-MS astrocytes were derived from adult human brain tissue obtained from 
patients with epilepsy who underwent temporal lobe resection surgery at King’s College 
Hospital to control their seizures. Tissue is most commonly removed from the anterior 
or mesial portions of the temporal lobe during this procedure, and was used for 
astrocyte isolation in accordance with the approval and guidelines of the Local Ethics 
Committee of King’s College Hospital, London. Astrocytes from MS patients were 
prepared by Dr. Romero’s research group at the OU (Flynn et al., 2003), using brain 
tissue supplied by the UK MS Tissue Bank. Reciprocal ethical approval is in place 
between the UK MS Tissue Bank, the OU, and Sheffield Hallam University, which 
enables their use at both sites.
3.3.1.2 Cell culture of primary human astrocytes
All cell culture techniques were conducted using sterile materials and conditions in a 
high efficiency particulate air (HEPA)-filtered class II laminar flow cabinet (Heraeus, 
Germany). Sterile plasticware was obtained from BD Falcon (BD Biosciences, UK) and 
all constituents of growth media were from Invitrogen, UK, unless otherwise stated.
Cells derived from 5 epileptic patients (EP14, EP15, B73, B327/01, and 668/01), and 3 
patients with MS (SM S12, MS16, MS21) were used in various experiments, up to 
passage 8. SM S12 was obtained from normal appearing white matter (NAW M ) of an 
MS patient, and M S16 and MS21 were from MS lesions. Cells were stored in cryovials 
(Nalgene, Hereford, UK) kept in a dewar (Forma Scientific Inc., Ohio) containing liquid 
nitrogen until required, by slow-freezing at 1°C per minute in a ‘Cryo Freezing 
Container’ (Nalgene), in astrocyte culture media containing 10% v/v dimethyl 
sulphoxide (DM SO ) (Sigma). Cells were cultured in either 25 or 75 cm2 filter-cap flasks 
(Nunc, UK) in an incubator (Heraeus, Germany) providing a humid environment at 
37°C, containing 95%  air and 5% C 0 2. Astrocyte medium was composed of a 1:1 
nutrient mixture of M EM -a and F-10, supplemented with 250U/m l fungizone, 100U/ml 
penicillin/1 OOpg streptomycin (1% v/v), 10% v/v heat-inactivated foetal calf serum (H l- 
FCS) (56°C for 30min) and 1% v/v human AB serum (Sigma, UK). Medium was 
changed twice weekly and the astrocytes passaged when almost confluent. Passaging 
was performed by removal of medium, cells were rinsed briefly with phosphate buffered
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saline (PBS) without calcium and magnesium, and then 5ml of trypsin/EDTA (0.5g/L  
trypsin, 0.2g/L EDTA) was applied at 37°C  for no more than 5min.
3.3.1.3 Cytokine treatment of astrocytes to increase chemokine expression
In order to increase expression of CCL2 and CXCL10 and to mimic the inflammatory 
environment of the CNS in MS, astrocytes were treated with pro-inflammatory 
cytokines. It is known that TN F  and IL-1(3 induce expression of CCL2, and IFN-y 
induces CXCL10 expression (Oh et al., 1999). Astrocytes were plated at 1 x 105 
cells/well into a 24-well plate, in 1ml per well of media without FCS and human serum, 
i.e. serum-free media (SFM ), containing 0, 1, 10 or 100ng/ml of IFN-y, IL-1(3, or TNF  
(Peprotech, EC), for 24-48h. Cytokine treatment was performed prior to selected 
western blotting and MSpec procedures, and astrocytes were treated with 100ng/ml of 
TNF, IL-1 (S, or IFN-y prior to RNA extraction for R T-PC R  experiments.
3.3.2 Immunocytochemistry for detection of GFAP and S100-p to assess 
astrocyte purity
3.3.2.1 Principles of immunocytochemistry
Immunostaining was first devised in the 1930s but it took until 1942 for the first study to 
be reported, which used fluorescently-labelled antibodies to localise pneumococcal 
antigens in tissues. Immunocytochemistry is based on the affinity of an antibody for an 
antigen in a cell, whereas immunohistochemistry applies to the same process, but in 
tissue sections. The antigen and antibody form a complex, held together by forces such 
as ionic interaction, hydrogen bonding, and hydrophobic interaction. The part of the 
antigen that is recognised by the antibody is known as the epitope, and many epitopes 
can exist on the same protein molecule. Polyclonal antibodies bind to more than one 
epitope, whereas monoclonal antibodies recognise a single epitope. Antibodies only 
form complexes with the specific antigen that stimulated their production, but some 
cross-reactivity can occur, however, whereby one antibody can recognise two similar 
proteins, as the epitope may be a short amino acid sequence common to both proteins 
(Ramos-Vara, 2005).
As antibodies are large molecules, with IgG having a molecular weight of 150,000, for 
example, the amino acid side chains can be conjugated with fluorochromes (e.g. 
fluorescein isothiocyanate (FITC)) or enzymes (e.g. horseradish peroxidase (HRP)). 
This antibody-labelling allows antigen-antibody complexes to be detected, a process 
which forms the basis of immunocytochemistry (Fig. 3.1) (Ramos-Vara, 2005).
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In order to test the specificity of the antibodies used, immunoglobulins of the same 
class, namely isotype controls, can be used under the same experimental conditions. 
Optimal conditions for each antigen-antibody reaction must be determined, as antigen 
and antibody availability, antigen-antibody affinity, and detection methods will vary.
3.3.2.2 Direct immunofluorescence
The simplest form of antibody detection is the direct fluorescent method, where 
antigens are localised by combination with a fluorescently-labelled antibody (Fig. 3.1 (i)). 
Direct immunofluorescence was applied in flow cytometry, in Chapter 5. Direct 
fluorescent antibody methods lack sensitivity, however, and if the antigen concentration 
is low, the density of bound fluorochrome molecules may be insufficient to be detected.
3.3.2.3 Indirect immunofluorescence
Indirect immunofluorescence techniques are more commonly employed, as they offer 
greater sensitivity due to the increase in potential binding sites for the fluorescently- 
labelled antibody (Fig.3.1 (ii)). Indirect methods involve incubation of the sample with an 
unlabelled primary antibody, followed by washes, and addition of a labelled secondary 
antibody. The secondary antibody is directed against the species that the primary 
antibody was raised in, and is able to bind to Fc segments of bound primary antibody, 
as these are identical within the same species. In this way, the antigenic sites of the 
sample are identified by the fluorochromes of the secondary antibody, which binds to 
the primary antibody attached to the antigen (Fig. 3.1 (ii)).
3.3.2.4 Detection of cell antigens using antibodies with enzyme conjugates
Antibodies can also be labelled by conjugation with enzymes, such as HRP or alkaline 
phosphatase. Detection of the antibody-bound antigen is dependent upon the 
production of a precipitating or intensely coloured product after the enzyme label has 
reacted with its substrate, or by chemiluminescence, where light is produced at the 
target sites, as seen in the reaction of HRP with luminol (Ramos-Vara, 2005).
3.3.2.5 Use of biotinylated antibodies in immunocytochemistry
Primary antibodies used in direct immunocytochemistry, and secondary antibodies 
used in the indirect method, can be biotinylated to generate increased amplification of 
signal. Biotin is a water-soluble B-complex vitamin which binds very strongly, and 
almost irreversibly, to avidin, strepatavidin, or extravidin. Avidin, strepatavidin, or 
extravidin, conjugated to either a fluorochrome or an enzyme, are added after
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application of a biotinylated antibody, and are capable of binding to multiple sites on 
the biotinylated antibody. This amplifies the signal that can be detected and is more 
sensitive than simply using enzyme or fluorochrome-conjugated antibodies alone 
(Ramos-Vara, 2005) (Fig. 3.1 (iii)).
3.3.2.6 Blocking of non-specific binding in immunofluorescent staining
A blocking step is usually included prior to antibody application, particularly with tissue 
sections, most commonly involving incubation with a 3%  solution of the serum of the 
species that the secondary antibody was raised in, thereby occupying non-specific 
binding sites, such as Fc receptors. Blocking was not found to be necessary for 
immunocytochemistry of the astrocytes.
3.3.2.7 Use of human astrocytomas (U373MG) as a positive control in 
immunocytochemistry for detection of GFAP and S100-p in astrocytes
The human glioblastoma astrocytoma (grade III) cell line (U373M G ) (European  
Collection of Cell Cultures (ECACC), Wiltshire, UK), derived from a 61 year old 
Caucasian male (Ponten and Mackintyre, 1968), was used as a positive control for 
astrocyte characterisation by immunocytochemistry. U373 cells were cultured in MEM  
media containing 10% v/v HI-FCS, 2mM (1% v/v) L-glutamine, ‘1% v/v 
penicillin/streptomycin, 1% v/v non-essential amino acids, and 1mM sodium pyruvate. 
These cells were passaged and frozen down as described for the astrocytes (3.3.1.2).
3.3.2.8 Cell culture preparation prior to immunocytochemistry
Astrocytes were plated into 8-well chamber slides (Fisher Scientific, Loughborough, 
UK), 400pl per well, with a seeding density of 1 x 105 cells per ml, and left overnight to 
attach. Media was removed and 2 rinses in PBS, of 5min each, were performed to 
remove media.
3.3.2.9 Fixation of astrocytes
Cells were fixed prior to use to preserve their structure by preventing autolysis. 
Fixatives also stabilise specimens so that they can withstand subsequent processing. 
Formaldehyde and paraformaldehyde are often used when the antigen of interest is a 
protein of low molecular weight. Acetone, ethanol and methanol (often pre-cooled to - 
20°C) are commonly used with larger protein antigens, and offer fixation by a different 
means, namely denaturing the protein by coagulation (Ramos-Vara, 2005).
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Figure 3.1 Schematic diagram of immunocytochemistry methods
i) Direct immunofluorescent staining of a cell involves using an antibody with a 
fluorescent dye attached, which binds to antigens it has been raised against, 
expressed by cells or tissue. This simple and quick technique allows the location of the 
antigen to be observed using a fluorescent microscope, but it lacks sensitivity, and is 
less commonly used than indirect methods.
ii) Indirect immunofluorescence involves binding of an unlabelled primary antibody 
to the antigen it is specific for. After careful washing following binding of the primary 
antibody, a secondary antibody is applied, which is directed against the Ig of the 
species the primary antibody is raised in. This secondary antibody is conjugated with a 
fluorophore, and will bind to Fc domains of the primary antibody, thereby linking 
indirectly to the antigen and enabling detection by fluorescent microscopy. Several 
secondary antibody molecules can bind to one primary antibody molecule, resulting in 
signal amplification and greater sensitivity.
Hi) The streptavidin-biotin method uses a secondary antibody with a biotin conjugate, 
which binds to the primary antibody, using the same principles as in (ii). A third reagent 
of labelled streptavldin is used, which binds firmly to large numbers of biotin molecules, 
giving Increased sensitivity. The label can be an enzyme, such as peroxidase (detected 
by formation of an insoluble product after reaction with a substrate), or a fluorophore.
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Experimenting with different fixatives, and fixation times, was undertaken to optimise 
cellular structure but minimise epitope masking or destruction. Astrocytes were fixed 
using 4%  paraformaldehyde (PFA) (see Appendix I) for 5min at RT, followed by 3 
consecutive 5min PBS washes prior to incubation in primary antibody. Alternatively, 
ice-cold acetone for 5 -  10min at RT, followed by air drying for 15min, was used for 
comparative purposes in some preliminary experiments.
3.3.2.10 Detection of GFAP and S100-P antigens in astrocytes by indirect 
immunofluorescence
The optimal working concentration of each antibody was determined for each set of 
experimental conditions using a series of dilutions, to obtain a positive result with 
minimal background staining. Temperature, pH, incubation times, and buffer 
composition were also optimised, as they can all affect antibody binding.
The plastic upper part of the chamber slide was removed prior to antibody application, 
leaving the rubber gasket in place. Following fixation, primary antibodies (Table 3.1) 
(100pl per well, diluted in PBS + 0.5%  Triton® X -100) were applied to cells in each well, 
apart from the negative controls, where PBS + 0.5%  Triton® X -100 alone was used. 
Addition of non-ionic detergent helped to reduce hydrophobic interactions between the 
reagent proteins and the cells and permeabilise the membranes (Stuart and Oorschot,
1995). Slides were incubated in a humid chamber for between 90-120m in at RT, or, 
alternatively, overnight at 4°C (Table 3.1). Slides were transferred to Coplin jars and 
unbound primary antibodies washed off in PBS, in 3 consecutive 5min washes on an 
orbital shaker (Stuart Scientific, Staffordshire, UK). Secondary antibodies (Table 3.1) 
were then applied to the slides, for 90-120min, in the dark, and were subsequently 
removed as for the primary antibodies.
3.3.2.11 Mounting and final processing of slides
Rubber gaskets on the slides were removed, and the slides were mounted with 22 x 
50 mm coverslips with 4',6-diamidino-2-phenylindole (DAPI) mountant (Vector 
Laboratories, Peterborough, UK), which forms blue fluorescent complexes with DNA, 
thereby labelling cell nuclei (Degtyareva et al., 2007). The mountant also contained 
anti-fading agents to prolong the viewing time by limiting the fading of fluorescence 
under UV light. The edges of the coverslip were sealed with nail varnish to prevent the 
slides from drying out. Slides were protected from light by wrapping in foil, and stored 
at 4°C until required for viewing.
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Table 3.1 Antibodies used in detection of GFAP and S100-p to assess astrocyte purity
PR IM A R Y
A N T IB O D Y
SPEC IES
R AISED
IN
DILUTIO N INCU B A TIO N  TIM E (S) S U PPLIER
a-hum an
G FAP
(polyclonal)
Rabbit 1:1000 2h at RT Abeam, Cambridge, UK
a-hum an
GFAP
(m onoclonal) Mouse 1:400
2h at RT Sigma, Dorset, 
UK
a-hum an
S100-P
(m onoclonal) Mouse
1:500 90min at RT Sigma, Dorset, 
UK
SE C O N D A R Y
A N TIB O D Y
a-rab b it IgG  
A lexa F luor 
488
Goat 1:500 90min at RT
Molecular 
Probes, 
Invitrogen, UK
a-m ouse
FITC Rabbit 1:50 90min at RT Dako, Ely, UK
Primary antibodies against G FAP and S 100-/3 were detected by the appropriate 
fluorescently labelled secondary antibody.
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3.3.2.12 Use of confocal microscopy to detect fluorescently-labelled antibodies
A confocal laser scanning microscope (CLSM) works by systematically illuminating 
single points of a specimen, usually with focused laser beams to excite the fluorophore 
in the sample, followed by use of a photodetector, such as a photomultiplier tube or 
charge-coupled device (CCD), to capture the emitted light that has passed through a 
pinhole aperture from the point of focus. Light originating away from the point of focus 
is eliminated by the use of a pinhole aperture. The detector pinhole is positioned to be 
in a conjugate plane with both the point of excitation of the laser defined by the 
excitation pinhole and the plane of focus of the microscope objective (Fig. 3.2). In 
confocal microscopy, the sequential scanning of the specimen and assembly of the 
final image are controlled by a computer. A single laser point beam of a specific 
wavelength is scanned across the sample using oscillating mirrors. The emitted light, of 
a longer wavelength, is separated from the excitation light by a dichroic mirror and 
passed through the pinhole aperture to the detector, which then transmits the data for 
each individual point to the computer (Fig. 3.2) (Cox, 2002).
3.3.2.13 Image acquisition using the confocal microscope
The confocal microscope used throughout this project was a Zeiss LSM 510 (Germany), 
equipped with argon (450-530nm ) and helium-neon lasers (543 and 633nm). It was 
linked to a Fujitsu Siemens computer, running Windows 2000, with LSM 510 software 
installed, and the use of 2 monitors. Single track images of 512 x 512 pixel resolution 
were obtained of the FITC or Alexa 488 green fluorescence, and overlaid with images 
of the DAPI fluorescence before being exported as JPEGs.
3.3.3 Western blotting for detection of GFAP to assess astrocyte purity
3.3.3.1 TRI Reagent® method for extracting protein from astrocytes
Protein was extracted from both the supernatant of cultured astrocytes, using TRI 
Reagent LS® (Sigma) designed for liquid samples, and from the cells, with TRI 
Reagent® (Sigma). Both types of TRI Reagent® were used according to the 
manufacturer’s protocol (Appendix II). TRI Reagent® is a mixture of guanidine 
thiocyanate and phenol in a mono-phase solution used for homogenising or lysing 
samples. Addition of chloroform causes the mixture to separate into 3 phases which 
can each be isolated: RNA is found in the aqueous phase, DNA in the interphase, and 
protein in the organic phase (Siebert and Chenchik, 1993). Extracted protein samples 
were stored in 1% SDS at -20°C until required.
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Figure 3.2 Schematic diagram of the optics of a confocal microscope
In confocal microscopes, light from a laser passes through a pinhole before being 
reflected by a dichroic mirror and focused through the objective onto a single spot of 
the specimen on the microscope slide, as represented by the green path in the figure. 
The excitation of the specimen from the laser results in emitted light in random 
directions, a selection of which passes through the objective and then through a 
pinhole to the detector, as seen in red. The detector pinhole prevents out-of focus 
emissions from the sample from reaching the detector, ensuring three-dimensional 
resolution is possible. Only a single point of the sample is imaged at one time, so to 
obtain the whole image, the laser beam systematically scans across the sample, and 
the image is built up in layers or ‘optical slices’.
128
3.3.3.2 Alternative method for extracting protein from astrocytes
W hen protein yields were low using TRI Reagent®, the following method, suitable for 
cell monolayers, was used as an alternative. Sample and extraction buffers were made 
the day before use (Appendix I), and stored at 4°C.
A protease inhibitor tablet (Roche, East Sussex, UK), containing mannitol (80-90% ), 4- 
(2-aminoethyl)-benzenesulphonyl fluoride hydrochloride (AEBSF) (1-5% ), EDTA (5- 
10%), polyvinylpyrrolidone (1-5% ) and polyethylene glycol (1-5% ), which inhibits serine 
proteases, cysteine proteases, and metalloproteases, was added to 10ml extraction 
buffer (Appendix I) just before use, and 500pl of this added per 25cm 2 flask of cells that 
had been previously washed in PBS. Cells were detached using a scraper (BD), 
transferred to a tube, homogenised using a grinding action with a glass rod, 495pl cell 
homogenate transferred to an Eppendorf tube, and 5pl (1% ) Triton® X -100 was added. 
This mixture was incubated for 1h at 4°C, and was vortexed for 3min every 7min.
It was then spun in a ‘Mini Spin Plus’ micro-centriguge (Eppendorf, Cambridge, UK) at 
11337gfor 10min at 4°C. The supernatant was removed to a clean tube and the pellet 
resuspended in 500pl dH20 . 2X  sample buffer (Appendix I) was added in an equal 
volume to both the pellet and supernatant, heated to 85°C for 2.5min, and protein 
samples stored at -80°C until required.
3.3.3.3 Bicinchoninic acid (BCA) assay to assess the concentration of protein 
extracted from astrocytes
BCA assays were performed to determine the protein concentration of the samples 
obtained from the cell extractions. It is based on the reaction of protein with Cu2+ ions in 
an alkaline environment, producing cuprous (Cu+) ions. Cu+ ions are then detected by 
the interaction of 2 molecules of BCA to each Cu+ ion, forming a soluble purple product 
which absorbs strongly at 570nm.
Dilutions for a standard curve were prepared using bovine serum albumin (BSA). A  
stock solution of 20mg/ml BSA was prepared in dH20  (or 1% SDS, if this was used as 
a diluent for the samples), and further diluted to yield concentrations of 10, 8, 6, 4, 2, 1, 
0.8, 0.6, 0.4, 0.2, and 0.1 mg/ml. 20pl aliquots of the BSA standards, samples, and 
appropriate blanks (dH20  and extraction buffer) were added in triplicate to wells of a 
96-well plate. BCA reagent was prepared by adding 10ml BCA to 200pl 4%  (w/v) 
copper sulphate solution, and 200pl of this was added to each well. The plate was 
incubated at RT for 30min, and then read at 570nm using a W allac Victor2 plate reader 
(PerkinElmer, USA). A mean value was calculated for all triplicate readings and a
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standard curve plotted for mean absorbance of the BSA standards at each  
concentration. The protein concentration of the samples was then derived from the 
standard curve using the linear equation y = mx + c, rearranged to give x = (y -  c) /  m, 
where x is the concentration (mg/ml), y is the absorbance of each sample minus the 
blank, m is the gradient, and c is the y intercept. Once the sample protein concentration 
was derived, the volume required to load a set amount of protein (usually 4pg) for use 
in SDS-PAG E was calculated.
3.3.3.4 Gel electrophoresis of protein samples extracted from astrocytes
Gel electrophoresis was performed as described in 2.3.2.2, loading up to 20pl 
(containing ~4pg protein) of each astrocyte cell lysate and supernatant sample into 
lanes of a 12-well, 1 mm thick, precast 12% Bis-Tris gel. SeeBlue Plus2 pre-stained 
standard (7pl), with bands in the 4-250 kDa range, was run in the end lane of the gel to 
enable visualisation of molecular weight bands and confirm blotting transfer efficiency.
3.3.3.5 Principles of western blotting
When detection of a specific protein in a complex mixture is required, western blotting 
is used, after separation of proteins by gel electrophoresis. Electrophoresis is also used 
to transfer the proteins from the gel to a support membrane, with the electrodes being 
parallel to the plane of the gel so that uniform voltage is applied across the whole 
surface. Transfer can either be performed in a tank with a buffer containing methanol to 
increase the membrane binding capacity, or in a semi-dry system, which uses minimal 
buffer and low voltages. Proteins migrate from the gel and are immobilised on the 
membrane in the same pattern as in the gel. Membranes are typically nitrocellulose, 
offering good sensitivity, or polyvinylidene difluoride (PVDF), giving high protein binding 
capacity. Non-specific antibody binding is prevented by incubating the membrane with 
reagents such as non-fat dried milk or BSA, to block excess protein-binding sites. 
Proteins of interest are located by exposing the membrane, or ‘blot’, to appropriate 
antibodies, in a similar process as described for immunocytochemistry, with 
chemiluminescence being a popular detection method (3.3.2). Working with a 
membrane instead of a gel offers several advantages, as low antigen densities are 
more readily detected due to increased accessibility, and membranes are easier to 
handle.
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3.3.3.6 Protein transfer from separating gel to the membrane
Gloves were worn throughout the procedure to prevent keratin proteins being 
transferred to the membrane. After separation of proteins from cytokine-treated and 
untreated astrocyte supernatant and lysate samples by gel electrophoresis, the gel was 
rinsed for 5-10min in 100ml NuPAGE® transfer buffer (Invitrogen) (5%  v/v 20X  transfer 
buffer, 10% v/v methanol, 85%  v/v upH20 ). Porous components of the western blot 
assembly were pre-soaked in cooled transfer buffer, arranged as in Figure 3.3, using a 
Hybond C nitrocellulose membrane (Amersham, UK) and slotted into a transfer tank, 
with the black plate nearest to the negative electrode. The tank was filled with cold 
transfer buffer, and placed in a large container filled with ice to prevent over-heating. 
The transfer was conducted at 150 volts for approximately 90min, or overnight at 35 
volts at 4°C.
3.3.3.7 Blocking of non-specific binding to the membrane
Tris buffered saline (TBS) (20mM Tris, 0.9%  NaCI w/v, pH of 7.5) had 0.05%  v/v 
Tw een®  20 freshly added, to yield TBST. The membrane was removed from the 
assembly apparatus and blocked in 5% non-fat milk powder in TBST, either overnight 
at 4°C, or for 1 h at RT, on an orbital shaker.
Blocking was later assessed using 5% ‘Marvel’ non-fat milk powder (Premier Brands 
Ltd., Birmingham, UK) in TBS, during optimisation of the technique. Blocking was 
followed by 3 consecutive, 10min washes at RT in TBST, on an orbital shaker.
3.3.3.8 Antibody application for detection of GFAP by western blotting
Primary antibody solutions were made in TBST and included monoclonal mouse anti­
human GFAP at 1:5000 (0.2pg/ml) (Chemicon), and polyclonal rabbit anti-human 
GFAP at 1:2500 (Dako). Membranes were incubated with primary antibody (or TBST  
for the negative control) for either 90min at RT, or overnight at 4°C, on an orbital shaker. 
During optimisation, primary antibodies were initially applied in TB ST containing 5%  
non-fat milk powder.
Primary antibodies were washed off with 3 consecutive, 10min TBST washes. Mouse 
anti-GFAP (Chemicon) primary was detected with a polyclonal rabbit anti-mouse HRP- 
conjugated secondary antibody (Dako), used at 1:1000, for 90min at RT. The rabbit 
anti-GFAP (Dako) primary was detected using a goat anti-rabbit HRP-conjugated 
secondary antibody (Sigma), used at 1:40,000 for 90min at RT.
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Figure 3.3 Schematic of assembly order of western blotting equipment
All components o f the above assembly were pre-soaked in transfer buffer before use. 
The outer plates, sponges, and filter paper sheets were used to sandwich the gel 
against the nitrocellulose membrane, in the order detailed above, carefully avoiding 
introduction o f air bubbles. The black plate was postioned nearest to the negative 
electrode, and the electrophoretic transfer o f proteins from the gel to the membrane  
achieved at 4 °C in a tank filled with buffer. The electric current ‘pulls’ proteins from the 
gel to the membrane, whilst maintaining their arrangement, so that a replica pattern, or 
‘blot’, is achieved on the membrane. Proteins bind to the membrane, and can be 
detected by the use o f antibodies.
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Secondary antibody was washed off with 3 consecutive, 5min TB ST washes with 
orbital shaking, followed by 3 consecutive, 5min TBS washes.
3.3.3.9 Detection of bound antibody using chemiluminescence
Enhanced chemiluminescence (ECL) reagent ECL Plus (Amersham Biosciences) was 
prepared immediately before use by mixing 2ml of Solution A with 50pl of Solution B 
and storing in the dark until required. Approximately 1ml of this was applied to each 
membrane for 5min at RT. This was then tapped off by handling the membranes with 
forceps, and the membrane was transferred to the inside of a washed clear plastic 
wallet. Light emitted from areas where the primary and secondary antibodies were 
bound was detected using an EpiChemi II Darkroom UVP system (Biolmaging 
Systems), and images of the membrane obtained using LabWorks image acquisition 
and analysis software. To increase visibility of the SeeBlue Plus 2 rainbow marker 
bands, they were highlighted in pencil on the membrane prior to detection in the UVP  
system.
3.3.4 Detection of astrocyte expression of CCL2 and CXCL10
To assess the feasibility of isolating intact and truncated forms of CCL2 and CXCL10  
from astrocytes, cell supernatants and lysates were investigated for the presence of 
these chemokines by western blotting and MALDI MSpec. To test the detection levels 
of these techniques, known concentrations of CCL2 and CXCL10 were prepared using 
recombinant proteins, and run alongside astrocyte-derived samples.
3.3.4.1 Western blotting for detection of CCL2 and CXCL10 in astrocyte samples 
and determination of detection limit
CCL2 and C XCL10 standards (Peprotech, EC) were prepared by dilution of 
recombinant proteins with dH20  and LDS sample buffer (4X) to give final protein 
amounts of 15, 10, 7.5, 5, 2.5, 2, 1, 0.5, and 0.25ng, and 1X sample buffer, for loading 
onto a gel. These amounts were chosen to reflect a range within which CCL2 and 
CXCL10 had been previously found in astrocyte cell supernatants (Suliman et a/., 
2006). Chemokine standards were run alongside supernatant and lysate samples from 
SM S12 astrocytes, treated with 0, 10, and 100ng/ml IL-1 p, TN F  and IFN-y for 24 and 
48h.
Western blotting was performed as described above, using a mouse monoclonal anti­
human CCL2 primary antibody (Abeam) at 1:500 (0.2pg/ml) for either 90min at RT or 
overnight at 4°C, and a polyclonal rabbit anti-mouse HRP-conjugated secondary
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antibody (Dako), used at 1:1000, for 90min at RT. Biotinylated primary antibodies 
against CCL2 and CXCL10 (R&D Systems) were also used in western blotting at 
0.2pg/ml, with detection of biotin by extravidin-peroxidase (Sigma), applied at 1:2000 
for 1 h at RT, prior to ECL detection as described above.
3.3.4.2 Detection of CCL2 and CXCL10 in astrocyte supernatant by MALDI-QTOF 
mass spectrometry
Supernatant from primary human astrocytes (EP15 P8) treated with 0, 1, 10, and 
100ng/ml IFN-y for 24h, was collected, the protein extracted using TRI Reagent®, and 
the protein pellet dissolved in 10pl dH20 . This was mixed with 3pl a-C H C A  (25mg/ml) 
matrix, and 1.5pl spotted onto a target plate and analysed by MALDI mass 
spectrometry using an Applied Biosystems/MDS Sciex “QStar” hybrid quadrupole mass 
spectrometer. A laser power of 40 - 60% and a pulse rate of 1000Hz were used for this 
analysis. This process was repeated, with zip tipping (see 2.3.5.2) of the samples, prior 
to analysis.
3.3.4.3 Assessment of the detection limit of CCL2 and CXCL10 by MALDI-QTOF 
mass spectrometry
To assess the MALDI detection limit for CCL2 and CXCL10, SF media was spiked with 
recombinant chemokine and analysed by MALDI mass spectrometry. Serial dilution of 
CCL2 was done to prepare concentrations of 1000, 800, 400, 200, 100, and 50pg/ml. 
CXCL10 concentrations prepared were 1000, 240, 120, 60, 30, and 15pg/ml, as 
expression of this chemokine was lower than for CCL2 in previous in vitro experiments 
with human adult astrocytes (Suliman et a/., 2006). 1pl of the various concentrations 
were mixed with 4pl of aCH C A  matrix and 1.5pl spotted onto a target plate. A laser 
power of 15% and a pulse rate of 500Hz were used during MALDI analysis. This 
process was repeated, with zip tipping (see 2.3.5.2) of the chemokine solutions, prior to 
analysis.
3.3.4.4 Concentration of chemokine-spiked media by freeze drying
The effect of concentrating astrocyte supernatants for detection of chemokine by 
MSpec was investigated, since there were concerns that chemokines in the 
supernatant would be present at a range below the detection limit. 20ml SFM  was 
spiked with 1pl of 0.1 mg/ml CCL2 or CXCL10 to give 5000pg/ml, which contained 
approximately 581 femtomoles (fmoles) of chemokine. 1ml of this was serially diluted 
by adding 1ml of SF media to produce concentrations of 2500, 1250, 625, and
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312.5pg/ml (containing ~290, 145, 73, and 36 fmoles of chemokine respectively). 
Samples were stored frozen at -80°C for 2 days. For the freeze-drying process, these 
samples were transferred to15ml conical tubes with holes pierced in the lids, and 
placed in a pre-cooled glass vessel which was fitted to a ModulyoD freeze-drier 
(Thermo Electron Corporation, Cheshire, UK). The freeze-drier had been turned on 
30min before to reduce the temperature. Once the glass vessel was in place, a vacuum  
was applied, and the tubes left to dry overnight. Dried samples were resuspended in 
80pl dH20  + 20pl sample preparation solution (0.5%  TFA) before being zip-tipped and 
2pl spotted onto a target plate for MALDI analysis. These spots were analysed using 
20%  laser power, and a pulse rate of 1000Hz.
3.3.5 Detection of MMPs expressed by astrocytes using TaqMan® polymerase 
chain reaction (PCR)
To determine the range of MMPs and TIM Ps that chemokines might be exposed to in 
vivo, and to investigate if any particular MMPs were more abundant than others, their 
RNA expression profiles were investigated in astrocytes.
3.3.5.1 Principles of TaqMan® PCR
TaqM an®  PCR is a real-time PCR method that utilises a probe with attached 
fluorescent tags, namely a reporter dye such as VIC®, or 6-carboxy-fluorescein (FAM), 
which has its emission spectra suppressed due to the proximity of a quencher dye, 
such as TAM RA (6-carboxy-tetramethylrhodamine) (Osgood-McW eeney et al., 2000). 
Forward and reverse primers anneal to particular sequences of the target DNA, and 
then extend. The TaqM an®  probe hybridises to target DNA, internal to the primer 
sequences. The forward primer displaces the TaqM an®  probe, and the 5 ’ exonuclease 
activity of Taq DNA polymerase then hydrolyses it during the extension phase of PCR, 
thus liberating the reporter dye from the quencher, resulting in fluorescence (Fig 3.4). 
After several amplification cycles, sufficient reporter dye is released through this 
cleavage, enabling detection of fluorescence, proportional to the quantity of PCR  
product formed, using a laser-coupled spectrophotometer. The cycle threshold (Ct) 
represents the cycle number at which a positive result above background fluorescence 
is obtained, illustrated by the level at which amplification entered the exponential phase 
(Fig. 3.5). Lower Ct values indicated a higher quantity of target RNA initially in the 
sample (Vega et al., 2005).
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Figure 3.4 Principles o f TaqM an®  PCR
A cDNA copy of the RNA template of interest is used in TaqMan® PCR. The TaqMan® 
probe contains a quenching molecule (orange circle labelled ‘Q’ above) at the 3’ end, 
which, when it is close by, prevents observation of fluorescent signal from the reporter 
dye (green circle labelled R ’ above) at the 5’ end. After denaturation, both probe and 
primer bind to the target cDNA. During the polymerisation step (i), Taq polymerase 
creates a complementary strand via its 5’ nuclease activity, which displaces (ii) and 
cleaves the probe (Hi). Disruption of the probe results in fluorescence from the reporter 
molecule, in a directly proportional manner to the number of molecules released during 
that cycle, so that accumulation of PCR product is detected by measuring the increase 
in fluorescence (iv).
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3.3.5.2 Preparation of cDNA samples
RNA extracted from astrocytes (cytokine-treated and untreated) using TRI Reagent®, 
following the manufacturer’s protocol (Appendix II), was used in the preparation of 
cDNA samples, which were stored at -20°C for 2 days and then transported to the 
University of East Anglia (UEA) for analysis by TaqM an®  PCR.
RNase-free filter tips (Fisher Scientific, Loughborough, UK) and tubes (Sigma) were 
used throughout the preparation of cDNA. RNA was incubated in a mix containing 
deoxynucleotide triphosphates (dNTPs), which carry the bases adenine (dATP), 
guanine (dGTP), cytosine (dCTP), and thymine (dTTP), from which DNA is constructed. 
The primers, in the mix bind to the RNA randomly, and the reverse transcriptase (RT) 
inserts dNTPs into the gaps to complete the cDNA strand, which represents all the 
transcribed RNA. Control samples of RNA without RT, and the negative with no RNA + 
RT were included. For each 1pl sample of RNA in dH20  (kept at -20°C until required), 
the following ‘mastermix’ was added:
1pl Deoxynucleotide triphosphates (dNTPs) (Bioline, London, UK)
0.5pl RNase inhibitor (Invitrogen)
0.5pl Random Hexamers (Invitrogen)
9pl Molecular grade H20  (Sigma)
1 pi Super Script II reverse transcriptase (RT) (Invitrogen)
The RT was added last and was kept frozen until required. It was pipetted gently to 
avoid degradation. After the mastermix and RNA were combined, mineral oil was 
added to prevent evaporation on the heat block. The samples were heated to 42°C for 
1 hour, and then 95°C for 5min to inactivate the enzyme, using a Biometra 'Trio- 
Thermoblock' heating block (Biometra, Hamburg, Germany). The samples were then 
stored at -20°C.
3.3.5.3 TaqMan® PCR method for detecting MMPs and TIMPs using cDNA from 
astrocytes
TaqM an®  PCR was performed at the UEA, in the laboratory of Prof. D. Edwards, under 
the supervision of Dr. R. Nuttall. Samples were analysed only once due to high costs, 
which precluded statistical analysis of the results. By screening astrocytes for the entire 
range of MM Ps and TIM Ps, however, it was hoped that detection of specific mRNAs at
4pl 5 x 1st strand buffer 
2pl 0.1M  dithiothreitol (DTT) Provided with th e  e n zym e  (Invitrogen)
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high levels following treatment with pro-inflammatory cytokines might indicate which 
MMPs are likely to play important roles in chemokine processing in the inflamed CNS. 
Trends in M M P expression revealed by this pilot investigation could then be considered 
in future investigations of chemokine processing.
All pipetting procedures were conducted in a designated clean area, and water used 
was molecular grade (Sigma). Preliminary experiments were conducted with 18S and 
GAPDH housekeeping genes to establish which one gave the least variation in 
expression between the samples. The gene for 18S ribosomal RNA (rRNA) was 
selected and used as a control to normalise for variations in the amount of total RNA in 
each sample by using 18S rRNA primers and probe (Applied Biosystems, Warrington, 
UK) alongside each set for the target genes.
All reagents were from Applied Biosystems, unless otherwise specified. 4pl of each 
cDNA sample was diluted 1:100 with 396pl water. Each well of a 96-well plate had 10pl 
cDNA sample, 8.5pl TaqM an®  mastermix, 0.5pl forward primer, 0.5pl reverse primer, 
0.5pl probe, and 5pl water added. Reverse pipetting was used for greater accuracy.
For each well containing the housekeeping gene, 2pl cDNA, 8.5pl TaqM an®  mastermix, 
0.125pl forward primer, 0.125pl reverse primer, and 0.125pl probe, were added.
Five RNA standards (S1 -  S5) of known amounts (4, 2, 1, 0.5, and 0.25ng), kindly 
provided by Dr. R. Nuttall (obtained from U251 human glioblastoma cells), were run for 
each gene. A negative control sample (no RNA), and a sample with no reverse 
transcriptase, were run for each MMP. Plates were sealed with an adhesive film and 
placed in the ABI Prism 7700 sequence detector (Applied Biosystems).
The PCR program was operated using Sequence Detection System (SDS) V1.9  
software, using the ‘FAM ’ setting for all genes, except the housekeeping gene 18S, 
where the ‘V IC ’ setting was used, according to the reporter dyes present. Plates were 
run using a 2-step PCR process incorporating 40 cycles, which heated the plates to 
60°C for 1min, and then 94°C for 15 seconds. Ct values for each M M P and T IM P  were 
obtained from plots generated by the software, once the threshold had been set 
manually. Comparing gene expression using Ct alone is imprecise, so Ct levels were 
converted to quantitative relative expression levels. This was done by preparing 
standard curves (see Fig. 3.11) for each reaction using the standards S1-S5, which 
had also been subjected to PCR. Standard curves for Ct versus RNA level were used 
to determine relative starting RNA levels within the sample, which were then 
normalised to 18S rRNA levels of the same sample.
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3.3.5.4 Primer and probe sequences
Sequences for the primers and probes used (of the TIM Ps only) are given below, in the 
5 ’ to 3 ’ orientation. M M P primer and probe sequences are not shown, as they remain 
the property of Applied Biosystems (Warrington, UK). The 5 ’ end of the probes 
contained a FAM fluorescent reporter, and the 3 ’ end had a TAM RA quencher. .
TIMP-1
Forward primer: G A C G G C C TTCTG CAATTC C  
Reverse primer: G TATAAG G TG G TC TG G TTG A C TTC TG  
Probe: A C C TC G TC A TC A G G G C C A A G TTC G T
TIM P-2
Forward primer: G AGCCTG AACCACAG G TACCA  
Reverse primer: AG G AG ATG TAG CACG G G ATCA  
Probe: CTG CG AG TG CAAG ATCACG CG C
TIM P-3
Forward primer: CCAG G ACG CCTTCTG CA A  
Reverse primer: CCCCTC C TTTA C C A G C TTC TTC  
Probe: CG ACATCG TG A TC C G G G C C A
TIM P-4
Forward primer: C ACCCTCAG CAG CACATCTG  
Reverse primer: G G C C G G A AC TAC CTTCTCACT  
Probe: CACTC G G C A C TTG TG A TTC G G G C
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3.4 Results
3.4.1 Characterisation of astrocytes by immunocytochemistry
All primary astrocytes showed positive staining results using both monoclonal and 
polyclonal anti-GFAP antibodies (Figs 3.5 a-f and 3.6 a -f), but the pattern of staining 
was grainy, and diffuse in appearance with both antibodies, and of a weak intensity. 
The monoclonal antibody gave stronger staining overall than the polyclonal, and this 
was particularly noticeable with the astrocyte preparation 668/01. These astrocytes 
exhibited the poorest GFAP expression out of the 6 preparations examined (Figs 3.5d 
and 3.6d), and were only very weakly positive with the polyclonal antibody (Fig 3.6d). 
668/01 astrocyte cells also appeared to have a small and round morphology, whereas 
all the other astrocytes had irregular processes. Thus, 668/01 cells were not used in 
further experiments. The fibrillary staining pattern characteristic of GFAP was clearly 
demonstrated by U373 astrocytoma cells (Figs 3.5g and 3.6g), which gave a strongly 
positive result. The negative control revealed no detectable background staining (Figs. 
3.5h and 3.6h).
Primary astrocytes gave strongly positive results with the S1OO-0 antibody, with all but 
B73 cells, giving clear and extensive fibrillary staining patterns (Fig. 3.7 a, b, c, e, f). 
B73 cells gave a more limited and grainy staining pattern, and demonstrated a smaller, 
rounded morphology (Fig. 3.7d), and were thus not selected for further analysis. 
Cellular processes were well defined with the S100-(3 antibody on U373 astrocytoma 
cells (Fig.3.7g), but staining was weaker in appearance than with the primary 
astrocytes. Interestingly, this contrasts with the GFAP staining patterns, where U373  
cells gave stronger, more fibrillary staining, than primary astrocytes. The negative 
control involved omission of the primary anti-s100-f3 antibody, and revealed no 
detectable background staining (Fig. 3.7h).
3.4.2 Characterisation of astrocytes by western blotting for detection of GFAP
Optimal conditions for western blotting were obtained by conducting the transfer at 4°C  
using 150 volts for 90min, blocking for 90min at RT without Tw een®  20, removing the 
milk from the TB ST containing the primary antibody, and incubating overnight at 4 °C. 
Blots demonstrating evidence of GFAP in the astrocytes were obtained (Fig. 3.8) under 
these conditions. The Triton® X-100 protein extraction method (3.3.3.2) was found to 
be the optimal choice for obtaining protein from astrocytes (data not shown).
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Primary astrocyte lysate samples from SM S12, EP15, M S16, and B327/01 gave clear 
bands at ~50kDa, which indicated the presence of GFAP (Reeves et al., 1989). MS21 
gave weaker expression in comparison (Fig. 3.8a). Astrocyte supernatants (Fig. 3.8a) 
showed no significant GFAP expression as expected, although some reactivity at 
~62kDa was seen on the negative blot. Astrocyte lysate samples showed no reactivity 
in the negative control blot (Fig. 3.8b).
Using protein extracted from lysate and supernatant samples from astrocyte 
preparations EP14 and EP15, revealed very clear bands for the lysate samples at 
~50kDa (Fig. 3.8c), indicating the presence of GFAP. Supernatant samples showed 
minimal reactivity (Fig. 3.8c), and no reactivity was seen in the negative control blot 
(Fig. 3.8d).
3.4.3 Detection of CCL2 and CXCL10 by western blotting
Recombinant human CCL2 and CXCL10 standards were detected at all concentrations 
in western blots using biotinylated antibodies and Extravidin (Fig. 3.9). The lowest level 
of standard seen was 2.5ng, which was just evident for CCL2 (Fig. 3.9a), and clearly 
visible for CXCL10 (Fig. 3.9b), suggesting the an ti-CXCL10 antibody was the most 
sensitive. The negative controls showed no reactivity in the 8-9kDa region.
No CCL2 or CXCL10 could be detected in either astrocyte lysate preparations or cell 
supernatant samples, with or without cytokine treatment (Fig. 3.9). Non-specific bands 
were seen at ~64kDa in all the astrocyte preparations, with both anti-CCL2 and anti- 
CXCL10 antibodies, and were more prominant in lysate samples. These non-specific 
bands were also seen in the negative controls, which indicated that they were not due 
to non-specific binding of the primary antibody (Fig. 3.9). Thus, levels of these 2 
chemokines present in the astrocyte lysate and supernatant samples were below the 
detection limit (2.5ng).
3.4.4 Detection of CCL2 and CXCL10 by MALDI-QTOF mass spectrometry
3.4.4.1 MALDI-QTOF analysis of serum-free media spiked with chemokine to 
assess detection limits
SFM spiked with 50-1000pg/m l recombinant CCL2 or CXCL10 did not produce any 
peaks, other than matrix peaks, when analysed by MALDI MSpec, without prior zip 
tipping of the samples (data not shown). By zip tipping the same chemokine samples, 
1000pg/ml CCL2 (Fig. 3.10) could be detected, but not 1000pg/ml CXCL10 (data not 
shown).
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Figure 3.8 Detection by western blotting of GFAP in six preparations of primary 
human astrocytes to assess astrocyte purity
Western blots o f 6 different primary human astrocyte lysate (L) and supernatant (S) 
preparations, using a-G FA P primary antibody (1:1000, rabbit a-human, Dako) (a) and
(c), and goat a-rabbit IgG H R P  secondary antibody (1: 50,000, Sigma).
(b) Negative (omission o f primary) corresponding to gel in (a)
(d) Negative corresponding to gel in (c)
In (a) and (b), samples represented in lanes 1-9 are: (1) SeeBlue Plus 2 M W  marker; 
(2) SM S12 (L); (3) E P 15 (L); (4) M S16 (L); (5) MS21 (L); (6) B327/01 (L); (7) M S 16 (S); 
(8) MS21 (S); (9) B327/01 (S)
In (c) and (d), samples represented in lanes 1-9 are: (1) E P 15 (S); (2) E P 14 (S); (3) 
E P 15 (L); (4) EP14 (L); (5) SeeBlue Plus 2 M W  m arker
A distinct band can be seen at the expected molecular weight o f G FAP at ~ 50kDa for 
each astrocyte lysate preparation.
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Figure 3.9 W es tern  blo t analysis fo r de tec tion o f CCL2 and C XCL10 in prim ary  
hum an as trocytes (SM S12) to assess de tection lim it using chem okine standards
(i) Western blot of CCL2 standards and primary human astrocyte (SMS12) lysate (L) 
and supernatant (S) samples, using anti-CCL2 biotinylated antibody (1:250) (R&D 
Systems), followed by Extravidln (1:2000), and detection by chemiluminescence. The 
negative control involved omission of the primary antibody.
Lanes 1-12 represent the following samples: (1) Negative - SMS12 (L) 24h treatment 
with 10ng/ml TNF; (2) 15ng; (3) 10ng; (4) 7.5ng; (5) 5ng; (6) 2.5ng; (7) SMS12 (L) 24h 
treatment with 10ng/ml TNF; (8) SMS12 (S) 24h treatment with 10ng/ml TNF; (9) 
SMS12 (L) untreated; (10) SMS12 (S) (untreated); (11) SeeBlue Plus 2 MW marker
(ii) Western blot of CXCL10 standards and primary human astrocyte (SMS12) lysate (L) 
and supernatant (S) samples, using anti-CXCL10 biotinylated antibody (1:250) (R&D 
Systems), followed by Extravidin (1:2000), and detection by chemiluminescence. The 
negative control involved omission of the primary antibody.
Lanes 1-12 represent the following samples: (1) Negative - SMS12 (L) 24h treatment 
with WOng/ml IFN; (2) 15ng; (3) 10ng; (4) *7.5ng; (5) *5ng; (6) 2.5ng; (7) SMS12 (L) 
24h treatment with 100ng/ml IFN; (8) SMS12 (S) 24h treatment with 100ng/ml IFN; (9) 
SMS12 (L) untreated; (10) SMS12 (S) untreated; (11) SeeBlue Plus 2 MW marker.
* not visible as obscured by air bubble.
Bands for CCL2 and CXCL10 standards can be detected at the 2.5ng level.
No bands at ~ 8-9kDa are visible with the astrocyte lysate or supernatant samples, but 
non-specific bands are seen in all the astrocyte preparations at ~65kDa.
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Figure 3.10 MALDI-QTOF mass spectrometric analysis of serum free media 
spiked with 1000pg/ml of CCL2 to assess detection levels
Recombinant human CCL2 (Serotec, Oxford, UK) was added to serum-free media 
(SFM), to give a final concentration of 1000pg/ml. Samples (10pl) were zip tipped to 
concentrate and desalt them, spotted onto a MALDI target plate, and analysed by 
M ALDI-Q TO F mass spectrometry. Mass spectra shown are as follows:
(a) SFM  spiked with 1000pg/ml CCL2 (equivalent to a maximum of 10pg eluted on to 
the target). A peak was only just evident on the spectra at around 8600 m /z in the 
region circled.
(b) Detailed spectra o f region circled in (a), showing m/z values o f 8400 -  8950. A low 
intensity peak o f 8680 m /z was visible, which corresponded to the m /z value previously 
obtained for CCL2 (Chapter 2), indicating it was possible to detect 1000pg/ml CCL2.
The dominant peak at 1329 m /z  was seen in all spectra, including media spiked with 
CXCL10, and  was likely to have originated from a component o f the media.
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As 10|j| of the 1000pg/ml solution was zip tipped, this bound a maximum of 10pg of 
CCL2 for elution onto the target plate.
Freeze drying of SFM  spiked with recombinant chemokine did not improve the 
detection of chemokines by M ALDI-Q TOF MSpec. The dried samples were too rich in 
salts and required too large a volume for reconstitution to be suitable (data not shown).
3.4.4.2 MALDI-QTOF analysis of supernatant from astrocytes (EP15) with and 
without cytokine treatment
MALDI M Spec results did not reveal any CCL2 or CXCL10 in the supernatant of either 
IFN-y-treated or untreated primary human astrocytes EP15 (data not shown), 
suggesting that these chemokines were present at concentrations below 1000pg/ml.
3.4.5 TaqMan® PCR Detection of MMPs and TIMPs mRNAs
3.4.5.1 Expression of housekeeping genes
The housekeeping gene18S was found to be more suitable than G A PD H  for use with 
the astrocyte lysate samples in TaqM an®  PCR. 18S gave the most stable expression 
in the samples investigated, at adequate levels, with little variation in Ct values between 
samples. A  standard curve for 18S expression by the RNA standards (S1-S5) is shown 
in Figure 3.11. ^
3.4.5.2 TaqMan® PCR detection of MMPs mRNAs expression by astrocytes
Results of the expression of MMPs in astrocytes are summarised in Table 3.2, and in 
Figures 3.12 and 3.13. Key findings included: high expression of M M P2 in treated and 
untreated astrocytes; high expression of MMPs 1, 3, and 10, in SM S12 astrocytes 
when treated with IL-1(3; an increase in M M P9 expression when astrocytes were 
treated with either T N F  or IL-1 (3; a reduction in M M P11, following treatment with 
cytokines; and no expression of MMPs-7, -8, -20, -21, and -26 (Figs. 3 .12 and 3.13).
3.4.5.3 TaqMan® PCR detection of TIMPs mRNAs expression in primary human 
astrocyte cell cultures
Results of the expression of TIM Ps in astrocytes prepared from control brain (EP15), 
and MS NAW M  (SM S12) are summarised in Table 3.3, and displayed in more detail in 
Figure 3.14. T IM P3 mRNA was found to be the most abundant, and TIM P4, the least 
expressed.
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Figure 3.11 Standard curve for expression of the housekeeping gene 18S using 
RNA standards obtained from U251 human glioblastoma cells
The log o f the concentration o f each RNA standard (S1-S5), M/as plotted against the Ct 
value, resulting in a standard curve for the housekeeping gene 18S. The equation 
generated by the curve M/as used to calculate the log o f relative expression of 18S RNA  
in each astrocyte and tissue sample, by subtracting the y-intercept (14.228) from the Ct 
value, and dividing this value by the gradient o f the curve (-2.1426). An inverse log was 
then used to obtain a value for relative mRNA expression. Standard curves were 
created for each o f the M M P and TIM P target genes in the same way, and used in the 
calculation o f their relative RNA levels, which were then normalised to 18S levels by 
dividing by the corresponding relative RNA level o f 18S.
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All samples showed some expression of all 4 TIMPs, with SM S12 astrocytes generally 
expressing higher T IM P levels than EP15 astrocytes, particularly when treated with 
cytokines. TN F  treatment appeared to decrease expression of T IM P2 in both SM S12  
and EP15 astrocyte cells (Fig. 3.14b). Results from cytokine treatment were variable, 
but IL-1 p generally created the largest increase in T IM P m RNA expression in 
astrocytes, particularly SM S 12.
3.4.5.4 Effects of cytokine treatment on primary human astrocyte expression of 
MMPs and TIMPs mRNAs, as detected by TaqMan® RT PCR
Of the 3 cytokines used to treat astrocytes from control (EP15), and MS NAW M  
(SMS 12), IL-1(3 increased the expression of the majority of MMPs, with notable 
exceptions being M M P 11, and MM P25. IL-1(3 exerted its most dramatic effects on 
SM S12, particularly with MMP1 relative mRNA expression, which increased from ~100  
to 2300, when astrocytes were treated with 100ng/ml IL-1(3 (Fig. 3.12a). MMPs 3, 10, 
and 12 mRNAs were not expressed in untreated astrocytes, but appeared with both 
SM S12 and EP15 astrocytes that had received 24h of 100ng/ml IL-1(3. This 
enhancement in expression was particularly marked with M M P10 mRNA in SM S12  
astrocytes, increasing from 0 to -2 2 0 0  (Fig. 3.12e). T IM Ps 1 and 4 showed no less 
than two-fold increases in their relative mRNA levels following IL-1 (3 treatment on 
SM S 12 astrocytes (Fig. 3.14a and d).
Treatment with TN F  increased relative mRNA levels of M M P9 in both SM S12 and 
EP15 astrocytes, and had the opposite effect on expression of M M P 11 and M M P14  
(Fig. 3.12). TN F  treatment appeared to decrease expression of all four TIMPs, 
particularly TIMP1 and TIM P3 (Fig. 3.14).
IFN-y treatment decreased expression of MMPs 11, 14, and19 (Figs. 3.12 and 3.13) 
mRNAs, with little effect on other MMP mRNAs. IFN-y induced an increase in T IM P2  
(Fig. 3.14b) m RNA expression, however.
152
Figure 3.12 Relative mRNA levels detected by TaqMan® RT PCR of MMPs 1, 2, 3, 
9,10,11 ,12 ,13 ,14, and 15, in two primary human astrocyte preparations from 
either control or MS NAWM
Relative RNA levels o f each M M P  detected in astrocytes isolated from M S white matter 
(SM S12) and control brain (EP15) are shown, expressed in arbitrary units as a ratio to 
18S RNA. Colour coding is used to indicate the cytokine treatment status of the 
astrocytes prior to RNA extraction, with either no treatment (blue), or 100ng/ml IL-1p  
(purple), TNF (red), or IFN -y (green). Levels for M M P-7 and -8  were below detection 
levels in all samples. Notably, high RNA levels were seen for M M Ps -1 and -10  after 
treatment with IL-1(S, and M M P2 RNA  was detected at moderately high levels, with and 
without cytokine treatment.
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Figure 3.13 Relative m RNA levels detec ted by T aqM an®  RT PCR of M M Ps 16, 17, 
19, 23, 24, 25, 27, and 28, in tw o prim ary hum an as trocyte prepara tions from  
either con tro l or MS NAW M
Relative RNA levels of each MMP detected in astrocytes isolated from MS white matter 
(SMS12) and control brain (EP15) are shown, expressed in arbitrary units as a ratio to 
18S RNA. Colour coding is used to indicate the cytokine treatment status of the 
astrocytes prior to RNA extraction, with either no stimulation (blue), or 100ng/ml IL-1/3 
(purple), TNF (red), or IFN-y (green). Levels for MMP-20, -21, and -26, were below 
detection levels in all samples.
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Table 3.2 Summary of TaqMan® RT PCR results of MMPs mRNAs expression in
primary human astrocyte cell cultures and effects of cytokine treatment
MMP RELATIVE mRNA EXPRESSION IN ASTROCYTES(Figs. 3 .1 2  and 3 .1 3 )
1 IL - ip t  expression, and to very high levels in S M S 1 2 . 
S M S 1 2  > E P 15 .
T N F  a ls o f  expression to lesser ex ten t
2 High expression  ±  trea tm en t. 
T N F l  expression slightly
3 IL - 1 p f  expression, and to high levels in S M S 1 2 . 
S M S 1 2 > E P 1 5 .
N o n e  seen  ± IF N
7 N o n e
8 N o n e
9 T N F f  expression; IL -1 p f  expression in E P 1 5 . 
N o n e  seen  ±  IFN
10 IL -1p  induced very high expression in S M S 1 2 . 
N o n e  seen  ±  IFN
11 All t re a tm e n t !  expression, especia lly  IL-1 p and T N F . 
U ntrea ted  cells show ed high expression
12 IL-1 p fe x p re s s io n ; S M S 1 2 > E P 1 5 . 
N o n e  seen  ±  IFN
13 V e ry  low expression, and only with T N F  and IL-1 p
14 I L - i p f  expression, T N F  and IFN  s lig h tly ! am ount. 
S M S 1 2 > E P 1 5
15 Low  expression.
IL - 1 p f  and T N F  !  expression very slightly
16 Low  expression . T rea tm en t !  expression  in S M S 1 2 . 
S M S 1 2 > E P 1 5
17 Low  expression
19 IFN  and T N F !  expression in S M S 1 2 . 
S M S 1 2 > E P 1 5
20 N o n e
21 N o n e
23 IL-1 p fe x p re s s io n  in S M S 1 2  
N o n e  in un trea ted S M S 1 2
24 V e ry  low expression.
IL-1 p 't  expression in S M S 1 2
25 Low  expression
N o n e  with IL-1 p in S M S  12
26 N o n e
27 O nly induced by IFN  in S M S 1 2  and very  low  expression
28 V e ry  low expression  
N o n e  seen  with IFN
t  = increase; |  = decrease; > = higher overall expression than
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Figure 3.14 Rela tive m RNA levels de tec ted by TaqM an®  RT PCR o f T IM P s 1,2, 3, 
and 4, in prim ary hum an as trocytes from  con trol and MS NAW M
Relative RNA levels of each TIMP detected in astrocytes isolated from MS white matter 
(SMS12) and control brain (EP15) are shown, expressed in arbitrary units as a ratio to 
18S RNA. Colour coding is used to indicate the cytokine treatment status of the 
astrocytes prior to RNA extraction, with either no treatment (blue), or 100ng/ml IL-1 (5 
(purple), TNF (red), or IFN-y (green).
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Table 3.3 Summary of TaqMan® RT PCR results of TIMPs mRNAs expression in
primary human astrocyte cell cultures and effects of cytokine treatment
t i iv ip R E L A T IV E  m R N A  E X P R E S S IO N  IN  A S T R O C Y T E S(Fig. 3 .1 4 )
1 t  seen  with IL-1 (3 
S M S 1 2 > E P 1 5
2 N o trea tm en t g ave  sim ilar levels as IL-1 p. 
T N F l  expression.
IFN  fe x p re s s io n  in S M S 1 2
3 M os t highly expressed.
U n trea ted  sim ilar to trea ted  in E P 15 .
IL-1 p and untrea ted show ed higher levels than T N F  and IF N  in S M S 1 2
4 Low  level o f expression.
T re a te d  and un trea ted sim ilar, excep t f o r t  seen  with IL-113 in S M S 1 2
f  = increase; |  = decrease; > = higher overall expression than
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3.5 Discussion
3.5.1 Characterisation of primary human astrocytes
Adult human brain tissue has been used to produce in vitro cell cultures since the 
1960s (Ponten and Macintyre, 1968), but the exact cellular composition of these 
cultures is often questionable. Purity of cell cultures is essential for meaningful results, 
as astrocyte responses to stimuli will vary greatly if neurons are present, and other 
contaminating cell types, such as fibroblast-like cells, that can proliferate rapidly and 
dominate after several passages (Lee et a/., 1994). Astrocytes commonly have their 
purity assessed by measuring reactivity for GFAP (Gibbons et al., 2007). GFAP  
immunoreactivity often diminishes with successive passages (Lue et al., 1996), and 
cultured astrocytes are known to modulate GFAP synthesis in response to growth 
media composition (Morrison et al., 1985), and cell density (Goldman and Chiu, 1984). 
GFAP expression is not considered to be a definitive astrocytic marker by some, who 
argue that astrocytes in situ exhibit very little (Walz, 2000). In addition, low GFAP  
expression can escape detection depending on the fixative and antibodies used (Eng 
et al., 2000). To attempt to confirm the GFAP staining pattern observed with astrocytes 
used in this project, both a change of fixative, and the use of different antibodies was 
tried. PFA gave better results than acetone, possibly due to the protein coagulation 
actions of acetone producing grainy staining patterns (Farmilo and Stead, 1989).
S100-p was used an additional astrocytic marker to support results obtained with 
GFAP. The differences in GFAP and S100-p staining seen between primary astrocytes 
and the astrocytoma cells might result from a higher level of maturity of astrocytomas, 
and/or alterations acquired during cell culture. The stronger GFAP staining seen in the 
astrocytoma cells (U373) supports the suggestion that U373 cells express more of the 
marker GFAP than S100-(3, compared to astrocytes, due to their immortality giving a 
greater level of maturity. S100-(3 is less specific for astrocytes than GFAP, and has 
been localised by immunohistochemistry to many neural cell types in humans, 
including OLGs, ependymal cells, ECs, lymphocytes, neurons, and the choroid plexus 
epithelium (Steiner et al., 2007).
Brightfield microscopy examinations and immunofluorescent results suggest that EP14  
and EP15 had a fibrous morphology, whereas B327, 668/01, M S16 and MS21 showed 
more of a protoplasmic structure. Protoplasmic astrocytes tend to be considerably less 
GFAP immunoreactive than fibrous cells (Lue et al., 1996).
Collectively, results from immunocytochemistry and western blotting indicated that 
EP14, EP15 and SM S12 astrocytes demonstrated a morphology and positivity for
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GFAP and S100-(3 highly consistent with that of astrocytes. Thus, the study was 
restricted to use of these 3 cultures for assessment of astrocyte M M P expression, and 
detection of truncated chemokines in astrocyte supernatant.
3.5.2 Detection of CCL2 and CXCL10 in primary human astrocyte cell culture 
supernatants
It has previously been reported that astrocytes in vivo and in vitro express CCL2 and 
CXCL10, particularly when exposed to inflammatory stimuli (Farina et al., 2007). CCL2 
is considered one of the most abundant chemokines produced within the brain, 
predominantly by astrocytes, and plays a key role in leukocyte recruitment (Guillemin et 
al., 2003). C XCL10 has been shown to be expressed by a subpopulation of both 
resting and reactive astrocytes in control brain (Xia et al., 2000), and is associated with 
reactive astrocytes around inflamed lesions in MS (Sorensen et al., 1999). Aside from 
their inflammatory roles, CCL2 and CXCL10 are involved in CNS tissue regenerating 
roles, such as regulation of myelination and migration of microglia (Farina et al., 2007). 
Astrocytes have been shown to have a central role in regulating neuroinflammation, 
which corresponded to their expression of these two chemokines. Transgenic mice with 
selective inactivation in astrocytes of the transcription factor NF-kB, showed a 
reduction in lesion volume and white matter damage following injury. This 
corresponded to decreased leukocyte recruitment into the lesion, due to reduced NF- 
xB-dependent expression of CCL2 and CXCL10 (Brambilla et al., 2005).
Human foetal astrocyte secretion of CCL2 has been reported to be greatly increased 
by 24-72h treatment with TNF, IL-1 (3, TNF/IFN-y, IFN-y/IL-113, and TNF/IL-6, with a 
maximum CCL2 concentration of 201ng/ml detected by enzyme-linked immunosorbent 
assay (ELISA) after 72h (Guillemin et al., 2003). In adult primary human astrocytes, 
chemokine expression was much lower. An increase (~5-fold) in CCL2 secretion by 
primary adult human astrocytes was detected by ELISA following treatment with IL-1 (3 
and TN F for 48h, thereby yielding ~9ng/ml. Similarly, astrocyte CXCL10 secretion 
increased (~2-fold) to ~1.9ng/ml after 48h exposure to IFN-y (Fouillet et al., 2005).
Thus, IL-1 (3, TNF, and IFN-y were used to maximise secretion of these chemokines 
and reflect the elevated cytokine expression demonstrated in MS lesions.
Since astrocytes also secrete MMPs (Leveque et al., 2004), the cleavage of CCL2 and 
CXCL10 that occurs in vitro, as detailed in Chapter 2, could take place in vivo. Thus, 
astrocyte supernatants were investigated for the presence of chemokine cleavage 
products. Initial experiments using recombinant chemokines, performed to assess the 
detection limits of CCL2 and CXCL10, revealed that western blotting detected 2.5ng
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chemokine, and MSpec was able to identify a very low intensity peak from a zip tipped 
solution of 1000pg/ml CCL2, equivalent to a maximum of 10pg of protein. No 
chemokine could be detected in astrocyte supernatant or lysate samples by either 
method, despite treatment with IL-1 (3 (for CCL2) or IFN-y (for CXCL10). Difficulties 
arose due to the small volumes needed for analysis, and concentrating supernatants 
by freeze-drying created a sample with a very high salt concentration, that would 
interfere with MALDI MSpec and prevent detection of the chemokine. As chemokines 
are close to the upper range of ~10 kDa capable of detection by MALDI on the QStar 
instrument, this may add further to the difficulties in detection. It was calculated that 
1000pg/ml chemokine only contains ~ 1 .16 fmoles CCL2 and ~1.17 fmoles CXCL10, 
when the volume applied to the MALDI target plate is considered. The level of 
detection of the instrument was given as ~50 fmoles, so it would not be possible to 
detect anything less than had already been achieved, without additional concentrating 
and desalting steps. This indicated that detection of basal expression of CCL2 and 
CXC L10 in astrocyte supernatant, and their reported levels following cytokine treatment, 
is beyond the sensitivity of the instrument with the current method. Previous reports of 
isolation and purification of chemokines from cell supernatants involve concentrating 
several litres of medium (Proost et al., 1996), which was beyond the scope of the 
current study.
3.5.3 Detection of MMPs and TIMPs mRNAs in primary human astrocytes
Results from TaqM an®  PCR tend to be reliable and reproducible due to low inter-assay 
variation (Bustin and Mueller, 2005). The accuracy of the standards is responsible for 
the accuracy of the quantification used for comparison, and using a standard curve 
generally gives highly reproducible results (Bustin and Mueller, 2005). Caution must be 
employed when comparing samples with each other, as although results are 
normalised to expression of the housekeeping genes, real-time PCR involves 
amplification, so small differences in the amount of cDNA loaded from each sample, 
will lead to much larger fluctuations of product amount (Bubner at al., 2004). Screening 
for expression of MMPs in astrocytes served useful, however, to help identify MMPs  
worthy of further investigation into the chemokine cleavage that might occur in the 
inflamed CNS. Protein expression does not always mirror that of mRNA, but a good 
correlation was found by Anthony and colleagues (1998), who examined expression of 
both for a range of MMPs, in a rat model of MS.
M M P9 is thought to be particularly important in MS as studies consistently find 
increases in brain tissue, serum, and CSF (Yong et al., 2007b). Both astrocyte 
preparations assessed here by TaqM an® PCR showed an increase of M M P9 mRNA
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following TN F treatment, and the largest increase resulted from IL-1 (3 treatment of 
EP15 astrocytes. TaqM an®  data from the astrocytes is in agreement with previous 
findings, in that basal expression of mRNAs of M MP2, T IM P1, and TIM P2, are seen, 
but little, if any secretion of M M P9 (Leveque et al., 2004). In the current study, relative 
mRNA expression of M M P2 was approximately 10 times greater than maximal MM P9  
expression.
TIM P3 was found to be the most abundant inhibitor mRNA expressed in astrocytes, 
which contrasts with reports of T IM P2 and T IM P4 being the most prevalent in normal 
brain (Nuttall et al., 2003). Observations that TIM Ps -1, -2, and -3, m RNA are 
expressed in substantial quantities in astrocytes, is consistent with the findings of Muir 
et al. (2002), however.
Following cytokine treatment of human astrocytes, IL-1 (3 was found to produce the 
most dramatic increases in expression of many of the MMPs. This finding is in 
agreement with that of Muir and colleagues (2002), who found upregulation of MM P2  
and M M P9 with IL-1 (3 treatment, and also TNF-induced increases in M MP9. MMP11 
appeared to be down-regulated in astrocytes by all the cytokine treatments tried. 
Previous studies have reported a reduction in T IM P3 expression in astrocytes following 
TN F and IFN-y treatment, but an upregulation of TIMP1 after TN F treatment (Bugno et 
al., 1999). The results with SM S12 are consistent with this decrease in T IM P3, but 
those from the EP15 astrocytes are not. Moreover, EP15 and SM S12 astrocytes did 
not follow this increase reported for TIMP1 expression after TN F treatment.
MM P expression in MS lesions has received much attention. A  study using PCR to 
investigate the expression of MMPs -2, -3, -7, -8, -9, -12 , and the TIM Ps, in MS brain 
tissue, detected strong induction of M M P7 and M M P9 in lesions and NAW M (Lindberg 
et al., 2001). M M P7 and M M P9 were also reported by Cossins et al., (1997) to be 
elevated in active lesions in MS. Using immunohistochemistry, Anthony and colleagues 
(1997) detected increased expression of MMP2, M M P7, and M M P9 in microglia and 
macrophages of acute MS lesions. The upregulation of M M P7 in chronic lesions was 
associated with macrophages within PVCs, which might explain the lack of detection of 
M M P7 mRNA in astrocytes, in the current study. M M P7 and M M P2 were located in the 
active borders of active-chronic MS lesions and are likely to have major roles in MS 
pathogenesis, including breakdown of the BBB, particularly as levels of M M P2 and 
M M P7 were low in control brain (Anthony et al., 1997). Kouwenhoven et al. (2001) 
used in situ hybridisation to look at RNA levels of MM Ps -1, -3, -7, -9, -14 and TIMP1 in 
monocytes from peripheral blood of MS patients and healthy controls, and detected 
elevations in MS, compared to controls, of all MMPs, except M M P14.
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It is apparent that in addition to MMPs 2 and 9 investigated in this study, previous 
studies suggest a role for M MP7, which could also be implicated in interactions with 
chemokines in MS. TaqM an®  PCR data presented here showed very high relative 
MMP1 mRNA expression in astrocytes treated with IL-1 (3, compared to other MMPs. 
This may also be of significance in MS, particularly as MMP1 has been shown to 
destroy the chemotactic activity of CXCL12 (by cleaving 4 residues from the N- 
terminus) (McQuibban et al., 2001), and elevated levels of CXCL12 protein have been 
demonstrated on astrocytes and blood vessels of active and chronic inactive MS 
lesions (Krumbholz et al., 2006).
Anthony et al. (1997) concluded that MMP expression patterns in CNS lesions were 
dependent on the nature of the lesion, given the considerable variation between MS 
and stroke. Astrocyte MM P expression data obtained in the current study supports this, 
as expression patterns varied significantly depending on cytokine treatment, and also 
between individual astrocyte cultures. Further work to follow up data obtained here 
could include detection of cleavage products generated after incubation of recombinant 
chemokine with astrocyte supernantants.
3.6 Summary
The primary astrocyte preparations used in this project were not all identical in their 
GFAP expression, and cells with appropriate morphology and clear GFAP expression 
were selected to obtain high purity of the astrocyte cell cultures used in investigations 
of chemokine and M M P expression. CCL2 and CXCL10 were not be detected by 
western blotting, dot blotting (data not shown), or MALDI MSpec, in astrocyte 
supernatants, either with or without cytokine treatment. Expression of mRNA of MMPs 
and TIM Ps was detected by TaqM an®  real- time PCR, in both cytokine-treated and 
untreated astrocytes. M M P2 mRNA was expressed in all astrocyte samples, and 
M M P9 was expressed in astrocytes treated with TN F  or IL-1 (3. The expression patterns 
were partially, but not fully, in agreement with previous studies, depending on the MM P  
or T IM P in question.
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Chapter 4
CD26 expression in control and MS CNS
white matter
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4.1 Introduction
The structure and function of CD26, and its potential role in MS is discussed in section 
1.5, and its ability to cleave chemokines detailed in section 1.6.2.
4.1.1 Lymphocyte expression of CD26
The lymphocyte cell surface antigen CD26, associated with an effector phenotype, is 
increased during T  cell activation, and exhibits serine protease activity (Abbott et al., 
1994). CD 26 is expressed on all lymphocytes and is considered to play a critical role in 
regulating the immune response via regulation of cytokine and chemokine expression, 
and T  cell activation and proliferation (Ansorge and Reinhold, 2006). CD26 is also 
expressed by a minority (0-5% ) of resting B cells isolated from peripheral blood, which 
is increased to 51%  following stimulation with pokeweed mitogen, suggesting an 
involvement of CD26 in B cell activation (Buhling et al., 1995).
4.1.2 CD26 expression in tissues
The human CD26 gene on chromosome 2 encodes mRNA of 4.2 kilobases (kb), and 
also one of 2.8 kb, both of which are expressed at high levels in kidney and the 
placenta, and to a lesser extent in liver and lung (Abbott et al., 1994). Little is known 
about CD26 expression in the human brain, but the 4 .2  kb mRNA has been detected at 
low levels. In goldfish, the protein has been found in several neuronal populations, and 
in the radial glia of the visual processing area, known as the optic tectum (Beraudi et al., 
2003).
4.1.3 CD26 activity
CD26 is a multifunctional molecule involved in various physiological processes 
throughout the body (Fig. 4.1). The enzymatic activity of CD26 was first shown to be 
involved in the regulation of DNA synthesis of immune cells in 1985, when a CD26  
inhibitor suppressed the proliferation of mitogen-stimulated PBMCs (Schon et al., 1987). 
CD26 is inhibited by HIV-1 Tat protein, the N-terminal peptide Tat (1-9), and synthetic 
inhibitors e.g. Lys[Z(N02)]-pyrrolidide (I40) (Lorey eta !., 2003).
The ability of CD26 to cleave chemokines can lead to unpredictable results on 
chemotactic activity. Truncation of CCL5 by CD26, for example, reduces signalling 
through two of its receptors, CCR3 and CCR1, but generates a more potent ligand for 
CCR5, compared to intact CCL5.
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Figure 4.1 CD26 as a multifunctional protein with proteolytic and binding activity 
in physiological processes
CD26 has diverse effects on several physiological processes, as shown, with no known 
tissue-specific differences in enzymatic activity. Substrates o f CD 26 include cytokines, 
chemokines, hormones, and peptides associated with glucagon homeostasis. The use 
o f enzyme inhibitors to modulate CD 26 activity has been investigated as a potential 
therapy in various pathological conditions, such as for Type 2 diabetes.
E C M  = extracellular matrix
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Monocyte and eosinophil chemotactic activity was lost due to this increased specificity 
for CCL5, but lymphocyte chemotaxis was retained (Struyf et al., 1998).
Inhibition of CD 26 was shown to be effective as a therapy in EAE, through induction of 
autocrine production of the anti-inflammatory cytokine, TGF-(31, and suppression of T  
cell proliferation and proinflammatory cytokine secretion in response to myelin antigens 
(Reinhold et al., 2006). The immunosuppressive effects of TGF-(31 are proposed to 
arise because it maintains the expression of the cell cycle regulator p27kip, thereby 
encouraging arrest of the cell cycle in G1 (Kahne et al., 1999).
O ther studies also support the potential role of CD26 inhibitors as therapeutic agents in 
T  cell-mediated inflammatory diseases of the CNS (Steinbrecher et al., 2001). T  cell 
clones taken from MS patients and stimulated with MBP expressed high levels of CD26  
and exhibited reduced production of IFN-y, IL-4, and TN F in a dose-dependent manner 
when exposed to CD 26 inhibitors, suggesting CD26 is involved in regulation of 
activation of autoreactive T  cells. Inhibiting the catalytic activity of CD 26 has several 
consequences, including p38 MAP kinase activation, tyrosine phosphorylation, 
suppression of DNA synthesis, and reduced production of TGF-J31 (Reinhold et al., 
1998).
Preller and colleagues (2006), however, have shown that deletion of CD26 genes in 
mice resulted in deregulation of Th1 immune responses and an increase in clinical EAE 
scores, by reduction in vivo and in vitro of T  cell production of TGF-p1 in response to 
myelin antigens, although IFN-y and TN F were elevated. In addition, ligands of CD26  
induced TGF-(31 production from T  cells in wild-type mice, but failed to do so in C D 26(- 
/-) mice. EAE scores were increased in CD26 knockout mice immunised with M OG  
peptides. These results thus led to CD26 being viewed as an inhibitory receptor 
controlling T  cell activation and Th1-driven autoimmune responses, with potentially 
important implications in the treatment of MS (Preller et al., 2006).
CD26 has attracted great interest as a target for development of anti-inflammatory 
therapy, after successfully being targeted in animal models of rheumatoid arthritis 
(Tanaka et al., 1997), transplantation (Korom et al., 1997), and MS (Steinbrecher et al., 
2001). In MS, CD26 was found to be expressed on myelin-reactive T  cells (Reinhold et 
al., 1998). In a study of 35 MS patients, a markedly elevated percentage of effector 
CD4+ T  cells in the peripheral blood were C D 26+, compared to 27 healthy controls 
(Jensen et al., 2004). In a study of 15 RRMS patients and 14 healthy controls, C D 4+ 
C D 45R 0+ memory T  cells with high CD26 expression were increased in MS and cell 
counts of this subset correlated with disease severity (Krakauer et al., 2006).
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4.2 Aims and objectives
Results from Chapter 2 have shown that CD26 cleaves a dipeptide from the N-terminus 
of both recombinant CCL2 and CXCL10 with dramatic rapidity, but little is known about 
the distribution of CD26 in the human brain. To investigate the potential significance of 
this chemokine cleavage within the brain in MS, it must be established whether CD26  
is expressed in human white matter, and the cell type expressing it. Since CD26 has 
been shown to be involved in EAE (Reinhold et al., 2006), and two small studies have 
suggested a role for expression of CD26 on T  cells in MS (Constantinescu et al., 1995; 
Krakauer et al., 2006), further investigation of this protein in the CNS in MS was vital. 
The objectives, therefore, of Chapter 4 were to:
•  Determine CD26 expression in frozen human brain sections using 
immunohistochemistry
•  Identify the cell types within the brain associated with CD26 expression, using 
dual staining immunohistochemistry
•  Investigate levels of CD26 expression in MS brain tissue, compared to levels in 
control brain
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4.3 Materials and Methods
Unless otherwise stated, all reagents used were purchased from Sigma, UK.
4.3.1 Human brain tissue
The UK MS Tissue Bank, situated in the Imperial College School of Medicine at 
Charing Cross Hospital in London, was established in 1998 by the Multiple Sclerosis 
Society to co-ordinate the collection of tissue from donors, and distribute high quality 
CNS tissue samples to MS researchers.
Snap-frozen brain blocks (~20 x 20 x 10 mm) of lesions from MS patients, and control 
(non-neurological) white matter (Table 4.1) were obtained from the Tissue Bank (UK  
Multicentre Research Ethics Committee), and transported on dry ice, before being 
stored in a -80°C freezer until required. Control tissue was matched to MS tissue as 
closely as possible, in terms of corresponding areas of the brain, cause of death, age 
and sex of the donor.
4.3.2 Histopathology of frozen brain tissue
4.3.2.1 Haematoxylin and eosin staining
Brain blocks were mounted on a chuck by embedding the base in Cryo-M-bed 
mounting medium (Bright Instrument Co. Ltd., Huntingdon, UK), 10pm sections were 
cut on a cryostat (Leica Microsystems, Germany) at -20°C, and collected onto polysine 
microscope slides (VW R  International, Lutterworth, UK). Slides were air-dried for 
~30min, and stored at -80°C until required, or fixed in 4%  PFA for 5min at RT and used 
immediately for staining.
Haematoxylin and eosin (H&E) is a routine histological stain that uses the basic dye 
haematoxylin to colour basophilic structures, such as ribosomes, the nucleus, and 
RNA-rich cytoplasmic regions, a blue/purple shade, and the acidic dye, eosin Y, to 
stain eosiniphilic structures, typically the cytoplasm, connective tissue, and collagen, 
bright pink (Ross and Pawlina, 2006).
Slides were immersed in filtered Harris’s haematoxylin for 1min, rinsed in tap water 
until it ran clear, immersed in eosin Y  for 2min, and rinsed in tap water until it ran clear. 
Slides were then dehydrated by immersing them in 50% , 70% , 80%  and 95%  ethanol 
consecutively, for 2min at each concentration. Four changes of xylene were applied to 
the slides in a fume hood for 1min each time, to clear them, before the slides were 
mounted by application of a 22 x 50 mm coverslip with DPX mountant.
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Table 4.1 Case details of the subjects used in the study of CD26 expression in 
control brain and MS lesions
CASE 
NUMBER 
(BLOCK NUMBER)
AGE
(YRS)
SEX PMD
(H)
BRAIN
WEIGHT
(G)
DIAGNOSIS CAUSE 
OF DEATH
C11
(A1B5)
77 M 26 1375 Normal Carcinoma 
of the lung 
(metastasised)
C14
(P2C3)
64 F 18 1431 Normal Cardiac failure
MS74 
(A1C6: lesion) 
(A1E7: lesion)
64 F 7 889 SPMS Gastrointestinal
bleed/
obstruction,
aspiration
pneumonia
MS90 
(P2E3: lesion)
62 M 17 1127 SPMS MS
MS130 
(P2D3: lesion) 
(P2F4: lesion)
57 F 22 1150 SPMS MS
Snap-frozen brain blocks o f lesions from M S patients, and control (non-neurological) 
white matter were kindly provided by the UK M S Tissue Bank. Control blocks were 
selected from donors that were age and sex-matched to M S donors, and from similar 
brain regions, identified by the 4 digit block code. Brains were cut coronally through 
mamillary bodies into anterior (A) and posterior (P) halves, and 1 cm slices were 
numbered towards frontal and occipital poles, respectively. Slices were divided into 
blocks, with the grid co-ordinates of the block (letters for the rows, and numbers for 
columns) listed after the anterior/posterior slice number.
PM D  = post-mortem delay (death to tissue preservation interval)
M  = male, F  = female
SPM S  = secondary progressive MS
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Slides were allowed to harden in the fume hood and examined using light microscopy 
with an Olympus BX60 microscope with a CoolSNAP-Pro (Media Cybernetics) imaging 
system.
4.3.2.2 Oil Red O staining
ORO  is a red, fat-soluble dye used to stain neutral triglycerides and lipids on frozen 
sections (Ross and Pawlina, 2006). O RO  solution was prepared by adding 1g of ORO  
powder to 60ml of triethyl phosphate (TEP) and 40ml of dH20 , heating to 100°C for 
5min whilst stirring continuously. The ORO solution was filtered through filter paper 
(Whatman, UK) whilst hot, and again, when cold.
Frozen sections were prepared for Oil Red O (ORO ) staining by fixation in 4%  PFA at 
4°C for 1h, After fixation, slides were washed in tap water, briefly rinsed in 60%  TEP, 
and stained in filtered O RO  solution for 10-15min at RT. Stained slides were then 
briefly rinsed in 60%  TEP, and given a further rinse in tap water. Nuclei were stained 
with Harris’s haematoxylin (diluted with dH20  to 20%  v/v), the slides washed in dH20 ,  
and mounted using 22 x 50 mm coverslips containing the aqueous mountant glycerol 
gelatin.
4.3.2.3 Characterisation of tissue blocks
The pathological state of the blocks used in this study was investigated by observation 
of sections stained with H&E, and ORO.
To examine levels of inflammation, H&E stained slides were graded according to the 
extent of perivascular cuffing observed, being given scores of 0, 1+, 2+, 3+, or 4+, 
ranging from none, to severe immune cell infiltration (see Fig. 4.2).
Sections stained with O RO  were used to assess the extent of myelin loss, and were 
given scores of 0 for absence of staining, 1 + for evidence of scattered ORO-positive 
cells, 2+ for clusters of ORO-positive cells, and 3+ for evidence of O RO  staining 
throughout the section (see Fig. 4.3). Blocks positive for O RO  which showed 
inflammation were classified as containing chronic active plaques.
4.3.3 Immunohistochemistry of normal and MS brain
4.3.3.1 Single labelling immunofluorescence for CD26
Prior to immunofluorescence, sections used in single and dual labelling were fixed in 
ice-cold acetone in Coplin jars for 10min at RT, and air-dried at RT for 20min.
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Each antibody used in dual labelling was first optimised individually by changing the 
primary and secondary antibody dilutions (see Table 4.2), incubation times (1h at RT, 
or overnight at 4 °C), and washing medium (PBS + 0.5%  Tw een®  20, or PBS). The  
primary antibodies used were goat anti-CD26 (R&D Systems), mouse anti-GFAP  
(Chemicon), mouse anti-CD3 (BD), mouse anti-HLA-DR (Novocastra), and mouse anti- 
von Willebrand factor (VW F) (Dako). Alexa 488 (green) donkey anti-goat antibody 
(Invitrogen) was used as the secondary antibody with the an ti-CD26 primary, and Alexa 
568 (red) rabbit ant-mouse (Invitrogen) with all of the other primary antibodies. 
Appropriate isotype controls were used to confirm specificity of the primary antibodies 
to the target antigens, which involved using myeloma proteins of the same isotype and 
concentration as the primary antibodies to establish the amount of non-specific staining. 
Details of the primary and secondary antibodies, and the experimental conditions used 
during and after optimisation, are given in Table 4.2. Negative controls with omission of 
the primary antibodies were also performed.
After fixation, the tissue area of the slide was defined to contain the antibody solution 
by drawing a wax circle around it with an “ImmEdge” pen (Vector Labs, Peterborough, 
UK). Primary antibodies (180pl) were applied in PBS + 0.5%  Tw een®  20, and the 
slides incubated in a moist chamber for 1h at RT. Antibody was removed by 3 x 5min 
PBS + 0.5%  Tw een®  20 washes, on an orbital shaker. Secondary antibodies (180pl 
per slide, in PBS + 0.5%  Tw een®  20) were then added for 1h at RT, whilst the slides 
were incubated in a moist chamber in the dark. Secondary antibodies were washed off 
in the same way as primary antibodies, and then Sudan Black B (SBB) staining was 
performed as described in 4.3.2.2, prior to mounting in DAPI medium.
4.3.3.2 Sudan Black B
Brain tissue is prone to autofluorescence caused by the fluorescent pigment lipofuscin, 
present in the cytoplasm of cells of the CNS. This becomes more pronounced when 
dealing with aged tissues, as lipofuscin accumulates over time, and creates problems 
due to its broad emission and excitation spectra (Schnell et al., 1999). It is, therefore, 
often necessary to treat sections of CNS tissue to reduce lipofuscin-like 
autofluorescence to enable detection of specific fluorescence from bound antibody.
SBB is a fat-soluble dye that stains neutral triglycerides and lipids a blue-black colour 
by readily dissolving in lipids, thereby concealing them (Yao et al., 2003). SBB has 
been used successfully to eliminate autofluorescence without significantly reducing the 
intensity of fluorescent labels associated with antibodies (Schnell et al., 1999).
SBB (1%  w/v) was prepared by dissolving 1g in 100ml 70%  ethanol.
172
Table 4.2 Details of the primary and secondary antibodies used in single and 
dual immunofluorescence for detection of CD26 expression in human CNS
ANTIBODY SPECIES 
RAISED IN & 
ISOTYPE
DILUTION/
CONCENTRATION
(ug/mi)
INCUBATION
TIME
SUPPLIER
a-CD26
Polyclonal
Goat
IgG
1:10(10)
1:20 (5) 
1:40 (2.5)
1h at RT
O/N at 4°C
R&D
Systems,
UK
a-GFAP
Monoclonal
Mouse lgG1 1:200 (5) 
1:500 (2)
1:1000 (1)
1h at RT
O/N at 4°C
Chemicon,
UK
a-CD3
Monoclonal
Mouse lgG1 1:25 (20) 
1:50 (10)
1h at RT
O /N at 4°C
BD, UK
a-HLA-DR
Monoclonal
Mouse
lgG2b
1:25 (1) 
1:50 (0.5)
1h at RT
O /N at 4°C
Novocastra
a-VWF
Monoclonal
Mouse lgG1 1:50 (6.3) 
1:100 (3.15)
1h at RT
O/N at 4°C
Dako, UK
2° Alexa 488 Donkey a 
goat
1:400
1:500
1:1000
1h at RT Molecular
Probes,
Invitrogen,
UK
2° Alexa 568 Rabbit a 
mouse
1:400
1:500
1:1000
1h at RT Molecular
Probes,
Invitrogen,
UK
IgG isotype 
control
Goat
IgG
Same as for CD26  
1:100 (10)
1h at RT
O/N at 4°C
Pro Sci Inc., 
USA
!gG1 isotype 
control
Mouse lgG1 Same as for: 
GFAP (2) 
CD3 (10) 
W VF (3.15)
1h at RT
O /N at 4°C
Sigma, UK
lgG2b
isotype
control
Mouse
lgG2b
Same as for 
HLA-DR (0.5)
1h at RT
O/N at 4°C
Sigma, UK
Antibodies were optimised to investigate expression o f CD26 in the human brain. 
Dilutions and incubation times shown in bold represent those that were found to be 
optimal, which were used for dual immunofluorescence.
2° = secondary antibody, or = anti, R T  = room temperature, O /N  = overnight
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The solution was stirred in the dark for 2h at RT, filtered, and stored at 4°C for a 
maximum of 2 months. SBB staining was performed on all brain tissue sections, after 
the final PBS wash of the immunofluorescence procedure. Slides were immersed in 1% 
SBB in the dark for 5min at RT, rinsed briefly 8-10 times in PBS, and mounted using 
DAPI mountant on a 22 x 50mm coverslip.
4.3.3.3 Dual labelling immunofluorescence
To identify the cellular location of CD26 in the human brain, dual labelling 
immunofluorescence was performed. The procedure for single labelling was used 
(4.3.2.1), incubating the sections with the polyclonal anti-CD26 and Alexa 488  
antibodies first, followed by sequential addition of the monoclonal antibody and Alexa 
568 secondary. After the final secondary antibody had been washed off, slides were 
treated with SBB (4.3.2.2) to quench autofluorescence of the tissue, and mounted 
using DAPI mountant.
Various controls were performed alongside the slides that were dual labelled, including 
single labelling, omission of the first or second primary antibodies in turn, omission of 
the first or second secondary antibodies, incubation of one primary antibody with both 
secondary antibodies, and the use of isotype controls as primary antibodies.
4.3.3.4 Image acquisition
Images were acquired using a Zeiss LSM510 confocal scanning laser microscope (see 
3.3.2.13). Multi-track acquisition was used, to enable collection of dual-labelling data. 
Filter sets for 488 and 568nm were selected, which loaded predefined parameters for 
data acquisition. In continuous scan mode, and using the range indicator of the palette 
setting, detector gain and amplifier offset were adjusted, so that only a few red and 
blue pixels were visible on the screen, to optimise scanning conditions. The pinhole 
was set to 1 Airy unit, and the optical slice to 2, for both red and green channels. 
Composite ‘Z-stack’ images were then obtained by scanning from the manually 
selected deepest focal point to the highest focal point, of ~15 optical slices in the Z- 
plane. Colocalisation was detected using the histogram function of the LSM 510  
software, with pixels detected in both fluorescent channels at >100 intensity appearing 
white. Images were saved, overlaid with images of the DAPI staining of nuclei if 
required, and exported as JPEG files, without further manipulation. The detector gain 
setting used during image acquisition was also applied for visualisation and image 
capture of the negative control slides (isotype controls), to enable direct comparison of 
visible fluorescence levels.
174
4.4 Results
4.4.1 Characterisation of tissue blocks by H&E and ORO for the extent of 
inflammation and demyelination
H&E staining was used to detect areas of inflammatory perivascular cuffs, within the 
brain tissue used for this study, and ORO used to identify areas of demyelination. No 
inflammation or demyelination was seen in control brain tissue, although a few immune 
cells were observed associated with blood vessels, indicative of routine surveillance of 
the CNS (Xiao and Link, 1998). Minimal perivascular cuffing was seen in MS block 
M S74 A1E7, but some O RO  staining was evident. All other lesion blocks showed 
extensive inflammation, perivascular cuffing (Fig. 4.2), and O RO  staining (Fig. 4.3). 
Results of characterisation of the blocks used, based on grading illustrated in Figs. 4.2  
and 4.3, are summarised in Table 4.3.
4.4.2 CD26 expression in control brain tissue
Frozen brain sections were dual labelled for CD26 with either GFAP, VW F, CD3, or 
HLA-DR. In control, non-neurological white matter, diffuse CD26 staining was evident 
on the abluminal surface of blood vessels, which was not colocalised with VW F  
expression (Fig. 4.5). Staining was quite extensive around some blood vessels, which 
may indicate CD26 secreted by ECs binding to connective tissue components. Some 
colocalisation of CD26 was seen with CD3 (Fig. 4.6) and also HLA-DR (Fig. 4.7), but 
not with GFAP (Fig. 4.4).
4.4.3 CD26 expression in chronic active MS lesions in block MS74 A1E7
Block M S74 A1E7 showed minimal levels of inflammation and moderate demyelination. 
In demyelinating lesions, CD26 was expressed at higher levels than in control brain, 
and appears to be associated with infiltrating perivascular cells. The diffuse CD26  
staining surrounding blood vessels appeared to be diminished (Figs. 4.8, 4.9, 4 .10  and
4.12) compared to control brain. Colocalisation of CD26 and CD3 was seen, with a 
subset of T  cells surrounding the blood vessel appearing as C D 3+C D 26+ (Fig. 4 .10). 
Cells staining positive for HLA-DR were common throughout the parenchyma, and also 
surrounding blood vessels (Fig. 4.11). Colocalisation of CD26 and HLA-DR was 
observed in several cells in the parenchyma, but there were approximately equal 
numbers of cells that stained positive for either CD26 or HLA-DR alone (Fig. 4.11 and
4.12). Colocalisation of CD26 and HLA-DR around blood vessels was also seen (Fig.
4.12), but to a lesser extent than in the parenchyma (Fig. 4.11). Co-expression of CD26  
and GFAP was insignificant (Fig. 4.8), and colocalisation with VW F was not observed 
(Fig. 4.9).
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Table 4.3 Characterisation of tissue blocks used in this study by H&E and ORO
staining
BLOCK
NUMBER
H&E:
INFLAMMATION
ORO:
DEMYELINATION CLASSIFICATION COMMENTS
C11 A1B5 0 1 + Control brain Minimal ORO
C14 P2C3 0 0 Control brain No inflammation / 
demyelination 
seen
MS74
A1C6
2+ 2+ Lesion 
(Chronic active)
Large part of 
block is grey 
matter; few and 
small PVCs
MS74
A1E7
1 + 2+ Lesion 
(Chronic active)
Minimal T  cell 
infiltrate and 
PVCs
MS90
P2E3
2+ 3+ Lesion 
(Chronic active)
Clear plaque 
border; extensive 
cellular infiltrate
MS130
P2D3
2+ 2+ Lesion 
(Chronic active)
Large part of 
block is grey 
matter; moderate 
cellular infiltrate
MS130
P2F4
4+ 2 + - ^ Lesion 
(Chronic active)
Plentiful and 
large PVCs
H&E and O RO  staining was performed on snap-frozen, PFA-fixed, 10pm sections of 
human brain, obtained from the UK M S Tissue Bank from M S and control tissue blocks. 
Blocks were graded according to the amount o f inflammation/perivascular cuffing 
identified by H&E, ranging from 0-4+ with increasing abundance, and the extent of 
demyelination, ranging from 0-3+. All lesions were classified as chronic active, due to 
the presence o f both plaques and O RO+ staining.
176
i s p ^
3 r a & a t i £ &
Figure 4.2 Grading of levels of inflammation in white matter MS lesions detected 
by H&E staining
Snap-frozen human MS brain tissue from an area containing lesions (MS 130 P2F4) 
was stained using H & E ,  and various stages of inflammation were identified by the 
degree of perivascular cuffing observed: a=1+, b=2+, c=3+ and d=4+ (200X). The 
grading of inflammation around blood vessels was used to characterise the blocks 
used in this study.
177
Figure 4.3 Grading of levels of demyelination in white matter MS lesions detected 
by ORO staining
ORO staining of snap-frozen human MS brain tissue from: (a) an area with minimal 
infiltrate (MS74 A1E7); and (b and c), lesions showing substantial infiltrate (MS90 
P2E3). Nuclei were subtly counterstained pale blue using 20% Harris’s haematoxylin. 
ORO stains lipids red and can be used to identify areas of myelin loss, and phagocytic 
macrophages. White matter in (a) stained positive (1+) with ORO (200X). The blood 
vessel in (b) shows extensive perivascular macrophage staining, and also significant 
ORO staining (3+) in the surrounding tissue (100X). (c) shows the edge of the lesion 
(arrowheads), defined by an area of pallor on the right, where macrophages 
phagocytosing myelin have stained red. Pink tissue on the left indicates the presence 
of myelin, but contains blood vessels with some perivascular ORO staining (arrows) 
(40X). The grading of ORO staining was used to characterise the extent of 
demyelination seen in the tissue blocks used in this study.
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Figure 4.4 Dual-label im m unofluorescence o f GFAP and CD26 in contro l brain
Snap frozen, non-neurological, control human brain tissue (C14 P2C3) was fixed in 
acetone and dual-labelled for (a) GFAP (red) and (b) CD26 (green) expression, using 
Alex a 568, and 488, fluorescent antibodies, respectively. Nuclei were counterstained 
with DAPI and appear blue. The dual-labelled image (c) was screened for areas of 
colocalisation of GFAP and CD26 using LSM510 software; none was evident.
Figure 4.5 Dual-label im m unofluorescence o f VW F and CD26 in con tro l brain
Snap frozen, non-neurological, control human brain tissue (CM A1B5) was fixed in 
acetone and dual-labelled for (a) VWF (red) and (b) CD26 (green) expression, using 
Alexa 568, and 488, fluorescent antibodies, respectively. Nuclei were counterstained 
with DAPI and appear blue. The dual-labelled image (c) was screened for areas of 
colocalisation of VWF and CD26 using LSM510 software; none was detected.
Figure 4.6 Dual-label im m unofluorescence o f CD3 and CD26 in con tro l brain
Snap frozen, non-neurological control human brain tissue (C11 A1B5) was fixed in 
acetone and dual-labelled for (a) CD3 (red) and (b) CD26 (green) expression, using 
Alexa 568, and 488, fluorescent antibodies, respectively. Nuclei were counterstained 
with DAPI and appear blue. Areas of colocalisation of CD3 and CD26 were identified 
by the presence of pixels in quadrant 3 of the intensity grid in (c), and appear as white 
areas on the image. Arrows indicate colocalisation of CD3 and CD26 on a few T cells.
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Figure 4.7 Dual-label im m unofluorescence o f HLA-DR and CD26 in con tro l brain
Snap frozen, non-neurological control human brain tissue (C14 P2C3) was fixed in 
acetone and dual-labelled for (a) HLA-DR (red) and (b) CD26 (green) expression, 
using Alexa 568, and 488, fluorescent antibodies, respectively. Nuclei were 
counterstained with DAPI and appear blue. Areas of colocalisation of HLA-DR and 
CD26 were identified by the presence of pixels in quadrant 3 of the intensity grid in (c), 
and appear as white areas on the image. Arrows indicate the colocalisation of HLA-DR 
and CD26 of several cells, possibly perivascular macrophages.
4.4.4 CD26 expression in chronic active MS lesions in block MS74 A1C6
Block M S74 A1C 6 showed moderate levels of inflammation and demyelination. 
Increased levels of CD26 and the presence of PVCs were seen in the white matter, 
compared to control brain. GFAP expression was increased in lesions, compared to 
control, as is commonly seen with reactive astrocytes, but colocalisation of GFAP with 
CD26 was an insignificant rarity (Fig. 4.13). Similar to control tissue, no colocalisation 
was seen with CD 26 and VW F in lesions with extensive PVCs (Fig. 4 .14). The diffuse 
CD26 staining seen around blood vessels in control brain was reduced in lesional 
tissue (Fig. 4 .15). C D 26+ cells were seen in the parenchyma, a proportion of which 
were colocalised with either CD3, or HLA-DR (Fig. 4.16). A  marked increase was seen 
in HLA-DR+ cells (Fig. 4.16) compared to control brain. Although lesions in block M S74  
A1C6 gave staining patterns consistent with abundant activated microglia that were 
HLA-DR+C D 26‘ (Fig. 4 .15), significant numbers of C D 26+HLA-DR+ cells were also 
detected (Fig. 4.16).
4.4.5 CD26 expression in chronic active MS lesions in block MS90 P2E3
Block M S90 P2E3 showed moderate levels of inflammation and extensive 
demyelination. Increased numbers of CD26+ cells (Fig. 4 .17) were seen, compared to 
control brain. Significant colocalisation of CD3 and CD26 was seen in PVCs, although 
some C D 3+C D 26' and CD3'C D 26+ cells were also seen (Fig. 4.18). Only relatively 
small numbers of C D 26+HLA-DR+ cells were seen surrounding blood vessels in some 
lesions (Figs. 4 .17  and 4.19). The edge of a lesion was evident by O R O  staining, which 
showed abundant macrophages in an area of myelin pallor (Fig. 4 .19a). Dual-labelled 
immunofluorescent images from serial sections, showing the same blood vessel from 
this area (Figs. 4.19b-f), demonstrated that CD26 was primarily associated with T  cells 
around the blood vessel, rather than elsewhere in the parenchyma. Selected lesions in 
this block demonstrated a staining pattern consistent with foamy macrophages that 
were HLA-DR+CD26', suggesting that CD26 had not contributed to MS pathogenesis at 
the edge of these actively demyelinating lesions. No colocalisation of CD26 was seen 
with either GFAP or VW F.
4.4.6 CD26 expression in chronic active MS lesions in block MS130 P2F4
Block M S130 P2F4 showed extensive inflammation and moderate demyelination. A  
grade 4+ PVC (Fig. 4.2d) was identified as having C D 3+C D 26+cells throughout. HLA- 
DR+C D 26+ cells were also evident, to a lesser extent than C D 3+C D 26+ cells, and were  
mainly focused near the periphery of the PVC, further from the lumen of the blood 
vessel (Fig. 4 .20). No colocalisation of CD26 was seen with either GFAP or VW F.
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Figure 4.8 Dual-label immunofluorescence of GFAP and CD26 in MS brain (M S74 A 1E7)
Snap frozen, white matter from an MS brain was fixed in acetone and dual-labelled for 
(a) GFAP (red) and (b) CD26 (green) expression, using Alexa 568, and 488, 
fluorescent antibodies, respectively. Nuclei were counterstained with DAPI and appear 
blue. Areas of colocalisation of GFAP and CD26 were identified by the presence of 
pixels in quadrant 3 of the intensity grid in (c), and appear as white areas on the image. 
Small areas of colocalisation of GFAP and CD26 above are identified by arrows.
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Figure 4.9 Dual-label immunofluorescence of VW F and CD26 in MS brain (M S74 A1E7)
Snap frozen, white matter from an MS brain was fixed in acetone and dual-labelled for 
(a) VWF (red) and (b) CD26 (green) expression, using Alexa 568, and 488, fluorescent 
antibodies, respectively. Nuclei were counterstained with DAP! and appear blue. The 
dual-labelled image (c) was screened for areas of colocalisation of VWF and CD26 
using LSM510 software; none were evident.
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Figure 4.10 Dual-label immunofluorescence of CD3 and CD26 in MS brain (M S74 A 1E7)
Snap frozen, white matter from an MS brain was fixed in acetone and dual-labelled for 
(a) CD3 (red) and (b) CD26 (green) expression, using Alexa 568, and 488, fluorescent 
antibodies, respectively. Nuclei were counterstained with DAPI and appear blue. Areas 
of colocalisation of CD3 and CD26 were identified by the presence of pixels in quadrant 
3 of the intensity grid in (c), and appear as white areas on the image. Colocalisation of 
CD3 and CD26 of several, but not all, T cells is seen above, with arrows showing a few 
examples.
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Figure 4.11 Dual-label im m unofluorescence o f HLA-DR and CD26 d is tan t from  
blood vessels in MS brain (M S74 A1E7)
Snap frozen, white matter from an MS brain was fixed in acetone and dual-labelled for 
(a) HLA-DR (red) and (b) CD26 (green) expression, using Alexa 568, and 488, 
fluorescent antibodies, respectively. Nuclei were counterstained with DAP! and appear 
blue. Areas of colocalisation of HLA-DR and CD26 were identified by the presence of 
pixels in quadrant 3 of the intensity grid in (c), and appear as white areas on the image. 
Arrows show colocalisation of HLA-DR and CD26 of several, but not all, immune cells 
(morphologically identified as microglia/macrophages), distant from blood vessels.
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Figure 4.12 Dual-label im m unofluorescence o f HLA-DR and CD26 associa ted  w ith  
a blood vessel in MS brain (M S74 A1E7)
Snap frozen, white matter from an MS brain was fixed in acetone and dual-labelled for 
(a) HLA-DR (red) and (b) CD26 (green) expression, using Alexa 568, and 488, 
fluorescent antibodies, respectively. Nuclei were counterstained with DAPI and appear 
blue. Areas of colocalisation of HLA-DR and CD26 were identified by the presence of 
pixels in quadrant 3 of the intensity grid in (c), and appear as white areas on the image. 
The arrow shows some colocalisation of HLA-DR and CD26 on a minority of immune 
cells, around the blood vessel.
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Figure 4.13 Dual-label immunofluorescence of GFAP and CD26 in lesions from 
MS brain (MS74 A1C6)
Snap frozen, lesional tissue from an MS brain was fixed in acetone and dual-labelled 
for (a) GFAP (red) and (b) CD26 (green) expression, using Alexa 568, and 488, 
fluorescent antibodies, respectively. Nuclei were counterstained with DAP I and appear 
blue. Areas of colocalisation of GFAP and CD26 were identified by the presence of 
pixels in quadrant 3 of the intensity grid in (c), and appear as white areas on the image. 
Arrows indicate the barely significant colocalisation seen of GFAP and CD26.
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Figure 4.14 Dual-label immunofluorescence of VWF and CD26 in MS brain (MS74 A1C6)
Snap frozen, lesional tissue from an MS brain was fixed in acetone and dual-labelled 
for (a) VWF (red) and (b) CD26 (green) expression, using Alexa 568, and 488, 
fluorescent antibodies, respectively. Nuclei were counterstained with DAPI and appear 
blue. The dual-labelled image (c) was screened for areas of colocalisation of VWF and 
CD26 using LSM510 software; none was evident.
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Figure 4.15 Dual-label immunofluorescence in MS brain (MS74 A1C6) of HLA-DR 
and CD26 in lesions with activated microglia/macrophages
Snap frozen, lesional tissue from an MS brain was fixed in acetone and dual-labelled 
for (a) HLA-DR (red) and (b) CD26 (green) expression, using Alexa 568, and 488, 
fluorescent antibodies, respectively. Nuclei were counterstained with DAP! and appear 
blue. Areas of colocalisation of HLA-DR and CD26 were identified by the presence of 
pixels in quadrant 3 of the intensity grid in (c), and appear as white areas on the image. 
Arrows indicate coiocalisation of HLA-DR and CD26 by a minority of cells. CD26+ cells 
are less abundant.
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Figure 4.16 Dual-label immunofluorescence of HLA-DR and CD26 distant from 
blood vessels in MS lesions (MS74 A1C6)
Snap frozen, lesional tissue from an MS brain was fixed in acetone and dual-labelled 
for (a) HLA-DR (red) and (b) CD26 (green) expression, using Alexa 568, and 488, 
fluorescent antibodies, respectively. Nuclei were counterstained with DAPI and appear 
blue. Areas of colocalisation of HLA-DR and CD26 were identified by the presence of 
pixels in quadrant 3 of the intensity grid in (c), and appear as white areas on the image. 
Arrows indicate significant colocalisation of HLA-DR and CD26 in the parenchyma, on 
cells with a macrophage/microglial cell morphology.
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Figure 4.17 Dual-label immunofluorescence of HLA-DR and CD26 in MS brain 
(MS90 P2E3)
Snap frozen, lesional tissue from an MS brain was fixed in acetone and dual-labelled 
for (a) HLA-DR (red) and (b) CD26 (green) expression, using Alexa 568, and 488, 
fluorescent antibodies, respectively. Nuclei were counterstained with DAPI and appear 
blue. Areas of colocalisation of HLA-DR and CD26 were identified by the presence of 
pixels in quadrant 3 of the intensity grid in (c), and appear as white areas on the image. 
Arrows show a minority of cells with colocalisation of HLA-DR and CD26. CD26+ cells 
are less diffusely spread.
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Figure 4.18 Dual-label immunofluorescence of CD3 and CD26 in MS brain (MS90 P2E3)
Snap frozen, lesional tissue from an MS brain was fixed in acetone and dual-labelled 
for (a) CD3 (red) and (b) CD26 (green) expression, using Alexa 568, and 488, 
fluorescent antibodies, respectively. Nuclei were counterstained with DAPI and appear 
blue. Areas of colocalisation of CD3 and CD26 were identified by the presence of 
pixels in quadrant 3 of the intensity grid in (c), and appear as white areas on the image. 
Arrows indicate that colocalisation of CD3 and CD26 occurs with many, but not all, T 
cells, both around the blood vessel, and distant from it.
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Figure 4.19 ORO of lesion edge, and dual-label immunofluorescence of CD26 and 
GFAP, HLA-DR, or CD3, in a blood vessel in MS lesions (MS90 P2E3)
Snap frozen, lesional tissue from an MS brain was fixed in acetone and dual-labelled 
for CD26 (green) and GFAP, HLA-DR, or CD3 (red) expression, using Alexa 488, and 
568, fluorescent antibodies. Images of the same blood vessel near the lesion edge 
were obtained using serial 10pm sections for ORO staining (nuclei counterstained with 
20% Harris’s haematoxylin), and each dual-label antibody combination (a) ORO 
staining; arrows indicate the lesion edge (100X), (b) CD26 + GFAP, (c) CD26, (d) 
CD26 + HLA-DR, showing a staining pattern consistent with foamy macrophage 
morphology, (e) CD3, (f) CD26 + CD3. Nuclei (in b-e) were counterstained with DAPI 
(blue). Areas of colocalisation of CD3 + CD26 (f) were identified by the presence of 
white pixels on the image, obtained using LSM510 software. Arrows indicate significant 
colocalisation of CD26 and CD3 associated with the cells around the blood vessel, but 
not in the parenchyma. No colocalisation of CD26 and GFAP, or CD26 and HLA-DR, 
was evident.
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Figure 4.20 D ual-label im m unofluorescence o f CD26 and VW F, CD3, or HLA-DR, 
in a grade 4+ perivascular cuff in MS lesions (M S130 P2F4)
Snap frozen, lesional tissue from an MS brain was fixed in acetone and dual-labelled 
for CD26 (green) and VWF, CD3, or HLA-DR (red) expression, using Alexa 488, and 
568, fluorescent antibodies. Images of the same PVC were obtained using serial 10pm 
sections for each dual-label antibody combination (a) CD26 (b) CD26 + VWF, with 
nuclei counterstained with DAPI (blue), (c) CD3, (d) CD26 + CD3, (e) HLA-DR, (f) 
CD26 + HLA-DR. Areas of colocalisation of CD3 + CD26 (d), and HLA-DR + CD26 (f), 
were identified by the presence of white pixels on the image, obtained using LSM510 
software. Arrows indicate significant colocalisation of CD26 and CD3 throughout the 
PVC, and to a lesser extent, colocalisation of CD26 and HLA-DR. No colocalisation of 
CD26 and VWF was evident.
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4.5 Discussion
CD26 is a multifunctional molecule, that is implicated in the pathology of MS, as aside 
from its enzymatic activity which cleaves chemokines, it exhibits several relevant 
properties linked to autoimmunity, as it is known to have co-stimulatory effects on T  
cells, and function as a receptor for some ECM proteins (Iwata and Moromoto, 1999). 
The discovery of a high expression of CD26 on activated T  cells led to increased 
interest in targeting this ectopeptidase immunopharmacologically, for treatment of a 
number of autoimmune diseases. Indeed, CD26 inhibitors tested in vitro on human 
PBMCs reduced T  cell activation and function (Reinhold et a/., 2006). Inhibition of 
CD26 suppressed T-cell proliferation in vitro, suppressed production of IL-2, IL-10, and 
IFN-y, whilst increasing TGF-(31 levels, and decreased antibody production in mice 
immunised with BSA (Kubota eta l., 1992). Following organ transplantation, inhibition of 
the enzymatic activity of CD26 is thought to diminish early humoral responses to 
alloantigens (Korom et a l,  1999). Collectively, the effects of CD26 inhibition strongly 
indicate a role for CD26 in immune regulation.
The expression of CD26 on the surface of immune cells is regulated by their 
differentiation and activation states, with induction upon stimulation (Bauvois et al., 
1999). Activated B cells and NK cells express CD26, and a small population of resting 
T  cells, with specific characteristics, express a high surface density of CD26 (C D 26bn9ht 
T  cells). These C D 26bright T  cells are memory (C D 45R 0+) T  cells responsible for most 
IL-2 production, with important roles in the proliferative response to antigens and CTL 
activity against antigens present in different allelic forms depending on the individual 
(alloantigens) (Morimoto and Schlossman 1998). C D 26bnghtT  cells are also responsible 
for the helper function of recruiting T-cell assistance for B-cell antibody synthesis. Th1- 
type cells are associated with CD26 expression (Cordero et al., 1997).
Substrates of CD 26 include an abundance of cytokines, haematopoietic growth factors, 
neuropeptides, and hormones, which possess either a proline or alanine as the 
penultimate amino acid at the N-terminus, with the proline conferring protection against 
non-specific proteolysis (Van Hoof et al., 1995). Synthetic N-terminal oligopeptides of 
IL-1 a, IL-1 p, and IL-2 are cleaved by CD26, unlike their intact and mature counterparts, 
which led to suggestions that only small molecules are natural substrates for CD26  
(Hoffmann et al., 1993). It is known, however, that peptides of at least 40 amino acids 
can be processed in vivo by CD26 (De Meester et al., 2003).
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The precise cellular mechanisms involved in the formation of demyelinating plaques in 
MS remain largely unknown. Little is also known about the changes that occur in pre­
plaque tissue, considered the NAWM, which could lead on to lesion formation in MS. 
Myelin-reactive Th1 cells express CD26 at high levels, and when CD26 inhibitors are 
used, their activity and Th1 cytokine production are blocked (Reinhold et al., 1998).
EAE induction is also prevented by inhibition of CD26 (Steinbrecher et al., 2001). It was 
thus considered important to examine the CD26 expression in the white matter of MS 
brain, particularly as this has not been previously investigated.
Several studies on CD26 expression in MS have focused on PBMCs in the circulation 
and CSF. Constantinescu and colleagues (1995) conducted a 12 month study, 
measuring T  cell activation molecules in peripheral blood, and their correlation with 
disease progression in 14 patients with chronic MS. They found that CD26 showed 
consistent patterns of expression, was elevated in MS, and unlike HLA-DR expression, 
correlated significantly with patients’ disability scores. The increase in CD26 compared 
to controls was not statistically significant, however, and many inconsistencies exist 
concerning the expression of this marker when examining results from other studies.
No increase in CD 26 in peripheral blood in MS patients, or correlation with disease 
activity, was found in one study (Chapel et al., 1990), and another research group also 
failed to find an increase in CD 26+cells in MS (Crockard et al., 1988). Hafler and 
colleagues (1985), however, detected increased CD26 levels on T  cells in peripheral 
blood, in the majority of their 35 patients studied. In a study of 40 MS patients, a 
correlation was observed between the increased CD26 expression by peripheral C D 4+ 
T  cells, and clinical and MRI activity (Khoury et al., 2000). A  more recent study of 44  
patients with clinically isolated syndromes, which is frequently the first manifestation of 
MS, found elevated levels of peripheral CD4+C D 26+ T  cells which correlated with MRI 
disease activity (Jensen et al., 2004).
The soluble form of CD 26 is normally found at low levels in CSF, moderate levels in 
plasma, and high levels in seminal fluid (De Meester eta l., 2000). In MS, increased 
CD26 expression on PBMCs from CSF has been found compared to both non- 
neurological controls and patients with other inflammatory neurological diseases 
(Hafler et al., 1985). During T  cell activation, different isoforms of CD26 are found, 
which might result from its ability to engage in a cycle of endocytosis/exocytosis, with 
glycosylation changes resulting from re-entry into the Golgi apparatus (Kahne et al., 
1996). Inconclusive results from the aforementioned investigations of peripheral blood 
CD26 levels might reflect wide genetic variation of CD26 expression, inclusion of
201
patients in remission, or use of an antibody reactive with a CD26 isoform not expressed 
at high levels, which emphasises the need for examination of more MS cases in our 
study before firm conclusions can be drawn.
It would be interesting to discover if an increased proportion of a subpopulation of T  
cells are C D 26+. In patients with AIDS, for example, there is a decrease in CD26  
expression, with a selective loss of CD4+CD 26+ cells (Blazquez et al., 1992). Our dual 
immunofluorescent staining results on MS lesions certainly show that not all T  cells are 
CD26+. Consistently in MS, C D 8+ suppressor/cytotoxic T  cells are reduced, or there is 
an increase in the C D 4+/C D 8+ ratio, and a loss of the C D 4+C D 45R + subset 
(Constantinescu et al., 1995). The C D 45R 0+ cells are antigen-experienced memory 
CD4+ T-cells, whereas the naive equivalent C D 4+ helper T-cells are CD45R0', and 
positive for L-selectin (Krakauer et al., 2006). C D 45R 0+ cells can be further divided 
according to their homing location, with central memory cells homing to secondary 
lymphoid organs, or effector memory cells, which traffic to inflammatory sites (Sallusto 
et al., 2004). A  study of 15 patients with RRMS revealed a subset of C D 4+ C D 45R 0+ 
C D 26bnght memory T  cells, whose numbers correlated with disease severity, and which 
exhibited high levels of markers of Th1 effector functions, activation, and migratory 
potential (determined by expression levels of: CCR5; CXCR3; CXCR6; L-selectin; VLA- 
4; Fas ligand, which can induce apoptosis in T  cells; and the receptor for IL-12, crucial 
for the development of Th1 cells) (Krakauer et al., 2006). This subset, therefore, had 
enhanced expression of markers previously linked to MS disease activity, as it is 
known that expression of CCR5 (Misu et al., 2001) and CXC R 3 (Mahad et al., 2003) by 
CD4+ Th1 Cells is elevated in peripheral blood. C D 4+ Th1 cells from MS patients during 
relapse express high levels of the adhesion molecule VLA-4, which is important in 
transmigration, and the target of the drug natalizumab (Barrau et al., 2000).
Interestingly, high-dose treatment of another drug used in MS, methylprednisolone, 
produces a decrease in CD26 expression on C D 4+ cells (Sellebjerg et al., 2000).
CD26 is implicated in immune deficiency syndromes, such as severe combined 
immunodeficiency (SCID), involving a deficit of the enzyme adenosine deaminase 
(ADA). ADA is possibly involved in the initial stages of T  cell activation, and is important 
in cellular and humoral immunity (Iwata and Morimoto, 1999). On the surface of T  cells, 
expressed CD26 is known to form complexes with ADA, thereby preserving the 
enzymatic activity of both molecules, which is thus reduced when CD26 is under­
expressed (De Meester et al., 1999). It is conceivable, therefore, that the opposite 
situation of increased immune activity, as is seen in MS, could be associated with 
greater T  cell activation due to higher levels of CD26 (Constantinescu et al., 1995).
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Using dual immunofluorescent staining, we found that CD 26 was present in control and 
MS brain tissue, and was often associated with cells that expressed either CD3 or 
HLA-DR. No significant colocalisation of CD26 with GFAP or VW F was observed, 
indicating astrocytes and endothelial cells do not show significant CD26 expression in 
the white matter examined. The anti-CD26 antibody also stained areas associated with 
the BM, which is consistent with previous findings of connective tissue staining (Seitzer 
et al., 1998). This staining was diminished in MS lesions, compared to control, 
indicative of the enzymatic activity that occurs as part of the breakdown of the BBB.
The high expression level of HLA-DR seen in white matter of MS brains compared to 
control brain, is consistent with the findings of previous studies, which reported the 
presence of activated macrophages/microglia throughout the white matter of all cases 
examined (Graumann et al., 2003; Woodroofe et al., 1986). This suggests that 
macrophage/microglial activity is common in MS brain, and may be a precursor to 
lesion formation. Previous findings have identified cells that co-express HLA-DR and 
CD26 as mature macrophages (Watkins et al., 1996) and monocytes (Ellingsen et al., 
2007). Based on morphological examination, our results indicate that a proportion of 
monocytes in PVCs, and macrophages or microglia in the parenchyma, stained 
positive for both HLA-DR and CD26.
Active phases of autoimmune diseases are associated with higher numbers of 
CD 26bn9ht T  cells and/or CD26 density, with corresponding decreases during 
immunosuppression. Results reported here are consistent with previous findings of the 
presence of high numbers of CD 26+ cells at sites of inflammation, and of significance to 
this study is that C D 26br,ght T  cells have a high transendothelial migration capacity 
(Mizokami et al., 1996). High levels of CD26+ cells in, and around, PVCs in MS tissue 
shown in this study are likely to play a crucial role in the regulation of local immune 
responses due to the rapid and specific enzyme activity of CD26, shown in data from 
Chapter 2. In chronic active MS lesions, CCL2 staining has predominantly been 
localised to the inner rim of the edge, adjacent to the hypercellular leading edge (Van  
der Voorn et al., 1999), and within hypertrophic astrocytes, adjacent to chronic active 
lesions (McManus et al., 1998). Binding experiments using isolated human brain 
microvessels led to reports of binding sites for CCL2 on the parenchymal surface of 
brain microvessels (Andjelkovic et al., 1999), which corresponds to an area where this 
current study identified CD26 expression in both control brain and MS lesions. Thus, 
CCL2 and CD26 are highly likely to be expressed within the same microenvironment, 
offering great scope for CCL2 regulation via cleavage. Similarly, in post-mortem brain 
tissue, CXCL10 is expressed within areas of demyelination, particularly around blood
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vessels, and by hypertrophic astrocytes at the edge of active MS lesions (Sorensen et 
al., 2002b). This CXCL10 expression pattern overlaps with results reported here for 
CD26 expression, which strongly suggests CXCL10 cleavage by CD 26 could occur in 
vivo in MS, due to the rapid truncation detected in Chapter 2.
It has been suggested that the ability of CD 26+ cells to migrate across endothelium to 
inflammatory sites might be due to the known coexpression of CD26 with CCR5 and 
leukocyte function-associated (LFA-1) (Sallusto eta l., 1998), which could be 
investigated in further immunofluorescent studies. CD26 is known to interact with 
fibronectin and collagen of the ECM (De Meester et al., 1999). The role of CD26 in cell 
adhesion is unclear, but via its ligation with fibronectin on the surface of breast cancer 
cells, it has been shown to act as an adhesion receptor on rat lung capillary endothelia 
for metastasising tumour cells (Cheng et al., 1998). High expression of CD26 in MS 
may be of pathological significance due to its ability to bind to fibronectin, thereby 
mediating adhesion of C D 26+ T  cells to the basal lamina. CD26 also plays a role in 
promoting M M P2 activity, thereby facilitating degradation of collagen and gelatin, and 
the ensuing passage across the BBB (Kumagai et al., 2005). This could help to explain 
the reduction in what appeared to be connective tissue staining, which was observed in 
MS lesions in our study.
It is possible that in MS, increased CD26 expression by immune cells is first linked to 
systemic activation of Th1 cells, including myelin-reactive T-cells, which then cross the 
BBB in significant numbers. Passage into the CNS may be assisted by increased 
adhesion due to the CD26 expressed by immune cells binding to fibronectin, and also 
by enhancement via CD 26 of the ability of M M P2 to degrade the BBB. Once inside the 
CNS, cleavage of chemokines by CD26 may cause either further inflammation, by 
enhancing chemotactic potential, or reduce immune cell infiltration by diminishing or 
destroying the functional activity of chemokines. CD26 has also been shown to inhibit 
mobilisation and attachment of fibroblasts to components of the ECM, thereby 
interfering with the healing process after inflammation (Kumagai et al., 2005). Despite 
the confusion surrounding the precise effects of CD26, it is clear that CD26 is a 
multifunctional molecule that is very likely to play a pathological role in the progression 
of MS, and future studies on its expression in human brain, and the effect on activity of 
its chemokine substrates, should yield interesting results.
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4.6 Summary
CD26 is a multifunctional glycoprotein that can truncate a number of substrates within 
the CNS, with implications for the immune, nervous, and endocrine systems of the 
body. Expression of CD26, particularly by peripheral blood T  cells, has been linked to 
disease activity in MS. W e have identified CD26 expression in human control brain and 
in MS lesions. In control brain, CD26 staining was principally associated with the BM 
region of blood vessels, and occasional T  cells performing surveillance. In MS lesions 
showing predominantly demyelination, CD26 staining was increased and principally 
associated with cells in the parenchyma that expressed HLA-DR, and a subset of T  
cells in PVCs. In MS lesions with extensive inflammation, CD26 was further increased, 
and most commonly associated with T  cells both in the parenchyma and in PVCs, but 
BM staining was reduced. Some dual staining of CD26 and HLA-DR was also 
observed in inflammatory lesions, predominantly in the parenchyma.
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Chapter 5
I n  v i t r o  chemokine-induced cell migration to 
intact and cleaved CCL2 and CXCL10
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5.1 Introduction
5.1.1 Cell rolling, adhesion and extravasation
PBMC migration into tissues involves a series of events, starting with selectin-mediated 
cell rolling on the endothelium, followed by firm adhesion and arrest mediated by 
leukocyte integrins, and culminating in extravasation via rearrangements of cell-cell 
contacts, and chemotaxis up a chemokine gradient (Butcher and Picker, 1996). 
Selectins mediate both the capture of free-flowing PBMCs and their rolling activity 
along the endothelium (Bianchi et al., 1997). Selectin bonds are unique in that their 
strength increases up to a point under pulling forces, thereby locking when blood flows 
over the cell (Fujiwara and Hamaoka, 2001).
Chemokines bound to the endothelium via interactions with GAGs interact with 
receptors expressed on leukocytes, leading to activation of leukocyte integrins and the 
cell then becomes firmly adhered, and arrests (Sperandio et al., 2006). Leukocyte 
transmigration into tissue follows this cell arrest, mediated by additional adhesion and 
signalling molecules (Fig. 5.1) (Muller, 2003). Small GTPases, such as RhoA and Rac1, 
are proteins which bind GTP, and are implicated in the process of transmigration. RhoA 
regulates adhesion receptor function in response to chemokine activation, and Rac1 
induces cytoskeletal changes resulting in lamellipodia formation during extravasation, 
as well as activating phosphoinositide 3-kinase (PI3K), involved in cell motility 
regulation (Bianchi et al., 1997). It has been suggested that leukocyte binding promotes 
signals in ECs that encourage opening of EC contacts and junctions, facilitating 
leukocyte passage (Vestweber, 2000). A transcellular route for leukocyte migration 
across the BBB has also been proposed, via membrane invagination and transcellular 
pore formation (Greenwood et al., 2002).
Protease-mediated digestion of junctional proteins is not considered essential for 
transmigration, as protease inhibitors do not prevent it, but proteases from ECs and 
stromal cells are often involved, nonetheless (Wolf et al., 2003). Indeed, engagement 
of a-ifr integrin on T-cells with VCAM-1 on ECs, induces transcriptional regulation of 
M M P2 (Bianchi et al., 1997). Inflammatory microenvironments often result in 
substances such as thrombin being produced, that can destabilise junctions between 
cells by their action on the EC cytoskeleton, thereby creating intercellular gaps that 
facilitate transmigration (Chapman, 2006). Chemokines contribute to the process of cell 
adhesion, prior to their role in migration, through their activation of integrin 
adhesiveness via their solid-phase immobilisation on the EC surface (Vestweber, 2002).
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Migrating leukocyte
Adluminal aspect
PECAM-1
VE-cadherin
Nucleus
Abluminal aspect Basement membrane
Reprinted from (Bianchi etal., 1997), ©  (1997), with permission from Elsevier
Figure 5.1 Transendothelial cell migration
Leukocytes and endothelial cells (ECs) express platelet/endothelial cell adhesion 
molecule-1 (PECAM -1), mainly in interdigitating E C  projections n ear to the lumen, 
which is implicated in the early stages o f cell transmigration. A 'molecular zipper' 
arrangement of PECAM -1 molecules m ay facilitate leukocyte progression through the 
junction between ECs, by helping to effectively pull them towards the BM. Leukocytes 
bound to ECs can promote disassembly o f adherens junctions (AJ), thus assisting with 
separation o f ECs to allow passage. Vascular endothelial (VE)-cadherin is the main 
transmembrane protein o f AJs, which interacts with identical molecules on opposing 
cells.
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5.1.2 Mechanisms of cell migration
Recruitment of PBMCs to sites of inflammation requires directional migration in a 
chemotactic gradient via a complex process of adhesion, cytoskeletal rearrangements, 
movement and detachment. Actin polymerisation within the cell drives its movement 
forward (Wells, 2003). Chemotactic agents trigger cells to polarise into a forward 
moving leading edge, and a retracting rear portion. Polarisation of a cell involves 
atypical protein kinase C (aPKC), partitioning defective (PAR) proteins, and production 
at the leading edge of phosphatidylinositol triphosphate (PIP3) via the action of PI3K  
(Vicente-Manzanares et al., 2005). In many cell types, cellular architecture is 
reorganised, such as positioning of the nucleus behind the microtubules, microtubule 
organising centre, and the Golgi apparatus. Polarisation is maintained by feedback 
loops involving PI3K, microtubules, Rho GTPases, integrins, and vesicular transport 
(Gomes et al., 2005).
Several integrated processes converge at the leading edge of a migrating leukocyte, 
with receptors for adhesion molecules, proteases, and chemokines establishing various 
associations with one another. Transient interactions between adhesion receptors and 
membrane proteases or their receptors, for example, are involved in directed migration 
where the subendothelial matrix is loosened or digested. The invasion of leukocytes 
through the interstitial matrix and across an extravascular space is co-ordinated by 
adhesion-dependent upregulation of proteases and their receptors, with a carefully 
regulated balance between adhesive and proteolytic activity being essential for 
migration (Bianchi eta l., 1997).
In the cytoplasm of a cell, actin filaments are fast-growing at one end, and slow- 
growing at the other, which facilitates the production of cellular protrusions. Protrusions 
can take the form of spike-like filopodia used to explore the environment, or broad 
lamellipodia, which provide a foundation for forward motion (Pollard and Borisy, 2003). 
The actin-related proteins (Arp)-2/3 complex is involved in the induction of new actin 
filaments in lamellipodia (W eaver et al., 2003).
Traction is required if a cell is to move forward, which is achieved by attachment of 
protrusions to the surroundings via integrins. Tractional force is created by the 
interactions of actin filaments, linked via adaptor proteins to integrins at adhesion sites, 
with the contractile properties of myosin II (Vicente-Manzanares et al., 2005). Adhesion 
assembly and disassembly mechanisms are poorly understood, but it is known that 
forward motion requires precise regulation to enable assembly at the front, with 
simultaneous disassembly at the rear. Myosin II is essential for retraction of the back
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end of the cell, and for development of sufficient tension to open calcium-channels and 
lead to activation of the protease calpain. Calpain cleaves integrins and other adhesion 
proteins, and the release of rear adhesions then provides positive feedback for the 
migration cycle (Franco et al., 2004). The cellular morphology and style of movement 
exhibited during migration varies according to the cell type. Leukocytes show an 
amoeba-like morphology and movement, have few integrin clusters, and adhesions 
that allow rapid movement (Gunzer et al., 2000).
5.1.3 Degradation of the extracellular matrix
In addition to movement, cells often engage in degradation of extracellular matrix (ECM ) 
proteins to reach their destination (Patel et al., 2001). Once past the EC barrier, the BM 
and connective tissue must be overcome (Fig. 5.1). MMPs play a key role in this, with 
T-cell migration, for example, being shown to be assisted across an in vitro BM by 
secretion of M M P2 and M M P9 (Bianchi et al., 1997). Leukocytes not only secrete 
proteases that promote breakdown of the ECM, but also contribute to degradation by 
converting plasminogen to plasmin, via activation of urokinase-type plasminogen 
activator (uPA) (Bianchi et al., 1997). The binding of uPA to its receptor, uPAR, 
catalyses the formation of plasmin, and initiates pericellular proteolysis and cell 
migration (Bruse et al., 2005). Macrophages and activated leukocytes produce uPA, 
and also express uPAR, which increases their adhesion in culture (Ossowski and 
Aguirre-Ghiso, 2000). In a study by Gyetko and colleagues (1994), the localisation of 
uPARs at the leading migratory edge of human monocytes exposed to a chemotactic 
gradient, was required for chemotaxis. Interestingly, uPARs also have high affinity for 
integrins, and are thought to be regulators of integrin activity during leukocyte adhesion 
(Ossowski and Aguirre-Ghiso, 2000). Thus, uPARs play a role in cell-surface 
proteolysis, cell adhesion, and migration.
5.1.4 Chemotactic gradients
The roles of chemokines and their receptors in cell migration is discussed in 1.3. 
Chemotactic gradients can be very complex, as they arise from solid-phase, and 
soluble-phase, chemokines. Chemokines have diverse abilities to form solid-phase 
gradients in situ by binding to the ECM via interactions with GAGs, but this ability is 
restricted in the extravascular space (Patel et al., 2001). W hen chemokines are 
immobilised on endothelial cells, unlike chemokines in solution, they can act to direct 
rolling leukocytes expressing the appropriate chemokine receptor to adhere to the 
endothelium, and are essential for firm adhesion (Vestweber, 2002). Activation of G- 
protein signals via GPCRs on tethered leukocytes, following brief contact with 
immobilised endothelial chemokines, leads to integrin clustering (Cinamon et al., 2001).
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Membrane-bound chemokines are, therefore, functionally different from their soluble 
counterparts. Chemotactic gradients, with important roles in extravasation of cells into 
tissue, are formed by both soluble and immobilised chemokines (Patel et al., 2001). To  
be able to sense chemokine gradients and engage in directional cell migration, rapid 
receptor internalisation and redistribution is essential (Loetscher et al., 1996).
Cytokines can have a dramatic effect on cellular chemokine production and chemotaxis, 
such as the rapid inhibition of CCR2 expression by monocytes when exposed to IFN-y, 
rendering them less responsive to chemokines, and perhaps serving to retain 
monocytes at inflammatory sites and engage in feedback in regulating cell recruitment 
from blood (Penton-Rol et al., 1998).
CCL2 is implicated in the arrest of rolling monocytes on endothelial cells expressing E- 
selectin, and this effect appears to be independent of chemotaxis (Gerszten et al.,
1999). CCL2 is also thought to be involved in the spreading and alterations in the 
shape of monocytes, attached to the endothelium under inflammatory and flow 
conditions, and subsequent transendothelial migration. As the shape change and 
migration were rarely seen under static conditions, it was suggested that a diffusible 
gradient of soluble CCL2 is required for these effects (W eber et al., 1999). Endothelial 
cells activated with TN F  have been shown to upregulate expression of both CXCL1 
and CCL2, which bind to receptors C XCR2 and CCR2 respectively, expressed by 
monocytes. CCL2 was secreted as a soluble form, but CXCL1 was immobilised to the 
endothelium via interactions with proteoglycans, and thus contributed substantially to 
the firm adhesion of monocytes. The differential presentation of chemokines in either a 
solid-phase or soluble form may determine functional specialisations required for the 
sequential steps of monocyte migration (W eber et al., 1999).
CCL2 is presented on the apical endothelial cell surface, focused into discrete regions 
by interactions with heparan sulphate. This apical chemokine presentation pattern is 
thought to provide a means for concentrating small quantities of chemokines produced 
by subendothelial tissues, thereby promoting activation and recruitment of leukocytes 
from the blood (Hardy eta l., 2004). Rapid, regulated secretion of chemokines from ECs 
is thought to occur via two distinct compartments. CXCL8, for example, has been 
observed in rod-like compartments called W eibel-Palade bodies (W PB), whereas CCL2  
was mainly localised to small granules (distinct from W PB), throughout the EC 
cytoplasm. CXCL10 was not observed in either compartment, and was thus not 
considered to be stored for subsequent regulated secretion in ECs (Oynebraten et al.,
2004).
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It is thought that CXCL10 recruits activated effector T  cells under inflammatory 
conditions, and that CXCR 3 is upregulated during effector T  cell generation in 
secondary lymphoid tissues. IL-2 links acquisition of chemotactic capability with T  cell 
expansion (Moser and Loetscher, 2001).
5.1.5 In vitro models of migration
Most in vitro migration has traditionally been performed using a Boyden chamber, i.e. a 
chamber composed of 2 compartments separated by a microporous membrane, with 3- 
8pm pore size. A  chemotactic gradient develops across the membrane when a 
chemotactic agent is placed in the lower compartment, and cells in the upper 
compartment migrate through the membrane for a set incubation time. The membrane 
is fixed and stained, and the number of migrated cells counted (Boyden, 1962). Many 
modifications of this technique exist, and it has also been described as a trans-well, or 
filter membrane, migration assay.
Transendothelial chemotaxis is often studied using filters coated with ECM proteins, 
with an overlying EC monolayer. The EC monolayer can be pre-treated with 
inflammatory cytokines in an attempt to mimic inflamed vessels and induce adhesion 
(Roth et al., 1995a). There is doubt, however, as to whether chemotactic gradients 
established in vitro mimic the endothelial chemokine distribution through which 
leukocytes would extravasate in vivo (Middleton et al., 1997). A further problem with 
the application of Boyden chamber assays to study transendothelial migration is the 
time frame commonly used, as in vivo studies have suggested leukocyte extravasation 
in post capillary venules of inflamed tissue occurs in a few minutes, yet migration 
assays are commonly left for 1-4h before readings are taken (Roth et al., 1995a). The  
prolonged time frame of an assay compared to the relatively short time of contact of 
PBMCs with the endothelium in vivo cannot give a true indication of the ability of 
adhered leukocytes to sense chemokine gradients, particularly as the shear forces of 
blood flow are missing (Cinamon and Alon, 2003). Shear forces are important as they 
may transfer strong pro-migratory signals to adherent leukocytes (Cinamon et al.,
2001). The use of an EC monolayer may slow and reduce transendothelial migration, 
as leukocytes that have traversed the monolayer may become trapped between ECs 
and the filter. In addition, once past the filter pores, lymphocytes have been observed 
to move along the lower side of the filter for a considerable time, before detachment 
into the lower chamber. It is also possible that ECs may form an additional layer on the 
underside of the filter, creating a further obstacle for migrating leukocytes (Mackarel et 
al., 1999). The measurement of leukocytes collected from the lower chamber, therefore, 
is no guarantee of a true reflection of the entire transmigrated population, and the
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migration rates are often lengthened compared to those observed for in vivo 
endothelial migration (Cinamon and Alon, 2003).
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5.2 Aims and objectives
Truncated CCL2 and CXCL10 could be important regulators of cell trafficking across 
the BBB in MS, and may result from local exposure to M M P2, M M P9, or CD26 in vivo, 
which are localised at the BBB or on inflammatory cells migrating into the CNS. Thus, 
the main objectives of this chapter were to:
•  Develop and optimise a quantitative method for measuring cell migration over 
time with minimal manipulation
•  Separate cleaved CCL2 and CXCL10 from the enzymes responsible for their 
truncation in the digestion mixtures detailed in Chapter 2
•  Assess migration of THP-1 cells to intact and cleaved CCL2
• Assess migration of Jurkat cells to intact and cleaved CXCL10
• Comparatively assess migration of PBMCs to intact and truncated CCL2 and 
CXCL10 in an in vitro assay
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5.3 Materials and Methods
5.3.1 Cell culture of THP-1 monocytic cell line and Jurkat T cell line
THP-1 cells, a human monocytic leukaemia cell line derived from a 1 year old male, 
were obtained from ECACC, Wiltshire, UK. Cells were cultured at 37°C and 5%  C 0 2 in 
75 cm2 flasks in RPMI 1640 medium (Sigma) containing 2mM L-glutamine (Invitrogen), 
10% v/v H I-FCS, 50U/ml penicillin, and 50pg/ml streptomycin. Stocks of THP-1 cells 
were maintained by freezing overnight at -80°C in 90%  v/v H I-FCS with 10% v/v 
glycerol (Sigma), before being transferred to a dewar containing liquid nitrogen. W hen  
cells were thawed from a frozen cryovial, they were added to 5ml medium, centrifuged 
at 150gfor 5min, the medium removed, and cells resuspended in medium as above, 
but with 20%  v/v H I-FCS. The serum concentration was reduced to 10% v/v after 5-7  
days.
5.3.2 Cell culture of Jurkat T cell line
Jurkat cells, a human lymphoblastic leukaemic T  cell line, were obtained from ECACC. 
Cells were cultured in medium as described for THP-1 cells above, but were frozen 
down in medium containing 10% v/v DMSO. Jurkat cells were recovered from frozen 
storage using their standard culture medium.
5.3.3 Treatment of lymphocytes and Jurkat cells with IL-2 and 
phytohaemagglutinin
Treatment with IL-2 has previously been shown to increase the migratory capacity of 
human lymphocytes, and their ability to adhere to endothelial cells (Pankonin et al., 
1992). Phytohaemagglutinin (PHA) has also been shown to increase the rate of 
migration of human lymphocytes (Shiu and Schor, 1987), and activates T  cells by 
binding to glycoproteins on the cell membrane (Kay, 1991). To enhance the migratory 
potential of lymphocytes derived from peripheral blood, they were thus cultured in TH P - 
1 medium with 1pg/ml PHA (Sigma) and 20ng/ml IL-2 (R&D Systems) for 7 days.
Jurkat cells were treated with 10ng/ml IL-2 for 6 days to assess the effects of short­
term IL-2 treatment.
5.3.4 Separation of whole blood to obtain peripheral blood mononuclear cells
Whole blood (10ml) was obtained from healthy volunteers using venepuncture 
performed by qualified personnel, and processed within 2h. Blood was injected into 
glass tubes coated with K2EDTA (BD Biosciences, Oxford, UK), and the tube inverted
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8-10 times to mix the blood with the anticoagulant coating. An equal volume of PBS 
without calcium and magnesium was mixed with the whole blood in 15ml conical tubes.
The following procedure was performed in a HEPA-filtered class II laminar flow cabinet 
(Heraeus, Germany). Histopaque-1077 (Sigma) was brought to RT and 5ml placed in 
each of 4 x 15ml conical tubes. An equal volume (5ml) of the blood/PBS mixture was 
gently pipetted down the side of the conical tube onto the Histopaque-1077, and care 
was taken to avoid mixing the 2 liquids. Histopaque-1077 contains polysucrose and 
sodium diatrizoate, adjusted to a density of 1.077 ± 0.001 g/ml, and is designed to 
facilitate rapid recovery of viable mononuclear cells via density centrifugation. Tubes 
were centrifuged (with the brake off) at 400g fo r 30min at RT, during which time, 
erythrocytes and granulocytes sediment due to aggregation by polysucrose, leaving 
mononuclear cells at the plasma-Histopaque interface. After centrifugation, the upper 
plasma layer was carefully removed with a Pasteur pipette, to within 5mm of the 
opaque layer containing mononuclear cells. The opaque layer was transferred to a 
conical tube using a Pasteur pipette, mixed with 10ml PBS without calcium or 
magnesium, and centrifuged at 250g fo r 10min at RT. The supernatant was discarded, 
and the cell pellet resuspended in 5ml PBS without calcium or magnesium, and 
centrifuged at 250g fo r 10min at RT. This last centrifugation step was then repeated. 
The majority of platelets were removed by these 3 centrifugation steps.
5.3.5 Separation of lymphocytes and monocytes
The washed pellet of mononuclear cells obtained from 5.3.4 above, was resuspended 
in 7ml PBS with cations and transferred to a 100mm petri dish (Sarstedt, Leicester, UK). 
This was incubated at 37°C and 95%  air/5% C 0 2for 1h to allow the monocytes to 
adhere to the plastic. The dish was rinsed three times with 5ml PBS, and these were  
pooled with the cell suspension, to collect lymphocytes. Monocytes were removed from 
the dish by adding PBS without cations, pre-cooled to 4°C, and employing a cell 
scraper (BD), if necessary. Cells were counted using a haemocytometer (Sigma) to 
ensure sufficient numbers were present for experimentation.
5.3.6 Cell viability determination by Trypan Blue exclusion
Trypan blue is an acid stain containing a negatively charged chromophore that only 
reacts with cells if the membrane is damaged (Green, 1990). Live cells do not take up 
the blue stain, whereas dead ones do. To test for cell viability, 10pl cell suspension was 
mixed with 10pl 0.4%  Trypan Blue solution (Sigma), left to stand for 5min at RT, and 
then viable and non-viable cells counted using a haemocytometer. The number of
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viable cells was then expressed as a percentage of the total number of cells counted. 
This procedure was repeated to ensure accuracy. Cells were tested for viability both 
before and after migration assays.
5.3.7 Flow cytometry to investigate cell phenotype and chemokine receptor 
expression
5.3.7.1 Principles of flow cytometry
Flow cytometry utilises measurements of the light-scattering ability, fluorescence, and 
absorbance of single cells as they flow past excitation sources in a liquid medium. 
These measurements are used for either quantitative analysis of a wide range of 
cellular characteristics, such as size, and levels of DNA, protein, and surface receptors, 
or for use in cell separation in a cell sorter (Rieseberg et al., 2001).
Flow cytometers encompass 5 main operating units (Fig. 5.2b): a light source, typically 
a laser; a flow cell; optical filter units for detection of different wavelengths; a 
photodiode or photomultiplier tube for signal detection; and an operating and data 
processing unit. Cells in suspension individually pass the light source positioned 
orthoganally to the flow (Fig. 5.2a), and excitation light is scattered in forward and 
sideways directions by the presence of the cells. Forward-scattered light provides 
information about the size of the cell and is detected by the forward-scatter sensor (Fig. 
5.2b). Sideways-scattered light is influenced by the granularity and morphology of the 
cell.
The use of specific fluorescent labelling facilitates the analysis of selective cell 
components. Direct labelling of cells with antibodies coupled to fluorophores enables 
detection of specific antigens by flow cytometry, and multiple lasers on one platform 
allow simultaneous analysis of several fluorophores with different emission spectra. 
Fluorescent light is processed through the PM T to the data processing unit (Rieseberg 
et al., 2001). Scattering and fluorescence can be combined to allow observation of all 
subpopulations of cells. Commonly, dual parameter dot plots are used to represent flow  
cytometry data, and frequency histograms (Davey et al., 1999).
Following separation of mononuclear cells from whole blood, as described in 5.3.4, flow 
cytometry was performed to investigate the proportion of cells that were monocytes or 
lymphocytes. The cell pellet obtained after the final rinse in 5.3.4 was resuspended in 
3ml of PBS without cations, and 25pl used for each flow cytometry investigation.
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Figure 5.2 Fluid dynam ics and op tics of a flow  cy tom e ter
(a) Cells in suspension are focused into a single column by laminar flow and 
hydrodynamic forces, using sheath fluid. The diameter of the laminar streams of sheath 
fluid and sample are gradually restricted until a single file of cells is achieved.
(b) The flow cell described above allows introduction of cells into a flow cytometer, 
where they are interrogated by a laser, and the scattered light measured at a low angle 
(forward scatter or FSC), and also a high angle (side scatter, or SSC). These 
measurements provide information about the physical properties of a cell, with side 
scatter representing the internal complexity. If cells have been labelled with fluorescent 
markers, high angle light, or side scatter, also contains fluorescent emission from cells, 
which is separated into different wavelengths by dichroic mirrors and band filters, for 
measurement by multiple fluorescent detectors. Photons detected by a photomultiplier 
tube (PMT) and photodiodes are converted to analogue voltages In the photodetector. 
The analogue signal is later digitalised into numerical files, displayed on a computer 
screen. The sensitivity of the instrument can be altered by adjusting the gain (Tarrant,
2005).
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All antibodies and isotype controls used in flow cytometry were obtained from R & D 
Systems (UK).
5.3.7.2 Analysis of mononuclear cell populations by flow cytometry
Unlabelled cells were kept on ice with 10pl PBS, alongside cells incubated for 1.5h at 
4°C in the dark with 10pl of either anti-CD4+ or C D 8+ fluorescein-conjugated 
monoclonal antibody, anti-CD14+phycoerythrin-conjugated monoclonal antibody (to 
detect monocytes), or their respective isotype controls of mouse lgG2a or mouse lgG1. 
The samples then had 1ml PBS without cations added, and were centrifuged at 500g  
for 5min at 4°C. The supernatant was discarded, cells resuspended in 300pl PBS 
without cations, and analysed using a FACS Calibur flow cytometer (BD).
The flow cytometer was flushed through with distilled water, and the unlabelled cells 
were used for optimisation of the flow settings, assisted by altering the voltage and 
amplifier gain, to obtain the population of cells displayed in approximately the centre of 
the x-axis, and in the lower half of the y-axis. The isotype control samples served as 
negative controls and were run next. Instrument settings were optimised so that the 
histogram plot for the negative control was aligned to the left for the whole of its normal 
distribution curve (Fig. 5.5b). The cells labelled with anti-CD4+, CD8+, or C D 14+ 
antibodies were analysed last, and if sufficient antibody was bound to the selected cell 
antigen, the histogram plot appeared to the right of that of the isotype control. For each 
sample, a gate was drawn around the dot plot of the cells of interest, and 10,000  
events within the gate were analysed by the flow cytometer. The percentages of cells 
positive for C D 4+, C D 8+, or CD 14+ expression were calculated by performing analysis 
with CellQuest software (BD) on an Apple Mac computer.
5.3.7.3 Analysis of THP-1 expression of CCR2 by flow cytometry
THP-1 cells were centrifuged at 200g, the medium removed, and the cell pellet 
resuspended in PBS without cations to give 1 x 107 cells per ml. Duplicate samples of 
25pl of cell suspension were incubated for 1.5h in the dark at 4°C with 1 OjjI of either 
anti-CCR2 phycoerythrin (PE)-conjugated monoclonal antibody, mouse PE-lgG 2B  
isotype control, or PBS without cations. The samples were then washed and analysed 
by flow cytometry, as above (see 5.3.7.2).
5.3.7.4 Analysis of Jurkat expression of CXCR3 by flow cytometry
Jurkat cells were processed similarly to THP-1 cells above (see 5.3.7.3), using an anti- 
CXCR3 PE-conjugated monoclonal antibody, and a mouse PE-lgG1 isotype control.
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5.3.8 Preparation of cleaved chemokines for use in migration assays
5.3.8.1 Separation of cleaved chemokine from enzyme following digestion
Mixtures of chemokine, enzyme, and assay buffer, obtained from the digestion detailed 
in 2 .2.1.3, were passed through Microcon® centrifugal filter units (Millipore, UK) to 
separate the chemokine from the larger Mr enzymes. Microcons® have an 
ultrafiltration membrane composed of regenerated cellulose acetate that enables 
collection of proteins in solution below the nominal molecular weight limit (NM W L) of 
the membrane, and concentration of proteins above the NMW L. Membranes with a 
NMW L of 30, and 50 kDa, were assessed.
Mixtures of chemokines and enzymes from 2.3.1.3 were pipetted into the upper 
chamber of the Microcon® filter unit, positioned in the accompanying tube. The lid was 
fastened onto the top of the filter unit, and the Microcons® centrifuged at 503g  for 
10min at RT. A further identical centrifugation step was performed if a substantial 
volume remained above the filter, although care was taken not to centrifuge to dryness. 
The filter was removed and inverted into a clean tube, and 10pl of the filtrate in the 
original tube processed for gel electrophoresis (see 2.3.2.2), whilst the remainder had 
10% HSA added, to create a final chemokine solution containing 0.1%  HSA. To 
recover the concentrated enzyme, the inverted filter was pulsed briefly in the centrifuge, 
the enzyme solution collected in the tube. Separated enzyme and chemokine solutions 
were stored at -80°C.
The above procedure for using Microcons® to separate chemokines from enzymes 
was optimised, comparing CCL2 and CXCL10 standards in different volumes (2pg 
protein in total volumes of either 65, 200, o r400p l assay buffer - 2.3.1.2), and flushing 
chemokine:enzyme mixtures (2pg chemokine + 2pg M M P2 in assay buffer + 1mM  
APMA) by adding 100pl assay buffer after centrifugation, and again after a further spin. 
Initially, centrifugation at 9447g fo r 10min was undertaken and the enzyme solution 
was recovered by inverting the filter and centrifuging at 503g fo r 3min.
5.3.8.2 Calculation of concentrations of cleaved chemokines using densitometry
Samples from the Microcon® separation (see 5.3.8.1) were used in gel electrophoresis 
with 12% Bis-Tris gels, alongside CCL2 and CXCL10 standards, with 20pl samples 
loaded per well. Chemokine standards were made by adding dH20  to recombinant 
chemokines to give concentrations of 2.5, 5, 7.5, 10, 15, 20, 30, and 40pg/ml. Each 
digestion experiment performed in 2.3.1.3 utilised 33pg/ml chemokine, so it was
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concluded that this would be the maximum possible concentration obtained after 
separation using Microcons®.
Gels were silver-stained, as described in 2.3.3.2, images captured using a UVP  
Bioimaging Systems instrument, running Lab Works (version 4) software, and used in 
densitometry. Using the single protein band analysis setting, each band was selected, 
background correction (‘joining valleys’) was applied, and the integrated optical density 
(IOD) calculated for each band using the software. The IOD of the standards were 
plotted against their known concentrations to generate a standard curve, from which 
concentrations of the cleaved chemokines, collected after filtration through Microcons®, 
were calculated. The appropriate volume of each cleaved chemokine could then be 
used to generate a concentration of 200ng/ml for the migration assay to compare intact 
and truncated chemokines.
5.3.9 In vitro cell migration assay
5.3.9.1 Labelling of cells with calcein AM
Acetoxymethyl ester of calcein (calcein AM) is an esterified fluorescein derivative that 
is membrane-permeant, and can be introduced into cells by incubation. Within the cell, 
calcein AM is hydrolysed by endogenous esterases into the negatively charged, green 
fluorescent calcein, which is retained in the cytoplasm of live cells. Calcein has 
excitation and emission wavelengths of 490nm and 515nm, respectively, and is rapidly 
lost under conditions that cause cell lysis (Weston and Parish, 1990). Calcein AM is not 
thought to interfere with cellular functions, such as lymphocyte proliferation or 
chemotaxis (Weston and Parish, 1990).
After the final PBS wash of PBMCs following separation from whole blood, or removal 
of media from THP-1 or Jurkat cells, the supernatant was discarded and the cell pellet 
resuspended in Hank's Balanced Salt Solution (HBSS) (PAA Laboratories, Somerset, 
UK), without calcium, magnesium, or phenol red. Calcein AM (50pg vial) (Invitrogen,
UK) was dissolved in 10pl DMSO, and mixed with the cell suspension in HBSS. The  
volume of HBSS was varied during optimisation of the labelling technique, with 8, 12,
33, and 44ml assessed, to give final molarities of calcein AM of 6.2, 4.1, 1.5, and 1pM 
respectively. Cells were incubated with calcein AM at 37°C in an incubator with 95%  
air/5% C 0 2 for either 30min, or 1h for comparison. Labelled cells were centrifuged at 
200g for 5min, supernatant removed, and cells washed twice in HBSS, before being 
used in migration assays.
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5.3.9.2 Comparison of cell number versus fluorescence
To ensure measurement of fluorescent values of calcein AM-labelled cells accurately 
reflected cell numbers, various experiments were performed to assess this. 
Lymphocytes (10.2 x 105 per ml) and monocytes (3 x 104 per ml) from whole blood 
were labelled independently for 30min with 4.12pM  calcein AM in HBSS without cations 
or phenol red, and then washed as before. Increasing volumes (50, 100, 200, 300, 400, 
500, 600, 700, 800, 900pl, and 1ml) of labelled cells were aliquoted into a 24-well plate, 
and made up to 1ml with HBSS. The plate was read at 530nm  using a W allac Victor2 
1420 plate reader, and graphs plotted of cell number versus fluorescence value.
The above comparison of cell number with fluorescence value was repeated using a 
mixed monocyte:lymphocyte population labelled with 4.12pM  calcein AM in RPMI 
medium without phenol red (PAA Laboratories) for 30min Fluorescence was measured 
on the W allac plate reader at 530nm from the top, and also on the GENios Plus plate 
reader (Tecan, Reading, UK) at 535nm from the bottom.
Following optimisation of the calcein AM concentration, the above procedure was 
repeated using THP-1 cells labelled with 1.5pM calcein AM in RPMI medium without 
phenol red + 0.1%  human serum albumin (HSA) for 30min, and fluorescence was 
measured on the GENios Plus plate reader at 535nm, from the bottom.
5.3.9.3 Optimisation of settings of the fluorescent plate reader
When trans-well inserts were used that had a fluorescent-blocking membrane (BD), it 
was essential that fluorescence was measured from the bottom of the plate using the 
GENios Plus plate reader, to enable detection of migrated cells alone, a feature not 
possible with the W allac plate reader. Companion plates (BD) used with the inserts 
were not of regular dimensions for a 24-well plate, so a plate definition file was created  
by inputting the specific dimensions of the plate (Appendix III). Using Xfluor4 software, 
a program was designed to read the plate from the bottom, with excitation and 
emission wavelengths of 485 and 535nm respectively, using a manual gain setting of 
60, 3 flashes from a high energy Xenon flash lamp per well, a lag time of Ops, an 
integration time of 20ps, and a 2x2 read formation in a square pattern per well. Gain 
settings of 50, 60, 80, and ‘optimal’ (derived by the instrument from assessment of the 
range of fluorescence in all wells) were tried, as were different read patterns (e.g. 
single central spot, or 4 circles). Plates were read with the lid off, as it autofluoresced.
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5.3.9.4 Migration of THP-1 cells to human serum albumin
As HSA was used in both the upper and lower chambers of the migration apparatus, 
the effects on migration of various HSA concentrations were analysed.
THP-1 cells were labelled with 1.5pM calcein AM for 30min: Cells were washed twice 
with HBSS without cations or phenol red, resuspensed in RPMI without phenol red + 
0.1%  HSA, and placed in migration inserts. FluoroBlok™ inserts (BD) have a 
polyethylene terephthalate (PET) membrane as their base, which blocks light 
transmission within the 490-700nm  range. The membrane had 3pm pores, which 
allowed labelled cells to migrate to the underlying chamber (Fig. 5.3). The inserts had a 
human fibronectin coating to promote attachment of cells to the amino acid sequence, 
RGD, which interacts with integrin receptors, thereby facilitating migration. Inserts were 
used in a 24-well companion plate, and 500,000 cells placed in each well. RPMI + 0, 
0.1, 1, and 5% HSA, or RPMI + 10'8 M N-formyl-methionyl-leucyl-phenylalanine (fMLP) 
(Sigma) were placed in the lower chamber, and migration investigated by measuring 
the fluorescence from the bottom of the plate, every 15min for 3h at 37°C, to detect 
cells that had passed through the filter. The non-specific chemoattractant fMLP is a 
synthetic peptide that mimics bacterially-derived peptides, which activates phagocytic 
leukocytes, causing chemotaxis and other responses (Prossnitz and Ye, 1997). It was 
included to serve as a positive control for migration.
5.3.9.5 Migration to CCL2 using THP-1 cells and monocytes
THP-1 cells or monocytes, labelled with either 1 or 1.5pM calcein AM, were used in 
migration assays to 0, 10, 25, 35, 50, 75, 100, 200, 400ng/ml recombinant human 
CCL2 (Peprotech, EC). Preliminary experiments were performed using a range of 
CCL2 concentrations to determine the optimum, in terms of generating maximum  
migration. The optimum cell density for use in migration assays was also investigated, 
by seeding 200pl of the cell types used at different concentrations, including 0.2, 1, 1.2, 
2.5, 3.85, and 4 million cells/ml, per trans-well insert.
RPMI + 0.1%  HSA containing CCL2, or a control of RPMI + 0.1%  HSA only, were 
pipetted into wells of a 24-well companion plate (BD), with 800pl added per well. 
Samples were run in duplicate or triplicate. The plate was incubated at 37°C for 5- 
10min to warm the contents. Inserts were positioned into wells of the companion plate, 
and 200pl of labelled cells (resuspended in RPMI + 0.1%  HSA) were added to the 
insert. The plate was read immediately, using a GENios Plus plate reader, by 
measuring fluorescence at 535nm from the bottom of the plate. Subsequent readings 
were taken every 15min, up to 3h.
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Figure 5.3 Schematic of the in vitro migration assay using fluorescent-blocking 
inserts and cells labelled with calcein AM
Cells were labelled with calcein AM. Labelled cells were counted and the required 
density placed in FluoroBlok™ inserts, which have a membrane (3pm pores) that 
blocked light transmission within the range of 490-7OOnm, so that cells in the insert 
were not detected from below. Inserts were positioned in a 24-well plate, containing 
chemoattractants or control solutions. Plates were incubated for up to 5h (depending 
on the cell type), and fluorescence quantitated as required from the bottom of the plate 
using a GENios Plus plate reader at 485nm excitation and 535nm emission.
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5.3.9.6 Migration to CXCL10 with Jurkat cells and lymphocytes
Jurkat cells or lymphocytes, labelled with either 1 or 1.5pM calcein AM, were used in 
migration assays to: 0; 10; 12.5; 25; 50; 100; 200; 250; 400; 500ng/ml; and 1pg/ml, 
recombinant human CXCL10 (Peprotech, EC). Preliminary experiments were 
performed using a range of CXCL10 concentrations to determine the optimum in terms 
of generating maximum migration. The migration assays were conducted as described 
in 5.3.10.5.
Jurkat cells and lymphocytes were used without prior treatment, and also following 
exposure to IL-2 (see 5.3.3) for 6 days, as this has been shown to increase CXCR3  
expression (Reckamp et al., 2007) and the migration response of cells to CXCL10  
(Beider et al., 2003).
5.3.9.7 Use of cleaved forms of CCL2 and CXCL10 in migration assays
To assess the effects on the chemotactic ability of CCL2 and CXCL10 following 
cleavage by M M P2, M M P9, and CD26, truncated chemokines were used alongside 
intact forms at the same concentration of 200ng/ml, in migration assays. Cleaved  
chemokines were generated as described in 2.3.1.3 and prepared for use in migration 
assays (see 5.3.8).
5.3.9.8 Blocking the activity of CCL2
Intact CCL2 was blocked using an antibody prior to use in migration assays, to indicate 
that increased movement of cells to CCL2 was due to chemotaxis, and not 
chemokinesis. Polyclonal goat IgG anti-CCL2 blocking antibody (R&D Systems) was 
incubated at a 1:7.5 dilution (267pg/ml) with 200ng/ml CCL2 in 2.5m l RPMI + 0.1%  
HSA, for 30min at RT.
5.3.10 Analysis of migration data
The mean fluorescence, and the standard error of the mean (SEM), for the number of 
inserts (normally n=3) used with each of the chemoattractant or control solutions in the 
plate wells were calculated. Statistical tests used were the analysis of variance 
(ANOVA) with Bonferroni’s test, or the unpaired, 2-tailed Student’s f-test, to look for 
statistically significant differences between various chemoattractant conditions (such as 
cleaved and intact CCL2), with a p-value of <0.05 being considered significant, 
illustrated by *, P<0.01 as **, and highly significant P<0.001 symbolised by *** 
(Wallenstein et al., 1980). Statistical tests were performed in Microsoft Excel, and using
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GraphPad Prism version 4 .00 for Windows, (GraphPad Software, San Diego, California 
USA).
The migration index of cells was calculated by dividing the mean fluorescence value of 
cells migrated to chemokine by the mean fluorescence value of the control (cells not 
exposed to chemokine), at the same time point.
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5.4 Results
5.4.1 Analysis by flow cytometry of PBMCs obtained after Histopaque separation 
of whole blood
Analysis of PBMCs, conducted with Dr Omer Suliman (BM RC), revealed that 60%  
were positive for C D 4+ /  C D 8+ (T cells), and 22%  were positive for C D 14+ (monocytes) 
(data not shown). Monocytes isolated from whole blood express CCR2 (Opalek et al., 
2007), the receptor for CCL2, and ~40%  resting lymphocytes express CXCR3, the 
receptor for CXCL10 (Loetscher et al., 1998), so separation of these 2 cell types was 
undertaken in order to assess migration to each chemokine individually with an 
appropriate cell type. Following plastic adhesion to separate monocytes and 
lymphocytes, a significant reduction in the number of cells was observed, most likely 
caused by the washing steps, precluding the use of monocytes alone in migration 
assays. The enriched lymphocyte population was cultured in the presence of IL-2 and 
PHA and used in migration assays to CXCL10.
5.4.2 Surface expression of CCR2 by THP-1 cells analysed by flow cytometry
THP-1 cells were analysed by flow cytometry to confirm their surface expression of 
CCR2, and thus, the suitability of using THP-1 cells in migration assays to CCL2.
CCR2 was found to be highly expressed by THP-1 cells, with a total of 83.6%  of cells 
analysed by flow cytometry found positive (Fig. 5.4d), compared to only 2.62%  of cells 
in the same specified region (M1) labelled with the isotype control (Fig. 5.4b).
5.4.3 Surface expression of CXCR3 by Jurkat cells analysed by flow cytometry
Jurkat cells were analysed by flow cytometry to confirm their expression of CXCR3, 
and thus, the suitability of using Jurkat cells in migration assays to CXCL10. CXCR3  
was strongly expressed by Jurkat cells, with a total of 90.45%  of cells positive, (Fig. 
5.5d), compared to only 5.68%  labelled with the isotype control in the same region (M1) 
(Fig. 5.5b).
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Figure 5.4 Flow cytometry of THP-1 cells for surface expression of CCR2
THP-1 cells were labelled with anti-CCR2 antibody, without prior fixation or 
permeabilisation, enabling surface receptor expression to be analysed by flow 
cytometry. Dot blots a and c show forward scatter peak height (FSC-H), indicating cell 
size, and side scatter peak height (SSC-H), indicative of cell granularity. The gates 
used are shown, R1 for THP-1 cells labelled with the isotype control, and R2 for CCR2 
labelling. Histograms of fluorescence from labelled cells in R1 and R2 gate regions are 
shown in b and d, respectively, with an overlay of negative control and CCR2-positive 
results in e. Flow cytometry channel 2 (FL2) was used to detect levels of phycoerythrin- 
labelled anti-CCR2 antibody, and the isotype control. Marker M1 was placed to the 
right of the isotype control result. The mean fluorescence intensity (MFI), and 
percentage of gated cells positive for CCR2, within the M1 zone, are given.
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Figure 5.5 Flow  cy tom e try  o f Jurkat cells fo r surface expression o f CXCR3
Jurkat cells were labelled with anti-CXCR3 antibody, without prior fixation or 
permeabilisation, enabling surface receptor expression to be analysed by flow 
cytometry. Dot blots a and c show forward scatter peak height (FSC-H), indicating cell 
size, and side scatter peak height (SSC-H), indicative of cell granularity. The gates 
used are shown, R1 for Jurkat cells labelled with the isotype control, and R2 for 
CXCR3 labelling. Histograms of fluorescence from labelled cells in R1 and R2 gate 
regions are shown in b and d, respectively, with an overlay of negative control and 
CXCR3-positive results in e. Flow cytometry channel 2 (FL2) was used to detect levels 
of phycoerythrin-labelled anti-CXCR3 antibody, and the isotype control. Marker M1 was 
placed to the right of the isotype control result. The mean fluorescence intensity (MFI), 
and percentage of gated cells positive for CXCR3, within the M l zone, are given.
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5.4.4 Optimisation of the migration assay
5.4.4.1 Optimisation of the use of Microcon® filter devices to separate 
recombinant chemokines from enzymes in the digestion mixture
It was necessary to remove the enzymes from the cleaved chemokines generated in 
2.3.1.3, as enzymes were not present in the intact chemokine solutions, and directly 
comparable solutions of cleaved and intact chemokines were required for cell migration 
assays.
Microcons® with 2 different cut offs were compared, to obtain the maximum chemokine 
yield with effective enzyme removal. Use of Microcons® was optimised by altering the 
centrifuge speed and volume, and flushing through with buffer. CCL2 was retained to a 
lesser extent than CXCL10.
Microcons® with a cut off of 30 kDa (YM 30) were shown by gel electrophoresis to 
retain all of CCL2 and CXCL10 if 0.1%  HSA was present in solution (data not shown), 
and the majority of chemokine in its absence. Flushing the Microcons® through with 
additional buffer reduced chemokine retention on the membrane. YM 30s were 
completely effective at removing enzymes (Fig. 5.6a). Comparing YM 30 Microcons®  
directly with YM 50s by gel electrophoresis indicated that YM 50s gave better recovery 
of CCL2 and CXCL10, whilst remaining effective at removing enzymes (Fig. 5.6b). 
YM 50s were thus selected for removal of enzymes from the chemokine digestion 
mixtures.
Decreasing the centrifugation speed from 9447g to 503g increased recovery rates of 
chemokine in the filtrate, although it was necessary to repeat the centrifugation 1 or 2 
times at the lower speed. Microcons® are suitable for volumes of 50-500pl, and larger 
starting volumes were found to facilitate the ultrafiltration process, but this had to be 
balanced with the chemokine concentration required for migration experiments.
5.4.4.2 Comparison of cell number and fluorescence of calcein AM-labelled cells
The fluorescence values of known numbers of calcein AM-labelled cells were 
measured using both plate readers, to ensure that a good correlation existed between 
fluorescence and cell number, thereby validating the use of fluorescence values as a 
measure of the number of migrated cells.
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Figure 5.6 Optimisation of separation of enzyme and chemokine mixtures: gel 
electrophoresis of samples separated using Microcon® ultrafiltration devices
Silver-stained 12% Bis-Tris gels were used to assess separation of recombinant 
chemokine from enzyme using Microcon® ultrafiltration devices YM30 and YM50.
(a) YM30, used with different sample volumes, and with and without flushing through 
with buffer. Lanes 1-12 represent 10pl of the following samples: (1) CXCL10 (400pl) 
retentate; (2) CXCL10 (400pl) filtrate; (3) CXCL10 (65pl) retentate; (4) CXCL10 (65pl) 
filtrate; (5) CCL2/MMP9 retentate; (6) CCL2/MMP9 filtrate; (7) CXCL10/MMP9 
retentate; (8) CXCL10/MMP9 filtrate; (9) Flushed CCL2/MMP9 retentate; (10) Flushed 
CCL2/MMP9 filtrate; (11) Flushed CXCL10/MMP9 retentate; (12) Flushed 
CXCL10/MMP9 filtrate. Flushing the Microcon® membrane was shown to improve the 
yield of chemokine in the filtrate.
(b) YM30 and YM50. Lanes 1-9 representing 10pl of the following samples: (1) Mark12 
MW marker; (2) CCL2 retentate from YM30; (3) CCL2 filtrate from YM30; (4) CXCL10 
retentate from YM30; (5) CXCL10 filtrate from YM30; (6) CXCL10/MMP2 retentate from 
YM50; (7) CCL2/MMP2 filtrate from YM50; (8) CCL2/MMP2 retentate from YM50; (9) 
CXCL10/MMP2 filtrate from YM50. YM50s gave a greater yield of chemokine in the 
filtrate, compared to YM30s.
234
Lane: 1
CCL2:
MMP9
filtrate
CCL2:
MMP9
retentate
6 8
Flushed
CCL2:
MMP9
filtrate
9 10 11 12
mmm
CXCL10
filtrate
CCL2
filtrate
CXCL10
filtrateCCL2filtrate
YM30 YM50
Lane: 1
Fluorescence values achieved with both the W allac Victor2 and GENios Plus plate 
readers correlated very well (R2 values typically of 0.99) with the number of labelled 
PBMCs (Fig. 5.7a), monocytes, lymphocytes, THP-1 cells (Fig. 5.7b and c), and Jurkat 
cells. Very low numbers of cells proved difficult to measure, however, particularly with 
the W allac Victor2 plate reader. This is an important consideration, as only a fraction of 
the total number of cells used in migration assays will migrate. Figure 5.7c shows a 
standard curve generated from fluorescence of THP-1 cell numbers of 0-901, which 
showed some discrepancies for cell numbers less than 200, and gave a lower R2 value 
of 0.93. Above 200 cells, correlation was excellent, which indicated measuring 
fluorescence of cells labelled with 1.5pM calcein AM achieves a good representation of 
cell number for the range expected to be relevant to migration assays. The linear 
relationship between fluorescence and cell number also remained constant for the 
duration of the assay for all cell types used, as no significant difference was observed 
in measurements taken immediately after labelling with calcein AM (Fig. 5.7b), and 4h 
25min, afterwards (Fig. 5.7a).
5.4.4.3 Optimal cell density per insert for migration assays
Optimal cell density for use in migration assays was assessed and found to vary 
depending on the cell type. A seeding density of THP-1 cells of 2-5 x 105 cells per 
insert gave good results in migration assays to CCL2 (data not shown).
5.4.4.4 Comparison of the migration of unlabelled PBMCs to cells labelled with 
calcein AM
Effects of calcein AM labelling of cells on their migratory capacity were investigated by 
comparing the migration of unlabelled and labelled PBMCs to 1 and 10% BSA.
Labelling with 6pM calcein AM did not interfere with the migratory capacity of PBMCs 
to BSA. Similar results were seen with labelled and unlabelled PBMCs, as they both 
showed migration after 18h to 1% BSA that was significantly greater (P>0.001) than 
migration to the control, HBSS (Fig. 5.8).
Migration to 10% BSA was significantly increased compared to control (P<0.01) when 
using unlabelled cells, but this significant difference was not evident with calcein AM - 
labelled cells (Fig. 5.8). This difference was not considered a cause for concern, as an 
increase in background fluorescence could account for the failure to find a significant 
difference between 0 and 10% BSA with labelled cells, particularly as a high molarity of 
calcein AM, and a long time course, were used.
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Figure 5.7 Correlation of number of calcein AM-labelled cells with fluorescence 
value at 535nm
(a) PBMCs were isolated from human blood by density gradient centrifugation, labelled 
with 4.1 gM  calcein AM, counted and further diluted with R P M I to give known cell 
numbers, and fluorescence m easured at 535nm using a GENios Plus plate reader. The 
R 2 value of 0 .9949 illustrates that the relationship between the num ber o f PBMCs and 
the associated fluorescence value is a linear one, and that fluorescence can be 
accurately correlated with cell number, 265min after labelling with calcein AM.
(b) THP-1 cells were labelled with 1.5pM calcein A M  and known cell numbers plotted 
against fluorescence m easured at 535nm using a GENios Plus plate reader. The plot 
generated for the whole range of 0-568,000 cells gave an R 2 value of 0.9979, which 
illustrates that the relationship between the num ber o f cells and the associated 
fluorescence value is a linear one, and that fluorescence can be accurately correlated 
with cell number immediately after labelling with calcein AM.
(c) The plot for low THP-1 cell numbers (from b) between 0-901 cells gave an R2 value 
of 0.9374 and showed a reduced correlation between cell num ber and fluorescence for 
cell numbers below 200.
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Figure 5.8 C om parison o f the m igra tion o f unlabelled and calcein A M -labelled  
PBM Cs to 1% and 10% BSA at 18h
Effects of calcein AM labelling of PBMCs on migration was assessed by using labelled 
and unlabelled PBMCs in a migration assay with uncoated inserts with 3pm pores. 
Each insert received 8 x 105 cells, suspended in HBSS, and HBSS, 1%, or 10% BSA 
were placed in the lower chambers. Cell migration into the lower chamber was 
measured after 18h at 37°C and 5% C02. Data are presented as mean ± SEM (n-2 
inserts); one-way ANOVA with Bonferroni's post test indicate differences from HBSS 
control, with **= P<0.01, and ***= P<0.001.
(a) Cells were not labelled prior to migration. After 18h, cells adherent to the filter 
underside were removed with trypsin-EDTA solution, pooled with cells in the lower 
chamber, and counted using a haemocytometer
(b) Cells were labelled with 6pM calcein AM for 30min at 37°C and 5% C02, and 
washed twice, prior to use in the migration assay. After 18h, the inserts were removed 
after gentle scraping of adherent cells into the lower chamber, and the level of 
fluorescence in the lower chamber measured at 535nm using a Wallac Victor2 plate 
reader.
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5.4.4.5 Optimal calcein AM concentration for labelling cells
The molarity of the calcein AM used to label cells was optimised, to ensure the lowest 
effective molarity was used, thereby reducing the likelihood of effects on the cells 
arising from calcein AM. Very high levels of fluorescence exceeded the upper detection 
limit of the GENios Plus plate reader, so lower molarities of calcein AM were used, with 
1 and 1.5pM giving good results (data not shown). A low calcein AM concentration also 
reduced the possibility of the dye interfering with cellular function, or being released 
from the cell. All cell types used gave a viability result of greater than 99%  as 
determined by Trypan Blue exclusion, both before labelling, and after labelling. This 
remained the case for the duration of the migration assays.
5.4.4.6 THP-1 cell migration to various concentrations of human serum albumin 
and fMLP
HSA was used in both the upper and lower chambers of the migration apparatus during 
assays using chemokines, so the effects on migration of THP-1 cells to various HSA  
concentrations were analysed to see if small deviations in HSA concentration between 
assays would affect results attributed to chemokines. Significant migration to 5%  HSA, 
compared to the control of 0% HSA, was first observed at 105min, and then maintained 
at similar levels at 120, 135, 150, and 165min, assessed using unpaired, 2-tailed, 
Student’s t-tests (Fig. 5.9). Significant migration to 5% HSA, compared to 0.1%  HSA, 
and fMLP, was also observed. No significant migration to 0.1%  or 1% HSA, or 10'8 M 
fMLP, compared to the control of no HSA, was seen (Fig. 5.9), indicating that the 0.1%  
HSA used in migration assays to chemokines is not responsible for the migratory 
response.
5.4.5 Cell migration to CCL2
5.4.5.1 THP-1 cell migration to various concentrations of CCL2
Significant migration was observed to 100, 200, and 400ng/ml CCL2, compared to no 
CCL2 (RPM I + 0.1%  HSA) (Fig. 5.10). CCL2 concentrations of 200 and 400ng/ml 
induced the highest level of migration, with P<0.001, compared to P <0.01 for 100ng/ml, 
when one-way A N O VA and Bonferroni’s multiple comparison post-test were performed. 
Migration peaked early on in the assay for all CCL2 concentrations, with high levels 
observed at 30min, with no further increase in cell migration for the remaining 90min. A  
more rapid initial migratory response was observed with 400ng/ml CCL2, as this 
appeared to peak at 15min (Fig. 5.10).
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Figure 5.9 Effec t o f HSA concen tration  on THP-1 cell m igration
THP-1 cells labelled with 1.5ijM calcein AM were placed in fluorescent-blocking inserts 
with 3pm pores (8.30 x 105 cells /  insert), and exposed to RPMI + 0, 0.1, 1, and 5% 
HSA, or RPMI + 10'8 M fMLP (used as a positive control), in the lower chamber. 
Migration was measured every 15min for 3h at 37°C, to detect cells that had passed 
through the filter to the lower chamber. Mean fluorescence (n=2) at 15min intervals, for 
each concentration of HSA is shown, and the error bars represent SEM. Results from 
unpaired, 2-tailed, Student’s t-tests, comparing fluorescence values of migration to 5% 
HSA to 0% HSA are shown for each time point, with *= P<0.05, and **= P<0.01. No 
significant difference was seen between 0.1% and 1% HSA, compared to 0% HSA.
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Figure 5.10 Effec t o f CCL2 concen tration  on THP-1 cell m igra tion
THP-1 cells labelled with 1.5pM calcein AM were placed in fluorescent-blocking trans­
well filters with 3pm pores (2.4 x105 cells / insert), and exposed to RPMI + 0, 100, 200, 
and 400ng/ml CCL2, in the lower chamber. Migration to CCL2 was measured by 
reading the fluorescence from the bottom of the plate, every 15min for 3h at 37°C, to 
detect cells that had passed through the filter to the lower chamber. Mean fluorescence 
(n=2) values (MFVs) for each concentration of CCL2 were divided by the MFVs of no 
CCL2 at each timepoint to give the fold increase. Error bars represent SEM. Results 
from Student’s t-tests (unpaired, 2-tailed) for each time point, comparing MFVs of 
CCL2 concentrations to no CCL2 are shown.
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5.4.5.2 Comparison of migration to intact and cleaved CCL2 by THP-1 cells
Truncated CCL2 (from 2.3.1.3) was used to compare the migratory response of THP-1 
cells to intact and cleaved CCL2.
Cleavage of CCL2 by either MMP2, M M P9 or CD26 significantly reduced the rate of 
THP-1 migration, as fold increases (~1.4-1.9) in migration to cleaved CCL2 at 15min, 
above that seen with no CCL2, were approximately half of the fold increase seen with 
intact CCL2 (~3.8 fold increase). CCL2 blocked by an antibody resulted in negligible 
migration (~1 .4 fo ld  increase) (Fig. 5.11). Performing one-way ANO VA  with 
Bonferroni’s post-test indicates that overall significant differences (P<0.01), exist 
between migration to CCL2 cleaved by M M P2 and CD26, compared to migration to 
intact CCL2 incubated with APM A alone. MMP9-cleaved CCL2 induced a more marked 
reduction in migration (P<0.001). Analyses by Student's t-tests at each time point 
indicate that the differences are not maintained over time, however. At 45min, 
migration to M M P2-cleaved CCL2 compared to APMA-incubated CCL2 does not show 
any significant reduction (P>0.05), whereas MMP9-cleaved CCL2 exhibits reduced 
migration (P<0.01), and CD26-cleaved CCL2 demonstrates significant differences 
(P<0.05). By 75min, the reduced migration to cleaved chemokines has been eradicated, 
compared to intact CCL2 (Fig. 5.11).
5.4.6 Migration to CXCL10
5.4.6.1 Lymphocyte migration to CXCL10
Treatment of lymphocytes with 1pg/ml PHA and 20ng/ml IL-2 for 7 days in culture, did 
not induce significant migration (7.7 x 105 cells per insert) to 250ng/ml CXCL10 (data 
not shown), as determined by an unpaired, 2-tailed, Student’s t-test. Difficulties 
associated with low lymphocyte recovery (following separation from monocytes and 
washing steps after calcein AM-labelling), and the need for pre-treatment with IL-2, 
precluded repetition of the migration assay.
5.4.6.2 Jurkat cell migration to CXCL10
No significant migration of Jurkat cells was observed at 0.25-2pg/m l CXCL10, either 
with, or without, prior treatment with 10ng/ml IL-2 for 6 days (data not shown).
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5.5 Discussion
5.5.1 Optimisation of the migration assay
Trans-well inserts are widely used in the study of chemotaxis of cells, for research into 
metastasis and inflammation, amongst others. These assays are time-consuming, and 
prone to operator error due to the manual fixation, staining, and counting of cells 
required. In addition, they do not allow measurement at more than one time point due 
to destruction of the sample. Detection of cells by fluorescence offers easy analysis, 
but is not easy to incorporate in traditional migration assays. The migration assay using 
FluoroBlok™ fluorescence-blocking inserts, optimised as part of this project, proved 
successful at measuring cell migration in real time, enabling comparison of 
enzymatically-cleaved CCL2 with the intact form. It offered a number of advantages 
over traditional Boyden chamber methods, as data acquisition was rapid, it offered 
good sensitivity with low cell numbers, and variation and errors were minimised as the 
inserts did not have to be manipulated to allow collection of data at various time points. 
The use of real-time monitoring proved a very useful tool, as the kinetics of migration 
vary according to the cell type, and choosing a single time point could give misleading 
results. In vitro models of migration can be used to demonstrate directional migration of 
leukocytes in response to a soluble chemotactic gradient, but it is important to 
remember that conditions in vivo include shear flow forces that normally prohibit 
formation of stable chemokine gradients within the vascular lumen.
Fibronectin-coated inserts were used in migration assays, as this glycoprotein 
promotes cell adhesion and motility (Yamada, 2000). Enzymatic digestion of fibronectin 
can yield a 120 kDa fragment, which has been shown to induce monocyte chemotaxis 
(Clark et a/., 1988). Potential variation caused by fibronectin digestion in trans-well 
inserts emphasised the need to remove enzymes from the cleaved chemokines used in 
assays, which was achieved by the use of ultrafiltration using Microcons®.
Of particular interest in this current study are the findings of Sobel and Mitchell (1989), 
who identified a significant increase in fibronectin in blood vessel walls of active, but 
not inactive, MS plaques. The degree of inflammation in MS was seen to correlate with 
fibronectin levels, active plaques possessed extracellular fibronectin, and the 
fibronectin receptor was found on macrophages (Sobel and Mitchell, 1989). Fibronectin 
is not typically a membrane protein, and normally forms cell surface fibrillary networks 
between adjacent cells and substrata (Hynes et al., 1979). In MS, fibronectin may be 
secreted by, or deposited on, ECs and macrophages in the CNS, and might encourage 
PBMC migration (Sobel and Mitchell, 1989). Accordingly, it is highly relevant to include
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fibronectin in a migration assay whose findings will be considered in the context of 
potential effects in MS.
Very recently, Czepluch and colleagues (2007) reported that pre-labelling monocytes 
with calcein AM (5pM) decreased their adherence to plastic and reduced overall 
migration to TGF-J31 and fMLP, although size and viability were not affected. This 
conflicts with previous reports that claim calcein AM has only negligible effects on 
cellular functions (Weston and Parish, 1990), but effects on chemotaxis (Abbitt et al.,
2000) and adhesion (De Clerck et al., 1994) were assessed for lymphocytes or 
neutrophils, rather than monocytes. Abbitt and colleagues tested various fluorescent 
dyes for their effects on adhesion and migration of leukocytes, and concluded that 
whilst acridine orange interfered with adhesion, and rhodamine 6G inhibited 
mononuclear cell migration, calcein AM was not found to significantly affect the capture 
and migration phases of any leukocytes. Preliminary comparisons of unlabelled and 
labelled PBMC migration to BSA performed as part of this project suggest that even 
relatively high concentrations (6pM) of calcein AM used in labelling do not significantly 
hinder the migration process. Moreover, a low concentration of calcein AM (1.5pM ) was 
used in migration assays in the present study. This warrants further investigation using 
THP-1 and Jurkat cells, however, as dyes can cause concentration-dependent 
alterations on the different stages of adhesion and migration, which vary according to 
the cell type and receptors involved.
Calcein AM was considered suitable for use in this study as it labels cells to high 
fluorescence intensity, in a persistent fashion, and it has previously been used for 
migration studies (Chiba et al., 1998). In the current study, numbers of labelled cells 
correlated well with fluorescence values, demonstrating a linear relationship, thereby 
enabling calculation of the numbers of migrated cells from a standard curve. Increases 
in fluorescence with time were seen for all samples, however, and in the absence of 
chemokine, this could be explained by random chemokinesis of cells. It is also possible 
that small amounts of calcein were released from cells with time, particularly if they 
were dying, but cell viability was found to be well maintained during the time course of 
the assay.
It was initially thought that fMLP would be useful as a positive control in migration 
experiments, which would demonstrate the assay was working. Surprisingly, no 
migration was observed to fMLP, as fluorescence values generated by migrated THP-1  
cells were lower when exposed to this, than to RPMI alone. This might be explained by 
the findings of Resnati and colleagues (2002), that fMLP inhibits THP-1 migration by
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interfering with the uPA-associated chemotactic response in THP-1 cells and human 
monocytes.
5.5.2 In vitro cell migration assays to CCL2 and CXCL10
Results from this chapter are summarised in Table 5.1. Migration of THP-1 cells to 
CCL2 occurred rapidly, with maximum migration demonstrated at 15min when intact 
CCL2 was assessed. This result is considerably faster than the migration of monocytes 
across a model endothelial monolayer, observed by Hardy and colleagues (2004), 
where a significant level occurred within 60min of addition of CCL2. Results from 
migration assays described in this chapter demonstrate a significant delay in achieving 
the maximum fold increase in migration of THP-1 cells when cleaved CCL2 was 
assessed, as this occurred at 75min for all truncated isoforms present, compared to 
15min for full-length CCL2. At 15min, the fold increases in migration to all truncated 
CCL2 isoforms were approximately half that seen with the full-length version. All 
significant differences between cleaved and intact forms of CCL2 were eliminated at 
75min, suggesting that proteolytic processing may be most important in regulating the 
initial stages of cellular infiltration in vivo. As CD26 was shown to cleave CCL2 almost 
completely within 30min (Chapter 2), this enzyme stands out as being instrumental in 
rapidly reducing the chemotactic potential of CCL2.
Results using THP-1 cells in migration assays to cleaved and intact CCL2 reported 
here (Table 5.1) are in agreement with previous findings that loss of residues from the 
N-terminus of CC chemokines often reduces their chemotactic potential (reviewed in 
W olf et al., 2008). Moreover, McQuibban et al. (2002) reported that injection of the 5-76  
isoform of CCL2 demonstrated reduced cell migration in an inflammatory in vivo model, 
by inducing a 66%  reduction in the increase of oedema in rat paws following injection 
with carrageenan. They also reported a similar reduction in paw volume following 
injection of an engineered form of CCL2 (9-76). It is interesting to note that McQuibban 
concluded that M M P2 failed to cleave CCL2, reporting instead production of the 5-76  
isoform following processing by MMPs 1, 3, and 8, although the CCL2 in their study 
was generated using chemical synthesis and folded via air oxidation.
The striking similarity in THP-1 cell migration patterns seen in the current study (Table  
5.1) in response to CCL2 cleaved by MMPs 2 and 9, and CD26, suggest that 
chemotactic ability is reduced by the same extent, irrespective of whether 2 or 4 N- 
terminal residues are lost.
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Table 5.1 Summary of results from cell migration assays to cleaved and intact
CCL2 and CXCL10
INTACT CCL2
MMP2-
CLEAVED
CCL2
*5-76
MMP9-
CLEAVED
CCL2
*5-76
CD26-
CLEAVED
CCL2
*3-76
THP-1 cells
3-3.5 fold f  in 
migration within 
15min, reducing 
gradually after 
75min, to no 
detected 
migration at 3h
Significant j, 
in migration 
from 15-75min, 
compared to 
intact CCL2.
Greatest |  
seen at 15min 
( -5 0 %  |  in 
migration, 
compared to 
intact CCL2)
As for M M P2- 
cleaved CCL2
As for M M P2- 
cleaved CCL2
INTACT
CXCL10
MMP2-
CLEAVED
CXCL10
*6-73
MMP9-
CLEAVED
CXCL10
*5-73
CD26-
CLEAVED
CXCL10
*3-77
Lymphocyte- 
enriched 
population 
from PBMCs
No significant 
migration after 
short-term IL-2 
+ PHA  
treatment (data 
not shown)
NT NT NT
Jurkat cells
No significant 
migration after 
short-term IL-2 
treatment (data 
not shown)
Preliminary data 
(after long-term 
IL-2 treatment) 
indicated slight 
f in  migration 
(data not 
shown)
Preliminary data 
(after long-term  
IL-2 treatment) 
indicated slight 
f  in migration 
compared to 
intact CXCL10  
(data not 
shown)
Preliminary data 
(after long-term  
IL-2 treatment) 
indicated slight 
f in  migration 
compared to 
intact CXCL10  
(data not 
shown)
Preliminary data 
(after long-term  
IL-2 treatment) 
indicated no 
change in 
migration 
compared to 
intact CXCL10  
(data not 
shown)
N T  = not tested; f = increase; I  = decrease 
* Amino acids remaining after processing
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Preliminary data obtained following long-term treatment of Jurkat cells with IL-2 
indicated that cleavage of CXCL10 by CD26 does not alter its chemotactic potential, 
but M M P2 or M M P9 truncation of CXCL10 may lead to a slight increase in Jurkat cell 
migration after 1h and 4h respectively, compared to intact CXCL10 (data not shown). 
This warrants further investigation, and may be linked to loss of residues from the C- 
terminus of CXCL10, as truncation of both the N- and C- termini were reported with 
MMPs 2 and 9, whereas CD26 cleaved solely at the N-terminus (reported in Chapter 2). 
Previously, N-terminal cleavage of CXCL10 by CD26 was reported to result in a 30-fold 
decrease in lymphocyte chemotaxis, generating a C XCR3 antagonist (Proost et al.,
2001). Due to the extremely rapid and highly specific processing of CXCL10 by CD26  
(see Chapter 2), it is prudent that the effects of this truncation are investigated further.
Assessment of Jurkat cell migration to CXCL10 proved to be problematic, despite 
utilisation of several chemokine concentrations, pre-treatment of cells with PHA and IL- 
2, demonstration using flow cytometry of a high CXC R3 receptor density on the 
membrane of Jurkat cells, and extension of the assay length to account for potentially 
slower migration than was demonstrated using THP-1 cells to CCL2.
W hen lymphocyte-enriched cell populations from PBMCs were used in migration 
assays, it was possible that CXCR3 receptor expression was low, a factor that warrants 
further investigation. Resting and short-term TCR-activated (e.g. with PHA) T  cells 
have been reported to lack expression of transcripts for CXC R 3 and other inflammatory 
receptors, in contrast to homeostatic chemokine receptors, such as CXCR5. \n vitro 
investigations demonstrated that receptor expression and responses to inflammatory 
chemokines were strongly dependent on IL-2 (Loetscher et al., 1996). IL-2 has been 
shown to enhance the cytotoxicity and antigen-specific proliferation of T  cells 
(Waldmann e ta l., 1993). Resting lymphocytes constitutively express the (3- and y- 
chains of the IL-2 receptor, but the a-chain, necessary for formation of the high-affinity 
receptor, is evident only after T  cell activation (Waldmann, 1991).
IL-2 is considered a major regulatory factor of lymphocyte migration in vivo, and it is 
thought it activates and expands CD 45R O + T  cells for recruitment to inflammatory sites 
(Loetscher et al., 1996). Loetscher and colleagues (1996) reported that IL-2 was 
essential for lymphocyte migration and receptor expression involving CC chemokines, 
and that their migratory responsiveness was lost if IL-2 was removed. Their research 
also demonstrated that use of PHA when culturing lymphocytes delayed the effects of 
IL-2, as migration to CCL2 and CCL5 was only observed after 9 days of culture, 
instead of 4  days. If the same delay after PHA/IL-2 treatment occurs with lymphocyte
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migration to CXCL10, Loetscher’s findings could explain why the assay described in 
this thesis, performed after 6 days of dual treatment, failed to demonstrate any 
significant migration in lymphocytes. The situation is further complicated, as prolonged 
administration of IL-2 stimulates apoptosis of activated T  cells (Lenardo et al., 1999). 
Reports of the duration of lymphocyte culture with IL-2 necessary for maximal CXCR3  
expression vary, from 10 days (Loetscher et al., 1998), to 3 weeks (Cheeran et al.,
2003), and further work is needed to optimise the use of IL-2 treatment prior to the 
migration assays used here.
There is substantial evidence that migrating lymphocytes respond to CC rather than 
CXC chemokines, and that a C D 45R O + phenotype of T  cell are predominantly involved 
(Carr et al., 1994). Indeed, Roth and colleagues (1995b) found that CC chemokines 
stimulated transendothelial chemotaxis of lymphocytes, but CXC chemokines 
(including CXCL10), did not. It would, therefore, be of interest to extend the current 
study to include Jurkat cell and lymphocyte migration assays to intact and cleaved 
CCL2.
It is possible that each combination of experimental conditions using Jurkat cells or 
lymphocytes contained some prohibitive element, such as a cell density that was too 
high, or too low. Cell migration is affected by many parameters in an in vitro system, 
with cell concentration being a very important factor. Fibroblasts, for example, have 
demonstrated migration behaviour that depended on their distance to surrounding cells, 
with increases in both speed and distance travelled when seeded at a low density 
(Raeber et al., 2007). It is thought that high cell densities can be inhibitory for a number 
of reasons, including an increase in cytokines, blocking of adhesion sites by integrin 
fragments remaining from previously migrated cells, and cell-cell contacts causing 
contact inhibition (Huttenlocher et al., 1998).
A further factor that may account for the lack of cell migration to CXCL10 reported in 
the current study is the absence of shear stress in the assay system used. Cinamon 
and colleagues (2001) found that lymphocytes only engaged in transendothelial 
migration to CXCL12 or CCL19 when continuous exposure to shear forces was applied. 
They deduced that the shear stress triggered mechanoresponsive elements on 
lymphocytes, which combined with chemokine signals to facilitate migration. Linder 
shear flow conditions, stimulation of leukocyte integrins by apical chemokines was 
shown to be essential for cell adhesion. In vivo, apical immobilised chemokines may 
act alone, or with subendothelial chemokines, to promote transendothelial migration.
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Chapter 6
General discussion
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6.1 Chemokines in MS pathogenesis
MS is often described as an inflammatory demyelinating disease, characterised by the 
formation of plaques in the white matter of the CNS. Mechanisms involved in the 
pathogenesis of MS are complex and varied, resulting in a wide assortment of clinical 
manifestations. Current treatments have very limited benefit once the disease has 
entered the progressive phase, necessitating closer scrutiny of the pathology and 
immunology in an attempt to identify new targets for therapeutic intervention 
(Lassmann, 2007). The present study attempted to elucidate the involvement of 
cleavage of the chemokines, CCL2 and CXCL10, in the inflammatory process in MS, 
which may warrant further investigation as potential targets for drug development.
The extensive chemokine system is responsible for cell homing during homeostasis 
and inflammation, and contributes to regulation of many functions, such as 
angiogenesis, tumour growth, and haematopoiesis. The diverse actions of chemokines, 
and the redundancy that exists in the receptor and ligand system, emphasise the need 
for strict regulation of chemokine activity. Proteolytic cleavage can control chemokine 
activity by increasing or reducing the chemotactic response, and also by altering 
receptor selectivity (reviewed in W olf et al., 2008). Proteases such as MM Ps and CD26  
are known to cleave chemokines, and are often induced by the same stimuli, and 
produced in the sam e microenvironment as chemokines. This simultaneous production 
of chemokines and proteases may be designed to facilitate rapid regulation of 
chemokine activity. It is important to remember that proteolytic processing of 
chemokines is only one method of regulating chemokine activity, existing alongside 
control via gene expression, variations in chemokine secretion and storage (Catalfamo  
et al., 2004), interactions with GAGs (that create elevated local chemokine levels and 
offer potential protection from digestion) (Proudfoot, 2006), binding to non-signalling 
decoy receptors, such as D6 (Comerford et al., 2007), and regulation of chemokine 
receptor expression (e.g. via internalisation) (Marchese et al., 2003).
CCL2 is principally involved in recruiting monocytes and T  cells (Conti and Rollins,
2004), and CXCL10 attracts T  cells (Flier et al., 2001), with both cell types being major 
contributors to MS pathogenesis. Previous studies have revealed the expression of 
CCL2 and C XCL10 by astrocytes, and detected them in abundance in MS lesions 
(Simpson et al., 1998 and 2000b), but not in normal control brain, strongly indicating 
that these chemokines are very important in the disease process. Indeed, chemokines 
and their receptors have often been considered as potential therapeutic targets to 
reduce leukocyte trafficking in MS and other inflammatory disorders (Proudfoot et al., 
2003). As CXCL10 is induced by a cytokine profile indicative of chronically inflamed
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lesions (e.g. by IFN-y), it is possible that CXCL10 exerts its maximum effects during the 
later stages of MS pathogenesis, when rapid recruitment of immune cells is no longer 
pivotal (Oynebraten et a/., 2004). Understanding the precise mechanisms of how the 
inflamed CNS recruits PBMCs in MS is particularly important, as preventing normal 
leukocyte trafficking pharmacologically can have unforeseen consequences. This was 
demonstrated by the development of progressive multifocal leukoencephalopathy 
(PML), a lethal infection of the CNS, in three MS or Crohn’s patients treated with 
natalizumab, a monoclonal antibody against integrins on PBMCs (Berger and Koralnik,
2005).
Secretion of CCL2 by astrocytes has previously facilitated use of astrocyte supernatant 
as the chemoattractant source in THP-1 cell migration assays (Lehmann et al., 2006).
In Chapter 2, truncated forms of CCL2 and CXCL10 were identified using mass 
spectrometry and gel electrophoresis, following processing by recombinant enzymes. 
The same techniques were then applied to assess primary human astrocytes for the 
presence of truncated chemokines, in a quest to subsequently utilise supernatants 
containing cleaved chemokines in monocytic and T  cell migration assays. Since a 
concentration of 200ng/ml CCL2 was found to be optimal for THP-1 cell migration 
assays (Chapter 5), the levels of CCL2 (~9ng/ml) and C XC L10 (~1.9ng/ml) (Suliman et 
al., 2006) in astrocyte supernatant following cytokine treatment were too low to be 
assessed for chemotactic potential. In addition, sample volumes used in mass 
spectrometry were not sufficient to enable detection of either intact or cleaved CCL2 in 
astrocyte supernatant (Chapter 3).
6.2 Proteases in multiple sclerosis
Enzymes such as MMPs are found at elevated levels in patients with MS (Agrawal et 
al., 2008). They are important in MS pathogenesis as they contribute to the breakdown 
of the BBB, can cause neuronal death and axonal damage, and can cleave 
chemokines (Yong et al., 2007b). M M P2 and M M P9 received particular focus in this 
investigation, as previous studies have consistently demonstrated their upregulation in 
MS, especially M M P9 (Yong et al., 2007b). Increased expression of M M P2 and M M P9  
has been reported in lymphocytes and macrophages around PVCs, and high M M P9  
levels have been found in lesions (Lindberg et al., 2001). Brain ECs also express 
MMPs 2 and 9 (Harkness et al., 2000). The current analysis of m RNA expression of 
M M P2 and M M P9 by TaqM an®  PCR (Chapter 3) found high levels of M M P2 m RNA in 
all astrocyte samples analysed, consistent with constitutive M M P2 expression 
(Leveque et al., 2004), and an increase in M M P9 mRNA expression in astrocytes
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following treatment with TN F and IL-1 (3, which is in agreement with reports that M M P9  
is increased in the pro-inflammatory environment of MS lesions (Yong et al., 2007b).
The T  cell activation molecule, CD26, which possesses ectopeptidase activity and is 
known to cleave dipeptides from polypeptides with a proline or alanine at the 
penultimate position, is also implicated in the pathogenesis of MS (Aytac et al., 2001). 
Levels of CD26 in the peripheral blood and CSF have been shown to correlate with 
disease activity in MS (Krakauer et al., 2006), and as chemokines can be cleaved by 
CD26, this molecule warranted investigation in this study. Information about CD26  
expression in the human brain is scarce, but using immunohistochemistry, it was 
present in all white matter samples examined (Chapter 4). Increased CD26 levels were 
found in MS brain, compared to control brain. This increase is in agreement with 
findings detailing higher levels in MS of peripheral C D 26+C D 4+ T  cells (Krakauer et al.,
2006) and C D 26+C D 8+ T  cells (Jensen et al., 2006), but it was clear in the current study 
that not all T  cells present in lesions were C D 26+, and some HLA-DR+ cells 
(macrophage/microglia) were also CD 26+. Previous studies in MS have shown that the 
majority of T  cells in the CSF and the perivascular space are CD4+, whereas those that 
infiltrate tissue are C D 8+ (Woodroofe et al., 1986). C D 26+ cells were found in PVCs and 
also in the parenchyma of white matter from MS brains.
6.3 Chemokine and protease interactions
Recruitment of immune cells to inflammatory sites is dependent on the interactions of 
chemokines with their receptors. Alterations in the structure of a chemokine can 
dramatically affect its ability to bind to receptors, and thus functional activity, 
particularly if amino acids at the N-terminus of the chemokine are involved (Fig. 6.1). 
This study has focussed on chemokine processing by M MP2, M MP9, and CD26, but it 
is important to remember that numerous other enzymes may produce truncated forms. 
Elastase, for example, is released from activated monocytes (Wolf et al., 2008). In 
addition, chemokines can be cleaved in their core regions, such as the inactivation of 
CCL20 when exposed to cathepsin B (Hasan et al., 2006).
The effects of chemokine processing are largely unpredictable, rendering it important to 
investigate the effects on activity of each enzymatic cleavage individually. In addition to 
effects on receptor activation, truncated chemokines can occasionally exhibit 
unexpected biological responses that are independent of chemokine receptors (Zhang 
et al., 2003).
256
pH, io n ic  s treng th  
Concentration
Binding to GAGs 
Heterodimerization \ \
Processing kinetics 
Inhibitors
Co-factors/ Environm enta l
conditions
Proteolytic processing
Degradation
Inactivation
Activation
/ / X Change of receptor specificity
M odulation o f 
chem okine activ ity
Potentiation
Antagonism
Protease 
)  Fullsize chemokine 
C >  Processed chemokine
V
• Immune supression / enhancement 
-Chronification of inflammation 
-Tumor suppression / -growth
Biological
im plications
Reprinted from (Wolf et al., 2008) © (2008), with permission from Elsevier.
Figure 6.1 Proteolytic processing of chemokines
Many factors influence the cleavage of chemokines by proteases such as MMPs and 
CD26. Truncated chemokines can have decreased or enhanced activity, and altered 
receptor specificity. The altered function of proteolytically processed chemokines can 
influence the outcome of the biological response, and potentially affect the disease 
process.
257
M M P2 processing of CXCL12 at the N-terminus, for example, generates a highly 
neurotoxic form involved in neuronal apoptosis, resulting in neurodegeneration (Zhang 
eta!., 2003).
Interactions between chemokines and proteases should not be considered as one-way 
processes. Chemokines can modulate protease expression, as is seen by the 
stimulation by CCL2 of M M P9 expression in macrophages (Balkwill, 2004), and its 
regulation of M T1-M M P expression in ECs (Son et al., 2006). O ther protease activities, 
such as shedding of GAGs bound to the ECM, will affect chemokine actions by 
abolishing their ability to be retained on cell surfaces at high local concentrations 
(Proudfoot, 2006).
Protease-chemokine interactions warrant further investigation, as their complexities 
may reveal details pivotal in understanding the disease process, and the immune 
response might be substantially heightened or dampened depending on the activation 
or inactivation of chemokines processed by proteases released from infiltrating immune 
cells and surrounding cells. Chemokine cleavage has implications in many disease 
processes. It has been hypothesised, for example, that proteases upregulated in 
cancer might selectively cleave chemokines, thereby inactivating them and driving a 
preferred route of metastasis (Mohamed and Sloane, 2006).
This present study has expanded the current knowledge of truncated forms of these 
chemokines that might be formed naturally by enzymatic processing in the 
inflammatory environment of MS, and investigated the potential effects of this 
truncation on the ability to attract monocytes and T  cells.
6.3.1 N-terminal processing of chemokines
Forms of chemokines truncated at the N-terminus have been found naturally, which 
focussed the earliest studies of proteolytic processing of chemokines on this region. 
Indeed, CXCL7 and CCL14 need to be N-terminally truncated to become active. N- 
terminal processing is common due to the exposed and conformationally disordered 
nature of this terminus of chemokines (reviewed in W olf et al., 2008).
Approximately one third of human chemokines have a proline in the penultimate 
position at the N-terminus, making them candidate substrates for CD26. This region is 
not considered to be available for processing in many such chemokines, however, due 
to modification by pyroglutamate (Struyf e ta l., 2003). Indeed, this pyroglutamatic acid 
residue protection from N-terminal cleavage by CD26 has been observed with CCL2
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(Van Coillie et al., 1998). In the current study, CCL2 was susceptible to CD26 cleavage 
as the recombinant CCL2 utilised had a glutamine as the N-terminal residue. This 
demonstrates that discrepancies may arise when considering chemokine substrates 
occurring in vivo, and recombinant forms obtained from E.coli.
Several CC chemokines, including CCL2, have been shown to have strict requirements 
for an intact N-terminus for their biological activities to be fulfilled (Proost et al., 2006). 
This study supports this result for CCL2, as M M P2 and M M P9 cleaved 4 residues from 
the N-terminus, and CD26 cleaved a dipeptide, with all truncated forms showing a 
reduction in their ability to attract THP-1 cells. In addition to the reduced receptor 
binding and signalling capabilities that often result from N-terminal truncation of CC  
chemokines, the shortened forms can act as chemotaxis antagonists (McQuibban et al.,
2002). The negative regulatory effects of N-terminal processing of CCL2, for example, 
contrast with the more commonly minor effects on biological activity created by C- 
terminal truncation, or glycosylation (Proost et al., 1998c).
Results from the current study confirmed that cleavage at the N-terminus is a regular 
occurrence, as CCL2 was processed by all three enzymes used. M M P2, M M P9, and 
CD26, removed five, four, and two residues, respectively, from the N-terminus of 
CXCL10. Truncated forms of CXCL10 lacking two and five N-terminal residues have 
been found naturally (Hensbergen et al., 2004). N-terminal cleavage of CXCL10 by 
MMPs 2 and 9 has not previously been reported elsewhere. The mass spectrometric 
finding of this study indicated that the cleavage of an N-terminal dipeptide from 
CXCL10 by CD 26 is in agreement with previous findings (Proost et al., 2001), although 
the impaired activity and role of this truncated form as a CXC R 3 antagonist remains to 
be established.
Cleavage at the N-terminus of inflammatory CXC chemokines with an ELR motif often 
results in an increase in their activity (Proost et al., 2006). Contrastingly, removal of 
amino acids from the N-terminus of CXC chemokines without an ELR motif, such as 
CXCL10, has been shown to reduce chemotactic potential (Proost et al., 2001).
Impaired receptor binding and signalling properties of C XC R 3 ligands truncated by 
CD26 have been shown, together with simultaneous retention of the anti-angiogenic 
activity of CXCL10 in vivo (Proost et al., 1993). It is important to consider that MM Ps 2 
and 9 appeared to simultaneously cleave 4 amino acids from the C-terminus of 
CXCL10 in the current study, generating a form of CXCL10 altered at both termini.
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6.3.2 C-terminal processing of chemokines
Few studies have reported proteolytic processing of chemokines at the C-terminus, but 
it is generally considered to have minimal effects on activity (Hensbergen et al., 2004). 
The C-terminus plays an essential role in direct antibacterial activity exhibited by some 
chemokines, such as CXCL7 (Krijgsveld et al., 2000). CXCL10 has also been shown to 
have microbicidal activity independent of activation of CXCR3, but C-terminal 
truncation does not appear to affect this response (Cole et al., 2001).
Analysis of mass spectrometric data from this study revealed that M M P2 and M M P9  
cleaved 4 amino acids from the C-terminus of CXCL10. The C-terminally truncated 
form of CXCL10 was identical to one previously reported following processing by the 
enzyme furin, which has been isolated from natural sources (Hensbergen et al., 2004). 
Previous studies have not confirmed the C-terminal cleavage of CXCL10 by M M P2 that 
was observed here.
This study found that M MPs 2 and 9 cleaved CXCL10 at both the N- and C-termini, and 
it would make an interesting comparison to assess the effects of processing of CXCL10  
at both termini, with effects on chemotactic activity arising from truncation by CD26 at 
the N-terminus alone.
6.4 Implications of cleavage of CCL2 or CXCL10 in MS
There is no shortage of chemokines identified as substrates for proteases, but the 
relevance of their processing often remains undiscovered. The true situation in vivo can 
be difficult to establish, as chemokine availability and protease activity in a 
physiological environment will differ significantly from conditions created in in vitro 
digestion experiments. Chemokines can be completely degraded in vitro, for example, 
whereas tighter regulation in vivo would prevent this (Wolf et al., 2008). By assessing 
the chemokines and proteases that have key roles in MS pathogenesis and are 
expressed in the same milieu, however, the results from this study may add to the 
understanding of cellular events that occur in the inflamed CNS.
This study has demonstrated the expression of CD26 in MS lesions, and the 
expression of MMPs 2 and 9 by astrocytes. All three of these enzymes have the ability 
to cleave CCL2 (with glutamine as the N-terminal amino acid), and CXCL10. Mass 
spectrometric detection of the processing of CCL2 and CXCL10 by CD26 indicated that 
it occurred very rapidly, taking only a few minutes, suggesting potential physiological 
significance. Previous studies indicate that CCL2 in vivo would be protected from 
cleavage by CD26 due to the N-terminal pyroglutamic acid residue (Van Coillie et al.,
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1998), but this residue is thought to derive from glutamine and be formed just prior to 
cellular protein secretion, or as a post-translational event. Moreover, enzymes capable 
of removing pyroglutamic acid have been isolated from mammalian cells, where they 
have a ubiquitous distribution (Abraham and Podell, 1981). It is not improbable, 
therefore, that CCL2 can be cleaved by CD26, or M M Ps 2 and 9, in vivo, as isoforms of 
CCL2 may exist with glutamine as the N-terminal residue, or the pyroglutamic acid may 
be removed by endogenous enzymes. N-terminal processing of CCL2 by MMPs 2 and 
9, and CD26, produced a truncated form with a severely restricted ability to attract 
monocytic cells, and thus CCL2 cleavage would contribute to abrogation of the 
damaging inflammatory response. This is of particular relevance in MS, as CCL2 
attracts both monocytes and T  cells. Pharmacological inhibition of M M P2, M M P9, or 
CD26, could, therefore, eliminate this beneficial effect of CCL2 truncation, but 
administration of a drug based on N-terminally cleaved CCL2 could be advantageous 
in reducing overall immune cell infiltration across the BBB, and further inflammation in 
lesions, by competing with native intact CCL2 for CCR2.
Similarly for CXCL10, once the effects of proteolytic processing are confirmed, 
implications and possible therapeutic targets could be identified. As CXCL10 was 
processed even more rapidly than CCL2 by CD26, and at both termini by MMPs 2 and 
9, perhaps regulation of CXCL10 activity is more relevant, particularly as MS is 
considered a T  cell-driven disease.
6.5 Summary
Chemokines are implicated in the pathogenesis of MS both through their induction of 
protease release, and their ability to attract immune cells across the BBB. Proteases 
can then process the chemokines that induced them, with N-terminal processing 
altering chemokine receptor interaction, with ensuing increases or decreases of 
biological activity. The principal findings of this study concerning chemokine-protease 
interactions are summarized in Figure 6.2.
The role reversals that can occur as a result of chemokine cleavage demonstrates the 
importance of simultaneously detecting proteases and chemokines when considering 
the pathogenesis of diseases. Proteases not only assist with leukocyte migration 
across the BBB in MS, but also regulate this infiltration of the CNS by modifying 
chemokine activity. The presence of chemokine antagonists that occur naturally 
following their proteolytic cleavage provide interesting avenues for exploration in drug 
design to treat not just inflammatory diseases such as MS, but also AIDS and cancer.
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Figure 6.2 Schematic summarising principal findings of this study and potential 
implications for MS pathogenesis
Chemokines CCL2 and CXCL10, and the proteases MMP2 and MMP9, are expressed 
by astrocytes in contact with CNS blood vessels. CD26 is expressed as a cell-surface 
peptidase on activated T cells in peripheral blood, and was demonstrated on T cells 
and microglia/macrophages in PVCs and the parenchyma of MS lesions. Each 
enzyme cleaved CCL2 and CXCL10 at the N-terminus. CXCL10 was also cleaved by 
MMPs 2 and 9 at the C-terminus. Cleaved CCL2 reduced migration of THP-1 cells, 
which may have implications for the in vivo inflammatory environment in MS.
Proteolytic processing by CD26 or MMP2/9 ( I )
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6.6 Further work
Astrocytes are known to express CCL2 (Simpson et al., 1998), CXCL10 (Simpson et al., 
2000b), and M MPs -2 and -9 (Gottschall and Deb, 1996), with implications for MS 
pathogenesis. This formed the rationale for investigating the effects of proteolytic 
processing on these two chemokines, as the loss of only a few residues has previously 
been demonstrated to radically alter chemokine activity (reviewed in W olf et al., 2008). 
CD26 has also been implicated in MS, and is known to cleave several chemokines 
(Mentlein, 1999), and was thus similarly examined. Experiments were performed using 
recombinant proteins purchased externally. Further studies could involve the use of 
expression vectors and protein purification to generate the chemokines and proteases 
required, thereby producing a greater supply at lower cost.
Previous reports led to an expectation that CCL2 would not be cleaved by M M P2  
(McQuibban et al., 2002), and the effect of M M P9 was unknown. Both M M P2 and 
M M P9 preferentially cleave proteins at sites with a hydrophobic residue immediately 
upstream, which suggested that CCL2 might be a substrate of these MMPs, however, 
due to possessing lie as the fifth residue at the N-terminus (Seltzer et al., 1990). As 
CCL2 has a proline as the penultimate residue, it was a likely substrate for cleavage by 
CD26, although previous reports have shown this not to be the case in vivo due to a 
protective pyroglutamic acid as the N-terminal residue (Iwata et al., 1999). Results from 
this current in vitro study revealed that CCL2 was cleaved at the N-terminus by MMP2, 
MMP9, and CD26. The effects of this processing were expected to substantially reduce 
chemotactic activity, as the isoform of CCL2 generated following N-terminal removal of 
four residues by MMPs 1, 3, and 8, had previously been shown to lack activity when 
used in trans-well migration assays with THP-1 cells (McQuibban et al., 2002). Results 
from the current study concurred with this reduction in chemotactic potential of cleaved 
CCL2, although activity was not completely lost. Further work could be done to assess 
whether the reduction in chemotaxis was due to reduced receptor binding of cleaved 
CCL2, or if the truncated form acts as a receptor antagonist.
CXCL10 has previously been shown to be a substrate of CD26 (Proost et al., 2001), 
with the loss of an N-terminal dipeptide also being demonstrated in this study. Van den 
Steen et al. (2003) demonstrated C-terminal processing of CXCL10 by M M P9, which 
resulted in degradation after prolonged exposure. Results from the current study 
confirmed C-terminal processing of CXCL10 by M M P9, but also revealed limited N- 
terminal cleavage, and contrastingly, some intact CXCL10 remained after a 
comparable duration of M M P9 exposure. The effects of M M P2 on CXCL10 were
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previously unknown, but results presented here suggest that M M P2 processes 
CXCL10 at both the N- and C-termini, and may culminate in complete degradation of 
the chemokine after 72h. It was anticipated that cleaved CXCL10 would demonstrate 
reduced activity, based on evidence from previous studies (Van Damme et al., 2004), 
but problems encountered in the current study prevented conclusions as to the effect of 
processing of C XCL10 on chemotaxis.
The activity of cleaved forms of chemokines was assessed using an in vitro migration 
assay, which lacked the shear forces provided by blood flow in vivo. It has been argued 
that shear stress is required for facilitation of cell migration (Cinamon et al., 2001), 
which may partially account for some of the negative results described here. There 
were particular difficulties associated with investigating the chemotactic activity of 
CXCL10, however, such as the requirement to culture cells for several days in the 
presence of IL-2 to achieve high levels of functional expression of the receptor C XCR3  
(Loetscher et al., 1998), and the consideration that in vivo, oligomerisation of CXCL10  
is necessary for its retention on the endothelium, and resulting chemotactic gradient 
(Campanella et al., 2006). Further work could be done to optimise the migration assay 
performed in this study for use with CXCL10, such as perfecting the IL-2 treatment of 
the cells. Alternatively, a different T  cell chemoattractant, such as CCL5, could be 
selected for further investigation, particularly as this is known to play a significant role 
in MS pathogenesis (Szczuciriski and Losy, 2006). The long time course required to 
obtain significant levels of cleaved CXCL10 following incubation with MM Ps -2 and -9  
must also be considered critically, as such prolonged exposure is unlikely to be of 
relevance to the in vivo situation, in MS brain. CD26 processed CXCL10 within a few  
minutes, however, and it might be prudent to focus further studies of the significance of 
chemokine processing on rapid and highly specific interactions of this nature.
The use of natural forms of chemokines and proteases, derived from cells known to 
secrete them in the CNS, would be likely to yield results about chemokine processing 
that were highly relevant to the inflamed CNS. Mass spectrometry was used in the 
current study in an attempt to detect truncated chemokines in astrocyte supernatant. 
Difficulties encountered during sample preparation, whereby concentrating supernatant 
created a sample very rich in salts, limited the effectiveness of this approach. ' 
Ultracentrifugation or ultrafiltration techniques could be investigated for concentration of 
several litres of astrocyte supernatant (Russell et al., 2007), followed by purification 
using high-performance liquid chromatography (HPLC) to obtain chemokines. 
Chemokines derived in such a way could then be used in cell migration assays, and 
also in digestion experiments with proteases derived from astrocyte supernatants or
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MS brain tissue extracts. Further studies could also include the use of microglia for 
isolation of chemokines, and to screen for M M P expression. The use of chemokines 
derived from cell supernatants would help to minimise discrepancies that may occur 
between the processing of chemokines that occur naturally in the CNS, and 
recombinant forms derived from E.coli.
ELISA has traditionally been used to detect serum proteins, a method that requires 
appropriate monoclonal antibodies. Alternative techniques are being developed, which 
use surface-enhanced laser desorption ionisation (SELD I)-TO F MSpec, with protein 
chip arrays containing immobilised polyclonal antibodies (Favre-Kontula e t a i ,  2006). A  
study using a variant of CCL5 found that the SELD I-TO F method was able to detect 
protein modifications that would be missed by ELISA, namely being processed twice to 
truncated forms, and being oxidised in serum (Favre-Kontula et al., 2006). The use of 
SELDI-TO F to detect cleaved chemokines in astrocyte supernatant could be explored.
The pilot data generated by screening astrocyte lysate samples for M M P mRNAs could 
be utilised to identify MM Ps worthy of further investigation in chemokine processing 
experiments. Microglia express IL-1 (B (reviewed by Stock et al., 2006), which may 
increase expression of some MMPs in the brain, as was suggested by results from the 
current study which showed an increase in the mRNAs of several MMPs, notably 
MMPs -1, -10, and -12, following treatment of astrocytes with IL-1 p. The RT PCR  
investigations could be repeated several times, with a focus on only the MMPs found to 
be of interest in preliminary results, thereby enabling statistical analysis to be 
performed to identifiy significant differences in MM P m RNA expression that occur with 
cytokine treatment. Brain tissue samples, from both control and MS donors, could also 
be examined similarly for M MP mRNAs.
CD26 definitely warrants further investigation as to its role in MS pathogenesis. The  
study described in Chapter 4 could be extended to include more tissue blocks and 
NAW M from MS brains, in addition to dual labelling for T  cell subsets, to further 
characterise the cellular distribution of CD26 in relation to MS lesions. Quantitative 
investigations of individual lesions would provide valuable information, whereby the 
number of C D 26+ T  cells could be expressed as a percentage of the total number of T  
cells observed. It would also be interesting to perform dual label immunofluorescence 
to detect potential co-localisation of CD26 and the basal lamina, using an anti-laminin 
antibody.
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Cell migration experiments could be expanded to incorporate culture of ECs and 
astrocytes on opposite sides of trans-well inserts (allowing astrocytic processes to 
contact ECs via 3pm pores), to more closely resemble the three-dimensional nature of 
the BBB (Eugenin et al., 2006).
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Appendix I
Fixation in paraformaldehyde (PFA)
0.2M Phosphate buffer
0.2M phosphate buffer was made by mixing solutions A and B below (pH to 7.2 once 
mixed).
Solution A: 11.36g Na2H P 0 4 was dissolved in 400ml dH20  
Solution B: 3.2g NaH2P 0 4.2H20  in 100ml dH20  
4%  Paraformaldehyde
In a fume hood, 16g PFA was added to 100ml dH20  and heated to 60°C. Drops of 2M  
NaOH were added until the PFA dissolved. dH20  was added to give a total volume of 
200ml and then 200ml 0.2M phosphate buffer was added and a pH of 7.2 reached. 
This solution was filtered prior to use and stored at 4°C for 2 weeks only.
Protein extraction buffers
2X Sample buffer
2.5ml 0.5M  Tris-HCI pH6.8; 4ml 10% SDS; 2ml glycerol; 0.2ml (3-mercaptoethanol; 
0.2mg bromophenol blue; made up to 10ml with dH20  and stored at 4°C.
Extraction Buffer
0.1475g Tris base; 0.7938g Tris-HCI; 0.09305g EDTA; in 250ml dH20
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Appendix II
Protein and RNA extraction using TRI Reagent®
The following manufacturer’s protocol from Sigma was used for extraction of RNA and 
protein from cells:
0.75ml of TRI Reagen t®  was mixed with 0.25ml of sample and the cells lysed (or 
cellular debris) by passing the suspension several times through a pipette. At least
0 .7 5 . l  of TRI Reagen t®  per 5-10 x 106 cells was used. Samples were then stored at - 
80°C for up to one month if necessary, before completing the protocol below.
Phase Separation: To ensure complete dissociation of nucleoprotein complexes, 
samples were allowed to stand for 5min at RT. Chloroform (0.2ml of per 0.75ml of TRI 
Reagen t®  used) was added, the sample covered, shaken vigorously for 15 seconds 
and left to stand for 2-15min at RT. The resulting mixture was centrifuged at 12,000g  
for 15min at 4°C . Centrifugation separated the mixture into 3 phases: a lower red 
organic phase (containing protein), an interphase (containing DNA), and a colourless 
upper aqueous phase (containing RNA). The volume of the aqueous phase was about 
70%  of the volume of TRI Reagent® used for homogenisation.
RNA Isolation
Note: The organic phase was stored at 4°C  for subsequent isolation of proteins.
1. RNA Precipitation: The aqueous phase was transfered to a fresh tube and 
isopropanol (0.5ml per 0.75ml of TRI Reagent® used for the initial homogenisation) 
added. The sample was allowed to stand for 5-10min at RT, centrifuged at 12 ,000gfo r  
8min at 4-25°C  and the RNA precipitate formed a pellet on the side and bottom of the 
tube.
2. RNA W ash: The supernatant was removed and the RNA pellet washed by adding 
1ml (minimum) of 75%  ethanol per 0.75ml of TRI Reagen t®  used for the initial 
homogenisation. The sample was vortexed and centrifuged at 7 ,500g fo r 5min at 4 - 
25°C.
(Notes: If the RNA pellet floated or accumulated on the side of the tube, the wash was 
performed in 75%  ethanol at 12,000g; samples were stored in ethanol at 4°C  for up to 
1 year at -20°C).
3. RNA Solubilisation: the RNA pellet was dried for 5-10min by air-drying or under a
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vacuum, but not allowed to dry completely, as this greatly decreases its solubility. An 
appropriate volume of dH20  was added to the RNA pellet, the solution mixed by 
repeated pipetting and incubated at 55-60°C  for 10-15min, if necessary to aid 
dissolution.
Protein Isolation
1. DNA removal: the remaining aqueous phase overlaying the interphase was 
discarded. To precipitate the DNA from the interphase and organic phase, 100%  
ethanol (0.3ml per 0.75ml of TRI Reagent® used in sample preparation) was added, 
the sample mixed by inversion, left to stand for 2-3min and centrifuged at 2 ,000g  for 
5min at 4°C . The supernatant was removed and stored at 4°C , if necessary, prior to the 
procedure below.
2. Protein precipitation: proteins were precipitated (see note below) from the phenol- 
ethanol supernatant with 1.5ml of isopropanol per 0.75ml of TRI Reagent®  used in the 
initial sample preparation. Samples were left to stand for at least 10min at RT and 
centrifuged at 12 ,000gfo r 10min at 4°C.
3. Protein wash: the supernatant was discarded and the pellet washed 3 times in 0.3M  
guanidine hydrochloride/ 95%  ethanol solution, using 2ml per 0.75ml of TRI Reagen t®  
used in the initial sample preparation. During each wash, samples were stored in wash 
solution for 20min at RT prior to centrifugation at 7 ,500g  for 5min at 4°C . After the 3 
washes, 2ml of 100% ethanol was added, the protein pellet vortexed, left to stand for 
20min at RT and centrifuged at 7 ,500g for 5min at 4°C .
Note: Protein samples suspended in 0.3M guanidine hydrochloride/95% ethanol 
solution or 100%  ethanol were stored for up to 1 month at 4°C  or 1 year at -20°C , if 
necessary.
4. Protein solubilisation: the protein pellet was air-dried for 5-15min and dissolved in 
1% SDS, aided by pipetting up and down. Some protein pellets required incubation at 
50°C for complete solubilisation. Any insoluble material was removed by centrifugation 
at 10,000g for 10min at 4°C. The supernatant protein solution was transferred to a new  
tube and was used immediately for western blotting or stored at -20°C .
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Appendix III
The plate dimensions for BD 24-well companion plates (for use with migration inserts) 
are not symmetrical and a plate definition file was created as follows in Xfluor4.xls for 
use with the GENios Plus plate reader:
1. The ‘Xfluor4’ menu tab was selected, and then the ‘Edit PlateDefinition...’ tab.
2. The plate parameters shown below were entered, then ‘Update’ and ‘Close’ 
(this did not save the file).
3. Under ‘File’ menu ‘Save PlateDef a s ...’ was selected and the Plate Definition 
File named and saved.
Measurement parameters for BD companion plates 
for use with FluoroBlok™ 24- multiwell insert
Columns 6
Rows 4
Well Form Round
Well Diameter 6.5
Upper Left Well X -1560
Start Position Y  2812
Lower Right Well X  94825
End Position Y  60937
Unlidded Plate Height 22500pm
Plate Height with Cover 24500pm
To use fluorescence-based detection of migration using the GENios Plus plate reader, 
‘Xfluor4.xls’ software was opened (macros were enabled) and a connection made to 
the reader. The ‘Edit Measurement Param e ter...’ menu item was opened, and in the 
‘General’ tab in the drop down menu, ‘Fluorescence’ detection mode was selected. The  
plate definition created via the above procedure was selected from the ‘Plate’ tab; 
‘Multiple reads per well’ was selected, with a square pattern and 2 x 2  for the number of 
replicates. The 485nm  excitation and 535nm emission filters were selected from the 
‘Meas. Param s’ tab (drop down menu); and ‘Bottom’ selected as the read mode. A  
manual Gain setting method was selected, and integration parameters of a zero time 
lag, and 20psec integration time were used. The ’Edit Measurement Param e ter...’ 
menu item was closed, and ‘Start’ selected to commence the reading.
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Appendix IV
Publications and presentations 
Published abstracts
DENNEY, H., CLENCH, M., and W O O D R O O FE, M.N. (2005).
Investigations into the significance of the truncation of chemokines CCL2 and CXCL10  
by M MP2, M M P9, and CD26, in multiple sclerosis.
Immunology, 116 (Supplement 1) p. 42.
DENNEY, H., BUNNING, R.A.D., CLENCH, M. AND W O O D R O O FE , M.N. (2007). 
Expression of C D 26/D P P IV  in normal CNS and MS lesions: Implications for 
pathogenesis via cleavage of chemokines CCL2 and CXCL10.
Poster presented at Multiple Sclerosis Society “MS Frontiers” event, London, UK.
Oral presentations
Mar. 2006 “Truncation of chemokines CCL2 and CXCL10 by M M P2, M M P9 and 
CD26: implications for multiple sclerosis” at the British Society of 
Immunology 50th Anniversary Regional Meeting, Sheffield, UK.
Jun. 2007 “Cell migration in vitro in response to chemoattractant
proteins: a model system for assessing immunomodulatory treatments 
in M S” at the National Multiple Sclerosis Society Meeting, Sheffield, UK
Poster presentations
Sep. 2005 British Mass Spectrometry Society, Annual Meeting, York, UK.
Dec. 2005 British Society of Immunology Congress, Harrogate, UK.
May 2006 Yorkshire BioEnterprise Networking Event, W akefield, UK.
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